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As an introduction to this work I describe the genes and pathways that are involved 
in the development of the gonad, from the undifferentiated gonad to the completely 
developed testicles and ovaries. Implicated genes in the formation of internal and 
external genitalia that lead to sexual differentiation are also explained. Then, the 
widely varied disorders of sex development caused by impaired alterations in those 
previously mentioned genes are explained. Finally, I describe current clinical 
management of the sex anomalies and the role of next generation sequencing in the 
molecular diagnosis of this pathology.  
 
 
1. SEX DEVELOPMENT AND GENETIC REGULATION  
 
In humans and other mammals, sex development is a sequential process that 
involves a large number of genes and pathways acting to completely acquire functional 
gonads and consecutive differentiation of internal and external genitalia to finish with 
secondary sexual characterization at puberty (Figure 1A and 1B). The first step, sex 
determination refers to the decision of the bipotential gonad to continue through the 
testicular or ovarian pathway. In contrast to other organs, the early gonads have the 
potential to differentiate into two functionally different organs, testes or ovaries. 
Later, sex differentiation comprises the formation of the internal and external genitalia 
due to the sex-specific hormones secreted by the developing gonads and the 
secondary sexual characterization at puberty. 
 
In males and females, sex determination and the correct development of the 
gonad and genitalia depend on a tightly controlled network of transcription factors 
and signalling pathways. Moreover, sex steroid hormone production is dependent on 
consecutive enzymatic steps and functional hormone receptors. Any changes in this 
delicate genetic system result in atypical sex development leading to disorders of sex 
development (DSD) in humans.  
 
 
1.1. FORMATION OF THE UNDIFFERENTIATED GONAD  
 
This process starts during the fourth week of embryonic life with the formation 
of the undifferentiated urogenital ridge, comprising the pronephros, mesonephros and 














Figure 1. A, Overview of the development of male and female genitalia. B, Overview of the genes and 
pathways involved in the sex development.Black arrows indicate activation of a downstream target. Red 
lines ending in bars show repression of a downstream target. Modified from Ohnesorg T., 2014 (2). 
 
 
In humans, the testis and the ovary arise from a sexually undifferentiated 
precursor, the genital ridge (GR) which appears as a thickening of the coelomic 




epithelial cell layer. Together with the proliferation of the CE, the epithelial cells from 
the underlying membrane move towards the mesonephros and as mesenchymal cells 
colonize the space between the coelomic epithelium and the mesonephros. The 
mesenchymal cells of the GR are gonadal precursors that differentiate into interstitial 
and somatic supporting cells of the early differentiated gonad. For the testicular 
development, supplementary cells are recruited from the mesonephros into the 
genital ridge to increase the endothelial cell population that establish the male 
vascular system (1). Prior to gonadal determination, primordial germ cells, precursors 
of sperm and oocytes, migrate into the GR. In case of male sex determination, the 
mesonephros also gives rise to the mesonephric or Wolffian duct and to a primordial 
urogenital tissue that develops epididymis, vas deferens and seminal vesicles. In 
females, the paramesonephric or Müllerian duct is also comprised in the mesonephros 
(3).  
 
At 5 weeks, the early gonad is bipotential and has the ability to differentiate 
into a testis or an ovary, depending on the presence or absence of the SRY (Sex 
determining region of Y chromosome) gene on the Y chromosome. However, at this 
point no morphological differences are observed between the XX and XY early gonads. 
Furthermore, genes that are later associated with the testicular fate such as Sox9 (SRY-
Box 9) or ovarian fate, as Wnt4 (Wnt Family Member 4), are expressed equally in XX 
and XY gonads, until the beginning of the differentiation (4). 
 
In mice at least seven genes, including Nr5a1 (Nuclear Receptor Subfamily 5 
Group A Member 1), Wt1 (WT1 Transcription Factor), Lhx9 (LIM Homeobox 9), Emx2 
(Empty Spiracles Homeobox 2), Cbx2 (Chromobox 2), Pbx1 (Pre-B-Cell Leukemia 
Transcription Factor 1) and Gata4 (GATA Binding Protein 4) have been demonstrated 
to be necessary for the initial thickening of the coelomic epithelium, progression and 
maintenance of the genital ridge (5). Knock-out (KO) mouse studies have revealed that 
mutations or absence of these gene products might lead to a failure in the gonadal 
progress or to the presence of streak gonads (3, 6), emphasising the critical role of 
some genetic factors in both males and females.  
 
Despite their early role in gonadal development, the loss-of-function of these 
genes in humans, result in a range of phenotypes that vary from complete gonadal 
dysgenesis to adult infertility (3). 
 
1.1.1. Nuclear Receptor Subfamily 5 Group A Member 1 (NR5A1) 
 
NR5A1, encoding steroidogenic factor 1 (SF1) is a member of the orphan 
nuclear receptor located on 9q33. It plays a central role in regulating adrenal 
development, gonadal determination and differentiation and in the hypothalamic-




conception) and thereafter, in the Sertoli and Leydig lineages, as well as in the adrenal 
gland. Nr5a1-null models showed gonadal agenesis and lack of adrenal glands (7).  
 
Human SF1 is a 461 amino acid protein that contains a DNA (Deoxyribonucleic 
Acid) binding domain (DBD) with two zinc fingers, an accessory “A”-box that extends 
the DBD and mediates specific DNA binding, and a hinge region followed by a ligand-
binding domain (LBD) that forms two activation function domains (AF-1 and AF-2) 
(Figure 2). The expression of NR5A1 has been demonstrated during the formation of 
the bipotential gonad and adrenal glands (32-33 dpc), but also in gonad development 
and steroidogenesis (8).  
 
 
Figure 2. Diagram of the SF1 protein. The critical functional domains found in SF1, a DNA-binding 
domain (DBD) at the amino terminal (From amino acid 13 to 112), the flexible hinge region (amino acid 
112-225) and a ligand-binding domain (LBD) (amino acid 225-458). Modified from Tantawy S., 2014 (9). 
 
 
SF1 upregulates a number of testis-determining genes, such as SOX9 in the 
somatic cells of early testis, anti-Müllerian hormone (AMH) in Sertoli cells, and the 
enzymes included in the steroidogenic system in Leydig cells (8, 10). While the 
expression of Nr5a1 continues during testicular development in mice, it is 
downregulated during ovarian development. However, SF1 has been detected in 
Granulosa and theca cells of an adult ovary in humans but its role is unclear (8). It has 
been suggested that SF1 may promote the expression of FOXL2 (Forkhead Box L2), 
which ultimately suppresses SOX9 (8) and exemplifies the outcome of antagonistic 
pathways that compete to manage the differentiation and repression of supporting 
cell precursors to develop the bipotential gonad into a testis or an ovary.  
 
In 1999, Achermann et al identified the first NR5A1 heterozygous mutation in a 
patient with 46,XY gonadal dysgenesis, Müllerian structures and primary adrenal 
failure (11). Now, human variations in NR5A1 show variable phenotypic expressivity 
and incomplete penetrance and have been widely characterized in 46,XY DSD, primary 
ovarian insufficiency (POI) and 46,XX testicular (T DSD) and ovotesticular DSD (OT DSD) 
(12-14).  
 
1.1.2. Wilms’ tumour Suppressor 1 (WT1) 
 
The WT1 gene, located on 11p13, codifies a zinc finger transcription factor and 
is known to act as a repressor or activator of numerous genes involved in the 




expressed in Sertoli and Granulosa cells. Among the multiple protein isoforms that are 
generated in mammals through complex regulatory mechanisms, two main WT1 
isoforms are important in the gonadal development and are defined by the presence 
or absence of three amino acids, lysine, threonine and serine (KTS) between zinc finger 
three and four (15). 
 
Wt1-null mice of both sexes fail to develop gonads and kidneys, suggesting an 
early role in the formation of the bipotential gonad (16). Moreover, the expression of 
Wt1 begins with that of Nr5a1 and the DNA-binding form WT1 (-KTS) acts together 
with Sf1 to ensure proper formation of the urogenital system (2). The other WT1 
isoform (+KTS), is involved in the early testis development. Mice lacking the gene, 
presented male-to-female sex reversal through the failure in the Sry expression 
regulation, which influences cell proliferation and Sertoli cell differentiation (3). Other 
genes regulated by WT1 (-KTS) are Sry, Amh, Sox9, Wnt4 and Nr0b1 (Nuclear Receptor 
Subfamily 0 Group B Member 1) (10).  
 
 Mutations in the WT1 gene have been classically identified in anomalies of 
testicular development leading to 46,XY DSD. Also, WT1 gene deletions in the Wilms’ 
tumour (OMIM 194070) and missense variants in the zinc finger domains or in intron 9 
in Denys-Drash (DDS, OMIM 194080) and Frasier syndromes (FS, OMIM 136680), 
respectively, have been reported (2, 17). However, the application of NGS to the 
molecular diagnosis of DSD patients and associated syndromes has enlarged the 
phenotypic spectrum, like the WT1 frameshift activating variant in a zinc-finger domain 
found in a 46,XX T DSD girl (18) or the six intronic and two missense changes identified 
in a cohort of women presenting with POF (Premature ovarian failure, OMIM 311360). 
Further in vitro analyses showed that missense variants downregulated AMH and 
CDH1 (Cadherin 1), while increased expression of FSHR (Follicle Stimulating Hormone 
Receptor) and CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) (19).  
 
1.1.3. GATA binding protein 4 (GATA4) 
 
The human GATA4 gene on chromosome 8p23.1 encodes an essential 
transcription factor for the developing gonad and heart (20). GATA proteins have two 
zinc fingers (ZNI and ZNII), which are highly conserved and are necessary for protein–
protein interactions with other transcription factors (Figure 3). The sequences of the 
carboxyl-terminal and amino-terminal domains are required for the DNA recognition 
and binding, and contribute to stability (21). 
 
Gata4-null mice die due to severe abnormalities in heart tube formation and 
ventral morphogenesis. Gata4 expression and function seems not only essential for 
normal testicular and genital development (22), but also to initiate formation of genital 




formation and failure of LHX9 and SF1 gonadal markers, suggesting an earlier role in 
gonadogenesis than Sf1, Wt1, Lhx9 and Emx2 (3). In humans, GATA4 interacts with 
several proteins, including SF1, WT1, and FOG2 (Friend Of GATA Protein 2) to regulate 
the expression of sex determining genes SRY, SOX9, and AMH, as well as genes 
involved in sex differentiation such as STAR (Steroidogenic acute regulatory protein), 
CYP17A1 (Cytochrome P450 family 17 subfamily A member 1), CYP19A1, INHA (Inhibin 
subunit alpha) and HSD3B2 (Hydroxy-delta-5-steroid dehydrogenase, 3 Beta and 
steroid delta-Isomerase 2) (22-24). 
 
 
Figure 3. Scheme of the structure of the GATA4 protein. GATA4 contains two distinct zinc finger domains 
(ZNI and ZNII) and a carboxi terminal nuclear localization sequence (NLS) which consists of a DNA-
binding domain and a protein-protein interaction domain. Transcriptional activation domains (TAD) are 
located in the N-terminus. Modified from Martinez de LaPiscina I., 2018 (25). 
 
 
GATA4 haploinsufficiency has been described in patients with different forms of 
congenital heart defects (CHD) since 1999, while only few studies have reported 
mutations related to a 46,XY DSD phenotype (12, 25-29). 
 
1.1.4. Chromobox Homolog 2 (CBX2) 
 
This gene, located on 17q25.3, codifies for a component of the polycomb group 
complex of proteins responsible for epigenetic regulation through the recognition of 
methylated histones. Among other adrenal and spleen defects, the targeted deletion 
of Cbx2 caused male-to-female sex reversal in XY gonads. Posterior forced expression 
of Sry and Sox9 in this murine model resulted in smaller testes and indicated its role in 
testis differentiation through regulation of Sry. Cbx2 is also involved in the 
upregulation of other genes, such as Nr5a1 and Wt1, and downstream targets such as 
Sox9 (30). Variants in this gene are associated with gonadal dysgenesis in humans (31, 
32). 
 
1.1.5. Pre-B-Cell Leukemia Transcription Factor 1 (PBX1) 
 
PBX1 encodes a three amino acid loop extension (TALE) class homeodomain 
protein that plays an important role in the adrenal and urogenital development. Pbx1-/- 
mice decreased cell proliferation in the genital ridge and thus, testicular development 
was impaired. In the female reproductive system, the inactivation of the gene led to 
the absence of uterus and vagina (33). More recently, a missense mutation in the TALE 




the loss-of-function results in an altered interaction with CBX2 and EMX2, driving to 
irregular downstream events that interrupted the gonadal development in the patient 
(34). 
 
1.1.6. Empty-Spiracles Homeobox 2 (EMX2) 
 
EMX2, encoding a homeobox-containing transcription factor is expressed in the 
urogenital system and in the early stages of the cerebral cortex and olfactory system. 
The role of this protein in the early gonadal development was supported when KO 
mice (Emx2-/-) showed complete gonadal and genitourinary system agenesis (35). As 
mentioned, it interacts with other partners to bind DNA regulatory targets and activate 
transcription (34). In males, few deletions that encompass the gene in 10q26.11 have 
been reported (35). 
 
1.1.7. Lim Homeobox 9 (LHX9) 
 
LHX9, encodes a protein of the LIM gene family and contains a homeodomain and 
two cysteine domains involved in protein interactions. During mice embryonic 
development, Lhx9 protein transcripts are present in urogenital ridge. In Lhx9-deficient 
mice, somatic cells of the genital ridge don’t proliferate and gonad fails to form. In the 
absence of testosterone and AMH the genetically XY mice develop a female phenotype 
with reduced expression of Nr5a1 (36). In vitro studies demonstrated the regulation of 
Nr5a1 gene through the direct binding of Lhx9 and Wt1 to the promoter (22, 37). 
Recently, two heterozygous variants in LHX9 have been reported in two 46,XY DSD 
patients with variable degrees of undervirilization (38). 
 
 
1.2. MOLECULAR GENETICS IN MALE GONADAL DETERMINATION 
 
In humans, gonadal differentiation occurs from 6 to 10 gestational weeks and in 
mice from embryo day 11 to 12. During sex development, the gonadal precursors 
differentiate into two somatic cell lineages. The supporting cell precursors contribute 
to Sertoli and Granulosa cells in the XY and XX gonads respectively, whereas 
steroidogenic progenitors give rise to Leydig cells in the male gonads or theca cells in 
the ovary. The differentiation of the germ cell depends on the surrounding niche, then 
the sex role chosen by the cell lineage begins a differentiation cascade that finishes 
with a complete functional gonad (39). 
 
Differentiation of the bipotential gonad into testis or ovary is the result of the 
antagonistic male and female pathways that take part to control the differentiation of 
supporting cell precursors, via regulation of SOX9 and others. The commitment of the 




repression of the alternative pathway of development as well as the control of the 
gonad field and the fate of other somatic lineages and germ cells. The SRY gene works 
as a switch that guides the initial gonadal determination to a testicular fate, while 
RSPO1 (R-Spondin 1) and FOXL2, among others, direct gonadal development to an 
ovarian destiny. 
 
SRY gene is necessary and sufficient to initiate testicular development. At 
around week 6 of gestation in humans and embryo day 11 in mice, pre-Sertoli cells 
express the SRY in the XY gonad and together with NR5A1, trigger the testis 
development program through activation and maintenance of the SOX9 signalling 
pathway. Other important target genes and components of the early testis 
development are NR0B1, AMH and GATA4 and its co-factor FOG2 (40). In the absence 
of SRY, female-specific pathway is initiated which includes genes such as RSPO1, WNT4 
and NR0B1 to promote the organogenesis of the ovaries (22).  
 
1.2.1. Sex determining region Y (SRY) 
 
This single-exon gene encodes a member of the high-mobility group (HMG) box 
family of transcription factors. It is characterized by the presence of the highly 
conserved HMG box DNA-binding domain and acts as the testes determining factor. 
Approximately 80% of the 46,XX T DSD and 10% of OT DSD had SRY material 
translocated into one of their X chromosomes. Moreover, nearly 20% of the 46,XY DSD 
females with gonadal dysgenesis had a loss-of-function variant in the SRY gene. Female 
mice transgenic for Sry developed testes, which finally demonstrated that this gene 
triggers male sexual determination and testis formation (2). 
 
In mice, the expression of Sry begins in pre-Sertoli cells at 10 days post-
conception (dpc), stimulating the development of testicular cords and Leydig cell 
formation. Its expression reaches the highest levels at 11.5 dpc and diminishes at 
around 12.5 dpc, thus Sry is not required for the maintenance or function of the testis. 
In contrast, in humans SRY is expressed in male somatic cells at 6 weeks and continues 
to be expressed in the adult testis (2). It seems that SRY acts upregulating Sox9 and 
stimulates Sertoli cell formation and thus, testicular differentiation. In the absence of 
Sry, Sox9 is suppressed and female gonadal development begins (41).  
 
Positive regulators of the Sry gene expression include GATA4, FOG2, WT1 and 
NR5A1. As mentioned before, Cbx2 regulates the expression of Sry itself (30). 
 
1.2.2. SOX family genes  
 
The SOX (SRY-Box) genes encode transcription factors involved in the 




DNA after binding to the minor groove, which allows the interaction of activating or 
repressing cofactors to the promoter or regulatory regions of target genes. Thus, Sox 
proteins modulate the expression of downstream genes to correctly differentiate and 
preserve the distinct tissues and cell types (42). Besides SRY, three other members of 
the SOX family are expressed in the XY gonad but SOX9 was the first to be related to 
testis development.  
 
In mice, Sox9 is slightly expressed in the genital ridge at embryo day 10.5. 
Immediately after the onset of Sry expression in XY pre-Sertoli cells, expression levels 
of Sox9 increase. At this time Sox9 becomes sexually dimorphic as XX gonads decrease 
its expression levels. Up to date Sox9 is the only known target of SRY (2). 
 
Sox9 is also essential in the chondrogenic lineage specification and 
differentiation. Then, SOX9 loss-of-function alterations cause campomelic dysplasia 
(OMIM 114290), a condition characterized by skeletal defects and typical facies. 
Approximately 75% of 46,XY individuals present with campomelic dysplasia combined 
with complete or partial gonadal dysgenesis (2, 43). Furthermore, genomic 
rearrangements upstream the regulatory region of the SOX9 gene have been identified 
in a wide spectrum of DSD, including 46,XX T DSD and 46,XY OT DSD (44, 45). Studies in 
Oddsex mice showed sex reversal phenotypes when a 150Kb deletion occurred 
upstream Sox9 (46) and a testis-specific enhancer (TES) was found as a gene 
expression regulator. Sf1 and Sry bind the testis-specific enhancer core element 
(TESCO), located 13Kb upstream Sox9, to upregulate its expression. Once Sox9 is 
increased, it displaces Sry and synergizes with Nr5a1 to regulate its own expression by 
a positive feedback loop (47). This positive regulatory loop occurs via Fgf9 (Fibroblast 
growth factor 9), which in turn activates the FGF receptor 2 (Fgfr2) and Prostaglandin 
D synthase (Ptgds), resulting in the secretion of Prostaglandin D2, Amh or Vnn (Vanin 
1) (48, 49). Other genes have been identified downstream Sry and Sox9 and might act 
as potential targets of these, but evidence is still insufficient. On the other side, Sox9 
represses the WNT4/FOXL2 pathways, involved in the ovarian formation. Fgf9/Wnt4 
double mutant XY mice developed male gonads which indicated that the principal role 
of Fgf9 is to repress Wnt4 (50). 
 
Studies in murine models have suggested that Sox9 could effectively replace Sry 
as the sex-determining gene. Transgenic Sox9 XX mice developed testes while KO XY 
embryos led to the formation of ovaries. Moreover, specific annulation of the gene in 
Sertoli cells resulted in normal testicular development and fertile mice (46, 51). This 
phenomenon may be due to the functional redundancy amongst the Sox gene family 
members, which means that functionality of the Sertoli cells might have been rescued 





SOX8 and SOX10 are also expressed in the XY gonad. In mouse model, Sox8 is 
expressed in the testis cords at embryo day 13.5 and in vitro it upregulates the 
expression of anti-Müllerian hormone (Amh). Sox8-deficient male mice have abnormal 
Sertoli cells and infertility, but normal male internal structures (22, 52). Moreover, 
SOX8 variants have been recently described in a range of reproductive anomalies (53). 
In contrast, Sox8 and Sox9 double KO mice lack testis cord, which supports the 
functional redundancy between these two proteins in testicular differentiation, either 
by the mediation of the HMG-box or to the inadequate expression of HMG-box 
proteins (42). The transgenic expression of Sox10 in XX gonads has resulted in the 
development of testes and male phenotype, suggesting that Sox10 is able to activate 
transcriptional targets of Sox9 (2). On the other hand, SOX3 a single-exon gene located 
on the X chromosome is expressed in brain and gonads. Studies in animal models 
demonstrated that Sox3-null female mice were able to develop defective ovaries while 
male mice (-/Y) developed testes with loss of germ cells and disruption of seminiferous 
tubules. They conclude that Sox3 is important for testicular differentiation and 
gametogenesis (54). In humans, SOX3 gene variants have been identified in X-linked 
mental retardation (OMIM 309530) and in a 46,XX DSD patient with bilateral ovotestes 
(55). 
 
1.2.3. Fibroblast growth factor 9 (FGF9) 
 
The FGF9 gene encodes a member of growth factors critical in cell proliferation, 
survival, migration and cell differentiation (22). It is expressed after Sry in the 
bipotential gonad. Studies with Fgf9-deficient mice have shown different results, 
either a male to female sex-reversed phenotype or mutant mice that died with 
gonadal abnormalities after birth (56). Some data support that Sry and Nr5A1 begin 
the upregulation of Sox9, increasing the expression of Fgf9 which in turn further 
increases Sox9 expression (48). Therefore, in the absence of Fgf9, the expression of 
Sox9 is not maintained, and Sertoli cells don’t differentiate. Then, the balance between 
Fgf9 and Wnt4 favours to female development  
 
The molecular function of FGF9 is mediated through its receptor FGFR2, which 
is embedded in the membrane of progenitor Sertoli cells. Although an important 
crucial role of both genes is suspected in human sex development, a single variant in 
FGFR2 has been identified in a patient with 46,XY sex reversal and craniosynostosis 
(57) and a FGF9 gain of copy number in a 46,XX male with elevated FSH (Follicle 
Stimulating Hormone) level, low testosterone and ambiguous genitalia (58). 
 
1.2.4. Nuclear Receptor Subfamily 0 Group B Member 1 (NR0B1) 
 
The NR0B1 gene encodes DAX1 (DSS-AHC, dosage-sensitive sex reversal, 




chromosome Xp21.2, which is an orphan nuclear hormone receptor. The carboxil-
terminal region of the protein, shows similarities to ligand-binding domain of other 
nuclear receptors and contains twelve helices, whereas the N-terminal represent a 
domain involving 3.5 repeats of a 65 to 67 amino acid motif with two putative zinc 
fingers, which possibly act as nucleic acid-binding domain (41). DAX1 acts throught the 
retinoic acid receptor as an inhibitory protein of the SF1 nuclear receptor, estrogen 
receptor and androgen receptor (59).  
 
In humans, loss-of-function mutations or deletions of NR0B1 results in patients 
with X-linked congenital adrenal hypoplasia (AHC, OMIM 300200) and 
hypogonadotropic hypogonadism (HH). Patients with AHC have poorly differentiated 
adrenal gland after fetal stage and present with steroidogenesis disturbances and a 
disorganized testis cord (59). On the other side, duplications of NR0B1 have been 
shown to cause 46,XY gonadal dysgenesis and a female phenotype (60).  
 
It has been proposed that DAX1 functions as a dosage-based mechanism. In 
46,XY males, NR0B1 is maintained inactive by SRY and the testicular differentiation 
pathway continues. When duplications occurs, SRY is not enough to block the amount 
of DAX1 and the female pathway is followed after DAX1 has repressed testis-specific 
enhancer (TES), the enhancer of SOX9, and the testicular formation is stopped. Lack of 
testosterone and AMH blocks development of external genitalia and the regression of 
Müllerian ducts (59).  
 
As mentioned, NR0B1 also promotes the ovarian pathway and loss-of-function 
heterozygous and homozygous nonsense mutations in XX individuals have been 
associated with delayed puberty and hypogonadotropic hypogonadism (61, 62), which 
disagrees with mouse modelling studies. Due to the dimorphic expression between 
ovary and testis NR0B1 was considered an “anti-testes” gene. It has been indicated 
that DAX1 inhibits the interaction of SF1 and WT1 and thus, reduces the activation of 
SOX9, which blocks steroidogenesis and the production of anti-Müllerian hormone 
(59). 
 
This was validated when Dax1-/Ypos murine models, testes were not 
differentiated due to Sox9 low levels and absence of Amh (63), suggesting that Sry and 
Dax1 may act to upregulate Sox9. These genetic males had female external and 
internal genitalia. SRY and DAX1 interact in early development of the gonadal ridges 
and are expressed in both testicular and ovarian tissue. In the absence of Nr0b1 male 
mice showed complete gonadal sex reversal, suggesting its role in testicular 
determination (64). After sex-determining period, Dax1 is downregulated in the testes 
to be upregulated again at 17.5 days post-conception. This break is necessary for the 




both important in the testicular development (65). In differentiating ovaries, Dax1 is 
upregulated downstream Wnt4, which indicates that Dax1 support Sry (66).  
 
1.2.5. GATA binding protein 4 (GATA4) and Friend of GATA 2 (FOG2) 
 
The role of GATA4 in male sex determination has been explained before (See 
1.1.3, page 6). 
 
FOG2 is a zinc finger cofactor that binds the N-terminal zinc finger of the GATA4 
protein and acts as a transcriptional coactivator or corepressor. Fog2 (or ZFPM2, Zinc 
Finger Protein, FOG Family Member 2) is co-expressed with Gata4 in XY gonad during 
Sertoli cell formation and although the exact mechanism is unknown, the physical 
interaction between Gata4 and fog2 proteins is needed for testicular development 
(67). Indeed, an impaired interaction between GATA4 and FOG2 was reported in a 
46,XY DSD patient presenting with a missense variant in the zinc finger of GATA4 (27). 
In humans, mutations in the FOG2 gene have demonstrated to cause 46,XY DSD due to 
modulation of the expression of target genes involved in testes development (67). It 
was found that Fog2-null mice died before embryo day 15.5 with a complex cardiac 
defect, failure of testis differentiation and reduced gene expression, such as those 
required for Sertoli cell differentiation and Leydig cell function. Moreover, 
haploinsufficiency of either Gata4 or Fog2 is sufficient to induce gonadal sex-reversal 
in murine model.  
 
1.2.6. Desert Hedgehog (DHH) 
 
DHH, located on 12q12 and encoding a 396-amino acid protein, is a member of 
the hedgehog family of signalling molecules. Among them, Dhh is expressed at 11.5 
days post-conception in Sertoli cell precursors, after the expression of Sry had begun. 
This protein is also expressed in Schwann cells, vascular endothelium, endocardium 
and seminiferous epithelium of the mouse embryo (39) and no expression has been 
detected in female gonads. Dhh-/- mutant mice were sterile and showed abnormal 
peripheral nerves (68). Dhh signalling is also required for the upregulation of Nr5A1 
and receptor Patched 1 (Ptch1) expression in Leydig cells (69). Several mutations have 
been associated with complete or partial 46,XY gonadal dysgenesis (22, 69). 
 
1.2.7. Doublesex and Mab-3 Related Transcription Factor 1 (DMRT1) and 2 
(DMRT2) 
 
DMRT1 protein is a transcription factor with a DNA-binding domain similar to a 
zinc finger, named DM (DNA-binding motif) domain. In mice, Dmrt1 is expressed in the 
primordial gonads of both sexes at 10.5 days post-conception (dpc). Later it is only 




whereas its expression is decreased in the ovary. In humans, DMRT1 is expressed in 
undifferentiated XY gonadal primordium at 6 weeks of gestation and in Sertoli cells 
between gestation weeks 8 to 40. During childhood and postpuberty it is also 
abundant in spermatogonia. At about gestation week 20, it has been detected in 
oogonia and oocytes but is downregulated when germ cells enter at meiosis (70). 
 
Studies in mice revealed that the gene important in the maintenance and 
growth of the testis in the postnatal and adult period, whereas in humans is required 
for the development of the testis during foetal period (71). DMRT1 is involved in sex 
determination and gonadal development across a broad range of species. In humans, 
the role of DMRT1 in male sex determination was confirmed when subtelomeric 
deletions causing sex reversal and gonadal dysgenesis in 46,XY individuals, were 
mapped to gene location 9p24.3. 
 
In mice, Dmrt1 activated testis-promoting genes including Sox9, Sox8 and 
Ptgds, and repressed ovary-promoting genes such as Foxl2, Wnt4 and Rspo1, as well as 
retinoic acid (RA) signalling and its feminizing effects (70, 72). Moreover, it has been 
shown that the loss of Dmrt1 in mouse Sertoli cells activates Foxl2, and thus, Sertoli 
cells differentiate to Granulosa and theca cells, with its consequent oestrogen 
production (73). Dmrt1-/- mice showed postnatal defects in testis maturation and germ 
cells died at 7 dpc. This gene may not have a critical role in the early stages of 
gonadogenesis in mice, however the default in germ cell migration and survival is 
related to the expression pattern in both somatic and germ cell types. 
 
Further analysis of the 9p locus showed that DMRT2 also maps to 9p24.3. The 
two DMRT1 and DMRT2 are 80% identical in the core region of the DM domain and are 
expressed in testis, suggesting that it might potentially be involved in 9p sex reversal. 
Although it was not believed to be a common cause of 46,XY sex reversal, it has been 
probed that deletions in 9p include the removal of both DMRT1 and DMRT2 genes 
(71). Individuals with distal monosomy 9p presented with both normal or ambiguous 
external genitalia and varying degrees of mixed gonadal dysgenesis, including fibrous 
streak gonads, hypoplastic testicles, or ovotestes (74, 75).  
 
1.2.8. a-Thalassemia/Mental retardation X-linked gene (ATRX) 
 
The ATRX protein is a member of the SW1/SNF (SWItch/Sucrose Non-
Fermentable) DNA family, involved in chromatin remodelling. It is  a nuclear protein 
found at heterochromatic structures, such as pericentromeric heterochromatin and 
ribosomal DNA (rDNA) repeats. These repeat elements are essential for the 
transcriptional regulation. ATRX modulates gene expression by binding to G-rich 




diverse gene expression levels could explain the phenotypic variability observed within 
families with the same mutation (39). 
 
The amino-terminal of the ATRX protein is an ATRX-DNMT3-DNMT3L (ADD) 
domain with a plant homeodomain-like zinc finger. In the middle of the protein lies the 
helicase/adenosine triphosphatase (ATPase) domain that displays nucleosome-
remodelling activity. Most of the mutations described so far, lie in the helicase and 
ADD domain. Mutations in this last region are associated with more severe 
psychomotor impairments. The C-terminus encodes the conserved P-box domain, 
involved in transcriptional regulation and a Q-box responsible for protein interaction. 
This region seems to be in charge of the urogenital formation. Patients lacking this C-
terminal region have severe urogenital anomalies such as female external genitalia 
with streak gonads or ambiguous genitalia (76). 
 
Mutations in this gene cause alpha-thalassemia/mental retardation syndrome 
X-linked (ATR-X, OMIM 301040), a sex-linked condition characterized by alpha-
thalassemia, psychomotor retardation, distinct dysmorphic facies, skeletal, renal and 
cardiac anomalies, as well as genital abnormalities (76). Testicular irregularities are 
present in 80% of the XY patients, ranging from complete gonadal dysgenesis to mild 
hypospadias or micropenis. Histopathological analysis of dysgenetic testis in two ATRX 
positive patients confirmed its function after sex determination, possibly during 
neonatal period (77).  
 
1.2.9. Anti-Müllerian hormone (AMH) and its receptor AMHR2 
 
AMH is a member of the transforming growth factor-b family and is released by 
immature Sertoli cells at sex differentiation in foetal life. AMH expression begins in the 
pre-Sertoli cells, declines in the perinatal period and is highly maintained until Sertoli 
cells are mature in puberty. In females, its expression begins during the perinatal 
period and remains low in Granulosa cells until menopause (39). AMH is coded by a 5-
exon gene located on 19p13.3 (78) and is translated as a dimeric precursor comprising 
2 polypeptide chains, containing a large N-terminal fragment important for the correct 
folding of the protein, and smaller C-terminal mature domain.  
 
In contrast, AMHR2 (Anti-Müllerian Hormone Receptor Type 2) gene, located 
on 12q13 contains 11 exons and codifies for a protein with an intracellular domain 
with serine/threonine kinase activity, a transmembrane domain and an amino-
terminal extracellular domain that binds AMH.  
 
Anti-Müllerian hormone is responsible for regression of the female Müllerian 
ducts during male sex differentiation and mutations in AMH or its receptor AMHR2 




factors NR5A1, SOX9, GATA4 and WT1 regulate the transcription of AMH through a 
critical DNA-binding region on its minimal promoter. In mice, SOX9 demonstrated to 
be essential to start Amh expression, whereas NR5A1 interacts with either SOX9 or 
WT1 through its DNA-binding domain to upregulate Amh transcripts. GATA4 alone or 
together with NR5A1 upregulates the expression of AMH too. On the other side, 
NR5A1 can cooperate physically with DAX1 to repress the expression of AMH, but with 
lower affinity compared to NR5A1-WT1. In women, AMH has an important role as an 
ovarian reserve marker (79).  
 
1.2.10. Mitogen-activated protein kinase pathway (MAP3K1) 
 
The mitogen-activated protein kinase (MAPK) pathway was linked to the early 
stages of male gonadal development when the Map3k4 (Mitogen-Activated Protein 
Kinase Kinase Kinase 4) gene responsible for a male to female sex reversal in XY mice 
was discovered by Bogani et al. Moreover, expression analysis in Map3k4 KO models 
showed a decrease of Sox9 and Sry production which lead to the absence of Sertoli 
cells and the development of ovaries (80).  
 
Later, sequencing analyses revealed gain-of-function mutations in the MAP3K1 
(Mitogen-Activated Protein Kinase Kinase Kinase 1) gene in patients with streak gonads 
and female genitalia (12, 81, 82). In mice, Map3k1 is expressed during testicular 
development at embryo day 11.5 but KO mice do not have testicular abnormalities. 
The molecular mechanism behind the gain-of-function mutations in humans differs 
from mouse models. Mutations in MAP3K1 gene stimulate the ovarian-determining 
pathway, resulting in augmented β-catenin, WNT4 and FOXL2 expression and 
decreased SRY and SOX9 (82). 
 
1.2.11. Insulin receptor tyrosine kinases and insulin-like growth factors 
 
Insulin and insulin-like growth factors (IGFs) are also involved in cell regulation 
during embryonic and postnatal development and mediate their functions by 
membrane-associated tyrosine kinase receptors. Genes codifying for Insr (Insulin 
receptor), Igf1r (Insulin-like growth factor type 1 receptor) and Insrr (Insulin receptor-
related protein) are necessary for testicular determination pathway. Triple 
(Insr/Igf1r/Insrr) KO XY mice showed complete male-to-female sex reversal and 
reduced expression levels of Sry and Sox9 (83). Later, it was demonstrated that only 
Insr and Igfr1 were involved in genital ridge (GR) development and its absence is 
enough to cause the XY sex reversal phenotype (84). These mice embryos showed 
delayed Sry expression at embryo day 11.5, downregulation of several genes and 
delayed ovarian differentiation until embryo day 16.5. Genes which expression was 
decreased were Wt1, Lhx9, Nr5a1, Gadd45g and Wnt4, indicating the influence of 





In humans, sequence variants in these genes have not been described in DSD. 
 
1.2.12. Testis-Specific Y-Encoded-Like Protein 1 (TSPYL1) 
 
The TSPYL1 protein is a member of the TSPY/TSPYL/SET/NAP-1 (Testis-specific 
protein Y-encoded, Testis-specific protein Y-encoded like, Drosophila proteins 
Su(var)3-9, Enhancer-of-zeste and Trithorax, Nucleosome assembly protein 1) family of 
chromatin modifiers. Its expression is limited to male germ cells and contains a NAP 
and SET domain that interact with cyclin B to regulate the cell cycle. Actually, NAP 
domain containing proteins act as histone chaperones to control chromatin and 
nucleosome assembly and control gene expression of a variety of proteins, like HMG 
box containing proteins SRY, SOX8 and SOX9 key elements. This fact may propose the 
mechanism whereby TSPYL1 causes defects in testicular development (85). 
 
Variants in TSPYL1 were recognized in an autosomal recessive syndrome called 
Sudden infant death with dysgenesis of the testes (SIDDT, OMIM 608800) (86). 
Affected males presented with either 46,XY partial or complete gonadal dysgenesis at 
birth and developed later viscero-autonomic dysfunction followed by death. Sexual 
development in 46,XX individuals was normal (86). Further studies associated TSPYL1 
gene variants with isolated testicular dysgenesis (85).  
 
1.2.13. Mastermind-like domain-containing 1 (MAMLD1)  
 
MAMLD1 was firstly identified as the responsible gene for X-linked myotubular 
myopathy (MTM1, OMIM 310400) and abnormal genitalia in two patients with a 
deletion in Xq28. MAMLD1 acts as a transcription factor by transactivating the 
promoter of the non-canonical Notch targeted Hes promoter, and increases 
testosterone through the regulation of SF1. The possible role in sex differentiation was 
probed when studies in mouse models showed increasing Mamld1 expression in fetal 
Sertoli and Leydig cells at embryo day 12.5 to E14.5. Moreover, Mamld1-null mice 
showed reduced testicular expression of Cyp11a1, Cyp17a1, Hsd3b1, Star and Insl3, all 
Leydig-cell specific genes, although external genitalia and reproduction capacity was 
normal (13)(87).  
 
In humans, MAMLD1 sequence variations have been detected in 46,XY DSD in 
patients with a broad range of mild to severe phenotypes (87). A role in ovarian 
development was also suggested after a gain-of-function mutation was found in a 
46,XX DSD woman with virilization (88). However, further evidence has questioned 
whether MAMLD1 gene variants are able to explain the DSD phenotype. Besides the 
MAMLD1 variants found in normal population (89) and the aforementioned KO mice 




MAMLD1 mutations compared to Wt (87, 89-91). In fact, an oligogenic mechanism 
explaining the phenotype in MAMLD1 positive patients has been recently published 
(91). 
1.2.14. WW Domain-Containing Oxidoreductase (WWOX)  
 
WWOX (Tryptophan, Tryptophan Domain-Containing Oxidoreductase) gene is 
located at 16q23.1-q23.2 and is a tumour suppressor gene with causative 
rearrangements described in several cancers. This gene encodes a protein with two 
WW domains at the amino-terminal and a short chain oxidoreductase (SDR) domain in 
the middle, thought to have a role in steroid metabolism. The WW domains are 
involved in protein-protein interactions. KO mouse models showed defects of Leydig 
cell function. This is possibly explained because WWOX inhibits the Wnt/β-catenin 
pathway in a dose-dependent manner, even though this inhibition is reduced when 
the SDR domain is eliminated. In humans, WWOX is expressed in pituitary, testis and 
ovary and has been suggested to have a role in gonadotrophin or sex-steroid 
biosynthesis (92). Missense variants as well as duplications and exon deletions have 
been identified in 46,XY DSD patients with ambiguous genitalia and in a 46,XX DSD 
patient that was referred with primary amenorrhea and hypergonadotropic 
hypogonadism (92, 93). 
 
 
1.3. PATHWAYS INVOLVED IN THE DETERMINATION OF THE FEMALE GONAD  
 
Although the noteworthy increase in the identification of the essential 
regulatory genes associated with ovarian development, little is known compared to 
testicular formation.  
 
Female development has been considered the passive pathway in mammals, 
since the removal of male embryonic gonads before sex determination or the loss-of-
function mutations in early gonad genes led to a female phenotype (2). In the last 
years, genetic factors involved in ovarian development have been identified and it has 
become apparent that both male and female pathways actively suppress the alternate 
state to maintain the somatic sex identity of the gonad as either male or female.  
 
In the absence of SRY gene, the undifferentiated gonad activates a signalling 
pathway responsible for commitment to an ovarian fate. Ovarian sex determination 
requires Rspo1/Wnt4/b-catenin and Foxl2 signalling pathways. 
 
1.3.1. Rspo1/Wnt4/b-catenin signalling pathway 
 
WNT4 (Wingless-type MMTV integration site family member 4) and RSPO1 (R-




essential for starting the ovarian development (94). In mouse models, the activation of 
b-catenin in male gonads promoted ovarian development, leading to XY sex reversal, 
while conditional ablation of Ctnnb1 (Catenin B 1 gene) in XX somatic cells did not 
interrupt ovarian differentiation, suggesting that the loss of the Ctnnb1 causes sex 
reversal when happening in both somatic and germ cells (95).  
 
 Rspo1 and Wnt4 expression is increased in the ovary at embryo day 12.5 and 
although both are secreted by the somatic cells, Rspo1 has been detected in the 
membrane of germ cells too. In mice, loss-of-function mutations in either Rspo1 or 
Wnt4 cause complete or partial XX sex reversal and ovotestes (96). In Wnt4-deficient 
mice the expression of Rspo1 remains undamaged, whereas in Rspo1-null mice Wnt4 
expression is absent. Thus, Rspo1 might collaborate with Wnt4 in a linear pathway to 
stabilize b-catenin. Igfr1 expression is also diminished in these deficient mice, 
suggesting that feedback interactions may exist between these two signaling 
pathways. Rspo1 and Wnt4 also contribute in the early coelomic proliferation and 
double mutant null mice display a significant reduction in cell proliferation between 
embryo days 10.5 and 11.5 (97). 
 
In humans, mutations in RSPO1 are associated with a syndrome characterized 
with palmoplantar hyperkeratosis, predisposition to squamous cell carcinoma and 
46,XX DSD (98). Regarding WNT4, dominant heterozygous mutations have been 
reported in association with anomalies of Müllerian structures, androgen excess and 
different virilization degrees (97). A homozygous mutation was found in three XX 
foetuses with an embryonic lethal syndrome (SERKAL, OMIM 611812) encompassing 
female-to male sex reversal and kidney, adrenal and lung dysgenesis (99). 
  
RSPO1 and WNT4 activate other backup pathways that ensure the ovarian fate, 
including the insulin signalling pathway, Runx1 gene (Runt-related transcription factor 
1), which maintains Wnt4 expression (100), Fst (Follistatin) and Bmp2 (Bone 
Morphogenetic Protein 2. 
 
1.3.2. Forkhead transcription factors  
 
FOXL2 (Forkhead Box L2) is part of the forkhead box family of transcription 
factors and is required to maintain the ovarian phenotype at the postnatal stage. In 
mice, Foxl2 is one of the earliest markers of ovarian development, however in Foxl2-/- 
mice the male differentiation pathway is started in the ovaries, where cells acquire the 
Sertoli cells’ characteristics and Sox9 expression is observed (101). Similarly, lack of 
Dmrt1 in Sertoli cells resulted in the upregulation of Foxl2 and transdifferentiation into 
Granulosa and theca cells (73). These data support the hypothesis that the 






 In human, FOXL2 protein is expressed in the mesenchyme of developing 
eyelids, fetal and adult Granulosa cells of the ovary, in the developing pituitary and 
adult gonadotroph and thyrotroph cells. FOXL2 heterozygous mutations are 
responsible for the blepharophimosis ptosis epicanthus inversus syndrome (BPES, 
OMIM 110100), a dominant condition characterized by palpebral malformations 
associated with premature ovarian failure (POF). For the moment few sequence 
variants have been found in patients with POF (101). Although FOXL2 does not play a 
central role in sex differentiation in humans and mice, it seems to regulate the 
maintenance of gonad fate. Chromatin immunoprecipitation experiments showed that 
TESCO element, which regulates the expression of Sox9, is reactivated after deletion of 
Foxl2. Moreover, FOXL2 antagonises Wt1 and represses the expression of Sf1 (102).  
 
Other forkhead transcription factor demonstrated to have a role in ovarian 
function is FOXO3 (Forkhead Box O3). This function was highlighted when Foxo3a 
female KO mice showed early formation of ovarian follicles, followed by oocyte death 
and infertility (101), whereas constitutive expression of the gene demonstrated to 
cause delay in follicular development, oocyte growth and finally infertility. Further 
studies, revealed that Foxo3a reduced the expression of Bmp15 (Bone Morphogenetic 
Protein 15) (103). Although few gene variant have been found in POF presenting 
patients the pathologic role of FOXO3 remains unknown (101). 
 
In addition to these genes necessary for the determination of the ovary, other 
genes are required for the ovarian follicle development and are reviewed later (See 
1.4.5, page 33).  
 
 
1.4. SEX DIFFERENTIATION  
 
In the developing gonads Sertoli and Granulosa cells activate the formation of 
the steroidogenic Leydig (XY gonad) and theca (XX gonad) cells, which produce the 
necessary hormones for the subsequent correct differentiation of the fetus. The 
steroid hormones responsible for the phenotype of internal and external genitalia, as 
well as other reproductive tissues, are called androgens in males and oestrogens in 
females. At this time two duct precursor systems, the mesonephric (Wolffian) and the 
paramesonephric (Müllerian) co-exist, as well as two mesodermal swellings that 
develop to the urethral folds and labioscrotal swellings (8). These precursor structures 
differentiate into the internal and external genitalia under the influence of hormones 
secreted by the developing gonad. 
 
Sertoli cells begin the secretion of anti-Müllerian hormone which promotes the 




the stimulation of Leydig cells, via a hedgehog signalling pathway. AMH expression has 
been detected by the 9th week of gestation (104). Leydig cells produce androgens and 
insulin-like peptide 3 (INSL3) at 8-9 weeks of development. Androgens released by the 
testes, lead to the formation of male internal (epididymis, vas deferens, seminal 
vesicle) and external genitalia (penis, scrotum). Testosterone is responsible of 
developing Wolffian duct into male internal structures while INSL3 stimulates 
testicular descent. Furthermore, 5a-reductase enzyme transforms testosterone to 
dihydrotestosterone (DHT), promoting the development of the penis, scrotum and 
prostate (105). Defects in testosterone and dihydrotestosterone biosynthesis and the 




Steroid hormone biosynthesis comprises mineralocorticoid, glucocorticoid and 
sex steroid production from cholesterol in the adrenal glands and sex steroid 
production in the ovaries and testes (Figure 4). All steroidogenic processes take place 
in the adrenal cortex, where each zone is responsible for the synthesis of a specific set 
of steroid hormones, the mineralocorticoids in the outer zona glomerulosa, 
glucocorticoids in zona fasciculata, and androgen precursors, androstenedione and 
dehydroepiandrosterone (DHEA) in zona reticularis (106). Steroid production is 
regulated by external stimuli, such as adrenocorticotropic hormone (ACTH) released in 
the anterior pituitary. ACTH regulates cortisol synthesis and increases slightly 
mineralocorticoid and adrenal androgen synthesis  via the cAMP (cyclic Adenosine 
monophosphate) mediated protein kinase A (PKA) pathway which activates StAR 
protein and SF1 (107), as well as angiotensin II and potassium, which selectively 
increase mineralocorticoid synthesis via protein kinase C (PKC) pathway. In parallel, 
the transcription of steroidogenic genes (CYP11A1, HSD3B2, CYP17A1, CYP21A2, and 
CYP11B1) and co-factors relevant to glucocorticoid synthesis increases.  
 
Enzymes involved in steroidogenesis can be divided into two major groups: 
cytochrome P450 (CYP) and hydroxysteroid dehydrogenases/ketosteroid reductase 
(HSDs/KSR). Cytochrome P450 enzymes are a group of oxidative enzymes that contain 
a heme group. They are termed depending on their intracellular localization and the 
mechanism by which they obtain electrons from NADPH (Nicotinamide adenine 
dinucleotide phosphate hydrogen). Type 1 are targeted in the mitochondria and 
receive electrons from ferredoxin and ferredoxin reductase, whereas type 2 are 
targeted to the endoplasmic reticulum and get electrons from P450 oxidoreductase 
(POR) Each P450 enzyme can metabolize more than one substrate and is involved in 
broad steps of oxidations in steroidogenesis. Six enzymes take part in steroidogenesis. 
Mitochondrial P450 cholesterol side-chain cleavage (scc) enzymes (encoded by 
CYP11A1) catalyse 20,22-desmolase activities, isozymes P450c11 (CYP11B1) and 




18-hydroxylase and 18-methyl oxidase activities. In the endoplasmic reticulum 
P450c17 (CYP17A1) catalyses both 17a-hydroxylase and 17,20-lyase activities, P450c21 
(CYP21A2) catalyses 21-hydroxylation in the synthesis of glucocorticoids and 
mineralocorticoids, and P450 aromatase (CYP19A1) the aromatization of androgens to 
oestrogens. The regulation of the steroidogenesis is quantitatively determined by the 
production of these enzymes, especially P450scc. On the other side, HSD/KSR enzymes 
catalyse in vitro reversible reactions whereas, in vivo they continue in an oxidative or 
reductive mode. They are classified into dehydrogenases, which oxidize 
hydroxysteroids to ketosteroids using NAD+ (Nicotinamide adenine dinucleotide+) and 
reductases, which reduce ketosteroids to hydroxysteroids consuming NADPH cofactor. 
Relevant in steroid synthesis are the 3-HSD type 2 (HSD3B2), the 11-HSD type 1 and 
type 2 (HSD11B1 and HSD11B2), and some of 17-HSDs (108). 
 
 
Figure 4. Classic pathway of the adrenal and gonadal steroidogenesis. Arrows indicate chemical 
reactions and boxes are the enzymes involved in catalysing the respective reaction. Genes encoding the 
enzymes are adjacent to the boxes. Genes included in the panel are shown in dark grey. Modified from 
Häggström M., 2014 (109).  
 
 
Testosterone is required, as well as FSH, for optimal sperm production and 




involved in testosterone synthesis in Leydig cells, including 17,20-lyase which directs 
the biosynthesis of steroids toward the sex hormones. Meanwhile androstenedione is 
converted to testosterone by 17β-hydroxysteroid dehydrogenase (17β-HSD) type 3 or 
5 in Leydig cells (110), whereas type 2, found in prostate and placenta, performs the 
opposite reaction. Aromatase, which is expressed at low levels in Leydig, Sertoli, and 
germ cells converts testosterone to oestradiol. This step seems to be necessary for the 
correct initiation of spermatogenesis and mitosis of spermatogonia (111). 
Dihydrotestosterone (DHT) is the most potent androgen and is formed from 
testosterone by steroid 5α-reductase in the epididymis and prostate mainly. It has 
important physiological roles in maintaining sexual function.  
 
In the ovary, steroid hormones are produced for sexual and reproductive 
functions. Steroidogenesis takes place mainly in theca cells which produce 
progesterone and androgens that act as precursors for oestrogen synthesis in the 
Granulosa cells. Once androstenedione and testosterone diffuse into the cells, they are 
transformed to oestradiol, mainly via the action of aromatase and 17β-HSD types 1 
and 7 (110). During follicle maturation, LH and FSH upregulate aromatase and 
oestrogen synthesis increases. At this point ovulation is triggered due to the positive 
feedback created by oestrogens and responsible for the LH and FSH secretion. Then, 
follicle enters the luteal phase and develops to corpus luteum which predominantly 
synthesizes progesterone. The reduction of LH, aromatase expression and oestrogen 
production, as well as an increase in CYP11A1 and 3β-HSD activities, stimulate the 
synthesis of progesterone and the process of follicle rupture begins (112). 
 
Genetic variants in the genes involved in the initial steps of steroidogenesis 
(Figure 4) shared by the adrenal cortex and the gonads, affect synthesis of steroids in 
both organs and may lead to DSD and congenital adrenal hyperplasia (Table 1).  
 
Congenital adrenal hyperplasia (CAH) encompass a group of inherited 
autosomal recessive diseases characterized by impaired adrenal steroid synthesis and 
in some cases impaired gonadal steroid production with associated genital ambiguity. 
These inborn errors of steroidogenesis in which cortisol synthesis is impaired and the 
consequent overproduction of ACTH results in adrenal hyperplasia have been classified 
as CAH, being 21-hydroxilase (CYP21A2) deficiency the most common. But might also 
be caused by deficiencies of the following enzymes or cofactors: 17-hydroxylase 
(CYP17A1), 11-hydroxylase (CYP11B1), 3-HSD type 2 (3βHSD2), P450 oxidoreductase 
(POR), StAR (lipoid CAH) and P450 side-chain cleavage enzyme (CYP11A1). In the 
different types of CAH the adrenal steroidogenesis is interrupted at distinct points 
then, clinical manifestations are closely related to the type and severity of impairment. 













CF: Feminization, GI and infertility; 
NCF: HH. 
CF: absence of pubertal development and 




CF: Feminization and GI; NCF: none. 
CF: absence of pubertal development and 
POF. NCF: none. 
Yes  
3βHSD2 def (201810)/HSD3B2 CF: Undervirilization; NCF: None CF: Virilization; NCF: adrenarche, PCOS-like Yes  
17⍺OH and 17,20 lyase def 
(202110)/CYP17A1 
Feminization and GI Absence of pubertal development, GI. Rare 
Hypertension and hypokalemic 
alkalosis 
21OH def (201910)/CYP21A2 CF: precocious puberty; NCF: none. CF: Virilization; NCF: none. Yes Rapid skeletal growth 
11βOH def (202010)/CYP11B1 Precoious puberty Virilization Yes Hypertension 
P450 oxidoreductase deficiency 
(124015)/POR 
Feminization and GI Virilization, PCOS-like Variable 
Antley-Bixler syndrome in infants; 
Maternal virilization during 
pregnancy; changes in drug 
metabolism 
17βHSD3 def (264300)/HSD17B3 Virilization and gynecomastia at puberty None No  
Aromatase def (613546)/CYP19A1 None 
Virilization in newborns, delayed puberty, 
HH, multicystyc ovaries, primary amenorrhea 
at puberty. 
No 
Maternal virilization during 
pregnancy 
Steroid 5-⍺ reductase def 
(607306)/SRD5A2 
Virilization and gynecomastia at puberty None No  
CAH, congenital adrenal hyperplasia; CF, classic form; Def, deficiency; DSD, disorder of sex development; GI, gonadal insufficiency; HH, hypergonadotropic hypogonadism; 
HSD, hydroxisteroid dehydrogenase; LCAH, lipoid congenital adrenal hyperplasia; NCF, non-classic form; OH, hydroxylase; PCOS, Polycystic Ovary Syndrome; POF, primary 





An alternative pathway, called the “backdoor pathway” exists to activate androgen 
biosynthesis and might play a role in the physiology of CAH (106, 114). This pathway 
exemplifies a series of enzymatic reactions to transform 17-hydroxyprogesterone (17OHP) to 
dihydrotestosterone without testosterone as an intermediate. It seems to be active during 
fetal life in healthy individuals and might take part in male sex development (115). 
 
1.4.1.1. Steroidogenic Acute Regulatory Protein (STAR) 
 
Located on 8p11.23, codifies for the steroidogenic acute regulatory protein (StAR), 
which transports cholesterol from the cytosol to the inner membrane of the mitochondria 
where it becomes the substrate for the P450 side-chain cleavage/adrenodoxin/adrenodoxin 
reductase system (CYP11A1-FDX-FDXR) to be converted to pregnenolone (106). 
 
Variants in the STAR gene cause lipoic congenital adrenal hyperplasia (LCAH, OMIM 
201710), a severe disorder characterized by the impaired synthesis of all adrenal and 
gonadal steroid hormones due to loss of StAR action. It is believed to result from a two-hit 
event, a first genetic loss of steroidogenesis and the consequent cellular damage from the 
accumulation of cholesterol and cholesterol esters. Affected infants usually have adrenal 
insufficiency and the lack of gonadal steroid hormones leads to 46,XY DSD and infertility. 
46,XX females develop secondary sexual characteristics, anovulatory cycles and progressive 
hypergonadotropic hypogonadism later. A milder form of LCAH, called non-classic LCAH (NC-
LCAH) cause a partial loss of StAR activity in patients with primary adrenal insufficiency after 
infancy, including minimal mineralocorticoid deficiency. 46,XY cases have male external 
genitalia and mild hypergonadotropic hypogonadism (106). Most disease-causing gene 
variants are located between exons 5 and 7, encoding for C-terminal and the cholesterol 
binding site and are present in a homozygote or compound heterozygote state. In vitro 
studies have probed that mutations in the carboxil-terminal drive to diminished or absent 
function, while proteins lacking the N-terminal domain, including a mitochondrial target 
sequence, are able to stimulate steroidogenesis (116). 
 
1.4.1.2. Cytochrome P450 Family 11 Subfamily A Member 1 (CYP11A1) 
  
P450 cholesterol side-chain cleavage (P450scc) is the only enzyme that catalyzes the 
conversion of cholesterol to pregnenolone. It is expressed in the steroidogenic cell types of 
the adrenal, gonad and placenta, as well as in other tissues (106) and its transcription is 
regulated in a tissue-specific manner and hormonally, such as the action of SF1 in gonads 
and adrenal (117). 
 
The cytochrome P450scc is encoded by the CYP11A1 gene, which lies on 
chromosome 15q23-q24. It was thought that loss-of-function mutations in CYP11A1, 
required for the synthesis of progesterone would be incompatible with human gestation, 




birth, driving to a phenotype similar to LCAH with adrenal insufficiency and 46,XY sex 
reversal (118). In vitro analyses have shown that most mutants have enzymatic residual 
activity, although frameshift gene sequences have no activity (119). Clinical and biochemical 
findings in patients with LCAH due to STAR mutations or CYP11A1 are similar.  
 
1.4.1.3. Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-
Isomerase 2 (HSD3B2) 
 
The HSD3B2 gene in 1p12 is highly expressed in the adrenals and gonads. Deficiency 
in 3b-hydroxysteroid dehydrogenase type 2 (3βHSD2) causes reduced synthesis of 
progesterone and 17-hydroxypreogesterone, precursors of aldosterone and cortisol, 
respectively, as well as androstenedione, testosterone and oestrogens. In contrast, renin, 
ACTH and dehydroepiandrosterone (DHEA) are increased. The later DHEA is converted to 
testosterone by 3βHSD1 (3b-hydroxysteroid dehydrogenase type 1), which is expressed in 
placenta and peripheral tissues (120).  
 
Patients with HSD3B2 gene variants are characterized by impaired steroid synthesis 
in the gonads and adrenal glands, and variable clinical presentation depending on the 
alteration. Generally, severe forms result in salt-wasting phenotype caused by frameshift 
mutations, in-frame deletions, and nonsense mutations. On the contrary, missense variants 
retain a residual enzymatic activity and lead to a non-salt-wasting phenotype (121).  
 
Most patients present salt-wasting adrenal crisis in both sexes during childhood. High 
levels of androstenedione guide to relatively increased testosterone in females, but not in 
males. In 46,XY neonates, testosterone deficiency causes genital ambiguity, whereas in 
46,XX the relative high testosterone levels cause virilization with clitoromegaly and partial 
labioscrotal fusion. After childhood, females present with precocious puberty, acne, 
hirsutism and menstrual irregularities. Non-classic 3βHSD2 deficiency is extremely rare (121). 
 
1.4.1.4. Cytochrome P450 Family 17 Subfamily A Member 1 (CYP17A1) 
 
The CYP17A1 gene codifies for an enzyme with both 17α-hydroxylase and 17,20-lyase 
activities, principally in the adrenal and gonads. Hence, sequence mutation in the gene, 
located on 10q24.32, impair adrenal and gonadal sex steroid production (Figure 4), 
originating sexual infantilism and puberty failure (122).  
 
Deficient 17b-hydroxylase activity results in decreased cortisol synthesis, and 
elevated concentrations of 11-deoxycorticosterone (DOC) and corticosterone mediated by 
ACTH. The overproduction of DOC in the zona fasciculata causes sodium retention, 
hypertension and hypokalemia which suppress plasma-renin activity and aldosterone 
secretion in a variable mode and the presence of corticosterone prevents the adrenal crisis 




due to the obstruction of the dehydroepiandrosterone (DHEA), female patients are 
phenotypically normal with lack of pubertal development and adrenarche whereas 46,XY 
have absent or incomplete development of external genitalia. Both 46,XX and 46,XY patients 
present with hypergonadotropic hypogonadism, and low-renin hypertension. Among the 
identified alterations, 4 are recurrent (106) and include all type of changes in which all the 
enzymatic activity is impaired or reduced to 80%.  
 
Selective 17,20-lyase-deficiency has been reported and is caused by mutations in 
cytochrome b5, the cofactor needed to exert 17,20-lyase activity (120). 
 
1.4.1.5. Cytochrome P450 Family 21 Subfamily A Member 2 (CYP21A2) 
 
The CYP21A2 gene encoding for steroid 21-hydroxylase (21OH) lies in the middle of 
the HLA (Human leukocyte antigen) locus in 6p21, next to the nonfunctional pseudogene 
CYP21A1P. There is high degree of sequence similarity between these two genes, thus 
meiotic recombination is frequent and about 95% of cases with 21OH deficiency develop 
when CYP21A1P replaces the corresponding locus of CYP21A2 gene reducing the expression 
of the protein and its function (123).  
 
21-hydroxylase deficiency results in reduced glucocorticoid and mineralocorticoid 
formation and elevated 17-hydroxyprogesterone (17OHP), as well as other precursors. The 
lack of negative feedback of cortisol on ACTH (adrenocorticotropic hormone) production 
amplifies the adrenal androgen production. The severity of the CAH depends on the residual 
CYP21A2 function. Classic form of 21OH deficiency is divided in salt wasting and simple 
virilising depending on the severity of aldosterone insufficiency. Mutations that result in the 
salt wasting phenotype are completely inactivating and lead to an adrenal crisis if neonatal 
screening is not performed. Patients with simple virializing form retain 1-2% of the 
enzymatic activity and the neonatal crisis is prevented because minimal aldosterone is 
produced. In both forms, androgen excess results in virilization of external genitalia and 
rapid skeletal growth in 46,XX cases, and in males, simple virilizing form drives to precocious 
puberty as well as rapid skeletal growth. In the non-classic form, about 50% of the enzyme 
activity is maintained and do not show adrenal insufficiency. Patients might have partial 
glucocorticoid deficiency and present with milder androgen excess or asymptomatic. 
Females have normal genitalia (124). 
 
In patients with CYP21A2 sequence variants, the “backdoor pathway” contributes to 
the virilization of female external genitalia through a 17OHP excess. The pathway is reduced 








1.4.1.6. Cytochrome P450 Family 11 Subfamily B Member 1 (CYP11B1)  
 
CYP11B1, located on 8q24.3, encodes the steroid 11b-hydroxylase, which converts 
the 11-deoxycortisol to cortisol and deoxycorticosterone to corticosterone in the adrenal 
zona fasciculata under the regulation of ACTH. Mutations in CYP11B1 results in reduced 
corticosterone and cortisol synthesis, with successive ACTH and androgens increase. 
Elevated levels of deoxycorticosterone after neonatal period inhibit the renin-angiotensin 
system and drive to extracellular fluid volume expansion, hypertension, diminish plasma-
renin activity and low aldosterone concentrations. The hypertension, rather than salt loss is 
the clinical difference between patients with 11b-hydroxylase and 21-hydroxylase 
deficiency. Affected females are virilized due to fetal ACTH excess. Although mutations in 
CYP11B1 usually result in classic CAH phenotype because an absent or minimal enzyme 
activity, sequence variants causing the non-classic form have also been described (106).  
 
1.4.1.7. Cofactor defects: Cytochrome P450 Oxidoreductase (POR) and 
cytochrome b5 (CYB5) 
 
Cytochrome P450 Oxidoreductase (POR) plays a key role in electron transport in the 
endoplasmic reticulum, and several enzymes including 17α-hydroxylase, 21-hydroxylase, and 
aromatase depend on POR as a cofactor. Although POR-null mice die in utero (106), some 
enzymatic function is retained in humans and patients present CAH with DSD in both sexes. 
Deficiency is characterized by partial fail of P450c17 activity, with or without associated 
deficient activity of P450c21 and P450 aromatase. The phenotypes vary from women with 
amenorrhea and polycystic ovaries, virilized 46,XX newborn or androgen deficiency in 46,XY 
newborn to important hormone disturbances that lead to abnormal genitalia in both sexes. 
Additionally, the “backdoor pathway” of androgen synthesis contributes to the prenatal 
virilization of affected females (126). Mineralocorticoid deficiency is not observed in these 
patients because 17α-hydroxylase increases production of mineralocorticoid intermediates, 
thus affected adults might develop hypertension (24, 127). POR acts as an electron donor of 
other not steroidogenic enzymes and skeletal dysplasia and changes in drug metabolism is 
often observed in patients (128). Moreover, newborns with POR deficiency sometimes have 
a skeletal defect called Antley–Bixler syndrome (ABS, OMIM 201750), which is characterized 
by craniosynostosis, brachycephaly, radio-ulnar or radio-humeral synostosis, bowed femora, 
arachnodactyl, midface hypoplasia, proptosis and choanal stenosis (129).  
 
Regarding cytochrome b5 (CYB5), it facilitates the allosteric interaction between POR 
and CYP17A1. A missense and a premature stop coding CYB5A (Cytochrome B5 Type A) gene 
variants have been found in 46,XY DSD cases, all with low androgens and gonadal defect but 




1.4.1.8. Hydroxysteroid 17-beta dehydrogenase 3 (HSD17B3) 
 
HSD17B3 gene, localized in 9q22.32, encodes the 17b-HSD3 (17β-Hydroxysteroid 
dehydrogenase) enzyme. It is mainly expressed in male gonad and reduces DHEA and 
androstenedione to serve as precursors of testosterone (130, 131). In contrast, estrogens 
are poor substrates for the human 17bHSD3 enzyme. The enzymatic deficiency is caused by 
homozygous or compound heterozygous variants in HSD17B3 and is characterized by 
reduced sex hormones production and normal adrenal secretion of glucocorticoids and 
mineralocorticoids.  
 
Only 46,XY infants with a 17bHSD3 deficiency manifest a DSD. The scarce amount of 
produced testosterone during fetal development is suggested to be sufficient to trigger male 
internal genitalia, or alternatively other 17bHSD isoenzymes are able to synthesize 
testosterone from androstenediones, but not enough to compensate the deficiency. 46,XY 
children with 17bHSD3 deficiency present completely undervirilized with a blind vaginal 
pouch and undescended testes or varying degrees of hypospadias and micropenis with intra-
abdominal or inguinal testes. Wolffian derivatives including the epididymides, vas deferens, 
seminal vesicles, and ejaculatory ducts are present (131).They are mostly assigned as 
females when born. As in patients with SRD5A2 gene variants, these children begin to virilize 
at puberty (131). 46,XX with mutations in HSD17B3 show a female phenotype and produce 
normal levels of androgens and estrogens, which suggests that testosterone is produced in 
the ovary even in the absence of 17bHSD3 enzyme expression (106).  
 
The clinical presentation is not different from that of partial androgen insensitivity 
syndrome (PAIS) and 5a-reductase type 2 deficiency, thus molecular testing supports the 
diagnosis. Biochemical diagnosis is based on a low testosterone/androstenedione ratio 
(T/A<0.8). 
 
1.4.1.9. Cytochrome P450 Family 19 Subfamily A Member 1 (CYP19A1) 
 
The P450aro or aromatase is encoded by CYP19A1 gene on chromosome 15q21.1. 
This enzyme catalyzes a complex series of reactions in three precursors androstenedione, 
testosterone and 16α-hydroxyandrostenedione into estrone, estradiol and estriol, 
respectively and is expressed in steroidogenic tissues, like ovaries, testes, placenta, brain 
and non-steroidogenic tissues, such as bone and fat. The transcription of the gene is tissue-
specific and is regulated through different promoters and transcriptional start sites (132). 
 
Identified mutations in the CYP19A1 include missense, nonsense, deletions and 
insertions, splice site and also large intragenic deletions and are mainly found in exons 9 and 
10. Clinical features of patients vary depending on gender, age and enzymatic activity. 
Aromatase deficiency drives to androgen excess in the mother and the fetus, causing 




whereas no changes are observed in males at birth In adolescent girls, P450 aromatase 
deficiency may lead to delayed puberty, hypergonadotropic hypogonadism, multicystic 
ovaries and primary amenorrhea due to lack of estrogens. Signs of virilization may also be 
present. In both sexes, the subsequent estrogen deficiency causes delayed epiphyseal 
closure, eunuchoid habitus and osteoporosis (132). 
 
1.4.1.10. Steroid 5 Alpha-Reductase 2 (SRD5A2) 
 
Two isoenzymes convert testosterone to dihydrotestosterone (DHT), which has more 
affinity for the androgen receptor. During embryogenesis, DHT acts to form the male urethra 
and prostate at the urogenital sinus and induces swelling and folding at the genital tubercle 
to create the penis and scrotum (133). The 5a-reductase type I, encoded by SRD5A1 gene on 
chromosome 5p15 is expressed in peripheral tissues, such as the skin and hair follicles, 
whereas 5a-reductase type II enzyme is encoded by SRD5A2 on chromosome 2p23 and is 
predominantly found in stromal cells of internal and external reproductive organs and 
prostate. 
 
Up to date, human mutations in SRD5A1 have not been associated to DSD. But 
affected 46,XY with inactivating sequence variants in SRD5A2 lead to steroid 5α-reductase 2 
deficiency, an autosomal recessive form of 46,XY DSD, which results in a wide spectrum of 
phenotypes. Newborns present with ambiguous external genitalia, micropenis, scrotal 
hypospadias, cryptorchidism or inguinal testis and prostatic hypoplasia. They are generally 
raised as females. At puberty, these patients are virilized and present gynecomastia due to 
5a-reductase type I activity. Most patients with SRD5A2 deficiency are homozygous or 
compound-heterozygous (35%) for inactivating mutations. Heterozygous mutations have 
been also reported, proposing the dominant effect of certain gene variants (133).  
 
Both genes have a complex developmental regulation of expression.. 5a-reductase 
type I is expressed again in nongenital skin and liver after puberty, suggesting that it may be 
responsible of the pubertal virilization observed in the patients with 5a-reductase 
deficiency. Biochemical diagnosis is suggested when high testosterone/DHT ratio is observed 
although both isoenzymes reduce a variety of steroids in their degradative pathways and can 
be seen in a whole steroid profile (120), (106). 
 
1.4.2. Insulin Like 3 (INSL3) and Relaxin-family peptide receptor 2 (RXFP2)  
 
In humans and other mammals, testis descent follows two distinct steps: the intra-
abdominal and the inguino-scrotal stage. INSL3 (Insulin like factor 3), expressed in Leydig 
cells of the foetal and adult testis, was proposed to regulate the intra-abdominal step. Insl3-
null mice developed bilateral cryptorchidism with testes located in the abdominal cavity. 
Normal testicular descent was achieved when INSL3 was overexpressed in pancreatic b-cells 




receptor RXFP2 (Relaxin-family peptide receptor 2). RXFP2 gene, located on chromosome 13, 
encodes a protein with an extracellular ligand-binding domain, seven transmembrane 
domains and one intracellular domain. In mice, gene changes cause cryptorchidism, with 
bilateral intra-abdominal testes (135). 
 
In humans, several point alterations have been identified within the coding region 
and the promoter of INSL3 in DSD patients presenting with cryptorchidism (136). In contrast, 
studies investigating RXFP2 were scarce and have focused on the single found variant 
Thr222Pro in exon 8, which reduces RXFP2 expression on the cell surface membrane on 
patients with undescended testes (137). Recently, another missense variant was detected in 
4 members of the same family presenting with cryptorchidism. Functional analysis showed 
that the mutant protein failed to bind INSL3 or respond to the ligand with cAMP signalling 
(135). 
 
On the other side, the regulation of INSL3 is poorly known. Oestradiol and 
diethylstilboestrol may downregulate the expression of INSL3 in foetal Leydig cells which 
explains the lack of testicular descent in male embryos after exposure to oestrogen excess 
(138). It has been hypothesized that SF1 binds to one of the three binding sites in the gene 
and acts as a transcriptional activator of INSL3 promoter. However, in vivo studies 
demonstrated that the regulation of INSL3 expression and downregulation by oestrogens 
requires additional transcription factors (139). 
 
1.4.3. Androgen receptor (AR) 
 
Androgens action, testosterone and dihydrotestosterone (DHT), via AR is essential for 
male sexual development before birth and for secondary male sexual development at 
puberty, while in females androgens take part in sexual development at puberty and in 
adulthood (140). The AR gene, located on Xq11-12 encodes a transcription factor with three 
major domains: amino-terminal domain (NTD), a DNA-binding domain (DBD) containing two 
zinc fingers and a hinge region that connects to the ligand-binding domain (LBD) on the 
carboxil-terminal. More than 500 variants have been described varying from coding 
sequence (CDS) changes, splicing, 5’UTR (untranslated region) and partial or complete gene 
deletions (141). 
 
Androgen insensitivity syndrome (AIS, OMIM 300068) is a congenital disorder that 
manifests as a result of cellular resistance to testosterone and dihydrotestosterone. 
Mutations in the AR gene are associated with a wide spectrum that result in the formation of 
a feminine phenotype in a 46,XY individual and ranges from complete androgen insensitivity 
syndrome (CAIS) to partial (PAIS) or mild (MAIS). Sequence variants have been identified also 





AR is also expressed in the developing Granulosa cells and as shown in Ar-/- transgenic 
female mice presenting a phenotype similar to that of primary ovarian insufficiency (POI), it’s 
required for folliculogenesis. In humans, the CAG repetition in exon 1 of the gene has been 
proposed to cause POI (142). 
 
1.4.4. Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR) in males 
 
The production of androgens is under the control of human chorionic gonadotropin 
(hCG) and luteinizing hormone (LH) during fetal and postnatal life, respectivelly, that act by 
stimulating the transmembrane receptor LHCGR. In differentiating Leydig cells the secretion 
of androgens seems to be autonomous, later hCG produced by the placenta highly 
stimulates their differentiation and the androgen production, until second and third 
trimester of pregnancy when the levels decrease. At pubertal stage, LH through LHCGR 
drives to the secretion of androgens that give rise to pubertal changes (143).  
 
Defects in the LH receptor functionality cause impaired regulation of Leydig cell 
function and androgen production. LHCGR receptor is a member of the superfamily of G 
protein-coupled receptors, characterized by the presence of an extracellular hormone-
binding domain which consists of a leucine-rich repeat domain flanked by two cysteine 
clusters, and a last exon of the gene codifying for a seven transmembrane helix domain 
(Figure 5) involved in the G protein activation. After ligand binding to the receptor, G 
proteins are activated in the intracellular membrane and an increase in cAMP levels activate 
of cAMP-dependent protein kinase. The variants on the different domains in the LHCGR lead 
to distinct effects on LH receptor function. Then, missense alterations may alter the function 
of the protein inhibiting the signal transduction, while large deletions and nonsense changes 
cause a complete defective protein and lack of hormone binding. Both forms of inactivating 
mutants diminish the efficiency of the LH receptor transduction signal and are supposed to 




Figure 5. Scheme of the structure of the LHCGR protein. LHCGR comprises 4 main structures: A Cysteine-rich 
region (CRR) in the N-terminal, nine Leucine-rich repeats, a second CRR or hinge region and the 7 
transmembrane domains next to the carboxi terminal. Modified from Xu Y., et al (144). 
 
 
The complete form of Leydig cell hypoplasia or type 1 LCH, is described as 46,XY 
female external genitalia, lack of pubertal development, small undescended testes with 
seminiferous tubes, absence of mature-type Leydig cells and presence of rudimentary 




LH, with low testosterone and no response to hCG stimulation test. In contrast, the partial 
form or Leydig cell hypoplasia type 2, encompasses a wide spectrum with predominantly 
male external genitalia, micropenis with or without hypospadias and cryptorchidic or scrotal 
testes. At puberty, these patients are partially virilized and testes acquire a normal size while 
penis length is impaired. At this time, LH levels increase and testosterone ranges from infant 
to adult male levels (143). Homozygous or compound heterozygous inactivating variants are 
located along the gene and all type of changes have been identified, such as missense, 
nonsense and complete gene deletion. The mechanisms of inactivation may cause a 
misfolding of the receptor and a consequent reduced transport to the cell surface or 
decrease the ability to activate the signal transduction. The severity of the phenotype is well 
correlated with the residual activity of the receptor. For example a compound heterozygous 
patient presenting a small deletion in the intracellular region together with a missense 
variant in the transmembrane domain led to a more severe perineoscrotal hypospadias than 
two missense changes in the last exon causing micropenis (145). On the other side, female 
siblings of LCH cases present with primary amenorrhea, oligoamenorrhea, anovulation or 
infertility (146). 
 
In contrast, activating heterozygous variants have been described in male-limited 
precocious puberty or testotoxicosis (OMIM 176410) which is characterized by early puberty 
in boys, usually before 4 years of age, penis growth, pubic hair and other puberty signs. 
Gonadotropins are decreased indicating a peripheral cause of precocious puberty, while 
testosterone levels are high, in contrast to Leydig cell hypoplasia. In vitro expression analysis 
of the first identified activating gene variant, showed an increase of 10 to 20-fold in the basal 
activity of the LH receptor, amplifying the cAMP signal. Although the sixth helix and the third 
intracellular loop of the transmembrane domain seemed to be the hot spot of the activating 
mutations, further genetic analysis identified them in other regions (147). Indeed, molecular 
modelling studies revealed that changes in the interaction of conserved polar amino acids 
drive to an alternative conformation of the protein that allows the binding of the G protein 
to other amino acids side chains (148). 
 
Defects in AMH gene, also involved in male differentiation, have been described 
before (See 1.2.9, page 15). Other genes that take park in male differentiation, such as 
oestrogen recpetors and FSHR are explained later (See 1.4.5.4, page 36 and 1.4.5.1, page 
35). 
 
1.4.5. Formation of the ovarian follicle and differentiation of the female genitalia  
 
As mentioned before (See 1.3, page 18) other genes are required for the 
development of the ovarian follicle and differentiation of the female genitalia. The formation 
of the ovary is slower than testicular process, and is identifiable at the 11th week of 
gestation. In mice, the first sign of ovarian differentiation is at embryo day 13.5. At this time, 




primordial follicles at time of birth (149). Primordial follicles comprise a single oocyte 
enclosed with a layer of somatic Granulosa cells, separated from the ovarian interstitium by 
a basal lamina. As follicles grow to secondary and antral follicle, the Granulosa cells change 
to a cuboidal shape and proliferate into multilayers. Steroidogenic theca cells differentiate at 
the secondary follicle phase and surround the Granulosa cell layers outside the basal lamina 
(Figure 6).  
 
 
Figure 6. Schematic representation of oogenesis and ovarian folliculogenesis. Only genes sequenced in the 
targeted gene panel have been included in the image. Modified from Jiao 2018 (150). 
 
 
Once formed, the Granulosa cells begin the expression of the Hedgehog signalling 
pathway which starts the differentiation of theca cells. For that, DHH (Desert Hedgehog) 
binds HHIP (hedgehog interacting protein 1) and membrane receptors PTCH1 and PTCH2 
(Patched 1 and Patched 2) on the theca cells. GLI (glioma-associated oncogene) zinc finger 
transcription factor mediates the activation of the hedgehog signalling cascade (151). 
Progenitors of the theca cells derive from two cell populations. The transcriptional profiles of 
the cells coming from the mesonephros show high expression levels of genes involved in 
steroidogenesis, such as Star, Cyp11a1 and Cyp17a1, Hsd3b2 and Lhcgr. In contrast, genital 
ridge derived cells revealed higher expression of Esr1 (oestrogen receptor 1) and Wt1, 
amongst others (152). Theca cells produce androgens that are converted to oestrogens by 
Granulosa cells and support vascularization of the follicle. Secreted oestrogens allow the 
development of the Müllerian duct into uterus, Fallopian tubes and the upper part of the 
vagina. In the presence of androgens, the XX fetus lead to normal progress of fused urethral 
folds and labioscrotal swelling that develop to labia minora and majora respectively, the 
genital tubercle forms the clitoris and the vaginal plate creates the lower part of the vagina. 
Signs of this growth are present at 20 weeks of gestation. 
 
Sequence variations in the genes involved in hormonal signalling and folliculogenesis 
end in ovarian disorders, such as ovarian dysgenesis, premature ovarian failure (POF), 
polycystic ovary syndrome (PCOS) or cancer. Hereafter, I describe several genes (LHCGR, 
FSHR, BMP15, GDF9, INHA, ESR1, ESR2, HSD17B4 and PSMC3IP) in which genetic changes 






1.4.5.1. Gonadotropin receptors in females 
 
As I have described before (See 1.4.4, page 32), FSHR (Follicle Stimulating Hormone 
Receptor) and LHCGR are glycoprotein hormone receptors that belong to the membrane-
bound G-protein coupled receptors (GPCRs) family. These receptors, as well as their binding 
hormones FSH and LH, are involved in regulating hormonal signalling in males and females. 
In females, both receptors are expressed in the Granulosa cells when follicles progress from 
the primary to the secondary stage, together with oestrogen and androgen receptors. FSHR 
and LHCGR produce cAMP as the main second messenger, which in turn, stimulates ovarian 
follicular steroidogenesis, favouring puberty and menstrual cycles (153). Patients with 
pathogenic variants in these receptor genes form ovarian follicles up to the preantral stage, 
but further maturation is blocked.  
 
The FSHR gene is located on 2p16.3 and encodes a 695 amino acid protein 
characterized by an extracellular domain, seven transmembrane segments and an 
intracellular tail. In female mice, the disruption of Fshr leads to infertility while males show 
small testes but remain fertile, supporting that Fshr plays a major role in the development of 
the female gonad. Inactivating mutations in the extracellular domain lead to a complete FSH 
resistance with hypergonadotrophic hypogonadism and 46,XX ovarian dysgenesis, such as 
the p.Ala189Val missense change reported in Finnish population (153). This substitution 
inhibits the FSHR cell-surface trafficking and therefore mutant FSH is retained inside the cell. 
Other mutations throughout the receptor have been noted in women with primary ovarian 
insufficiency (POI), secondary amenorrhea and high FSH levels.  
 
LHCGR inactivating variants also cause primary ovarian insufficiency in 46,XX. Patients 
present with primary amenorrhea or oligoamenorrhea and infertility. The 
hypergonadotropic hypogonadism is characterized by high LH biochemical levels (143). 
 
1.4.5.2. Bone morphogenetic protein 15 (BMP15) and Growth differentiation 
factor 9 (GDF9) 
 
Bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9) 
are members of the transforming growth factor-beta (TGFb) superfamily that act 
synergistically to regulate folliculogenesis and ovulation. BMP15 and GDF9 have similar 
protein structure, expression patterns and interact with each other to regulate Granulosa 
cells. GDF9 and BMP15 bind to their corresponding transmembrane serine-threonine kinase 
receptors and finally drive to the regulation of target genes related to ovulation and 
luteinisation (154), such as KITL (Ligand for the receptor-type protein-tyrosine kinase) 
important in the growth of oocytes. Moreover, BMP15 reduces progesterone production by 
downregulating the expression of STAR, while GDF9 interacts with pituitary gonadotropins to 





BMP15 is an X-linked gene that encodes a growth/differentiation factor secreted 
from oocytes. It is involved in either follicular development, regulation of several processes 
in Granulosa cells, prevention of apoptosis and regulation of FSH sensitivity. Studies in 
different animal models confirmed the role in folliculogenesis and ovulation although Bmp15 
seems to be more critical in mono-ovulating species, like human or sheep rather than in 
poly-ovulating ones, as mice (155).. In women, variants in BMP15 have been associated to 
primary and secondary amenorrhea due to primary ovarian insufficiency (POI) and polycystic 
ovary syndrome (PCOS) (155). Recently a BMP15 gene duplication was reported in a patient 
with 46,XX/45,X0 karyotype and spontaneous menarche, which suggested a gene dosage 
contribution that enable an amount of follicles to reach puberty (156).  
 
GDF9 gene is located on 5q31.1 and is linked to the follicular development between 
the primary to secondary follicle stage. Several studies in different cohorts have related 
missense variants with POI and PCOS (157).. 
 
1.4.5.3. Inhibin Subunit Alpha (INHA) 
 
Inhibin is a heterodimeric glycoprotein structurally related to the transforming 
growth factor-beta (TGFb) superfamily. It is formed of inhibin A homodimers, codified by 
INHA, and inhibin B or activin codified by INHBA (Inhibin Subunit Beta A) and INHBB (Inhibin 
Subunit Beta B) genes. The principal function of inhibin in women is the regulation of 
pituitary FSH secretion and is an ovarian reserve marker. In vivo, inhibin functions as a 
tumour suppressor, as Inha-null transgenic mice developed stromal/Granulosa cell tumours 
with increased FSH levels and infertility(158). 
 
INHA gene maps to 2q35 and the first supporting evidence of the relation between 
INHA and primary ovarian insufficiency in humans was revealed when a translocation in the 
gene locus was found (158). However, the recurrent p.Ala257Thr substitution in different 
populations has been also reported in controls (159).  
 
1.4.5.4. Oestrogen receptor a and b  
 
Oestrogens control development, cell differentiation and maintenance of 
homeostasis in adults. All the estrogenic functions are done by binding and activating their 
nuclear receptors, Oestrogen receptor a (ESR1) and b (ESR2). Mouse modelling studies 
suggested that ESR2 is a dominant negative regulator of ESR1-dependent transcription as a 
way to maintain the balance between the two receptors. Esr1-null male mice showed 
infertility, hyperplasia, adipocyte hypertrophy, insulin resistance and glucose intolerance 
while female animals had hypoplasic uterus and multicystic ovaries. Esr2 deletions in animal 
models demonstrated different phenotypes, such as infertility without sex reversal in 
females (160) or normal phenotype but smaller litters, whereas male KO rodents were fertile 




essential for ovulation but not for sexual differentiation. In humans, ESR2 is more expressed 
in the Granulosa cell of the ovary in the developing follicle than ESR1, and also in the fetal 
ovary during gonadal development (161). However the identification of an ESR2 mutation in 
a 46,XY DSD patient presenting with gonadal dysgenesis demonstrated a role in early 
testicular development (160). However, the potential ESR2 functions in testes and prostate 
need to be probed. 
 
In humans ESR1 gene alterations cause oestrogen resistance, high oestrogen levels in 
male and females and delayed puberty, infantile uterus, primary amenorrhea and ovarian 
cyst in women (162). Two heterozygous variants in ESR2 have been reported in two 46,XX 
young woman. First was diagnosed with primary amenorrhea and second had streak gonads, 
infantile uterus, lack of puberty and breast development (161). Molecular modelling in the 
last case demonstrated that the mutant disrupted estradiol-dependent signalling and failed 
to interact with its coactivator. 
 
Other previously mentioned genes that take part in the follicle formation and 
maturation are: AR, NR5A1, WT1, NR0B1, MAMLD1, AMH and AMHR2.  
 
1.4.5.5. Other genes related to ovarian dysgenesis as part of a phenotypic 
spectrum 
 
Perrault syndrome is an autosomal recessive condition characterized by ovarian 
failure in females and deafness in both males and females. Some women also present 
neurological features (Perrault syndrome type II), including developmental delay or 
intellectual disability, cerebellar ataxia, motor and sensory peripheral neuropathy (163).  
 
Mutations in HSD17B4 (Hydroxysteroid 17-Beta Dehydrogenase 4), which encodes a 
17-beta-estradiol dehydrogenase involved in peroxisomal fatty acid beta-oxidation and in 
HARS2 (Histidyl-TRNA Synthetase 2, Mitochondrial), encoding the mitochondrial histidyl-
tRNA synthetase, have been detected in patients with Perrault syndrome (OMIM 233400) 
(163). Regarding the HSD17B4 gene, two compound heterozygous variants were found in 
two sisters with clinical features of DBP (D-bifunctional protein, OMIM 261515) deficiency, 
together with ovarian dysgenesis. In contrast, linkage-analysis and gene sequencing in five 
affected family members identified two heterozygous variants in HARS2. HARS2 is required 
for protein translation within the mitochondria and reduced activity was found in both 
mutants. However, the lack of HSD17B4 and HARS2 sequence changes in other cohorts 
evidenced the heterogenic cause of this disease (164). Further whole exome sequencing and 
linkage-analysis discovered other underlying genes causing the disease: C10orf2 
(chromosome 10 open reading frame 2), LARS2 (leucyl-tRNA synthetase 2, mitochondrial) 
and CLPP (caseinolytic mitochondrial matrix peptidase proteolytic subunit), essential for 





1.4.6. Genes affecting DNA replication, meiosis and DNA repair in the female 
gonad formation 
 
Gene sequence variants implicated in creation and repair of DNA double-strand 
breaks for recombination, damage control, cell cycle progression or development of the 
synaptonemal complex have been also associated with defects of the female gonad 
formation. 
 
PSMC3IP (Proteasome 26S Subunit, ATPase, 3-Interacting Protein) codifies a highly 
expressed nuclear protein in foetal and adult gonads, spleen and thymus in both human and 
murine models. It has a leucine zipper domain critical for nuclear receptor binding, a coiled-
coil domain in the middle of the protein and a C-terminal acidic region that acts as a ligand-
dependent transcriptional coactivation domain (165). As indicated by its yeast ortholog 
Hop2, it coactivates DMC1 (DNA Meiotic Recombinase 1) and RAD51 (DNA repair protein 
RAD51 homolog 1) proteins, fundamentals for homologous pairing and recombination in 
meiosis (166) and either mutations or deletions in Hop2 stop entry into meiosis I. In male 
mouse meiosis was blocked but since Sertoli, Leydig cells and spermatogonia were present, 
pubertal development was normal (165). However, in the female Psmc3ip KO mouse model, 
ovarian size was reduced and germ cells were lacking. The importance of the PSMC3IP gene 
in the germ cell development of both sexes was then revealed. 
  
PSMC3IP binds DNA-binding domain of glucocorticoid receptor, oestrogen receptor 1 
and 2, androgen receptor, progesterone receptor and thyroid hormone receptor beta, acting 
as a coactivator of hormone-dependent transcription (165).  
 
In humans the first mutation was identified in 5 members of a consanguineous family 
affected by 46,XX gonadal dysgenesis. It was a 3-bp C-terminal deletion that disturbed the 
coactivation of ESR1, which affected the follicular environment during formation in the fetal 
ovary (167). More recently, a homozygous stop mutation has been reported in a 
consanguineous Yemeni family in 4 sisters presenting with POI and a brother with 
azoospermia. The carboxyl-terminal variation inhibited the association with single strand 
DNA and the proteins required for homologous recombination (166). 
 
 
1.5. OPPOSING INTERACTIONS TO CORRECTLY DEVELOP AND MAINTAIN THE GONADS  
 
A complex interaction is needed between the female and male pathways to correctly 
trigger the initiation, development and maintenance of gonadal differentiation. Data suggest 
that pathways act antagonistically, suppressing the alternate fate through a sequence of 





During embryonic development, the most important antagonism occurs between the 
SRY/SOX9/FGF9 and WNT4/RSPO1/β-catenin signalling pathways (Figure 7) (48). Fgf9-null or 
Fgfr2-null transgenic mice resulted in the increased expression of Wnt4 and male-to-female 
sex reversal, whereas the deletion of WNt4, Rspo1 or B-catenin showed female-to-male sex 
reversal (168). In the male, SRY suppresses the activation of WNT transcription factor β-
catenin. Additionally, FGF9 supports the transcriptional activity of SOX9 and together, 
downregulate female-specific gene WNT4 leading towards testicular development (50). 
CBX2 might also participate in this feedback loop upregulating SOX9 and SOX3 in the 
testicular Sertoli-like cells and inhibiting FZD1 (Frizzled Class Receptor 1) and FOXL2 involved 
in ovarian development (169). By contrast, during sex determination in the ovary, β-catenin 
previously activated by WNT4 and RSPO1, limits the expression of Sox9 and therefore, 
suppresses the SOX9/FGF9 feedback loop (95). WNT4 signalling increases the transcription 
of FST (Follistatin) too, which antagonises Activin to inhibit the formation of the testes-
specific vasculature (170). MAP3K1 seems to play an important role in the maintenance of 




Figure 7. Simplification of the molecular signalling during sex differentiation of the gonads into testes and 
ovaries and maintenance of the cell fate. Black arrows indicate activation of a downstream target. Red lines 
ending in bars show repression of a downstream target. Modified from Ohnesorg T., 2014 (2). 
 
 
Sex identity of the gonadal cells must be maintained postnatally to avoid 
transdifferentiation. At least in mice, this is achieved by DMRT1 and FOXL2 transcription 
factors. In Dmrt1 KO XY adult, transdifferentiation of Sertoli cells into Granulosa-like cells 
occurred at 4 weeks postnatally because ablation of Dmrt1 resulted in the activation of 
ovary-promoting genes, Foxl2 and in the downregulation of Sox9 (73). In normal ovary, 




enhancer of Sox9 and inhibit its transcription. In Foxl2 deleted XX adult mice ovaries, Sox9 is 
upregulated and somatic cells (Granulosa and theca) convert into Sertoli and Leydig-like 
cells. Furthermore, complete deletion of Esr1/Esr2 or Cyp19a1 also resulted in 
transdifferentiation in the adult ovary, as well as germ cell loss (171). These results suggest 
that maintenance of testis or ovary fate is an active process in adult life, however 
transdifferentiation in the human gonad has not been clearly probed yet. 
 
 
2. DISORDERS OF SEX DEVELOPMENT 
2.1. DEFINITION AND PREVALENCE 
 
Disorders of sex development (DSD) are a heterogeneous group of congenital 
conditions in which development of chromosomal, gonadal, or anatomical sex is atypical. 
Many causes are genetically determined and progression in this understanding led to the re-
examination of the nomenclature in 2006 and a new classification of DSD was proposed 
(Table 2) (172).  
 
 
Table 2. Classification of Disorders of Sex Development according to the Chicago consensus (172).  
 
46,XY DSD 
Disorders of testicular 
development 
Complete gonadal dysgenesis 
Partial gonadal dysgenesis 
Gonadal regression 
Ovotesticular DSD 
Disorders of androgen 
synthesis or action 
Androgen biosynthesis defects (i.e. 5⍺-reductase deficiency) 
Defects in androgen action (AIS) 
LH receptor defects (i.e. Leydig cell hypoplasia) 
Persistent Müllerian duct syndrome (Variants in AMH or AMHR2 genes) 
Others Severe hypospadias, cryptorchidism, complex syndromic disorders 
46,XX DSD 





Disorders of androgen 
excess 
Fetal (i.e. 21-hydroxylase deficiency) 
Fetoplacental (Aromatase deficiency, POR deficiency) 
Maternal (i.e. Luteoma) 
Others 





45,X0 Turner syndrome and variants 
47,XXY Klinefelter syndrome and variants 
45,X0/46,XY Mixed gonadal dysgenesis, ovotesticular DSD 
46,XX/46,XY Chimerism, ovotesticular DSD 





The wide extent of different phenotypes ranges from minor genital abnormalities, 
such as hypospadias, to ambiguous genitalia and complete gonadal dysgenesis. In general, 
ambiguous genitalia are a relatively rare situation reported to occur in 1:4,500 life newborns 
(172), but considering all types of atypical genitalia together with chromosomal, gonadal and 
genital conditions, the prevalence of DSDs increases to 5 in 1000 births, being boys with 
hypospadias the 73% of these cases (173). About 75% of the children with atypical genitalia 
have a 46,XY karyotype, 10-15% a 46,XX and the remainder will have structural anomalies of 
the sex chromosomes (174). Among the 46,XX DSD, the most frequent genetic condition is 
congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, which occurs in its 
classic form in about 1:14,000-1:18,000 infants while nonclassic form is stimated to have a 
prevalence of 1:500 to 1:1000 in the general white population. CAH accounts for 90-95% of 
the individuals with a 46,XX DSD (113). In addition, DSDs are sometimes associated with 
syndromes or multiple congenital malformations (175). Expected clinical and biochemical 
features of each DSD is summarized in Supplementary data 1. 
 
 
2.2. CLASSIFICATION OF DSD BASED ON THE CHICAGO CONSENSUS 
 
2.2.1. 46,XY DSD: Disorders of testicular development 
 
2.2.1.1. Complete and partial gonadal dysgenesis 
 
Gonadal dysgenesis encompass several clinical conditions caused by the irregular 
development of the fetal gonad in 46,XY. Complete gonadal dysgenesis is characterized by 
female external and internal genitalia, absence of secondary sexual characteristics, normal 
or tall stature, eunuchoid habitus without other Turner syndrome features and bilateral 
dysgenetic gonads. Streak gonads don’t produce adequate testosterone for the 
development of male internal structures, or AMH with the subsequent persistence of 
Müllerian ducts that develop to hypoplastic or normal uterus and Fallopian tubes. In some 
cases clitoromegaly has been observed. These patients are raised as girls and are usually 
diagnosed at puberty due to infantilism and primary amenorrhea. On the other side, partial 
gonadal dysgenesis is described with distinct degrees of testicular development and 
function, as well as a wide spectrum of atypical genitalia and the presence or absence of 
Müllerian ducts. In both forms gonadotropins are increased, mainly FSH, and testosterone is 
at a prepuberal range in the complete form while in partial gonadal dysgenesis it varies from 
prepuberal levels to normal adult levels (175). Estradiol levels are decreased in both forms.  
 
46,XY gonadal dysgenesis has been estimated to occur in 1 out of 10,000 births (172, 
176). Regarding the genetic etiology, it is highly heterogeneous and might result from a 
defect in any gene contributing to gonadal development. However, alterationss in SRY are 




MAP3K1 (18%) and NR5A1 (13%). Few are caused by other rare changes in SOX9 or NR0B1 
(7, 105). Other genes causing 46,XY DSD gonadal dysgenesis are listed in Table 4 (Page 79).  
 
2.2.1.2. Gonadal regression 
 
Testicular regression syndrome (OMIM 273250), also termed vanishing testes, is a 
condition defined as the absence of testicular tissue in 46,XY individuals with a male 
phenotype. These individuals are born with male external genitalia, indicating a correct 
functioning testicular tissue during the first weeks of pregnancy. Micropenis is also present 
in 50% of the patients and all have hypergonadotropic hypogonadism and infertility (178). 
 
It has been proposed that testicular regression syndrome happens due to vascular 
accidents, such as testicular torsion. If this occurs in the second half of gestation, penile 
growth will be impaired due to testosterone deficiency, leading to micropenis. Otherwise the 
penile length is normal when the accident is close to term or after birth. Thus, the 
manifestations of testicular regression are associated with the intrauterine accident. Its 
prevalence is about 1 in 20,000 males In contrast, the coexistence of anorchia with genital 
ambiguity in a number of familial cases led to the hypothesis that some forms of the 
condition might have a genetic cause and be part of the clinical spectrum of 46,XY gonadal 
dysgenesis. However, molecular analyses have failed to identify any gene in association to 
anorchia but NR5A1 (178). 
 
2.2.1.3. Gonadal dysgenesis and related syndromes 
 
Several syndromes are associated with 46,XY gonadal dysgenesis in humans, caused 
by variants in genes involved in gonadal determination. 
 
2.2.1.3.1. WAGR syndrome 
 
WAGR syndrome or Wilms’ tumor, aniridia, genitourinary malformation and mental 
retardation (OMIM 612469) is a contiguous gene syndrome caused by deletions in 11p13 
encompassing both WT1 and PAX6 genes. Wilms’ tumor is developed in approximately 50% 
of the patients. The diagnosis is based on the presentation of sporadic aniridia in the 
newborn along with genital anomalies, although these are not always present. In older 
children, clinical diagnosis is made when aniridia and one of the other features are present 
(179). 
 
2.2.1.3.2. Denys-Drash and Frasier syndromes 
 
Denys-Drash syndrome (DDS) is characterized by Wilms’ tumor in the first decade of 
life, rapid progressive glomerular disease, and genitourinary abnormalities, mainly 46,XY 




is associated with WT1 gene mutations in the DNA-binding domain, affecting the 
transcription factor activity in a dominant negative manner (180). 
 
Frasier syndrome (FS) describes the combination of female to ambiguous genitalia in 
46,XY males, renal failure in the second decade of life, streak gonads and predisposition to 
gonadoblastoma. Heterozygous variants in the intron 9 of the WT1 gene are the most 
common cause (See 1.1.2, page 5). Splice site variants drive to an imbalance in the 
expression of the WT1 (-KTS) isoform and underexpression of WT1 (+KTS), indicating that a 
precise balance between the WT1 isoforms is necessary for the normal function of the 
protein (10). Since patients with Frasier syndrome do not produce nonfunctional proteins 
the clinical course of the nephropathy is slowly progressive compared to Denys-Drash 
syndrome, and require more years to reach complete renal failure. On the other side, Wilms’ 
tumour is not normally observed in cases with Frasier syndrome. It is thought that the -KTS 
isoform which is predicted to interact with DNA, is responsible for the tumour suppressor 
activity and therefore protects these patients against the development of the tumour (15).  
 
Specific localization of the genetic changes has been helpful in the differentiation of 
these two entities in many cases. 
 
2.2.1.4. Ovotesticular DSD 
 
OT DSD in 46,XY DSD patients is explained later (See 2.2.4.1, page 47). 
 
2.2.2. 46,XY DSD: Disorders in androgen synthesis or action 
 
2.2.2.1. Androgen biosynthesis defect 
 
Defects in the enzymes involved in the adrenal and androgen steroidogenesis result 
in 46,XY DSD. The clinical and molecular characteristics leading to a defect in the synthesis of 
testosterone and dihydrotestosterone have been explained before (See 1.4.1, page 21).  
 
2.2.2.2. Defects in androgen action 
 
Androgen insensitivity syndrome (AIS) is a disorder of androgen action due to a 
reduced or absent functionality of the androgen receptor (AR). It is the most frequent known 
monogenic cause of 46,XY DSD, estimated to be present in 1:20,000 to 1:64,000 male births 
(140) and is a X-linked recessive condition. The variable phenotypic expression due to the 
transcriptional activity of the AR has permitted the classification of AIS into complete (CAIS), 
partial (PAIS) or mild (MAIS) androgen insensitivity syndrome. CAIS phenotype is 
characterized by female external genitalia, inguinal or abdominal testes, complete breast 
development and scarce or absent axillary and pubic hair. The absolute resistance to 




producing AMH and thus, inhibits female internal genitalia and leads to primary 
amenorrhea. On the other side, PAIS presents either with male phenotype and minor 
undervirilization, such as hypospadias, or female phenotype with ambiguous genitalia and 
gynecomastia at puberty, while MAIS is characterized by normal male external genitalia and 
infertility.  
 
The clinical diagnosis of CAIS is easily confirmed, as about 85% of the cases harbor an 
alteration in the AR coding sequence (CDS), whereas the definitive diagnosis in PAIS is 
further complicated because less than 30% of the cases present an AR gene variant. (7). To 
elucidate the possibility of a clinical diagnosis of AIS without a variation in the AR coding 
sequence, Hornig et al analyzed the genital fibroblast of 46 individuals with a clinical 
suspicion of AIS and no molecular proof on the CDS using an APOD-assay tool. They found a 
subset of individuals with an androgen response, but 17 out of 46 presented a functionally 
proven androgen resistance compared to control groups. They proposed the term AIS type II 
for this new class of androgen resistance. In addition, some of these AIS type II patients had 
AR gene variants outside the coding sequence (181). 
 
2.2.2.3. LH receptor defects 
 
Defects caused due to LHCGR gene varitants have been described before (See 1.4.4, 
page 32). 
 
2.2.2.4. Disorders of AMH and AMH receptor 
 
Persistent müllerian duct syndrome (PMDS, OMIM 261550) is an autosomal recessive 
disorder defined as the presence of müllerian derivatives, uterus, and Fallopian tubes in 
otherwise normally masculinized 46,XY subjects. Bilateral intra-abdominal testes are found 
in the majority of the cases (40-60%). However, other cases have been reported with a 
scrotal testis and a contralateral inguinal hernia containing a testis, uterus and tubes (20-
30%) and a hernial sac containing both testes and the müllerian ducts (25%). Most of the 
cases are diagnosed because of bilateral or unilateral cryptorchidism with or without 
inguinal hernia. In adulthood the diagnosis of PMDS is made due to the degeneration of the 
testes or the müllerian derivatives. About 33% of the patients above 18 years have 
undergone either unilateral or bilateral malignant testicular degeneration, then early 
orchidopexy is recommended, although it’s not completely effective (182).  
 
Homozygous or compound heterozygous variants in AMH and AMHR2 result in an 
AMH deficiency or resistance, which is the cause of PMDS. There are not anatomical 
differences between the patients with AMH (PMDS type 1) or AMHR2 mutations (PMDS type 
2). However AMH serum levels are different, in those harbouring AMH sequence changes 




alterations hormone levels are normal or increased.. Molecular diagnosis is confirmed in 
approximately 88% of the cases with a persistent müllerian duct syndrome (182). 
 
2.2.3. 46,XY DSD: Others 
 
2.2.3.1. Hypospadias and cryptorchidism 
 
Hypospadias is a congenital anomaly in which the urethral opening is not correctly 
placed at the tip of the penis. After cryptorchidism, is the most common congenital disorder 
in boys, with an incidence of 1 in 200-300. Hypospadias occurs when the urethral closure is 
abnormal or incomplete during the first weeks of embryonic development. Defects in the 
genes or pathways involved in the phallus development and urethral closure give rise to the 
atypical location of the urethral opening on the ventral part of the penis and are classified 
regarding this location into distal or anterior, midshaft or middle and proximal or posterior. 
This anomaly may be associated with a ventral curvature of the penis, known as chordae and 
abnormal foreskin (183). 
 
A number of genes have been widely linked to hypospadias, although only the 30% of 
hypospadias cases have a clear genetic cause. Then, it was suggested that the basis of this 
anomaly is a combination of genetic susceptibility and environmental influences. In most of 
the cases, hypospadias appears as an isolated condition, but it can be associated with other 
anomalies of the urogenital tract mainly, such as undescended testes and micropenis, WAGR 
syndrome or Denys-Drash syndrome. Despite most of the cases of isolated hypospadias are 
idiopathic, familial aggregation has been found in about 10% of the cases (183).. Heritability 
of the condition is above 57% and depends on the severity of the hypospadias. Anterior or 
middle hypospadias are more frequent in families than proximal hypospadias. In humans 
several hypospadias association studies have been performed in large cohorts and 
expression analyses in the affected tissue. Sequence variants have been identified in patients 
with hypospadias in genes and pathways included in the early development of the genital 
tubercle, such as the hedgehog signalling pathway or WT1 gene; the testes signalling 
pathway, like MAP3K1, MAMLD1 and NR5A1; in enzymes necessary androgen synthesis, as 
HSD3B2 or in AR gene. Regarding the connection between environmental factors and the 
occurrence of hypospadias, it is well known that an elevated exposure to oestrogenic and 
anti-androgenic compounds that interfere with the creation or metabolism of endogenous 
hormones contribute to the incidence of the anomaly. For example, the exposure to EDCs 
(Endocrine-disrupting chemical) during foetal life is correlated with the risk of hypospadias. 
Chemical compounds such as dichlorodiphenyltrichloroethane (DDT) block AR affecting the 
testosterone production, while bisphenol A downregulates the expression of WT1, LHCGR, 
HSD17B3 and SRD5A2 (183). 
 
Cryptorchidism (OMIM 219050) or failure of testicular descent is the most common 




unilateral or bilateral depending on the affected testes and can be associated to additional 
anomalies. In the intra-abdominal phase, occurring between gestation weeks 8-15, INSL3 
stimulates the gubernaculum, or genito inguinal ligament, to enlarge and drives the testis to 
the abdomen, specifically to the caudal part of the abdomen. During the inguinoscrotal 
phase, between 25-35 gestation weeks, the gubernaculum, derived from the primitive 
mesenchyme, guides the descent of the testes to the scrotum. Lack of testosterone 
production by foetal Leydig cells or absence of a functional androgen receptor, stops the 
testicular descent. Anomalies in the first step of testicular descent are uncommon, whereas 
those in the inguinoscrotal phase and dependent on androgen action, account for most of 
the cases (184).INSL3 and RXFP2 genes have been implicated in testicular descent and 
cryptorchidism due to work in mouse models (135). 
 
2.2.3.2. Hypogonadotropic hypogonadism and related gene variants  
 
The increase of the hypothalamo-pituitary-gonadal (HPG) axis release at the 
beginning of puberty brings secondary sexual features and a mature reproductive system. 
Absence of puberty due to anatomical or functional defects that end in decreased 
gonadotropin releasing hormone (GnRH) and/or gonadotropin secretion is termed 
hypogonadotropic hypogonadism (HH). When the HH has no evident cause is called 
idiopathic HH (IHH) and can be divided into two major categories: Kallmann syndrome (KS) 
and normosmic IHH (nIHH). The first is characterized by HH and anosmia due to the 
interrupted migration of GnRH specific neurons and the olfactory receptor neurons into the 
hypothalamus. It is often associated with additional congenital anomalies such as cleft 
palate, unilateral renal agenesis, split hands and feet, short metacarpals, deafness, and 
synkinesis. nIHH refers to the IHH cases without anosmia and gives rise from the dysfunction 
of the GnRH neurons in the hypothalamus. However, these two entities seem to be 
overlapped in some cases. Male infants need the HPG axis active during gestation (between 
the 16th-22nd weeks) for normal virilization of the 46,XY fetus, then boys with IHH are born 
with micropenis and/or cryptorchidism. In contrast, there is no clinical manifestation before 
the first teen years in girls. Overall, pubertal delay is the most typical feature of IHH and is 
characterized by the lack of breast development in a girl at age 13 or a testicular volume less 
than 4mL in a boy age 14 (185). . In early infancy, between four to sixteen weeks, a 
temporary reactivation of the HPG axis happens (minipuberty) which is used as a diagnosis 
tool (186).  
 
Up to 50% of the IHH are known to be caused by gene sequence defects and around 
50 genes have been reported. Oligogenic inheritance in a patient is thought to account for 
nearly 20% of the cases (185). GNRHR (Gonadotropin Releasing Hormone Receptor) and 
TACR3 (Tachykinin Receptor 3) gene variants are the two most common causative genes 
observed in nIHH, but also KISS1R and KISS1. KISS1 (Kisspeptin) and KISS1R (KISS1 Receptor) 
gene alterations affect the pulse release of GnRH rather than the migration of GnRH 




for the ligand kisspeptin, a secreted neuropeptide that acts as an upstream regulator of the 
GnRH neurons.  
 
2.2.4. 46,XX DSD: Disorders of ovarian development 
 
2.2.4.1. Ovotesticular DSD 
 
Ovotesticular (OT) DSD is considered as the presence of both testicular and ovarian 
tissue in a single patient, either in the same gonad, in different gonads or as an ovary and a 
contralateral testis. In the gonadal biopsy, ovarian tissue is often normal and follicular 
growth, ovulation (50% of the cases) and oestradiol secretion that inhibits spermatogenesis 
and leads to Leydig’s cell hyperplasia in the testicular tissues is observed (151). Infants are 
born with ambiguous genitalia and are usually assigned as males but at puberty breast 
development and menarche is possible due to oestrogen secretion in the ovarian tissue 
(188). The incidence of OT DSD is about 1 in 100,000 births and only the 65% have a 46,XX 
karyotype, whereas a 10% correspond to 46,XY and the remaining have sex chromosome 
mosaicisms (151). Among the sex chromosome abnormalities 46,XX/46,XY chimerism 
(12.8%) is the most frequent, followed by 46,XX/47,XXY (5.6%) and 45,X0/46,XY (3.5%) 
mosaicism (189). 
 
From a molecular point of view, SRY gene is localized in 10% of 46,XX OT DSD due to a 
translocation  but in the majority of the cases the genetic diagnosis remains unknown (190). 
Heterozygous and homozygous variants have been detected in WNT4 in patients with 46,XX 
OT DSD and testicular DSD as part of a complex syndrome and also loss-of-function 
sequence changes in RSPO1 (99, 191, 192). Moreover, copy number gains were described 
upstream the regulatory region of SOX9 in three patients with 46,XX OT DSD (44) and an 
inversion of the long arm of chromosome 22 in another SRY-negative 46,XX OT patient (193), 
increasing the genes involved in the development of female-to-male sex reversal. A de novo 
gain in Xq27.1, including SOX3 gene was recently discovered in a 46,XX patient with 
ambiguous genitalia and bilateral ovotestes (55). Additionally, some well-known genes 
promoting the ovarian and testicular pathways are also able to cause OT DSD, for example 
NR0B1 and NR5A1 (194, 195).  
 
In contrast, few causes of 46,XY OT DSD have been noticed, such as variants in the 
SRY gene or SOX9. A partial deletion in the DMRT1 gene was also detected in a 46,XY OT DSD 
(196). In patients with chimerism or mosaicism, the coexistence of both gonads explains the 
phenotype.  
 
2.2.4.2. Testicular DSD 
 
Testicular (T) DSD is described in individuals with a 46,XX karyotype, male external 




two testicles. These patients are often infertile and the presence of hypospadias is reported 
in 10-15% of the cases. At birth are referred as ambiguous genitalia while after puberty, they 
present small testes, gynecomastia and azoospermia. The total incidence is 1:20,000-25,000 
in newborn (151). 
 
The 90% of the cases are caused by the translocation of the SRY gene to the X 
chromosome, which is sufficient to drive to male differentiation, short stature and produce 
gynecomastia. Other gain-of-function alterations have been found in the upstream region of 
SOX9 (45). Loss-of-function in genes involved in ovarian development such as the 
aforementioned RSPO1 and WNT4 also contribute to T DSD (190). 
 
2.2.4.3. Ovarian dysgenesis 
 
Females with a 46,XX karyotype and ovarian dysgenesis are born without ambiguity, 
but present later with absent or delayed puberty referred as primary or secondary 
amenorrhea. External genitalia are formed normally. Since streak gonads are found, 
oestrogens are not produced and the gonadotropins secretion is not inhibited by the 
hypothalamic-pituitary-gonadal axis, causing elevated gonadotropins levels which result in 
failure to begin puberty and menarche (43). 
 
Indeed, phenotype of ovarian dysgenesis is not uniform and variable expression has 
been observed. In several families, one affected sister presented with secondary 
amenorrhea due to ovarian hypoplasia while another had streak gonads and primary 
amenorrhea (197). 46,XX gonadal dysgenesis is very rare in childhood and might happen due 
to a sequence variant in genes involved in ovarian development in an autosomal recessive 
manner. Many of the 46,XX ovarian dysgenesis cases happen due to disturbances in 
hormonal signaling and folliculogenesis. As previously mentioned, inactivating mutations in 
FSHR and LHCGR genes disrupt the correct development of the ovarian follicle while BMP15 
and PSMC3IP act as modulators of FSH and other nuclear receptors. 
 
Primary ovarian insufficiency (POI) is a term used to include a spectrum of ovarian 
dysfunctions such as ovarian dysgenesis. Indeed, the distinction between the two entities is 
difficult, so the inconveniency to identify the 46,XX ovarian dysgenesis-specific genes. 
Among the newly identified genes in association with ovarian dysgenesis and POI, NOBOX 
and FIGLA seem to be the more representative. The Newborn Ovary Homeobox-Encoding 
Gene (NOBOX) is expressed in germ cell cysts, primordial and developing oocytes in mouse 
models and humans. Loss-of-function variants in NOBOX accounted for 6.2, 6.5 and 5.6% of 
the cases in three POI cohorts (198). Folliculogenesis specific bHLH transcription factor or 
FIGLA has a specific role in the development of primordial follicle and in the synchronization 
of the genes in the zona pellucida. In 2008, an study revealed the presence of FIGLA gene 





2.2.5. 46,XX DSD: Disorders of androgen excess 
 
2.2.5.1. Fetal androgen excess due to inborn errors of steroidogenesis 
 
In the virilizing form of CAH, androgen excess results in 46,XX DSD. As mentioned 
before, deficiencies caused by mutations in CYP21A2, CYP11B1 and HSD3B2 lead to specific 
manifestations in each patient, depending on the severity of the enzymatic defect (See 1.4.1, 
page 21). 
 
2.2.5.2. Fetoplacental androgen excess 
 
The steroids that are produced during fetal development are transferred to the 
placenta and transformed intro androgens and subsequently to oestrogens. Deficiencies in 
the aromatase enzyme or in the POR cofactor due to genetic variants result in accumulation 
of the precursors and masculinization of the female fetuses.  
 
2.2.5.3. Excess maternal androgen production 
 
The origin of the androgen excess or hyperandrogenism in the mother during 
pregnancy may be due to an ovarian tumor (luteoma), polycystic ovary syndrome (PCOS) or 
adrenal tumors. Luteomas are benign tumors of the ovary during pregnancy that produce 
masculinization of the fetus in about 65% of the mothers that are virilized (200). In most 
cases the tumors are small, don’t produce virilization and regress after pregnancy. PCOS is 
mainly characterized by androgen excess and reproductive defects associated to metabolic 
abnormalities, like insulin resistance. Carcinomas and adenomas of the maternal adrenal 
gland are very rare and may lead to virilization of the mother, among other clinical features 
such as hypertension or diabetes mellitus, but also ambiguous genitalia due to virilization of 
46,XX infants (201). 
 
2.2.6. 46,XX DSD: Others 
 
2.2.6.1. Non-CAH monogenic primary adrenal insufficiency 
 
Primary adrenal insufficiency is characterized by the impaired production of 
glucocorticoids, mineralocorticoids and hypersecretion of ACTH and could be classified as 
CAH and non-CAH monogenic primary adrenal insufficiency (PAI), in which adrenals are 
hypoplastic or normoplastic. Non-CAH monogenic PAI is a group of heterogeneous disorders 
caused by adrenal hypoplasia, ACTH resistance or impaired adrenal redox homeostasis (202). 
 
The best known transcription factors implicated in the defective organogenesis of the 
adrenal gland are DAX1 and SF1, although adrenal insufficiency is a rare condition in patients 




glands and is involved in the maintenance of adrenocortical progenitor cells, while the 
expression of SF1 begins in the adrenocortical primordium and continues to steroidogenic 
tissues. The age of onset of patients with NR0B1 gene mutations is younger than the rest. On 
the other hand, ACTH resistance occurs due to genetic defects in the ACTH signal 
transduction and depending on the residual signal transduction activity the size of the 
adrenal glands is normal or small. Up to date two genes have been identified in the ACTH 
signal transduction, MC2R (Melanocortin 2 Receptor) encoding the ACTH receptor and 
MRAP (Melanocortin 2 Receptor Accessory Protein), an accessory protein of melanocortin 2-
receptor (202). Finally, adrenal redox homeostasis presents, usually, with normal 
aldosterone production, as ACTH resistance. Array-based analyses in consanguineous 
patients with familial glucocorticoid deficiency (OMIM 202200) allowed the identification of 
responsible gene NNT (Nicotinamide nucleotide transhydrogenase), which codifies for a 
protein in the transfer system of the respiratory chain in the mitochondria (203). 
 
In general, patients with non-CAH monogenic PAI present symptoms related to 
adrenal insufficiency, such as vomiting and skin pigmentation, but also salt-wasting 
manifestation including dehydration and low blood pressure because aldosterone 
production is affected even in some patients with ACTH resistance and impaired adrenal 
redox homeostasis. Genital anomalies are frequently observed in reported PAI patients.  
 
2.2.6.2. Mayer-Rokitansky-Küster-Hauser syndrome 
 
Mayer-Rokitansky-Küster-Hauser (MRKH, OMIM 277000) syndrome is characterized 
by the congenital absence of the upper two-thirds of the vagina due to interrupted 
embryonic development of the Müllerian ducts. Otherwise, patients have a 46,XX karyotype 
and develop secondary sex characteristics normally. At puberty, they present amenorrhea, 
infertility and normal female phenotype and external genitalia. Anomalies of the genital 
track may range from upper vagina atresia to Müllerian agenesis and is classified as MRKH 
type I when is isolated or as type II when is associated to malformations, such as renal defect 
or skeletal malformations. The incidence of this syndrome is 1 in 4,500 newborn females.  
 
Candidate gene sequencing identified WNT4 as the monogenic cause for MRKH but 
aCGH (array-based Comparative Genomic Hybridization) analyses allowed the recognition of 
duplications and deletions in other genes. The most frequently affected chromosomal 
regions are 17q12, encompassing LHX1 (LIM Homeobox 1) and HNF1 (Hepatocyte Nuclear 
Factor 1) genes (6%), and 22q11 (4%), followed by 16p11.2 (1%) and 1q21.1 (1%) where 
rearrangements in TBX6 (T-Box Transcription Factor 6), RBM8A (RNA Binding Motif Protein 
8A) and in the Xpter pseudoautosomal region 1, including SHOX (Short stature Homeobox) 
genes have been reported. Nevertheless the etiology of the syndrome remains unknown 
because most of the cases are sporadic, although segregation analyses in few families have 
shown an autosomal dominant inheritance with incomplete penetrance. Oligogenic or 




have been described in MYCBP2 (MYC Binding Protein 2), NAV3 (Neuron Navigator 3)and 
PTPN3 (Protein Tyrosine Phosphatase Non-Receptor Type 3) in a Japanese cohort (205).  
 
2.2.7. Sex chromosome DSD  
 
2.2.7.1. 45,X0: Turner syndrome and variants 
 
Turner syndrome is associated with a complete or partial missing of the X 
chromosome and is a rare condition in females characterized by hypergonadotropic 
hypogonadism, infertility, short stature, endocrine and metabolic illnesses and augmented 
risk of autoimmune disease among others. The syndrome occurs with a prevalence of 
1:2,000 women in different ethnic populations (206). 
 
Different karyotypes have been observed in women with Turner syndrome. Nearly 
50% of them present 45,X0 (complete loss of one X chromosome), 15-25% 45,X0/46,XX 
mosaicism, an isochromosome of p or q arm (20%) and less, an X ring chromosome. 
Hypergonadotropic hypogonadism is present in almost all patients and drives either to 
primary or secondary amenorrhea and then, to infertility, possibly due to an accelerate loss 
of oocytes from the ovaries since fetal development. The onset of puberty depends on the 
karyotype as only 2-3% of women with 45,X0 karyotype present menstrual cycles. Breast 
development at puberty occurs in 21-50% of the patients and menarche in 15-30%. 
Moreover, spontaneous puberty has been correlated with viable follicles, younger age, 
mosaic karyotypes and normal levels of FSH and AMH  Spontaneous pregnancy happens in 
about 6% of these individuals, mainly in mosaic Turner syndrome, although the rate of 
natural miscarriage is high (206). 
 
SHOX is the only gene related to Turner syndrome. This gene belongs to the paired 
homeobox family and is located in the pseudoautosomal region 1 (PAR1) of X and Y 
chromosomes. SHOX (Short stature homeobox) controls proliferation and maturation of 
chondrocytes in the growth plate, regulates the expression of NPPB (Natriuretic Peptide B) 
and FGFR3 (Fibroblast Growth Factor Receptor 3), and interacts with transcription factors 
SOX5, SOX6 and SOX9.. Then, the reduced expression of SHOX elucidates the growth deficit, 
as women with the syndrome are about 20 cm shorter than their target height. Although 
other genes like TIMP1 (Tissue inhibitor of matrix metalloproteinase 1), may be implicated in 
the frequent bicuspid aortic valves and aortic dilation observed in Turner syndrome 
individuals, further studies are required. It is now emerging the possible impact of epigenetic 
changes and variants in RNA expression, as well as protein-protein interactions in the 
development of the pathogenesis of Turner syndrome, however the genomic mechanisms 







2.2.7.2. 47,XXY: Klinefelter syndrome and variants 
 
Klinefelter syndrome is the most common male chromosomal disorder. It is reported 
to occur in 1 out of 500 or 1000 male births and is mostly diagnosed later in life. Moreover, 
about 64% remain undiagnosed . The 90% of the cases present a 47,XXY karyotype while the 
remaining include 46, XY/47, XXY mosaicism, 48, XXXY or 49, XXXXY aneuploidies and 
structural irregularities in the X chromosomes, such as 47,iXq,Y. This genetic background is 
based on the failure of chromosomal separation or non-disjunction during meiosis I and II or 
mitosis, which leads to the presence of an extra X-chromosome. 
 
The clinical features in patients with Klinefelter syndrome are highly heterogeneous 
and depend on the supernumerary X chromosome and the consequences of hypogonadism. 
Common presentation is testicular failure with small gonads, hypergonadotropic 
hypogonadism, gynecomastia, sparse body hair, signs of androgen deficiency, azoospermia, 
difficulties in language processing, social and learning disabilities and tall stature with 
eunuchoid body. Infants are generally born with a normal male phenotype, although 
cryptorchidism and inguinal hernias have been reported too (207). It has been suggested 
that the phenotypic variability of the syndrome depends on the expression of altered genes, 
androgen deficiencies, variants in AR such as the number of CAG repetitions or random 
inactivation of the additional X-chromosome material. Certainly, few studies have reported 
the presence of complete or partial androgen insensitivity syndrome due to AR gene variants 
in 47,XXY patients (207). 
 
2.2.7.3. 45,X0/46,XY: Mixed gonadal dysgenesis and ovotesticular DSD 
 
The 45,X0/46,XY karyotype has an estimated incidence of 1 to 15,000 births  and the 
chromosome constitution arises from the mitotic errors that take place during early 
divisions. Among the different phenotypes that present with the 45,X0/46,XY karyotype, 
mixed gonadal dysgenesis (MGD) is characterized by ambiguous genitalia due to a streak 
gonad and one or two dysgenetic testes. Undifferentiated gonadal tissue (UGT) has been 
also noted. This, has the same characteristics as streak tissue but contains germ cells that are 
at increased risk of neoplastic transformation.The risk of developing a malignant germ cell 
tumor, is increased in patients with a DSD and a specific part of the Y chromosome in their 
karyotypes, more specifically the aberrant expression of the TSPY (Testis Specific Protein Y) 
gene (208). On the other side, the development of the male reproductive tract is going to be 
determined by the ratio of germ line cells expressing the XY genotype, and then completely 
male and female phenotypes might be observed (209). Phenotypes similar to partial gonadal 
dysgenesis can also result from 45,X0/46,XY karyotype. Recently, a positive correlation 






Structural rearrangements of the Y chromosome, including deletions, ring 
chromosomes and isochromosomes lead to 45,X0/46,XY mosaicism and have been described 
in mixed gonadal dysgenesis, but also in Turner syndrome and infertility (211). Yp (short 
arm) deletions including SRY gene directly affect testis differentiation leading to streak 
gonads and a female phenotype, whereas deletions of the long arm (Yq11), especially 
involving the Azoospermia Factor regions (AZF) AZFa, AZFb and AZFc on Yq11 lead to male 
infertility (212). 
 
The incidence of OT DSD in individuals with 45,X0/46,XY mosaicism is low and 
additionally, the distinction between OT DSD and MGD may be complicated. Clinical and 
molecular characteristics of the OT DSD have been already explained (See 2.2.4.1, page 47).  
 
2.2.7.4. 46,XX/46,XY: chimeric and ovotesticular DSD 
 
Clinical and molecular characteristics of the chimeric and ovotesticular DSD have 
been already explained (See 2.2.4.1, page 47).  
 
 
2.3. MANAGEMENT OF DSD AND THE RISK TO DEVELOP A GERM CELL TUMOR 
 
Caring for patients with DSDs require a multidisciplinary team (172), that integrates 
medical and other professional and social science disciplines (i.e. Psychologist). Patients with 
DSD should be followed-up to guarantee the correct transition of care from childhood and 
adolescence to adult life. When referred to clinician, the clinical evaluation of individuals 
should include family and prenatal history, the appearance of the genitals and external 
phenotype, molecular diagnosis and the use of techniques like ultrasonography or 
laparoscopy to assess gonadal location and description of the tissue. Molecular diagnosis 
includes karyotyping and gene analysis. Biochemical investigations are still used as a tool for 
the identification of the mechanism. In newborns, the measuring of 17-hydroxyprogesterone 
levels is used to discard CAH and facilitates diagnosis of overvirilized 46,XX. Hormone 
therapy is going to be necessary in most patients with DSD. During childhood, the treatment 
is critical because hormone therapy leads to irreversible effects and induction of puberty is 
performed according to practices used for adolescents with pituitary or gonadal failure 
(213). Surgical treatments are performed to allow the correct development of external 
genitalia and remove the internal structures. Regarding the sex of rearing, it should be 
considered the development of the patient at puberty and future fertility. Even though no 
recommendations exist for sex assignment in newborns with DSD, the social sex is favoured 
(172).  
 
Overall, reaching a molecular diagnosis is useful in relation to possible gender 
assignment, evaluation of gonadal and adrenal function, risk of gonadal cancer, infertility 




development of a germ cell tumor. Phenotypes with gonadal dysgenesis in 46,XY and sex 
chromosomal DSD are highly heterogeneous and the resulting gonad depends on the genetic 
variant. Normally, the earlier the gonadal development is disturbed the less the gonad is 
differentiated into a testis or an ovary. The different configurations that are recognized are: 
normal testes with occasionally immature germ cells, dysgenetic testes, primitive sex cords 
including germ cells, streak gonads with some testicular or ovarian differentiation and 
undifferentiated gonadal tissue containing isolated germ cells (214). A combination of these 
configurations may be found in the same patient within the same gonad or the opposite 
one. 
 
In undervirilized 46,XY DSD, the male gonad is a testis with immature germ cells that 
are derived to apoptosis and therefore postpubertal gonads lack germ cells unless a tumor 
has surfaced. Germ cell tumors, mainly carcinoma in situ (CIS) and gonadoblastoma (GB), 
emerge with increased frequency in patients with a specific region on Y chromosome, 
namely the testis specific protein Y (TSPY). Then, overvirilized 46,XX DSD patients are not at 
risk. Immature germ cells express OCT3/4 (Octamer-Binding Protein 4), a transcription factor 
expressed in fetal undifferentiated germ cells but not later. Immunohistochemical studies 
revealed high positivity for OCT3/4 and TSPY expression in the germ cells of CIS and 
gonadoblastoma and has been proposed to be of pathogenetic relevance in the formation of 
germinal cell tumors in these patients (214). 
 
Moreover, gonadal differentiation also determines the tumor risk. Mostly, 
undifferentiated gonadal tissue gives rise to germ cell tumors. Immunohistochemistry is 
used to evaluate the number and maturation of germ cells according to their location in the 
seminiferous tubule. Thus, early CIS or GB is discarded or an estimation of the risk for the 
development of an invasive germ cell tumour is made. The incidence of a germ cell tumor in 
DSD varied between 5 to 7% but more recent reviews reported that the risk is extremely low 
in CAIS compared to PAIS or patients with HSD17B3 gene variants. Overall, the incidence is 
about 2.3% in underviriled patients and as gonads are well differentiated CIS is only 
described in these populations. However, in cases with gonadal dysgenesis the risk increases 
up to 12% and GB is developed, although CIS has also been reported. Usually, 
gonadoblastoma appears in these patients before puberty, which indicates the poor role of 
pubertal hormones in its development. However, the risk of malignancy in patients with 
46,XY gonadal dysgenesis is dependent on the underlying genetic cause (214). 
 
In the past, early gonadectomy was performed in 46,XY patients before puberty to 
prevent degeneration of dysgenetic tissue. Now, tumor risk is predicted based on medical 
analysis, such as the presence of OCT3/4 positive cells and gonadal biopsies and in some 
cases, such as in CAIS, gonads are retained until late adolescence to take advantage of the 
secretion of hormones that allow the development of secondary sex characteristics (215). 
Table 3 summarizes the recommendations for a stratified treatment model of DSD patients 




Table 3. Schematic representation of the stratified model for gonadal management in the DSD. 









































Self-examination and annual US (postpubertal) 
Biopsy: 1 prepubertal (during orchidopexy) and 1 postpubertal 
CIS/GB: gonadectomy 





CGD: Bilateral gonadectomy before puberty  































































PAIS and testosterone synthesis defect: 
Orchidopexy 
Self-examination and annual US (postpubertal) 
Biopsy: 1 prepubertal and postpubertal (bilateral biopsy). Repeat after 10 years (?) 
CIS: gonadectomy 





CAIS: postpubertal gonadectomy or follow-up 















PAIS and testosterone synthesis defect: 
Bilateral biopsy 
Low threshold to gonadectomy 
CAIS, complete androgen insensitivity syndrome; CGD, complete gonadal dysgenesis; CIS, non-invasive 
precursors carcinoma in situ; GB, gonadoblastoma; PAIS, partial androgen insensitivity syndrome; PGD, partial 
gonadal dysgenesis; US, ultrasound. 
 
 
3. NEXT GENERATION SEQUENCING AND ITS USE IN DSD 
 
Advances in DNA-based techniques have improved diagnosis and management of 
human genetic diseases, including disorders of sex development.  
 
Since the highly variable aetiology of DSD, a large number of genes have been 
considered causative and thus, the arrival of next generation sequencing (NGS) completely 
changed the diagnostic strategies from the gene-by-gene sequencing to the massively 
parallel sequencing. Gene panel sequencing, in which the genes of interest are sequenced, 
has become the first approach to be used for DSD diagnosis. It combines a fast analysis of a 
large number of genes with adequate gene coverage. As targeted panels are restricted to 
known or candidate genes and lack consistent methods for copy number variant (CNV) 
analysis, molecular diagnosis is limited. Reduced sequencing costs and increasing 
bioinformatics expertise, have improved the practice of whole exome sequencing (WES) and 
whole genome sequencing (WGS) approaches. WES and WGS are more flexible than DSD-
related gene panel and allow the identification of new genes. While whole exome 




indels in the total exons present in the human genome, WGS will eventually become first-
line clinical test as it detects all variant types in both coding and non-coding regions (216).  
 
Few studies have screened a large targeted gene panel or have guided the 
sequencing of the whole exome to analyse known and candidate DSD genes. Baxter et al as a 
continuation of a previous work, screened forty-seven 46,XY DSD patients and evaluated 64 
known genes (81), while another study reported the findings in the NR5A1 gene in thirteen 
46,XX testicular and ovotesticular DSD (194). Bigger targeted gene panels have been used for 
the analysis of either small (217, 218) or larger cohorts, as the study by Eggers et al in which 
gene panel including 64 well-known DSD and 967 candidate genes was designed to test 326 
international DSD individuals (12) More recently, the efficiency of the method has been 
reinforced with the use of targeted panels of 30, 56 and 67 genes (93, 219, 220). The 
diagnostic rate varied from 20.7% to 38.6% in these analyses, supporting the use of targeted 
NGS as a first-tier diagnostic tool for DSD. (218) (12)  
 
WES and WGS facilitate the discovery of new disease genes or genomic loci involved 
in the pathogenesis of DSD. Moreover, new roles for well-known DSD genes are increasingly 
described. This further advance also increases the amount of data and complicates the 
interpretation of the results, mainly when detecting variants of unknown significance (VUS). 
(195). In some occasions the interpretation of a variant is direct, such as novel variants in a 
well-known gene. However, when the relationship between the variant and the phenotype is 
not clear, functional assays are used to determine the effects of an alteration on a gene 
(195). In order to avoid incidental findings or findings that cannot be interpreted, the 
European Society of Human Genetics (ESHG) as well as the current guidelines for genetic 
testing in DSD, have recommended the use of a targeted approach first, when the clinical 
and biochemical results are suggestive for specific genes, and whole exome or genome 
sequencing if this is not the case. A complete list of genes that contribute in human DSD was 
recently reported by the international registry DSDnet and included 62 genes in 46,XY DSD 
and 61 in 46,XX (174). (174). 
 
As well as in many other developmental disorders, gene dosage effects contribute to 
the pathogenesis of a big percentage of DSD patients. As previously stated, CNV detection in 
the whole genome is limited to WGS, although several algorithms for assessment on WES 
and gene panel data are available (216). Studies of gene copy number were initially done 
with karyotype banding, which only detected large chromosome rearrangements, and FISH 
(Fluorescence in situ hybridization), which was employed to identify smaller CNV. Nowadays, 
detection of intragenic and whole gene CNV may be done by MLPA (Multiplex Ligation-
dependent Probe Amplification), but aCGH (array-based Comparative Genomic 
Hybridization) are extensively used to detect small to large-scale duplications and deletions 
(<5 Mb) along the genome. The intragenic deletions are not always detected by Sanger 
sequencing (221) and therefore these techniques have become part of the routine 




gonad genes can also be detected (223). Additionally, arrays have been crucial in the analysis 
of regulatory regions in genes such as SOX9 and GATA4 (26) (44).  
 
Previous to new molecular diagnosis techniques, the investigation of DSD involved 
the Sanger sequencing of a small number of known genes, depending on the disease 
phenotype, and in combination with a MLPA for the analysis of bigger rearrangements. 
Many variants in gonad determining and differentiating genes, such as SRY or SOX9, were 
discovered by sequencing candidate genes and screening the appropriate DSD patients. 
However, the difficulty to define many DSD phenotypes complicated the choice (195) and 
large number of patients did not achieve a molecular diagnosis. Currently, candidate gene 
sequencing is mainly used when the massively parallel sequencing fails to interpret a result 
as in complex rearrangements, to sequence a region of interest in segregation analysis and 
to validate the variants found by NGS (174). The heterogeneous nature of DSD, as well as the 
increasing evidence of an oligogenic mode of inheritance has led to the replacement of 
individual gene sequencing also when clinical and biochemical profiles point to a specific 
gene (25, 224). Nevertheless, the sequencing of larger cohorts with novel genetic and 
genomic technologies is expanding our knowledge on the genetic changes leading to DSD, 
and may improve the understanding of the observed phenotypes (195). The use of these fast 
diagnostic tools enables better diagnoses and has changed the clinical diagnostic pathway in 
DSD. The traditional approach consisted on clinical examination including biochemical 
investigations, karyotype determination and testing for CNV in known DSD genes, mainly 
when DSD were associated with other malformations (222). Gene sequencing, both by 
Sanger or NGS, was often the last step and was based on the gathered phenotypic 
information (225). However, genome wide sequencing has supported a parallel approach in 
which biochemical and molecular evaluations are complementary (Figure 8). Nevertheless, 
the best strategy should be determined based on karyotyping, clinical and hormonal 
phenotype and family history (174, 226).  
 
Technology is constantly changing and rapid advances in machines and platforms 
occur, coverage is improved and new bioinformatic tools are created for the interpretation 
of variants identified. Current molecular techniques, in the form of aCGH or NGS allow a 
faster analysis of patients when targeted to known genes, while broaden approaches 
(WES/WGS) increase diagnostic rates and provide the opportunity to discover novel genes, 
developmental pathways and regulatory mechanisms in undiagnosed DSD patients, 
improving the understanding of molecular aetiology. Although the diagnostic process of rare 
diseases has been enhanced with the current molecular analyses, these results need to be 
placed in the correct clinical context. In the past, genetics were performed to confirm the 
biochemical findings, nowadays, NGS allows sequencing while essential clinical tests are 
done and thus, saving healthcare system’s resources. In any case, a complete examination 
including physical and biochemical testing should be placed to functionally assess the 
relevance of the gene mutation (7). Genome-wide sequencing has improved diagnostics, 




highlights the importance of underlying molecular mechanisms (12, 226). Beside the 
psychological circumstances that patients need to face, DSD may be associated to other 
conditions such as cardiovascular disease, obesity or cancer (226), that hinder the 
management of DSD and a well-founded diagnosis in individuals with such complex 
conditions. The advances in the understanding of molecular mechanisms, technology and 
expertise enable a better clinical practice in people with DSD, allowing the clinician to 
predict the prognosis and long-term outcome. 
 
 
Figure 8. Diagnostic approach in which the patient’s clinical and biochemical features are studied in parallel 

























 Disorders of Sex Development encompass a heterogeneous group of conditions in 
which multidisciplinary care is essential. Clinical examination, biochemical tests and 
karyotype determination, along with genetic investigations have a significant impact to 
assess the aetiology of the disease.  
 
Genetic testing prior to novel technologies was dependent on the clinical information 
and the suspicion of the involvement of a specific gene. With the arrival of next generation 
sequencing, new genes and pathways are being implicated in the pathogenesis and the 
genetic basis is gradually being elucidated. Previous studies have analysed cohorts of 
individuals with DSD, though reaching a specific molecular diagnosis remains challenging in 
nearly 50% of the 46,XY DSDs.  
 
Therefore, the hypothesis of this present work is that molecular analysis either by a 
gene-by-gene approach or using massively parallel sequencing technologies will identify the 
genetic cause in these patients and together with the clinical diagnosis determine a 




























MAIN OBJECTIVE  
 
Clinical and molecular characterization of patients with a disorder of sex 
development using a candidate gene approach or a targeted gene sequencing panel in those 




1. Implement a single-gene and a targeted gene sequencing panel analysis to 
genetically characterize a cohort of DSD patients /Improve the genetic 
characterization of patients with disorders of sex development using a single-gene 
and a targeted gene panel as a diagnostic tool. 
 
2. Identify genetic variants that explain the development of the disease in patients with 
DSD using a single-gene approach and a targeted gene panel. 
 
3. Functional characterization of identified variants either by the single-gene testing or 
next generation sequencing to stablish the impact of the genetic change in the 
pathogenesis of the disease. 
 
4. Establish a phenotype-genotype correlation between the clinical features of the 




















4. STUDY DESIGN 
 
Clinical and molecular analyses were performed in all the included patients.  
 
 
4.1. DESCRIPTION OF THE PATIENTS 
 
Clinical characterization of each proband, and relatives when applicable, was done 
after examination of the clinical data sheet collected in our Institute. For biochemical and 
hormonal parameters, values were compared based on age and sex-appropriate range of the 
hospital of origin according to the reference values recommended by the Spanish Society for 
Paediatric Endocrinology (SEEP, Sociedad Española de Endocrinología Pediátrica) working 
group on DSD in 2017 (227). 
 
Clinical and biochemical data of the 125 patients with DSD diagnosis that have been 
included in this study are summarized in Supplementary data 2 and 3.  
 
 
4.2. MOLECULAR STUDY 
 
The molecular analysis was carried out in three different phases (Figure 9).  
 
4.2.1. Candidate gene sequencing approach for DSD-related genes  
 
Candidate genes are chosen on the basis of either their functional relevance to the 
disease pathogenesis or their locations within implicated chromosomal regions. This 
approach has been applied for gene-disease research, among others. The first gene selected 
for testing is the more related to the disease. If no alteration is found, a second gene is 
chosen and successively, until a mutation explaining the phenotype of the patient is found. 
The success of this approach depends upon the correct choice of the genes to be studied 
and is limited by its support on existing knowledge about the theoretical biology of disease. 
 
Among included patients, 36 were genetically diagnosed for classical DSD-associated 
genes by a candidate gene approach using traditional Sanger sequencing technique, 
Multiplex Ligation-dependent Probe Amplification (MLPA), Quantitative Multiplex 
Polymerase chain reaction of Short Fluorescent Fragments (QMPSF) or a Comparative 
Genome Hybridization array (aCGH), depending on the suspected gene variants causing the 









Figure 9. Schematic representation of the molecular study developed in this work. 
 
 
4.2.2. Next generation Sequencing: targeted gene panel for DSD  
 
After the implementation of next generation sequencing (NGS) technology in our 
Institute, patients collected since 2015 were analysed with a customized gene panel for DSD. 
The testing panel was designed to contain a total of 48 genes, associated with sex 
determination, sex differentiation and hypogonadism. The list of the genes in the 
customized panel can be found in Table 4 (Page 79).  
 
Individuals with a previous negative result in the gene-by-gene study were also 
included in this procedure. Altogether, 89 subjects were studied in the panel.  
 
Among included clinical cases 11 positive controls with variants confirmed by Sanger 
sequencing were incorporated to the NGS study to validate the assay. These controls 
comprised 8 index cases diagnosed with DSD and 2 relatives of an affected patient, included 
due to the absence of DNA of the proband. These cases presented with changes in the SRY, 
HSD17B3, AR, NR5A1 and NR0B1 genes. Additionally, 1 subject diagnosed with Wilms’ 
tumour harbouring a known mutation in the WT1 gene was included. WT1 is a well-known 
gene that is also involved in the gonadal development in 46,XY DSD and is comprised in the 
customized panel. Four negative controls were also tested to ensure the efficacy of the 
methodology.  
 





An aCGH, MLPA or Fluorescence In Situ Hybridization (FISH) was performed for 
complete genetic diagnosis of some patients in which deletions, amplifications or complex 
rearrangements were suspected, as well as to validate the findings of the NGS technique.  
 
For both approaches, candidate gene and NGS approach, parents and family 
members were tested to establish the mode of inheritance, when available. 
 
4.2.3. Functional characterization of likely pathogenic variants or variants of 
unknown significance 
 
The main objective of these functional studies was to analyse the potentially 
pathogenic alterations mapped in three different genes in cells and determine the effect in 
the pathogenesis of the disease.  
 
 
5. CLINICAL DATA OF THE PATIENTS 
 
In this study, we have performed the clinical and genetic analysis of patients affected 
by a Disorder of Sex Development (DSD). A total of 125 index individuals with a clinical 
diagnosis of DSD were evaluated between 2002 and 2018. 
 
This multicentre study included patients attending an Endocrinology or Paediatric 
Endocrinology service from several Spanish and one Swiss hospital (Supplementary data 4). 
 
The inclusion criteria were as follow:  
• Clinical diagnosis of a DSD, according to the consensus statement on management of 
intersex disorders (172) 
• Complete clinical data sheet of the patient 
• Informed consent from patients and family 
 
Clinical data were provided by the different clinicians. Clinical data sheet included age 
at consultation, assigned gender, karyotype of the patient and family background comprising 
consanguinity of the parents, virilisation during pregnancy or infertility. At examination, data 
about external genitalia, Tanner stage in puberty, biochemical and hormonal values as well 
as treatment and progression were gathered. If performed, comments on Magnetic 
Resonance Imaging (MRI) and ultrasound (US) images were achieved, and reports from the 
gonadal biopsy were included. Lastly, previous molecular studies were also annotated. The 
clinical data sheet is included as Supplementary data 5. 
 
Written informed consent was obtained at the respective hospitals involved from all 
subjects and their family members after full explanation of the purpose and nature of all the 




6. SAMPLE COLLECTION AND STORAGE 
 
Blood samples or DNA (Deoxyribonucleic Acid) from the patients and family members 
were obtained during routine examination at the different hospitals, and together with the 
clinical data and informed consent, were collected at the Biocruces Bizkaia Health Research 
Institute (Barakaldo, Spain).  
 
Two different blood samples containers were used depending of the molecular study 
to be performed: 
• Blood sample on EDTA-containing (Ethylenediaminetetraacetic acid) tubes were used 
for the extraction of genomic DNA and its application on candidate gene sequencing 
approach and NGS, as well as validation of the variants by Sanger sequencing and 
CNV (copy number variant) by MLPA and aCGH. 
• Blood samples on Sodium Heparin were used for the FISH technique in which 
lymphocytes life long enough to yield a proper cell culture.  
 
Each sample was registered in the laboratory and identified with a family name. 
Then, blood samples on EDTA-containing tubes were stored at -40°C until use. On the 
contrary, samples on Sodium Heparine were kept at room temperature and procedure for 
fixing cells was done within the same day the sample was obtained. Slides with the fixed 
lymphocytes reared at metaphase were stored at -20°C until use.  
 
 
7. MOLECULAR STUDY 
 
7.1. GENOMIC DNA EXTRACTION 
 
Genomic DNA was extracted from peripheral blood leukocytes using either the 
manual QIAamp DNA Blood Mini kit (Qiagen NV, Venlo, Netherlands) or the automated 
MagPurix 12S system from Zinexts (Zinexts Life Science Corp., New Taipei City, Taiwan). 
 
7.1.1. Manual DNA extraction 
 
The purification procedure comprises 4 steps and is carried out using spin columns. 
After cellular lysis, DNA is adsorbed onto the membrane of the column and the washing 
steps remove contaminants. Finally, purified DNA is eluted.  
 
This method is designed for a purification of an average of 6μg of total DNA from 
200µL of whole human blood. 
 
Reagents and materials 




• QIAamp DNA Blood Mini kit (50u) (Qiagen NV, Cat. No 51104), containing QIAamp 
Mini Spin Columns (50), Collection Tubes (2mL) (150), Buffer AL (12mL), Buffer AW1 
(19mL), Buffer AW2 (13mL), Buffer AE (15mL), QIAGEN® Protease (1 vial) and 
Protease Solvent (1.2mL). 
• Centrifuge Heraeus Pico 17 (Thermo Fisher Scientific, Waltham, MA, USA, Cat. No. 
75002491). 
• Heating block (JP Selecta S.A, Abrera, Barcelona, Cat. No. 7462200).  




1. Pipet 20μl QIAGEN® Protease into a 1.5mL tube. 
2. Add 200μl blood sample to the tube.  
3. Add 200μl Buffer AL to the sample. Mix by vortexing for 15 seconds. 
4. Incubate at 56°C for 10 minutes. Spin the samples to remove drops from the inside of 
the lid. 
5. Add 200μl ethanol.  
6. Vortex for 15 seconds. Spin the samples to remove drops from the inside of the lid. 
7. Transfer the mixture to a QIAamp Mini spin column. 
8. Centrifuge at 8000 rpm for 1 min. Place the column in a new tube and discard the 
tube containing the filtrate. 
9. Add 500μl Buffer AW1 and centrifuge at 8000 rpm for 1 min. Discard the filtrate. 
10. Add 500μl Buffer AW2 and centrifuge at 13000 rpm for 3 minutes. Place the column 
in a new tube and discard the tube containing the filtrate. 
11. Centrifuge at 13000 rpm for 1 min.  
12. Place the QIAamp Mini spin column in a clean 1.5mL microcentrifuge tube. 
13. Add Buffer AE. For candidate gene sequencing, add 75μL of Buffer AE; however, for 
NGS analysis add 200μL of Buffer AE. 
14. Incubate at room temperature for 5 minutes. 
15. Centrifuge at 8000 rpm for 1 min. 
16. Transfer the eluted DNA to a 1.5mL screw tube, assign a new DNA number for the 
laboratory register and store at 4°C or -20°C for posterior use. 
 
7.1.2. Automated DNA extraction 
 
The Magpurix 12S system consists of a robotic workstation for automated nucleic 
acid purification that uses pre-filled reagent cartridges and disposable consumables, with the 
flexibility of processing 1-12 samples per run. The MagPurix technology uses magnetic beads 
to purify nucleic acids from samples and follows steps of lysis, binding, washing and elution. 
The MagPurix Blood DNA Extraction Kit 200 (36 preps) (Zinexts Life Science Corp., Taiwan) 
for gDNA (genomic DNA) extraction from 100-400μL mammalian blood cells was used. This 





Depending on the genetic approach to be performed, the required DNA 
concentration varies.  
While 25-50ng/µL human genomic DNA is recommended for Polymerase Chain Reaction 
(PCR), the optimal concentration for NGS is about 100ng/µL. Therefore, for candidate gene 
sequencing, we isolated and purified 300μL from each blood sample to get 300µL eluted 
DNA; however, for NGS analysis the elution volume was 100µL. 
 
Reagents and materials 
• Magpurix 12S system (Zinexts Life Science Corp., Cat. No. ZP01001). 
• MagPurix Blood DNA Extraction Kit 200 (36 preps) (Zinexts Life Science Corp., Cat. No. 
ZP02001), containing Reaction chamber (36 pieces, 6x6), Tip holder (36 pieces), 
Filtered tip (38 pieces), Piercing pin (38 pieces), Sample tube of 2mL (38 pieces), Elute 
tube of 1.5mL (38 pieces), Barcode paper and Reagent cartridge (36 pieces, 6x6). The 
Reagent cartridge includes:  
o Well 1: Proteinase K solution (40μl). 
o Well 2: Lysis Buffer 2 (1000μl). 
o Well 3: Binding Buffer 1 (600μl). 
o Well 4: Magnetic Bead Solution (800μl). 
o Well 5: Washing Buffer 1 (1000μl).  
o Well 6: Washing Buffer 2 (1000μl). 
o Well 7: Washing Buffer 3 (1000μl). 
o Well 8: Elution Buffer 1 (1000μl). 
o Well 9: Elution Buffer 2 (1000μl). 
o Well 10: Empty. 
 
Procedure 
1. Turn the power switch on. Open the sliding door and remove the sample rack from 
the instrument. 
2. Load reagent cartridges and all plastic disposables, such as, reaction chamber, tip 
holder, piercing pin and filtered tip.  
3. Load one reaction cartridge and one set of plastic disposable per sample. 
4. Load sample tube and elute tube to sample rack on the bench. 
5. Load 300µL of the blood sample to sample tube. 
6. Place sample rack on the instrument platform. Close the door. 
7. Scan the protocol barcodes to select purification protocol MagPurix Blood DNA 
Extraction Kit 200, sample volume 300µL and elute volume 300μL or 100μL. 
8. Follow the instructions displayed on the screen to check the operating steps. 
9. Push “Enter” to confirm and press “Start” button. The automated purification 
protocol begins and steps of the protocol. 
10. At the end of the run, open the instrument door and remove the elute tubes 




11. Discard the used cartridges and all plastic consumables into biohazard waste. Close 
the instrument door and turn the power switch off. 
12. Transfer the eluted DNA to a 1.5mL screw tube, assign a new DNA number for the 
laboratory register and store at 4°C or -20°C for posterior use.  
 
 
7.2. EXTRACTED DNA QUANTIFICATION AND PURITY CHECKING  
 
To check for concentration the NanoDrop® ND-1000 spectrophotometer (Thermo 
Fisher Scientific) and the Qubit® 2.0 Fluorometer (Thermo Fisher Scientific) were used. For 
measuring the quality of the extracted DNA samples the NanoDrop® ND-1000 
spectrophotometer was used.  
 
7.2.1. DNA quantification  
 
DNA concentrations can be assessed using different methods, such as absorbance or 
optical density (Spectrophotometric method) and fluorescent DNA-binding dyes 
(Fluorometric method).  
 
7.2.1.1. Spectrophotometric method 
 
Nucleic acids absorb ultraviolet (UV) light due to the heterocyclic rings of the 
nucleotides among the DNA. The wavelength of maximum absorption for DNA is 260nm 
(λmax = 260nm) with a characteristic value for each base, that will allow the determination 
of the concentration. 
 
At very high concentrations, especially if the material is scattering, the absorbance 
value and therefore the concentration can be inaccurate. UV absorbance measurements are 
not selective and cannot distinguish between single or double strand nucleic acids. Values 
are easily affected by other contaminants, such as free nucleotides, salts, and organic 
compounds, and variations in base composition. 
 
Reagents and materials 
• Buffer AE (15mL) from the QIAamp DNA Blood Mini kit (Qiagen NV). 
• Milli-Q ultrapure water (Merck KGaA, Darmstadt, Germany). 
• NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific). 
• NanoDrop 1000 Spectrophotometer Software v3.8 (Thermo Fisher Scientific). 
 
Procedure 
1. Clean the pedestal by pipetting 2µL bidistilled water onto the measurement pedestal. 




2. Pipet 1µL Milli-Q ultrapure water or AE buffer onto the pedestal to make the blank 
measurement.  
3. Lower the sampling arm and initiate the measurement by clicking on the software. 
4. When the measurement is complete, raise the sampling arm and clean. 
5. Pipet 1μL sample directly onto the measurement pedestal and measure. 
6. The software displays the results of the concentration measurement, as well as the 
purity checking values.  
7. Repeat step 1 once all the samples have been measured. 
 
7.2.1.2. Fluorometric method 
 
The Qubit® 2.0 Fluorometer in combination with the Qubit® dsDNA BR Assay Kit 
yields specific double-stranded DNA (dsDNA) quantitation and is accurate for initial sample 
concentrations from 100pg/μL to 1000ng/μL. The basis of the Qubit™ assay is a molecular 
probe dye that emits fluorescent signals only when bound to dsDNA. 
 
Reagents and materials 
• Qubit® 2.0 Fluorometer (Thermo Fisher Scientific, Cat. No. Q32866). 
• Qubit® dsDNA BR Assay Kit (500 preps) (Thermo Fisher Scientific, Cat. No. Q32853), 
containing Qubit® dsDNA BR Reagent (Component A) (1,25mL), Qubit® dsDNA BR 
Buffer (Component B) (250mL), Qubit® dsDNA BR Standard #1 (Component C) (5mL) 
and Qubit® dsDNA BR Standard #2 (Component D) (5mL). 
• Qubit Assay tubes (500 tubes) (Thermo Fisher Scientific, Cat. No. Q32856). 
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
 
Procedure 
1. Set up the required number of 0.5mL Qubit® assay tubes for the two standards and 
samples. Label the tube lids.  
2. Prepare the Qubit® working solution by diluting the Qubit® dsDNA BR Reagent 1:200 
in Qubit® dsDNA BR Buffer.  
3. Add 190μL of Qubit® working solution to each standard tube. 
4. Add 10μL of each Qubit® standard to the appropriate tube, then mix by vortexing. 
5. Add 198μL of Qubit® working solution to each assay tube. 
6. Add 2μL sample to each assay tube, then mix by vortexing. 
7. Incubate all tubes at room temperature for 2 minutes. 
8. On the Home screen of the Qubit® 2.0 Fluorometer, press DNA and select dsDNA 
Broad Range. 
9. Read the standards. Insert the tube containing Standard #1 into the sample chamber, 
close the lid, and then press Read. When the reading is complete remove Standard 
#1 and repeat with Standard #2.  




11. Insert a sample tube into the sample chamber, close the lid, and then press Read. 
When the reading is complete, remove the sample tube. 
12. The instrument displays the results on the Sample screen. 
13. Repeat step 12 until all samples have been read. 
 
7.2.2. DNA purity checking 
 
Absorbance measurements will measure any molecules absorbing at a specific 
wavelength. Nucleotides, Ribonucleic Acid (RNA), single-stranded DNA (ssDNA) and dsDNA 
will absorb at 260nm and contribute to the total absorbance. 
The ratio of absorbance at 260nm and 280nm is used to assess the purity of DNA. A ratio of 
1.8 is accepted as pure DNA. If the ratio is lower, it may indicate the presence of protein, 
phenol or other contaminants that absorb at nearly 280nm. 
 
The 260/230 ratio is commonly in the range of 2.0 for pure DNA. If it is appreciably 
lower, it may indicate the presence of contaminants which absorb at 230nm, such as EDTA, 
carbohydrates and phenol.  
 
 
7.3. POLYMERASE CHAIN REACTION  
 
This widely used technique exponentially amplifies a specific segment of DNA to 
generate multiple copies of a DNA sequence.  
 
The PCR comprises five steps developed at different temperatures in a thermocycler. 
The initialization step consists in the heat activation of the Taq polymerase at 94-95°C for 5-
10 minutes. In the denaturing stage, the hydrogen bonds between complementary bases are 
broken at 90-94°C and this breaks the dsDNA into two ssDNA molecules. In the annealing 
stage, the temperature is lowered to 50-65°C and the primers bind to their complementary 
sequence of DNA. This forms the double strand site which the polymerase can bind to and 
allows the elongation of DNA. In the elongation stage, at 72 to 75°C, the DNA polymerase 
synthesizes a new DNA strand, complementary to the DNA template strand, by adding free 
dNTPs (Deoxynucleoside triphosphates) in the 5’ to 3’ direction. At each elongation stage, 
the number of DNA target sequences is doubled. The processes of denaturation, annealing 
and elongation constitute a single cycle and are repeated among 35 to 40 times, leading to 
exponential amplification of the specific DNA target region. A final elongation step is 
performed at 72 to 75°C for 5 to 10 minutes to ensure that any remaining ssDNA is 
elongated.  
 
Besides DNA template containing the target region to amplify, several components 




• Buffer solution: It provides the suitable environment for the activity and stability of 
the DNA polymerase. It contains Tris-HCl to maintain the proper pH at 8-8.3, KCl to 
increase the activity of the enzyme and MgCl2 which provides the Mg2+ ions that 
work as cofactors of the polymerase.  
• dNTPs: The main subject from which the new strand is synthesized by the 
polymerase. Adenine, guanine, cytosine and thymine deoxynucleosides are added in 
the same concentration. 
• Two DNA primers: Specific short ssDNA fragments complementary to the 3’ ends of 
each of the sense and antisense strands of the target DNA. We custom-made the 
oligonucleotides for each region of interest and add a M13 tail (Forward: 5’-
TGTAAAACGACGGCCAGT-3’ and reverse: 5’-CAGGAAACAGCTATGACC-3’). With this 
M13 tailed primers we can use the same primers for sequencing, ignoring the original 
sequence.  
• Dimethyl sulfoxide (DMSO): An organosulfur compound that binds the cytoside 
residue, changing its conformations ant therefore, makes DNA more labile for heat 
denaturation. 
• Heat-stable DNA polymerase (Taq polymerase): Originally isolated from Thermus 
aquaticus bacteria. This enzyme polymerizes new DNA strands and it remains intact 
during the high temperature DNA denaturation process. We used the KAPA Taq DNA 
Polymerase (Kapa Biosystems, Boston, MA, USA), of the thermophilic bacterium 
Thermus aquaticus, purified from recombinant Escherichia coli (E. coli). It has 5’-3’ 
polymerase and 5’-3’ exonuclease activity.  
• Milli-Q ultrapure water (Merck KGaA, Darmstadt, Germany). 
 
We used PCR for the amplification of the genes of interest by the candidate gene 
approach, validation of variants found by NGS and amplification of regions not covered by 
the targeted gene panel. 
 
Reagents and materials 
• KAPA Taq PCR Kit (Kapa Biosystems, Cat. No. KK1014), containing KAPA Taq DNA 
Polymerase (5U/µL), KAPA Taq Buffer A (10X) KAPA Taq Buffer B (10X) and MgCl2 
(25mM). 
• dNTP Mix (10mM) (5mL) (Merck KGaA, Cat. No. D7295-5ML). 
• DMSO (C2H6OS) (50mL) (Merck KGaA, Cat. No. D8418-50ML).  
• Primers pool (250 μM) (Integrated DNA Technologies Inc, Skokie, Il, USA). 
• Milli-Q ultrapure water (Merck KGaA). 
• PCR-strip tubes (Sarstedt AG&Co KG, Nümbrecht, Germany, Cat. No 72.982.002).  
• PCR lid strips (Sarstedt AG&Co KG, Cat. No. 65.989.002).  
• GeneAmp®PCR System 9700 (Thermo Fisher Scientific, Cat. No. 4339386). 






For each amplification, a mix containing Milli-Q water, Buffer A, dNTPs (10mM), 
primers at 25pM, Taq DNA polymerase and DNA (25-100ng) is prepared. DMSO is added 
when required. Conditions in the thermocycler are also different for each DNA amplification 
sequence. Annealing temperature of the different primers was optimized by doing a 
temperature gradient PCR. 
 




7.4. AGAROSE GEL ELECTROPHORESIS 
 
Agarose gel electrophoresis is the most common way of separating DNA fragments of 
varying sizes for visualization and purification. Nucleic acid molecules are separated by 
applying an electric field to move through a matrix of agarose, in which the pore size is 
determined by the percentage of agarose in the buffer. When applying an electric field, 
negatively charged DNA, due to the phosphate backbone, will migrate to the positively 
charged anode in neutral pH conditions given by 1X TAE (Tris base, acetic acid and EDTA) 
buffer.  
 
Shorter DNA fragments migrate through the gel more quickly than longer ones. 
Consequently, the approximate length of a DNA fragment can be determined by running it 
on an agarose gel alongside a DNA ladder. After separation, the DNA molecules can be 
visualized under UV light after staining with the fluorophore GelRed™ (Biogen, Cambridge, 
MA, USA), an intercalating nucleic acid dye that when exposed to UV light will fluoresce with 
an orange colour after binding to DNA. Comparison of the band location with the molecular 
ruler confirms the specific amplification of the region of interest 
 
Reagents and materials  
• Agarose D-1 (Pronadisa, Madrid, Spain, Cat. No. 8016). 
• 50X TAE Buffer (40 mM Tris, 20 mM acetic acid and 1 mM EDTA, pH 8,3) (Bio-Rad, 
Hercules, CA, USA, Cat. No. 1610773). 
• EZ Load™ 100bp Molecular Ruler (Bio-Rad, Cat. No. 1708352). 
• 5X Nucleic Acid Sample Loading Buffer (Bio-Rad, Cat. No. 161-0767).  
• GelRed™ (Biogen, Cambridge, MA, USA, Cat. No. BT41003). 
• Milli-Q ultrapure water (Merck KGaA). 
• Electrophoresis chamber Sub® Cell GT MINI (Bio-Rad, Hercules, CA, USA, Cat. No. 
1704467). 
• PowerPac™ 3000 Power Supply  (Bio-Rad, Cat. No. 1655057). 
• G: BOX Chemi 16 Bio Imaging system (Syngene, Cambridge, UK, Cat. No. SGBOX). 




• Sub-Cell GT UV-Transparent Gel Tray (Bio-Rad, Cat. No. 1704435). 
• Fixed-Height Comb (Bio-Rad, Cat. No. 1704465). 
 
Procedure 
1. Melt the 1.5% agarose containing bottle (Supplementary data 7) and pour 50mL to a 
falcon. Add 2μL of GelRed™.   
2. Pour the mixture into a gel tray. 
3. Put the Fixed-Height Comb and cool. 
4. Remove the Fixed-Height Comb and put the gel into the electrophoresis chamber. 
Add 1X TAE buffer (Supplementary data 7) until the gel is covered. 
5. Mix 2μL of DNA products with 1μL of 5X Nucleic Acid Sample Loading Buffer. 
6. Load 1μL of the EZ Load™ 100bp Molecular Ruler on the first well. 
7. Continue loading 2μL of the DNA products mixed with loading buffer. 
8. Run the electrophoresis at 110V for 30 minutes. 
9. Visualize the PCR product in the imaging system and capture the image by using the 
GeneSnap Software v7.12.  
 
 
7.5. EXOSAP-IT PURIFICATION 
 
When the PCR amplification is complete, unconsumed dNTPs and primers remain in 
the PCR product mixture. ExoSAP-IT™ (Thermo Fisher Scientific) prepares PCR products for 
sequencing. It employs two hydrolytic enzymes, Exonuclease I and Shrimp Alkaline 
Phosphatase (SAP), to remove the remaining dNTPs and primers that would interfere with 
the sequencing reaction. Exonuclease I degrades residual primers and single stranded DNA 
while SAP hydrolyses the remaining dNTPs from the mixture.  
 
Reagents and materials 
• ExoSAP-IT™ (Thermo Fisher Scientific, Cat. No. 78202).  
• GeneAmp®PCR System 9700 (Thermo Fisher Scientific, Cat. No. 4339386). 
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
 
Procedure 
1. Add 5μL of the PCR product to a 0.2mL tube. 
2. Add 2μL ExoSAP-IT and mix by vortexing.  
3. Incubate at the thermocycler at 37°C for 15 minutes and at 80°C for another 15 
minutes. 








7.6. CAPILLARY SANGER SEQUENCING 
 
The principles of DNA replication were used by Sanger et al (228) in the development 
of the process known as Sanger dideoxy sequencing. This process takes advantage of the 
ability of DNA polymerase to incorporate 2¢, 3¢-dideoxynucleotides, base analogues that lack 
the 3¢-hydroxyl group essential in phosphodiester bond formation. 
 
Sequencing requires a DNA template, a sequencing primer, a thermal stable DNA 
polymerase, dNTPs, dideoxynucleotides triphosphates (ddNTPs), and reaction buffer 
containing manganese (Mn2+). Unlike Sanger’s method, which used radioactive material, 
fluorescence-based cycle sequencing uses fluorescent dyes to label the extension products 
and the components are combined in a reaction that is subjected to cycles of annealing, 
extension, and denaturation in a thermal cycler. Thermal cycling of the sequencing reactions 
creates and amplifies extension products that are terminated (dye terminators) by one of 
the four ddNTPs. Because each dye label emits a unique wavelength when excited by light, 
the fluorescent dye on the extension product identifies the 3ʹ terminal ddNTP as A 
(Adenine), C (Cytosine), G (Guanine) or T (Thymine). The ratio of dNTPs to ddNTPs is 
optimized to produce a balanced population of long and short extension products. 
 
During capillary electrophoresis, the extension products of the cycle sequencing 
reaction enter the capillary as a result of electrokinetic injection. A high voltage charge 
applied to the buffered sequencing reaction forces the negatively charged fragments into 
the capillaries. The extension products are separated by size based on their total charge. 
Before reaching the positive electrode, the fluorescently labelled DNA fragments move 
across the path of a laser beam, causing the dyes on the fragments to fluoresce. An optical 
detection device on the genetic analyser detects the fluorescence and the software converts 
the fluorescence signal to digital data. 
 
7.6.1. Cycle sequencing DNA templates 
 
Reagents and materials 
• BigDye® Terminator v3.1 Cycle Sequencing kit (Thermo Fisher Scientific, Cat. No. 
4337455), which includes 5X Sequencing Buffer (2 × 1mL) and BigDye® Terminator 
v3.1 Ready Reaction Mix (1 × 800µl).  
5X Sequencing Buffer, includes: Tris-HCl and MgCI2. 
BigDye® Terminator v3.1 Ready Reaction Mix, contains: dideoxynucleotide 
triphosphates (ddATP, ddTTP, ddCTP, ddGTP), deoxynucleotide triphosphates (dATP, 
dTTP, dCTP, dGTP) and Taq polymerase enzyme. 
• DMSO (50mL) (Merck KGaA, Cat. No. D8418-50ML).  
• Specific primers for each fragment (2.5μM) or M13-tailed primers (2.5μM) 
(Integrated DNA Technologies Inc). 




• MicroAmp® Optical 96-Well Reaction Plate (Thermo Fisher Scientific, Cat. No. 
4316813).  
• MicroAmpTM Clear Adhesive Film (Thermo Fisher Scientific, Cat. No. 4306311).  
• GeneAmp®PCR System 9700 (Thermo Fisher Scientific, Cat. No. 4339386). 
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
 
Procedure 
1. For each reaction add the following reagents to the MicroAmp® Optical 96-Well 
Reaction Plate: 
• BigDye® Terminator v3.1 Ready Reaction Mix: 1μL 
• 5X Sequencing Buffer: 1.5μL 
• Milli-Q ultrapure water: 3.5μL 
• DMSO: 0.5µl 
2. Mix using a Vortex 
3. Add 2.9µl purified PCR product and 1.3μL corresponding primers. 
4. Mix using a Vortex. 
5. Cover the plate with MicroAmpTM Clear Adhesive Film. 
6. Place the plate in the GeneAmp® PCR System 9700 thermocycler and perform cycle 
sequencing as follows:  
• Initial denaturation: 94°C for 3 minutes 
• Repeat the following for 25 cycles:  
o Denaturation: 96°C for 10 seconds. 
o Annealing: 50°C for 5 seconds. 
o Elongation: 60°C for 4 minutes 
• Hold at 4°C until purification 
 
7.6.2. Purification of extension products 
 
The presence of both unlabelled and dye-labelled reaction components can interfere 
with electrokinetic injection, electrophoretic separation, and data analysis. Purification of 
extension products reduces this interference.  
 
Alcohol-based nucleic acid precipitation techniques include a wide variety of 
methods, such as the choice of alcohol, concentration of salt, temperature and additives. 
Purification by Ethanol/EDTA/NaOAc was performed following the protocol by Applied 
Biosystems. 
 
Reagents and materials 
• EDTA (C10H16N2O8) (Merck KGaA, Cat. No. 431788). 
• Sodium acetate (CH3COONa) (NaOAc) (Merck KGaA, (Cat. No. S2889). 




• Formamide (CH3NO) (Thermo Fisher Scientific, Cat. No. 4311320). 
• Milli-Q ultrapure water (Merck KGaA). 
• Towel paper Scottfold (Kimberly-Clark, Cat. No. MRT116, Barcelona, Spain). 




1. Remove the 96-well reaction plate from the thermal cycler and centrifuge the plate 
at 100 x g for 1 minute. Then remove the seal. 
2. Prepare 125mM EDTA and 3M NaOAc (Supplementary data 7) 
3. Mix enough volume of 125mM EDTA and 3M NaOAc in 1:1 proportion. Add 2μL of 
the mix to each sample. 
4. Add 25μL absolute ethanol to each well and mix by pipetting up and down. 
5. Incubate the plate in darkness at room temperature for 15 minutes 
6. Centrifuge the plate at 3000 x g at 4°C for 30 minutes. 
7. Invert the plate onto a paper towel and spin the plate in the centrifuge. 
8. Add 35μL 70% ethanol to each well. 
9. Centrifuge the plate at 1650 x g at 4°C for 15 minutes.  
10. Invert the plate onto a paper towel and centrifuge the plate at 190 x g for 4 minutes.  
11. Add 12μL Milli-Q water. 
12. Add 12μL formamide 
13. Seal the plate with self-adhesive film, mix by vortexing.  
14. Remove the self-adhesive film. Cover the plate with the specific lid and place the 
reaction plate in the genetic analyser. 
 
7.6.3. Capillary electrophoresis and data analysis 
 
Capillary electrophoresis was performed on an ABI PRISM 3130xl (Thermo Fisher 
Scientific) Genetic Analyser, following manufacturer’s protocol. 
 
Obtained chromatograms were analysed using Sequencing Analysis Software v5.2 
(Thermo Fisher Scientific) and SeqScape® Software v3.1 (Thermo Fisher Scientific). 
 
Reagents and materials  
• 10X Genetic Analyser Running Buffer (Thermo Fisher Scientific, Cat. No. 402824). 
• POP-7™ Polymer (Thermo Fisher Scientific, Cat. No. 4352759). 
• ABI PRISM 3130xl Genetic Analyser (Thermo Fisher Scientific, Cat. No. 4359571). 
• Sequencing Analysis Software v5.2 (Thermo Fisher Scientific). 







7.7. TARGETED GENE SEQUENCING PANEL 
 
Next generation sequencing provides a high-throughput screening of multiple genes 
in a highly efficient manner. Although different platforms have been developed for the panel 
sequencing, they all include the following steps (Figure 10): 
1. Design of the panel 
2. Library preparation  
3. Preparation of the template and enrichment  
4. Sequencing 
5. Data analysis 
 
 
Figure 10. Diagram of the main steps involved in the targeted gene panel sequencing. Modified from Thermo 
Fisher Scientific (https://www.thermofisher.com/blog/). 
 
 
We performed the targeted gene sequencing panel with Ion Torrent technology 
(Thermo Fisher Scientific).  
 
7.7.1. Design of the panel 
 
After the implementation of NGS technology in our Institute, patients collected since 
2015 were analysed with the customized gene panel for DSD, unless the suspicion of the 
causative gene was clear and the methodology to be used was aCGH or MLPA. 
 
 We designed a targeted panel to sequence 48 genes associated with sex 
determination, sex differentiation and hypogonadism. Included genes were chosen after 
search in online databases and in the available literature, including HGMD (Human Gene 
Mutation database) (https://portal.biobase-international.com/hgmd/pro/start.php?), OMIM 
(Online Mendelian Inheritance in Man) (https://www.omim.org/) and Pubmed 
(https://www.ncbi.nlm.nih.gov/pubmed/). The list of the included genes in the customized 





Table 4. Included genes in the customized panel and their associated role and phenotype in DSD. 
 
Gene (locus) Alias Transcript Inheritance (OMIM) Role in DSD Associated phenotype 
AMH (19p13.3) Anti-Mullerian Hormone NM_000479.3 AR (600957) Sex Diff PMDS, POI 
AMHR2 (12q13.13) Anti-Mullerian Hormone Receptor Type 2 NM_020547.2 AR (600956) Sex Diff PMDS, POI 
AR (Xq12) Androgen Receptor NM_000044.3 X-linked (313700) Sex Diff 46,XY DSD AIS, hypospadias, POI 
ATRX (Xq21.1) ATP-Dependent Helicase ATRX NM_000489.4 X-inked (300032) G Diff 46,XY DSD assoc with Alpha thalassemia X-linked 
intellectual disability syndr 
BMP15 (Xp11.22) Bone Morphogenetic Protein 15 NM_005448.2 X-linked (300247) G Dev POI w/wot primary amenorrhea 
CBX2 (17q25.3) Chromobox homolog 2 NM_005189.2 AR, AD (602770) G Dev 46,XY DSD GD 
CYP11A1 (15q24.1) Cytochrome P450 Family 11 Subfamily A Member 1 NM_000781.2 AR, AD (118485) Sex Diff 46,XY DSD CGD and adrenal insuf; Hypospadias 
and adrenal insuf 
CYP11B1 (8q24.3) Cytochrome P450 Family 11 Subfamily B Member 1 NM_000497.3 AR (610613) Sex Diff 46,XX DSD, Steroid-11 beta-hydroxylase def, Non-
classic Steroid-11 beta-hydroxylase def, CAH 
CYP17A1 (10q24.32) Cytochrome P450 Family 17 Subfamily A Member 1 NM_000102.3 AR (609300) Sex Diff 46,XY DSD, 17-alpha-hydroxylase/17,20-lyase def, 
CAH 
CYP19A1 (15q21.2) Cytochrome P450 Family 19 Subfamily A Member 1 NM_000103.3 AR (107910) Sex Diff 46,XY DSD aromatase def 
CYP21A2 (6p21.33) Cytochrome P450 Family 21 Subfamily A Member 2 NM_000500.7 AR (613815) Sex Diff 21-hydroxylase def w/wo salt wasting; simple 
virilizing form 
DHH (12q13.12) Desert Hedgehog NM_021044.2 AD, AR (605423) G Dev 46,XY DSD GD 
DMRT1 (9p24.3) Doublesex And Mab-3 Related Transcription Factor 1 NM_021951.2 AD (602424) G Dev 46,XY DSD GD, OT DSD 
DMRT2 (9p24.3) Doublesex And Mab-3 Related Transcription Factor 2 NM_181872.4 AD (604935) G Dev 46,XY DSD GD 
ESR1 (6q25.1-q25.2) Oestrogen Receptor 1, Nuclear Receptor Subfamily 3 
Group A Member 1 
NM_001122740.1 AD, AR (133430) G Dev 46,XY DSD, male infertility, PP, MRKS 
ESR2 (14q23.2-q23.3) Oestrogen Receptor 2, Nuclear Receptor Subfamily 3 
Group A Member 2 
NM_001437.2 AD, AR (601663) G Dev 
46,XY DSD GD, Hypospadias, primary amenorrea, 
46,XX DSD GD 
FGF9 (13q12.11) Fibroblast Growth Factor 9 NM_002010.2 AD (600921) G Dev 46,XX T DSD 
FOXL2 (3q22.3) Forkhead Box L2 NM_023067.3 AD (605597) G Dev POI with and without BPES 
FOXO3 (6q21) Forkhead Box O3 NM_001455.3 AD (602681) G Dev POI 
FSHR (2p16.3) Follicle Stimulating Hormone Receptor NM_000145.3 AR (136435) CHH POI, hypergonadotropic hypogonadism 




Table 4. Included genes in the customized panel and their associated role and phenotype in DSD (Continuation). 
 
Gene (locus) Alias Transcript Inheritance (OMIM) Role in DSD Associated phenotype 
HARS2 (5q31.3) Histidyl-TRNA Synthetase 2, Mitochondrial NM_012208.3 AR (600783) Sex Diff Perrault syndr, including 46,XX DSD with ovarian 
dysgenesis 
HSD17B3 (9q22.32) Hydroxysteroid 17-Beta Dehydrogenase 3 NM_000197.1 AR (605573) Sex Diff 46,XY DSD 17b-hydroxysteroid dehydrogenase 3 
deficiency, hypospadias 
HSD17B4 (5q23.1) Hydroxysteroid 17-Beta Dehydrogenase 4 NM_000414.3 AR (601860) Sex Diff Perrault syndr, including 46,XX DSD with ovarian 
dysgenesis, and POI 
HSD3B2 (1p12) Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta and 
Steroid Delta-Isomerase 2 
NM_000198.3 AR, AD (613890) Sex Diff 
46,XY DSD GD, CAH with 3b-hydroxysteroid 
dehydrogenase type 2def, Hypospadias 
INHA (2q35) Inhibin Subunit Alpha NM_002191.3 AD (147380) G Dev POI, male infertility 
INSL3 (19p13.11) Insulin Like 3 NM_001265587.1 AD (146738) Others Cryptorchidism 
KISS1 (1q32.1) Kisspeptin-1 NM_002256.3 AR, AD (603286) CHH Puberty delay, HH 
KISS1R (19p13.3) KISS1 Receptor NM_032551.4 AD (604161) CHH Puberty delay, HH 
LHCGR (2p16.3) Luteinizing Hormone/Choriogonadotropin Receptor NM_000233.3 AR, AD (152790) Sex Diff PP, 46,XY DSD Leydig cell hypoplasia, amenorrhea 
MAMLD1 (Xq28) Mastermind Like Domain Containing 1, CXorf6 NM_001177465.2 X-linked (300120) G Dev 46,XY DSD, 46,XX DSD, Hypospadias 
MAP3K1 (5q11.2) Mitogen-Activated Protein Kinase Kinase Kinase 1 NM_005921.1 AD (600982) G Dev 46,XY DSD GD, hypospadias 
NR0B1 (Xp21.2) Nuclear Receptor Subfamily 0 Group B Member 1 NM_000475.4 X-linked (300473) G Dev Adrenal hypoplasia & HH, 46,XY DSD GD, 
hypospadias, 46,XX OT DSD 
NR5A1 (9q33.3) Nuclear Receptor Subfamily 5 Group A Member 1 NM_004959.4 AD, AR (184757) G Dev 46,XY DSD GD, POI, 46,XX T and OT DSD, 
hypospadias 
POR (7q11.23) Cytochrome P450 Oxidoreductase NM_000941.2 AR (124015) Sex Diff 
Hypospadias, Disordered steroidogenesis, Antley-
Bixler syndr with genital anomalies & disordered 
steroidogenesis 
PSMC3IP (17q21.2) Proteasome 26S ATPase Subunit 3-Interacting 
Protein 
NM_016556.3 AR (608665) G Dev POI 
RSPO1 (1p34.3) R-Spondin 1 NM_001242908.1 AR (609595) G Dev 46,XX OT DSD with palmoplantar hyperkeratosis 
with squamous cell carcinoma of skin 






Table 4. Included genes in the customized panel and their associated role and phenotype in DSD (Continuation). 
Gene (locus) Alias Transcript Inheritance (OMIM) Role in DSD Associated phenotype 
SOX3 (Xq27.1) SRY (Sex Determining Region Y)-Box 3 NM_005634.2 X-linked (313430) G Dev 46,XX OT and T DSD w/wo growth retardation and 
microcephaly 
SOX9 (17q24.3) SRY (Sex Determining Region Y)-Box 9 NM_000346.3 AD (608160) G Dev 46,XY DSD GD, 46,XX TDSD, 46, XX OT DSD, 46,XY 
DSD with campomelic dysplasia 
SRD5A2 (2p23.1) Steroid 5 Alpha-Reductase 2 NM_000348.3 AR (607306) Sex Diff 46,XY DSD Steroid 5-alpha-reductase def, 
Hypospadias 
SRY (Yp11.2) Sex Determining Region Y NM_003140.2 Translocation,AD 
(480000) 
G Dev 46,XX OT and Testicular DSD, 46,XY DSD GD 
STAR (8p11.23) Steroidogenic Acute Regulator NM_000349.2 AR (600617) Sex Diff 46,XY DSD, 46,XY DSD and LCAH, 46,XX DSD 
TSPYL1 (6q22.1) Testis-Specific Y-Encoded-Like Protein 1 NM_003309.3 AR (604714) G Dev 46,XY DSD GD, 46,XY DSD and Sudden infant death 
WNT4 (1p36.12) Wingless-Type MMTV Integration Site Family, 
Member 4 
NM_030761.4 AD (603490) G Dev 46,XY DSD CGD, 46,XX OT and T DSD, 46,XX MRKS 
WT1 (11p13) Wilms Tumour 1 NM_024426.4 AD (607102) G Dev 46,XY DSD GD, Frasier syndr, Denys-Drash syndr, 
hypospadias 
WWOX (16q23.1-
q23.2) WW Domain Containing Oxidoreductase NM_016373.2 AD (605131) G Dev 46,XY DSD GD, 46,XX DSD GD 
ZFPM2 (8q23.1) Zinc Finger Protein, FOG Family Member 2, Friend Of 
GATA 2 
NM_012082.3 AD (603693) G Dev 46,XY DSD GD, hypospadias 
AIS, Androgen insensitivity Syndrome; AD, Autosomal dominant; AR, Autosomal recessive; Assoc, associated; BPES, Blepharophimosis, ptosis epicanthus inversus syndrome; 
CAH, Congenital Adrenal Hyperplasia; CGD, Complete Gonadal dysgenesis; CHD, congenital heart defects; CHH, central causes of hypogonadism; Def, deficiency; Diff, 
differentiation; GD, gonadal dysgenesis; G Dev, gonadal development; HH, Hypogonadotropic hypogonadism; Insuf, insufficiency; LCAH, lipoid CAH; MRKS, Mayer-Rokitansky-
Küster-Hauser syndrome; OMIM, Online Mendelian Inheritance on Man; OT, Ovotesticular; PGD, Partial Gonadal dysgenesis; PMDS, Persistent Müllerian Duct Syndrome; POI, 





The customized gene panel was designed with the Ion AmpliSeq Designer tool v4.4.8 
(https://www.ampliseq.com/browse.action) (Thermo Fisher Scientific). Oligonucleotides 
against the entire coding region, exon-intron boundaries (± 50 base pair, bp) and the UTR 
(Untranslated Region) regions were included. Performance of the customized panel at any 
given locus is highly dependent on the sequencing of the amplicons that span the location. 
The panel designer tool automatically selected the amplicons to be amplified in each gene. 
In order to increase the coverage of certain genes, we chose the location of the amplicons by 
writing the locus of interest. We selected the region of interest of the following genes: AMH, 
CYP11B1, CYP21A2, FOXO3, GATA4, MAP3K1 and POR. The number of amplicons used to 
sequence each gene, missed base-pair and coverage is shown in Supplementary data 8.  
 
The final panel spanned a 233.46kb (kilobase) region with an expected coverage of 
98.55% for the targeted region (Table 5). The targeted regions that are not covered 
according to the Ion Ampliseq Designer tool are shown in Supplementary data 9. The final 
panel comprised 874 amplicons, from 125 to 375bp in size, divided in two pools of primers 
(441 and 433 amplicons per pool). 
 
To demonstrate the analytical performance of the test, the targeted gene panel was 
validated by measuring sensitivity, specificity plus false positive rate, and repeatability. 
 
7.7.2. Library preparation 
 
The preparation of the library consists in the selection and multiplex amplification of 
a targeted region. We used the Ion AmpliSeq™ Library Kit 2.0 (Thermo Fisher Scientific) to 
prepare template genomic DNA for sequencing.  
 
We used the protocol written in the “Ion AmpliSeq™ Library Kit 2.0 User Guide 
Targeted DNA and RNA Library Preparation for use with: Ion AmpliSeq™ Library Kit 2.0 
Catalogue Numbers 4475345, 4480441, 4480442, A31133, A31136, A29751, 4482298, 










Table 5. Coverage (%) of the DSD-associated gene panel according to the Ion Ampliseq Designer tool. Target and missed regions are indicated in base pairs (bp) for each gene. 
 
Genes Target (bp) Missed (bp) Coverage (%)  Genes Target (bp) Missed (bp) Coverage (%) 
AMH 1830 466 74.5  HSD3B2 2099 0 100 
AMHR2 2413 0 100  INHA 1531 0 100 
AR 11288 0 100  INSL3 1050 0 100 
ATRX 12970 45 99.6  KISS1 864 0 100 
BMP15 1362 0 100  KISS1R 1875 33 98.2 
CBX2 5246 11 99.8  LHCGR 3643 27 99.3 
CYP11A1 2928 0 100  MAMLD1 5260 22 99.3 
CYP11B1 2716 171 93.7  MAP3K1 7001 46 99.3 
CYP17A1 2270 0 100  NR0B1 1685 0 100 
CYP19A1 5064 0 100  NR5A1 3445 28 99.2 
CYP21A2 2385 148 93.3  POR 3311 100 97 
DHH 2084 0 100  PSMC3IP 2380 0 100 
DMRT1 2472 3 99.9  RSPO1 3539 4 99.9 
DMRT2 3135 19 99.4  RXFP2 3703 0 100 
ESR1 7568 0 100  SOX3 2124 0 100 
ESR2 4519 18 99.6  SOX9 4084 0 100 
FGF9 4680 155 96.7  SRD5A2 2695 0 100 
FOXL2 2967 104 96.5  SRY 3864 0 100 
FOXO3 7338 435 94.1  STAR 3045 32 98.9 
FSHR 3274 0 100  TSPYL1 5309 86 98.4 
GATA4 3436 422 87.7  WNT4 4155 182 95.6 
HARS2 3260 0 100  WT1 3864 0 100 
HSD17B3 1684 0 100  WWOX 3373 0 100 




Library preparation is divided into the following steps (Figure 11):  
1. Amplification of gDNA targets by multiplex PCR: The Ion AmpliseqTM HiFi Mix in 
conjunction with the pools of primers was used to prepare the amplification of 
the selected regions by PCR. For each pool of primers we used 15ng of gDNA of 
the patient.   
2. Partial digestion of primer sequences: The resulting DNA amplicons were 
treated with FuPa reagent, which partially removes PCR primers and repairs the 
endings of the fragments. 
3. Ligate barcode adapters and purify: We ligated adapters and assigned a unique 
barcode to each library to identify the sample. Ligation products were purified 
using Agencourt AMPure XP beads. 
4. Quantification by quantitative PCR (qPCR): The qPCR is a relative quantitation 
assay, in which the concentration of each library is calculated in relation to the 
values given in the DH10 dilutions in the standard curve. FAMTM dye is used as 
the probe reporter and ROXTM as the passive reference dye. To determine the 
concentration of each library we used the Ion Library TaqManTM Quantitation 
kit. Each sample, standards and negative control were analysed in duplicates.  
 
 









Reagents and materials 
• Ion AmpliseqTM Library kit 2.0 – 96LV (Thermo Fisher Scientific, Cat. No. 
4480441), which contains 5X Ion AmpliSeqTM HiFi Mix (1 x 384µL), FuPa Reagent 
(1 x 192µL), Switch solution (1 x 384µL), DNA Ligase (1 x 192µL), Ion Ampliseq 
Adapters (1 x 192µL), Platinum® PCR SuperMix HiFi (1 x 1.6mL), Library 
Amplification Primer Mix (1 x 192µL) and Low TE (1 x 12mL). 
• 2X Ion AmpliseqTM Primer Pool (100nM) (Thermo Fisher Scientific). 
• Ion XpressTM Barcode Adapters 1-16 kits ((Thermo Fisher Scientific, Cat. No. 
4471250), containing Ion XpressTM Barcodes (16 tubes x 20µL) and Ion XpressTM 
P1 Adapter (1 x 320µL). 
• Agencourt AMPure® XP reagent (60mL) (Beckman Coulter, Cat. No. A63881). 
• Ion Library TaqManTM Quantitation kit (Thermo Fisher Scientific, Cat no. 
4468802), containing 2X Ion Library TaqMan® qPCR Mix, 20X Ion Library 
TaqMan® Quantitation Assay and E. coli DH10B Control Library (68pM) (2 x 
25µL). 
• Absolute Ethanol (Thermo Fisher Scientific, Cat. No. BP2818100). 
• DynaMagTM -2 magnet (Thermo Fisher Scientific, Cat. no. 12321D).  
• DNA LoBind tubes (1.5mL) (Eppendorf AG, Hamburg, Germany, Cat. No. 
022431021). 
• Milli-Q ultrapure water (Merck KGaA). 
• Veriti 96-well Thermal Cycler (Thermo Fisher Scientific, Cat. No. 4375786). 
• Applied Biosystems 7300 Real-Time PCR System (Thermo Fisher Scientific). 
• Corning™ PCR Microplates (Thermo Fisher Scientific, Cat. No. 12799438). 
• Microseal® 'B' PCR Plate Sealing Film (Bio-Rad, Cat. No. MSA5001). 
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
 
Procedure  
1. Amplification of gDNA by multiplex PCR 
• Prepare dilution of input gDNA (5ng/µL) for each primer pool. 
• Prepare Mix. For each pool of primers and gDNA sample, add in a tube: 
o 5X Ion AmpliSeqTM HiFi Mix: 2µL 
o 2X Ion AmpliseqTM Primer Pool: 5µL 
o gDNA: 3µL 
• Mix using a vortex. 
• Place the plate in the Veriti 96-well Thermal Cycler and run the 
following program to amplify target genomic regions:  
o Activate enzyme: 99°C for 2 minutes. 
o Cycle 16 times: 99°C for 15 seconds and 60°C for 5 minutes. 
o Hold at 10°C. 





2. Digestion of primer sequences 
• Combine amplified libraries of each sample in one tube. 
• Add to each tube 2µL FuPa reagent and mix by pipetting. 
• Place the plate in the Veriti 96-well Thermal Cycler and run the 
following program to digest primer sequences:  
o 50°C for 10 minutes. 
o 55°C for 10 minutes. 
o 60°C for 20 minutes. 
o Hold at 10°C for up to 1 hour. 
3. Ligate adapters and purify 
• Prepare diluted barcode adapter mix. Dilute Ion XpressTM Barcodes and 
Ion XpressTM P1 Adapter with nuclease-free water (1:4). Vortex 
• Vortex Switch solution and add 4µL to each tube. 
• Add to ach tube: 
o Diluted barcode adapter mix: 2µL. 
o DNA Ligase: 2µL. 
• Mix using a Vortex. 
• Place the plate in the Veriti 96-well Thermal Cycler and run the 
following program to make ligation reaction:  
o 22°C for 30 minutes. 
o 72°C for 10 minutes. 
o Hold at 10°C for up to 1 hour. 
At this point PCR products could be stored at -20°C until purification. 
• Bring Agencourt AMPure® XP reagent to room temperature. Vortex 
thoroughly to disperse the beads before use. 
• Prepare 70% ethanol dilution. 
• Transfer each sample to a Low Retention tube. 
• Add 45µL Agencourt AMPure® XP reagent to each tube. Incubate the 
mixture for 5 minutes at room temperature. 
• Place the tubes in the DynaMagTM -2 magnet and incubate until solution 
clears. Without disturbing the pellet, remove and discard the 
supernatant. 
• Add 150µL 70% ethanol and move the tube side-to-side to wash the 
beads. Remove and discard the supernatant.  
• Repeat previous step.  
• Keeping the tubes in the magnet, air-dry the beads at room 
temperature for 2 minutes. If necessary, remove all the ethanol droplets 
with the pipette.  
• Remove the tubes from the magnet and elute the library by adding 50µL 
Low TE to the pellet and vortex. 




• Place the tubes in the magnetic rack until solution clears. Remove and 
transfer the supernatant to new Low Binding tubes. Discard the tubes 
with the pellet. 
At this point unamplified libraries could be stored at -20°C until 
quantification. 
4. Quantification by qPCR 
• Prepare 1/100 dilutions of each unamplified library. In a new 0.5mL 
tube add 2µL of each library to 198µL of nuclease-free water. 
• Prepare three 10-fold serial dilutions of E. coli DH10B Control Library 
(68pM) for the standard curve (6.8pM, 0.68pM and 0.068pM).  
• Prepare the reaction mix. For each library add in a tube: 
o 2X Ion Library TaqMan® qPCR Mix: 20µL 
o 20X Ion Library TaqMan® Quantitation Assay: 2µL 
• Dispense 11µL of the mix into the well of the PCR plate for each sample 
in duplicate.  
• Add 9µL of the diluted libraries, standards or Milli-Q water as a negative 
control to the corresponding well for a total volume of 20µL. 
• Program the real-time instrument as manufacturer’s instructions. The 
cycling program is as follows: 
o Hold: 50°C for 2 minutes. 
o Hold: 95°C for 20 seconds. 
o Cycle 40 times: 95°C for 3 seconds and 60°C for 30 seconds. 
• Calculate the average concentration of the undiluted library. Amplified 
libraries typically have a yield of 100-500pM. 
• Dilute each library to 100pM with Low TE. Proceed to the template 
preparation or store library at -20°C until use. 
 
7.7.3. Preparation of the template and enrichment 
 
Library fragments are clonally amplified onto Ion Sphere Particles (ISPs) through 
emulsion PCR (EmPCR) and then enriched for template-positive ISPs. This step was 
performed using the Ion OneTouch 2 System (Thermo Fisher Scientific, Cat. No.  
4474779), which consists of two modules: The Ion OneTouch 2 (OT2) Instrument and 
the Ion OneTouch ES (Enrichment System) (Figure 12).  
 
We used the protocol written in the “Ion PGM™ Hi-Q™ View OT2 Kit user guide 
for use with: Ion OneTouch™ 2 System Catalogue Number A29900. Publication 
Number MAN0014579 Revision C.0”. 
We followed the next steps: 
1. Prepare template: EmPCR is the method for template amplification that is used 




compartmentalization of template molecules in water droplets in a water-in-oil 
emulsion. Ideally, each droplet contains a single template molecule.  
2. Enrichment of the template: This allows the selection of the ISPs that contain 
the amplified library fragments to streptavidin coated magnetic beads, washing 
and denaturing the library strands to collect the template-positive ISPs. This 
step is made to improve the sequencing yield by using the Ion OneTouch ES.  
3. Quality control: To determine the percentage of templated ISPs that have been 
enriched we used the Qubit®2.0 Fluorometer (Thermo Fisher Scientific, Cat. No. 
Q32866) and the Ion Sphere Quality Control kit (Thermo Fisher Scientific, Cat. 
No. 4468656), following manufacturers’ instructions. We obtained >90% 
enrichment efficiency for all reactions  
 
 
Figure 12. A, Image of the Ion OneTouch 2 system including the Ion OneTouch 2 instrument (right) and 
the Ion OneTouch ES instrument (left). B, Schematic representation of the Ion OneTouch reaction filter 




Reagents and materials 
• Ion PGM™ Hi-Q™ View OT2 Kit (Thermo Fisher Scientific, Cat. No. A29900) 






• Ion PGM™ OT2 Supplies (Cat. No. A27744), containing: Ion OneTouch™ 
Reagent Tubes (2 tubes), Ion OneTouch™ Recovery Routers (8 routers), 
Ion OneTouch™ Recovery Tubes (16 tubes), Ion OneTouch™ Sipper 
Tubes (2 sipper tubes), Ion OneTouch™ Amplification Plate (8 plates), 
Ion OneTouch™ Cleaning Adapter (8 adapters), Ion OneTouch™ 
Reaction Filter (8 reaction filters) and tubes Ion OneTouch™ ES Supplies 
(12 pipette tips and 1 box of ES 8-well strips). 
• Ion PGM™ Hi-Q™ View OT2 Reagents (Cat. No. A29811), containing: Ion 
PGM™ Hi-Q™ View Reagent Mix (8 × 800µL), Ion PGM™ Hi-Q™ View 
Enzyme Mix (1 x 400µL) and Ion PGM™ Hi-Q ™ View ISPs (1 x 800µL). 
• Ion PGM™ Hi-Q™ OT2 Solutions (Cat. No. A27742), containing: Ion 
OneTouch™ Breaking Solution (2 × 1.2mL), Ion OneTouch™ Oil (1 x 
450mL), Ion OneTouch™ Reaction Oil (1 x 25mL) Nuclease-free Water (1 
x 30mL), Ion OneTouch™ Recovery Solution (1 x 350mL), Neutralization 
Solution (1 x 100µL), Ion OneTouch™ Wash Solution (1 x 16mL), 
MyOne™ Beads Wash Solution (2 tubes x 1.4ml) and Tween™ Solution 
(1 x 6mL). 
• Ion Sphere Quality Control kit (Thermo Fisher Scientific, Cat. No. 4468656), 
containing: Ion Probes (20µL), Alexa Fluor™ 488 Calibration Standard (400µL), 
Alexa Fluor™ 647 Calibration Standard (400µL), Annealing Buffer (400µL) and 
Quality Control Wash Buffer (20mL). 
• DNA LoBind tubes (1.5mL) (Eppendorf AG, Cat. No. 022431021). 
• Sodium hydroxide (NaOH) (Merck KgaA, Cat. No. S8045). 
• DynaMagTM-2 magnet (Thermo Fisher Scientific, Cat. No. 12321D). 
• Ion OneTouch 2 System (Thermo Fisher Scientific, Cat. No.  4474779). 
• Qubit® 2.0 Fluorometer (Thermo Fisher Scientific, Cat. No. Q32866). 
• Centrifuge Sorvall™ Legend™ Micro 17R (Thermo Fisher Scientific, Cat. No. 
75002440). 
• Minicentrifuge (Nippon Genetics Europe, Dueren, Germany, Cat. No. NG002R).  
 
Procedure 
1. Prepare template 
• Set up the Ion OneTouch TM Instrument 
o Open lid and dispense 150µL Ion OneTouch™ Breaking Solution 
into each of the two Recovery Tubes. Insert the Recovery Tubes 
into each slot of the centrifuge and close the lid of the 
centrifuge. 
o Install the Amplification Plate, disposable tubes and injector 
following manufacturers’ instructions. 
o Install the Ion OneTouch TM Oil and Ion OneTouch Recovery 




• Prepare the amplification solution 
o Prepare the Ion PGM™ Hi-Q™ View Reagent Mix at room 
temperature by vortexing for 30 seconds and centrifuging for 2 
seconds. Keep it at room temperature. 
o Prepare the Ion PGM™ Hi-Q™ View Enzyme Mix. Centrifuge for 2 
seconds and palace it on ice. 
o Place the Ion PGM™ Hi-Q™ View ISPs at room temperature for 
30 minutes. 
• Dilute the 100pM library to 8pM by adding 2µL of the library to 23µL of 
Nuclease free-water. Vortex the diluted library for 5 seconds, centrifuge 
for 2 seconds and place it on ice. 
• Prepare the Ion PGM™ Hi-Q™ View ISPs by vortexing for 1 minute. Then 
centrifuge for 2 seconds and mix the ISPs by pipetting up and down. 
• Add to the tube containing 800µL Ion PGM™ Hi-Q™ View Reagent the 
following components in order and pipet up and down to mix: 
o Nuclease-free Water: 25µL 
o Ion PGM™ Hi-Q™ View Enzyme: 50µL. 
o Diluted library (8pM): 25µL 
o Ion PGM™ Hi-Q™ View ISPs: 100µL 
• Vortex the amplification solution at maximum speed for 5 seconds. 
• Fill the Ion OneTouchTM Reaction Filter with the amplification solution 
and the Ion OneTouchTM Reaction Oil. Install the filled filter as indicated 
by manufacturers’ (Figure 12).  
• Run the Ion OneTouchTM Instrument, following manufacturers’ 
instructions. 
• Recover the template-positive ISPs. 
o Open lid and remove both Ion OneTouch™ Recovery Tubes from 
the instrument. 
o Remove all but 100µL of the Recovery Solution from each tube 
without disturbing the ISP pellet. 
At this point the Recovery Solution could be stored at 2 to 5°C for 3 days 
by adding 500µL of Ion OneTouchTM Wash Solution. 
• Process the ISPs. 
o Add 500µL of Ion OneTouch™ Wash Solution to the Recovery 
Tubes and pipet up and down to disperse the ISPs. 
o Combine the two tubes into the suspension from one 1.5mL 
Eppendorf LoBind™ Tube. 
o Centrifuge for 2.5 minutes at 15.500 × g. 
o Remove all but 100µL of the Wash Solution from the tube by 




• Asses the quality of the unenriched template-positive ISPs by 
transferring 2µL to a tube and using the Qubit®2.0 Fluorometer. Follow 
manufacturers’ instructions. 
 
2. Enrichment of the template 
• Prepare fresh Melt-Off Solution (Supplementary data 7). 
• Resuspend Dynabeads™ MyOne™ Streptavidin C1 Beads: 
o Vortex the tube for 30 seconds, then centrifuge for 2 seconds. 
o Pipet the pellet of beads up and down. 
o Transfer 13µl of Dynabeads™ MyOne™ Streptavidin C1 Beads to 
a new 1.5mL Eppendorf LoBind™ Tube and place it on a 
DynaMAgTM -2 magnet for 2 minutes. 
o Remove and discard the supernantant without disturbing the 
pellet. 
o Add 130µl of MyOne™ Beads Wash Solution to the Dynabeads™ 
MyOne™ Streptavidin C1 Beads. 
o Remove the tube from the magnet, vortex for 30 seconds, and 
centrifuge for 2 seconds. 
• Fill the 8-well strip by adding to the different wells (Figure 13): 
o Well 1, Template-positive ISP sample: 100µL. 
o Well 2, Dynabeads™ MyOne™ Streptavidin C1 Beads 
resuspended in MyOne™ Beads Wash Solution: 130µL. 
o Well 3, 4 and 5, Ion OneTouch™ Wash Solution: 300µL. 
o Well 6, empty. 
o Well 7, Melt-Off Solution: 300µL  
 
 
Figure 13. Schematic disposition of the 8-well strip on the Ion OneTouch ES. Modified from Ion PGM™ 






• Install the 8-well strip on the slot of the tray as indicated by 
manufacturers. 
• Prepare the Ion OneTouchTM ES and perform the run following 
manufacturers’ instructions. 
3. Determination of the enrichment efficiency using the Qubit®2.0 Fluorometer. 
Follow manufacturers’ instructions. 




Ion Personal Genome Machine™ (PGM™) System (Thermo Fisher Scientific) is 
based on semiconductor sequencing technology. This method detects hydrogen ions 
that are released during the polymerization of DNA, in which a complementary strand 
is built based on the sequence of a template strand. Each microwell in the chip 
containing a template DNA strand is displayed with one of the four types of dNTPs, and 
if the introduced dNTP is complementary to the template nucleotide, it will be 
incorporated to the complementary strand and therefore, the sensor detects the 
liberation of a hydrogen ion and leads to an electronic signal. 
 
We used the protocol written in “Ion PGM™ Hi-Q™ View Sequencing Kit user 
guide for use with: Ion PGM™ Hi-Q™ View Sequencing Kit Ion PGM™ System Ion 318™ 
Chip v2 BC Ion 316™ Chip v2 BC Ion 314™ Chip v2 BC Catalogue Number A30044 
Publication Number MAN0014583 Revision C.0”. 
 
We followed the next steps: 
1. Create a planned run: Perform the planning of all the settings used in a 
sequencing run in the Ion PGMTM Torrent Browser. 
2. Clean and initialize the sequencer: The sequencer requires cleaning every time 
the instrument is initialized. Cleaning with Milli-Q water is done daily, when 
instrument is in use, and if more than 27 hours since the last initialization. 
Cleaning with chlorite solution is done once a week or if the sequencer has 
been left with reagents more than 48 hours. 
3. Load the chip and sequence. 
 
Reagents and materials 
• Ion PGM™Hi-Q™ View Sequencing Kit (Thermo Fisher Scientific, Cat. No. 
A30044), includes the following components:  
• Ion PGM™ Sequencing Supplies (Part No. A25587), containing: Wash 1 
Bottle (1 bottle x 250mL), Wash 3 Bottle (1 bottle x 250mL), Ion PGM™ 




Sipper Tubes (8 tubes for 250mL bottles), Ion PGM™ Wash Bottle Sipper 
Tubes (4 tubes for 2L) and Reagent Bottles (25 bottles x 50mL). 
• Ion PGM™ Hi-Q™ View Sequencing Reagents (Part No. A30043), 
containing: Ion PGM™ Hi-Q™ View Sequencing Polymerase (1 tube x 
36μL), Ion PGM™ Hi-Q™ View Sequencing Primer (1 tube x 144μL) and 
Ion PGM™ Hi-Q™ View Control Ion Sphere™ Particles (1 tube x 60μL). 
• Ion PGM™ Hi-Q™ View Sequencing Solutions (Part No. A30275), 
containing: Ion PGM™ Hi-Q™ View Sequencing W2 Solution (4 bottles x 
125mL), Ion Cleaning Tablet (4 tablets), Annealing Buffer (1 tube x 
12mL) and Ion PGM™ Hi-Q™ View Sequencing W3 Solution (2 bottles x 
100mL). 
• Ion PGM™ Hi-Q™ Sequencing dNTPs (Part No. A25590), containing: Ion 
PGM™ Hi-Q™ Sequencing dGTP (1 x 80μL), Ion PGM™ Hi-Q™ Sequencing 
dCTP (1 x 80μL), Ion PGM™ Hi-Q™ Sequencing dATP (1 x 80μL) and Ion 
PGM™ Hi-Q™ Sequencing dTTP (1 x 80μL). 
• Ion PGM™ Wash 2 Bottle Kit (Cat. No. A25591) includes the following 
components: Wash 2 Bottle (2L) and Wash 2 Bottle Conditioning 
Solution (1 bottle x 125mL). 
• Sodium hydroxide (NaOH) (Merck KGaA, Cat. No. S8045). 
• Ion 316™ Chip Kit v2 BC (8 pack) (Thermo Fisher Scientific, Cat. No. 4488149). 
• Ion 318™ Chip v2 BC (8 pack) (Thermo Fisher Scientific, Cat. No. 4488150). 
• Ion PGM™ System and accessories (Thermo Fisher Scientific, Cat. No. 4462921) 
• Veriti 96-well Thermal Cycler (Thermo Fisher Scientific, Cat. No. 4375786). 
• Minicentrifuge (Nippon Genetics Europe, Cat. No. NG002R).  
• Ion PGM™ Torrent Server (Thermo Fisher Scientific, Cat. No. 4483643). 
 
Procedure 
1. Create a planned run  
To create the run plan, diverse setting need to be selected, such as the 
sequencing instrument, chip, library and template kit type and the plugins. 
2. Clean and initialize the sequencer 
• Cleaning with Milli-Q water and chlorite solution is performed following 
manufacturers’ instructions. 
• Before initialization 
o Remove the dNTP stock solutions to ice. 
o Rinse the Wash 2 Bottle 3 times with 200mL Milli-Q water. Rinse 
the Wash 1 and Wash 3 Bottles 3 times with 50mL of Milli-Q 
water. 





o Add the entire bottle of Ion PGM™ HiQ™ View Sequencing W2 
Solution to the Wash 2 Bottle. 
o Prepare 500μL of 100mM NaOH by diluting 50μL of NaOH 1M in 
450μL nuclease-free water.  
o Add 70μL of 100mM NaOH to the Wash 2 Bottle. Mix the bottle 
by inversion 5 times. 
o Add 350μL of freshly prepared 100 mM NaOH to the Wash 1 
Bottle. 
o Add Ion PGM™ Hi-Q™ View Sequencing W3 Solution to the 50mL 
line marked on the Wash 3 Bottle. 
• Begin the initialization as indicated in the screen of the Ion PGM™ 
System. 
• Prepare the Reagent bottles with dNTPs 
o Vortex each dNTP stock solution and centrifuge to collect the 
contents. Keep the dNTP stock solutions on ice throughout this 
procedure. 
o Transfer 20μL of each dNTP stock solution into its respective 
Reagent Bottle. 
o Store on ice until you are ready to attach it to the instrument.  
• Attach the sipper tubes and Reagent bottles 
o After the initialization, remove the used sipper tubes and 
collection trays from the dNTP ports. 
o Insert a new sipper tube into each dNTP port and attach each 
prepared Reagent Bottle to the correct dNTP port. 
3. Load the chip and sequence 
• Add controls to the enriched, template-positive Ion Sphere™ Particles 
(ISP) 
o Vortex the Control Ion Sphere™ Particles, then pulse-centrifuge 
in a picofuge for 2 seconds before taking aliquots. 
o Add 5μL Control ISPs directly to the entire volume of enriched, 
template positive ISPs (prepared using your template 
preparation method) in a 0.2mL non-polystyrene PCR tube. 
• Anneal the Sequencing Primer 
o Mix the tube containing the ISPs by pipetting up and down and 
centrifuge for 2 minutes at 15.500 x g. 
o Remove the supernatant from the top down and discard. Leave 
15μL in the tube 
o Vortex the Sequencing Primer for 5 seconds, centrifuge in a 





o Add 12μL of Sequencing Primer to the ISPs. Mix by pipetting to 
disrupt the pellet. 
o Place the tube in the thermal cycler and run the following 
program: 95°C for 2 minutes and then 37°C for 2 minutes. 
Remain the tube in the cycler at RT while the sequencing run is 
set up.  
• Perform chip check to ensure the functionality of the chip, as indicated 
in the screen of the Ion PGM™ System. 
• Bind the Sequencing Polymerase 
o Remove the Ion PGM™ Hi-Q™ View Sequencing Polymerase from 
storage and mix with the fingertip 4 times. Centrifuge for 3–5 
seconds and place on ice. 
o Remove the ISPs from the thermal cycler, add 3μL of Ion PGM™ 
Hi-Q™ View Sequencing Polymerase to the ISPs and mix by 
pipetting. Incubate at room temperature for 5 minutes. 
• Prepare and load the chip (Figure 14) 
o Remove the new chip from the Ion PGM™ Sequencer and insert 
a used chip in the clamp while loading the new chip. 
o Tilt the new chip at a 45° angle so that the loading port is the 
lower port. Insert the pipette tip firmly into the loading port, 
then remove as much liquid as possible from the loading port. 
Discard the liquid. 
o Place the chip upside-down in the minifuge bucket, then transfer 
the bucket with the chip tab pointing in. Centrifuge for 5 seconds 
to empty the chip completely. Remove the chip from the bucket.  
o Place the chip on a firm surface and insert the tip into the 
loading port of the chip.  
o Collect 30µL of prepared ISPs with a pipette and load the chip 
slowly by applying gentle pressure between the tip and chip and 
slowly dial down the pipette to deposit the ISPs. Avoid 
introducing bubbles into the chip and discard any displaced 
liquid from the other port of the chip. 
o Centrifuge the chip for 30 seconds with the chip tab pointing 
towards the centre of the minifuge. 
o Centrifuge the chip for 30 seconds with the chip tab pointing 
away from the centre of the minifuge. Remove the chip. 
o Tilt the chip 45 degrees. Slowly pipet the sample out and then 
back into the chip.  





o Spin the chip upside-down for 5 seconds in the minifuge. 
Remove and discard any liquid. Proceed immediately to perform 
the run. 
4. Perform the run 
• Select the planned run in the screen of the Ion PGMTM Sequencer. 
• Confirm the settings. Load and clamp the chip. 
• Perform the run. 
 
 
Figure 14. Images showing the preparation and loading of the chip. A, removal of the liquid. B, Chip 
upside-down in the minifuge bucket. C, load the chip on a flat surface. D, dial down the pipette to 
deposit the ISPs. E, Chip tab pointing towards the centre of the minifuge. F, Chip tab pointing away from 
the centre of the minifuge. 
 
 
7.8. DETECTION OF COPY NUMBER VARIATIONS 
 
Copy Number Variations (CNV) are a prominent source of genetic variation in 
human DNA and play a role in a wide range of disorders. We used four different 
techniques for the detection of deletions, amplifications and complex rearrangements. 
These are Multiplex Ligation-dependent Probe Amplification (MLPA), Quantitative 
Multiplex Polymerase chain reaction of Short Fluorescent Fragments (QMPSF), genetic 
markers or a Comparative Genome Hybridization array (aCGH). Furthermore, we 
analysed the relocation of the SRY gene by Fluorescence in situ hybridization (FISH). A 













Table 6. Summary of the different methods used to detect copy number variations. 
 
Method Commercial name Genes 
MLPA 
SALSA MLPA probemix P185-C2 Intersex NR0B1, CXorf21, SOX9, SRY, ZFY, WNT4, NR5A1 




Genetic markers  NR0B1 
aCGH 
SurePrint G3 Human CGH Microarray 
8x60K 
Genome wide probes 
FISH  SRY 
aCGH, Comparative Genome Hybridization array; MLPA, Multiplex Ligation-dependent Probe 




7.8.1. Multiplex Ligation-dependent Probe Amplification 
 
MLPA is a semi-quantitative technique, used to determine the copy number of 
DNA sequences in a single multiple PCR-based reaction. It is based on the amplification 
of several probes that detect a specific DNA sequence of approximately 60 nucleotides 
and its separation by capillary electrophoresis. 
 
The first step comprises the denaturation of the sample DNA and adding of a 
mixture of probes. These probes are two oligonucleotides that hybridize to adjacent 
target sequences so that are ligated to create a single probe. Then, all ligated probes 
are amplified simultaneously using the same PCR primer pair. One of the primers is 
fluorescently labelled, which allows the visualization of the amplification products 
during fragment separation on a capillary electrophoresis instrument. PCR amplicons 
result in products between 64-500 nucleotides in length. 
 
Compared to relative probe peak height in various control DNA samples, the 
relative height of each individual probe peak reflects the relative copy number of the 
corresponding target sequence in the sample. Thus, the deletion of one or more target 
sequence converts as a relative decrease in a peak height, while an increase in a 
relative peak height reflects amplification. 
 
We used the following SALSA MLPA probemix products to detect CNVs in our 
population of interest. 
 
1. SALSA MLPA probemix P185-C2 Intersex (MRC-Holland BV, Cat. No. P185-
050R). It contains 44 probes with amplification products between 130 and 
494nt for the following genes: NR0B1, CXorf21, SOX9, SRY, ZFY, WNT4 and 




2. SALSA MLPA P118 WT1 probemix (MRC-Holland BV, Cat. No. P118-050R), 
containing 34 MLPA probes with amplification products between 130 and 
409nt and 12 control fragments. It spans the WT1 and AMER1 genes.  
 
The included probes in the SALSA MLPA probemix P185-C2 Intersex and SALSA 
MLPA P118 WT1 probemix, as well as its gene location and partial sequence are shown 
on http://www.mlpa.com/. 
 
The amount of used DNA for this methodology ranges between 50 and 250ng. 
 
Reagents and materials 
• SALSA MLPA probemix (MRC-Holland BV, Amsterdam, The Netherlands), 
containing SALSA MLPA Buffer (1x 180µl), SALSA Ligase-65 (1x 115µl), Ligase 
Buffer A (1x 360µl), Ligase Buffer B (1x 360µl), SALSA PCR Primer Mix (1x 
240µl), SALSA Polymerase (1x 65µl) and Probemix (1x 80µl). 
• Formamide (Thermo Fisher Scientific, Cat. No. 4311320). 
• 10X Genetic Analyser Running Buffer (Thermo Fisher Scientific, Cat. No. 
402824). 
• POP-7™ Polymer (Thermo Fisher Scientific, Cat. No. 4352759). 
• Milli-Q ultrapure water (Merck KgaA). 
• ABI PRISM 3130xl Genetic Analyser (Thermo Fisher Scientific, Cat. No. 
4359571). 
• GeneAmp®PCR System 9700 (Thermo Fisher Scientific, Cat. No. 4339386). 
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
• Beckman Spinchron R centrifuge (Beckman Coulter, Cat. No. 358723).   
• MicroAmp® Optical 96-Well Reaction Plate (Thermo Fisher Scientific, Cat. No. 
4316813).  
• MicroAmpTM Clear Adhesive Film (Thermo Fisher Scientific, Cat. No. 4306311).  
• GeneScanTM 500 ROXTM dye size Standard (Thermo Fisher Scientific, Cat.No. 
401734). 
• GeneMapper® Software v4.0 (Thermo Fisher Scientific). 
 
Procedure 
The protocol can be divided into the following steps: 
1. DNA denaturation: 
• Add 5µL DNA sample to each tube. 
• Place the tubes in the thermocycler and run the following program:  
o DNA denaturation: 98°C for 5 minutes. 
o Hold at 25°C. 
2. Hybridization reaction 




• Prepare master mix on ice. For each sample add: 
o SALSA MLPA Buffer: 1.5µL 
o Probemix: 1.5µL 
• Mix by vortexing. 
• Add 3µL to each sample tube.  
• Place the tubes in the thermocycler and run the following program:  
o Incubation: 95°C for 1 minute. 
o Hybridization: 60°C for 16-20 hours. 
3. Ligation reaction 
• Vortex Ligase Buffer A and Ligase Buffer B.  
• Prepare the Ligase-65 master mix at RT. For each sample add: 
o Milli-Q water: 25µl  
o Ligase Buffer A: 3µl  
o Ligase Buffer B: 3µl  
o SALSA Ligase-65: 1µL 
• Mix by pipetting up and down. 
• Add 32 µl to each sample tube placed on the thermocycler and mix by 
pipetting up and down. Run the following program:  
o Ligation: Hold at 54°C  
o Activation of Ligase-65 enzyme: 98°C for 5minutes. 
o Hold at 20°C  
4. PCR reaction 
• Vortex SALSA PCR Primer Mix.  
• Prepare the Polymerase master mix at room temperature. For each 
sample add: 
o Milli-Q water: 7.5µL 
o SALSA PCR Primer: 2µL 
o SALSA Polymerase: 0.5µL  
• Add 10µL Polymerase master mix to each reaction. Mix by pipetting up 
and down. 
• Place the tubes in the thermocycler and run the following program:  
o Cycle 35 times: 95°C for 30 seconds, 60°C for 30 seconds and 
72°C for 60 seconds 
o Incubate: 72°C for 20 minutes. 
o Hold at 15°C 
At this point PCR products could be stored at 4°C for one week or at -25°C 
for longer periods. 
5. Fragment separation on a capillary electrophoresis instrument 
• For each sample prepare the following mix:  
o Formamide: 10µL 




• Add 10µL of the previous mix to 2µL of the PCR product. 
• Mix by vortexing and spin in a centrifuge.  
• Place the samples in the thermocycler at 95°C for 5 minutes. 
• Place the samples on ice for 5 minutes. 
• Place the plate on the genetic analyser. 
6. Data analysis 
Data analysis was performed with the GeneMapper® Software v4.0 (Thermo 
Fisher Scientific). To normalise MLPA, first each peak height is divided by the sum of 
the peak values of control probes. These control probes are not supposed to contain 
CNV and are outside the screened region. Given values are then compared to the 
height of control DNA samples. This ratio balance between 0.8 and 1.15 indicate 2 
gene copies or normal sample. According to the criteria established in our laboratory 
ratio balances under 0.8 indicate a decrease gene copy number and above 1.15 are 
indicative of a gene copy number increase in the sample. 
 
7.8.2. Quantitative Multiplex Polymerase Chain Reaction of Short 
Fluorescent 
 
QMPSF, as well as MLPA, relies on the simultaneous amplification of small 
genomic sequences under quantitative conditions, using fluorescent primers, and on 
the comparison of profiles generated from tested and control DNA. 
 
Comparing to the MLPA technique, QMPSF is faster and cheaper, but it is less 
specific due to the absence of a ligation step. We designed a QMPSF assay for those 
genes that were not included in the MLPA probemix available in the laboratory (P185-
C2 Intersex or P118 WT1). 
 
We made QMPSF to check variations in copy number in the AR and SRD5A2 
genes. We designed 5’ 6-FAM dye-labelled primers corresponding to five target 
regions that were simultaneously amplified. The PCR comprises the processes of 
denaturation, annealing and elongation, but it is stopped at exponential amplification 
allowing the quantification. In these cases, QMPSF was stopped at cycles 25 and 30, 
respectively. For the SRD5A2 two multiplex PCRs were done because of the similar size 
of some amplicons (Primers sequences and amplicons size are given in Supplementary 
data 6).  
 
QMPSF included control amplicons. For the detection of CNV on SRD5A2 and 
AR, control fragments from other not DSD-related genes, such as RET and HNF1B 
located on chromosomes 10q11.21 and 17q12, respectively, were used. We also added 
3 normal samples and a negative control containing water. All the samples were tested 





Reagents and materials 
• KAPA Taq PCR Kit (Kapa Biosystems, Cat. No. KK1014), containing KAPA Taq 
DNA Polymerase (5U/µL), KAPA Taq Buffer A (10X) KAPA Taq Buffer B (10X) and 
MgCl2 (25Mm). 
• GeneScanTM 500 ROXTM dye size Standar (Thermo Fisher Scientific, Cat.No. 
401734). 
• 10X Genetic Analyser Running Buffer (Thermo Fisher Scientific, Cat. No. 
402824). 
• Formamide (Thermo Fisher Scientific, Cat. No. 4311320). 
• dNTP Mix (5mL) (Merck KgaA, Cat. No. D7295-5ML). 
• DMSO (50mL) (Merck KgaA, Cat. No. D8418-50Ml).  
• POP-7™ Polymer (Thermo Fisher Scientific, Cat. No. 4352759). 
• 5’ 6-FAM Dye-labelled primers pool (250μM) (Integrated DNA Technologies Inc, 
Skokie, Il, USA). 
• Milli-Q ultrapure water (Merck KgaA). 
• ABI PRISM 3130xl Genetic Analyser (Thermo Fisher Scientific, Cat. No. 
4359571). 
• GeneAmp®PCR System 9700 (Thermo Fisher Scientific, Cat. No. 4339386). 
• Beckman Spinchron R centrifuge (Beckman Coulter, Cat. No. 358723).   
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
• MicroAmp® Optical 96-Well Reaction Plate (Thermo Fisher Scientific, Cat. No. 
4316813).  
• MicroAmpTM Clear Adhesive Film (Thermo Fisher Scientific, Cat. No. 4306311). 
• PCR-strip tubes (Sarstedt AG&Co KG, Nümbrecht, Germany, Cat. No 
72.982.002).  
• PCR lid strips (Sarstedt AG&Co KG, Cat. No. 65.989.002).  
• GeneMapper® Software v4.0 (Thermo Fisher Scientific). 
 
Procedure 
The protocol can be divided into the following steps: 
1. PCR multiplex reaction  
For each amplification a mix containing Milli-Q water, Buffer A, dNTPs, FAM dye 
labelled primers at 25μM, Taq DNA polymerase and DNA (100ng) is prepared. DMSO is 
added when required. Conditions in the thermocycler are also different for each DNA 
amplification sequence. Conditions for amplification and primers can be found in 
Supplementary data 6. 
2. Fragment separation on a capillary electrophoresis instrument 
• For each sample prepare the following mix:  




o GeneScanTM 500 ROXTM dye size Standard: 0.5µL 
• Add 10µL of the previous mix to 2µL of the PCR product. 
• Mix by vortexing and spin in a centrifuge.  
• Place the samples in the thermocycler at 95°C for 5 minutes. 
• Place the samples on ice for 5 minutes. 
• Place the plate on the genetic analyser. 
3. Data analysis 
Data analysis was performed with the GeneMapper® Software v4.0 (Thermo 
Fisher Scientific). To normalise data, first each peak height is divided by the sum of the 
peak values of control probes. These control probes are not supposed to contain CNV 
and are outside the screened region. Given values are then compared to the height of 
control DNA samples. This ratio balance between 0.8 and 1.15 indicate 2 gene copies 
or normal sample. According to the criteria established in our laboratory ratio balances 
under 0.8 indicate a decrease gene copy number and above 1.15 are indicative of a 
gene copy number increase in the sample. 
 
7.8.3. Localization of genetic markers 
 
A genetic marker is a fragment of DNA with a known location on a 
chromosome. They may be a short DNA sequence surrounding a single base pair 
change or a long one, like microsatellites. Microsatellites can be used for mapping 
locations within the genome to locate a gene or a mutation.  
 
In this case, we used microsatellites to determine the extension of the 
deletions previously showed by PCR and MLPA. For this study labelled primers were 
designed and analysed by fluorescent PCR and subsequent electrophoresis on the 
ABI3130xl genetic analyser using GeneMapper® v4.0 software (Applied Biosystems) 
was done. 
 
We analysed the microsatellites in two samples in which a NR0B1 complete 
gene deletion was observed by PCR and MLPA (GN0101 and POL0285). The 4 
microsatellites we studied were located in Xp21, specifically DX1218 and DXS8039 
were placed downstream NR0B1 while DXS1083 and DXS992 were located upstream 
the gene (Supplementary data 6). 
 
Reagents and materials 
• KAPA Taq PCR Kit (Kapa Biosystems, Cat. No. KK1014), containing KAPA Taq 
DNA Polymerase (5U/µL), KAPA Taq Buffer A (10X) KAPA Taq Buffer B (10X) and 
MgCl2 (25Mm). 





• 10X Genetic Analyser Running Buffer (Thermo Fisher Scientific, Cat. No. 
402824). 
• Formamide (Thermo Fisher Scientific, Cat. No. 4311320). 
• dNTP Mix (5mL) (Merck KgaA, Cat. No. D7295-5ML). 
• Agarose D-1 (Pronadisa, Madrid, Spain, Cat. No. 8016). 
• 50X TAE Buffer (Bio-Rad, Hercules, CA, USA, Cat. No. 1610773). 
• EZ Load™ 100bp Molecular Ruler (Bio-Rad, Cat. No. 1708352). 
• Nucleic Acid Sample Loading Buffer 5X (Bio-Rad, Cat. No. 161-0767).  
• GelRed™ (Biogen, Cambridge, MA, USA, Cat. No. BT41003). 
• DMSO (50mL) (Merck KgaA, Cat. No. D8418-50ML).  
• POP-7™ Polymer (Thermo Fisher Scientific, Cat. No. 4352759). 
• 5’ 6-FAM Dye-labelled primers pool (250μM) (Integrated DNA Technologies Inc, 
Skokie, Il, USA). 
• Milli-Q ultrapure water (Merck KgaA). 
• ABI PRISM 3130xl Genetic Analyser (Thermo Fisher Scientific, Cat. No. 
4359571). 
• GeneAmp®PCR System 9700 (Thermo Fisher Scientific, Cat. No. 4339386). 
• Beckman Spinchron R centrifuge (Beckman Coulter, Cat. No. 358723).   
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
• Electrophoresis chamber Sub® Cell GT MINI (Bio-Rad, Hercules, CA, USA, Cat. 
No. 1704467). 
• PowerPac™ 3000 Power Supply  (Bio-Rad, Cat. No. 1655057). 
• G: BOX Chemi 16 Bio Imaging system (Syngene, Cambridge, UK, Cat. No. 
SGBOX) 
• GeneSnap Software v7.12 (Syngene). 
• Sub-Cell GT UV-Transparent Gel Tray (Bio-Rad, Cat. No. 1704435). 
• Fixed-Height Comb (Bio-Rad, Cat. No. 1704465). 
• MicroAmp® Optical 96-Well Reaction Plate (Thermo Fisher Scientific, Cat. No. 
4316813).  
• MicroAmpTM Clear Adhesive Film (Thermo Fisher Scientific, Cat. No. 4306311). 
• PCR-strip tubes (Sarstedt AG&Co KG, Nümbrecht, Germany, Cat. No 
72.982.002).  
• PCR lid strips (Sarstedt AG&Co KG, Cat. No. 65.989.002).  
• GeneMapper® Software v4.0 (Thermo Fisher Scientific). 
 
Procedure 
The protocol can be divided into the following steps: 
1. PCR multiplex reaction  
For each amplification, mix Milli-Q water, Buffer A, dNTPs, FAM dye labelled 




required. Conditions for amplification and primers can be found in Supplementary data 
6. 
2. Perform an agarose gel electrophoresis  
PCR fragments are separated on the agarose gel and visualized when exposed 
to UV light. If amplification of the genetic marker happens, a specific band appears at 
the expected location compared to the molecular ruler.  
See above for agarose gel electrophoresis preparation.  
3. Fragment separation on a capillary electrophoresis instrument 
• For each sample prepare the following mix:  
o Formamide: 10µL 
o GeneScanTM 500 ROXTM dye size Standard: 0.5µL 
• Add 10µL of the previous mix to 2µL of the PCR product. 
• Mix by vortexing and spin in a centrifuge.  
• Place the samples in the thermocycler at 95°C for 5 minutes. 
• Place the samples on ice for 5 minutes. 
• Place the plate on the genetic analyser. 
4. Data analysis 
Data analysis was performed with the GeneMapper® Software v4.0 (Applied 
Biosystems). For each genetic marker, the results were determined by comparing the 
presence or absence of the region of interest with that observed on the DNA control 
samples. 
 
7.8.4. Array-based comparative genomic hybridization 
 
The main advantage of using aCGH is the facility to simultaneously detect 
aneuploidies, deletions, duplications and amplifications of any locus represented on 
the array, offering higher resolution than traditional cytogenetic methods.  
 
This method uses slides arrayed with small fragments of DNA, known as probes, 
as the targets for analysis. Probes vary in size and resolution is determined by the 
genomic distance between DNA probes and the length of these probes. The 
methodology uses the sample DNA and a control DNA, differentially labelled with 
fluorescent dyes, which are mixed and applied to the slide to hybridize with the 
arrayed single-strand probes. Digital imaging systems are used to capture and quantify 
the relative fluorescence intensities of the labelled DNA probes hybridized to each 
target. The fluorescent signal intensity of the sample DNA, relative to that of the 
control DNA, can then be linearly plotted across each chromosome, allowing the 





We used the SurePrint G3 Human CGH Microarray 8x60K (Agilent Technologies, 
Santa Clara, CA, USA), containing 55.077 biological probes and 41kb overall median 
probe spacing. The optimal amount of sample DNA for the aCGH is 500ng. 
 
Reagents and materials 
• SureTag Complete DNA Labeling Kit (Agilent Technologies, Cat. No. 5190-4240), 
containing 10X restriction Enzyme Buffer, BSA (Bovine Serum Albumin), AluI, 
RsaI, random primer, 5X Reaction Buffer, 10X dNTPs, Cyanine 3’-dUTP and 
Cyanine 5’-dUTP. 
• TE Buffer Solution (pH 8.0) (100mL) (Merck KGaA, Cat. No. 8890-100ML).  
• Oligo aCGH/ChIP-on-chip Hybridization Kit (Agilent Technologies, Cat. No. 5188-
5220), containing 10x aCGH Blocking Agent and 2xHI-RPM Hybridization Buffer. 
• Human Cot-1 DNA (1mg/mL) (Agilent Technologies, Cat. No. 5190-3393). 
• Agilent Oligo aCGH Wash Buffer 1 and 2 Set (Agilent Technologies, Cat. No. 
5188-5226). 
• Milli-Q ultrapure water (Merck KGaA). 
• SurePrint G3 Human CGH Microarray 8x60K (Agilent Technologies, Cat. No. 
G4450A). 
• Purification columns (50 u) (Agilent Technologies, Cat. No. 5190-3391). 
• GeneAmp®PCR System 9700 (Thermo Fisher Scientific, Cat. No. 4339386). 
• Minicentrifuge (Nippon Genetics Europe, Cat. No. NG002R).  
• Hybridization oven rotator (Sheldon Manufacturing, Inc., Cornelius, OR, USA, 
Cat. No. SHO1). 
• Hybridization Chamber (Agilent Technologies, Cat. No. G2534A). 
• Hybridization Chamber Gasket Slides (Agilent Technologies, Cat No. G2534A). 
• SureScan Microarray Scanner G4900DA (Agilent Technologies, Cat No. 
G4900DA).  
• Gasket slide, 8 microarrays/slide format (Agilent Technologies Cat. No. G2534-
60014). 
• Slide-staining dishes (VWR, Radnor, PA, USA, Cat. No. 470175-194). 
• Magnetic stir plate (Velp Scientifica, Usmate, Italy, Cat. No. F20700431). 
• SureScan Microarray Scanner (Agilent Technologies). 
• NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific). 
• NanoDrop 1000 Spectrophotometer Software v3.8 (Thermo Fisher Scientific). 
• Agilent CytoGenomics software v2.7 (https://www.agilent.com/en/download-
agilent-cytogenomics-software). 








The protocol can be divided into the following steps: 
1. Label the samples 
• For each reaction add the amount of DNA to the appropriate nuclease-
free water to bring to a final volume of 13µL. 
• Add 2.5µL of Random primer to each reaction tube. Mix by pipetting up 
and down. 
• Place the tubes in the thermocycler and run the following program:  
o 98°C for 10 minutes. 
o Hold at 4°C. 
• Spin the samples in the minicentrifuge 
• Prepare the Labelling master mix on ice. For each sample add: 
o 5X Reaction Buffer: 5µL 
o 10X dNTPs: 2.5µL 
o Cyanine3’-dUTP (For control DNA): 1.5µL 
o Cyanine 5’-dUTP (For samples DNA): 1.5µL 
o Exo (-) Klenow: 0.5µL 
• Add 9.5µL of the Labelling master mix to each sample. Mix by pipetting 
up and down. 
• Place the tubes in the thermocycler and run the following program:  
o 37°C for 2 hours 
o 65°C for 10 minutes 
o Hold at 4°C 
At this point reactions can be stored at -20°C in dark for 1 month. 
2. Purification of labelled gDNA 
• Centrifuge the samples for 1 minute at 6,000 x g. 
• Add 430µL TE to each reaction tube. 
• Place a column in a 2mL collection tube. Load each labelled gDNA onto a 
column and cover the column with a cap. 
• Spin for 10 minutes at 14,000 x g in a microfuge at room temperature. 
Discard the flow-through. 
• Transfer the column to a new 2mL collection tube. Spin for 1 minute at 
1,000 x g in a microfuge. Spin. 
• Dry the labelled gDNA to bring the sample volume to 9.5µL. 
• Take 1.5µL of each sample and measure the DNA concentration on the 
NanoDrop® ND-1000 spectrophotometer.  
• Combine 8µL test sample with 8µL control sample for a total volume of 
16µL. 





• Prepare the 10X Blocking Agent (Supplementary data 7): Vortex the 
solution before use. 
• Prepare the Hybridization master mix at room temperature. For each 
sample add: 
o Cot-1 DNA (1.0mg/mL): 2µL 
o 10X aCGH Blocking Agent: 4.5µL 
o 2x HI-RPM Hybridization Buffer: 22.5µL  
• Add 29µL of the Hybridization master mix to each sample. Mix by 
pipetting up and down. 
• Spin the samples in the minicentrifuge 
• Place the tubes in the thermocycler and run the following program: 
98°C for 2 minutes and 37°C for 30 minutes. 
• Prepare de hybridization assembly as manufacturers’ instructions.  
• Load 40µL of hybridization sample mixture into the gasket. 
• Hybridize at 65°C for 24 hours in the oven rotator. 
4. Microarray wash 
• Pre-warm Agilent Oligo aCGH/ChIP-on-Chip Wash Buffer 2 at 37°C 
overnight. 
• Prepare and fill slide-staining dishes as follows: 
o Slide-staining No. 1: Agilent Oligo aCGH/ChIP-on-Chip Wash 
Buffer 1 at room temperature. 
o Slide-staining No. 2: Agilent Oligo aCGH/ChIP-on-Chip Wash 
Buffer 1 at room temperature on a magnetic stir plate. 
o Slide-staining No. 3: Agilent Oligo aCGH/ChIP-on-Chip Wash 
Buffer 2 at 37°C on a magnetic stir plate. Add a magnetic stir bar 
and turn on the heating element to maintain temperature. 
• Remove the hybridization chamber from the incubator. 
• Disassemble hybridization chamber in Slide staining No. 1, following 
manufacturers’ instructions.  
• Remove the microarray slide to Slide staining No. 2 and stir at 350 rpm 
for 5 minutes. 
• Transfer to Slide staining No. 3 for 1 minute. 
• Slowly remove the slide rack trying to minimize droplets on the slides. 
 
5. Microarray scanning and analysis 
Put assembled slide holders in the scanner cassette and scan the slide. Extract 
features to process microarray image files with the Feature Extraction Software. This, 
locates microarray grids, rejects outliers and determines intensities and ratios. Finally, 
analyze the microarray image using the Agilent CytoGenomics software v2.7. The 
algorithm used by the software allows the data analysis by the conversion of the 




coloured plots along the chromosomes or loci where the log2 expression form is 
represented. When the sample DNA is normal, the fluorescence between both sample 
and control is similar, therefore the ratio between both fluorescence emissions is 1 
and log2 is 0, representing the same number of copies for both DNA sample and 
control. However, an variants in the Cy3:Cy5 ratio indicates a loss or gain of sample 
DNA in that specific region. We considered the log2 values above 0.5 or below -0.5 of 3 
consecutive probes as a gain or loss of a copy of a gene or region. 
 
To achieve a high accuracy quality control metrics should be within the normal 
ranges, according to manufacturers.  
 
7.8.5. Fluorescence in situ hybridization  
 
Sex determination in humans is dependent upon the SRY gene, located on 
chromosome Yp11.3. Translocation to the X chromosome or to an autosome results in 
a mismatch between the sexual phenotype and the cytogenetic genotype.  
 
Fluorescence in situ hybridization (FISH) represents a widely-used molecular 
technique that allows detecting relocation of the SRY gene away from its normal 
location on the Y chromosome. This procedure is based on the construction of one or 
several probes, designed to hybridize to those parts of the chromosome with a high 
degree of complementarity, and tagged with fluorophores. In our case, the results 
were visualized on a fluorescence microscope by using DAPI nuclear counterstain, 
which stains nuclei and contrast to fluorescent probes of other structures.  
 
For the analysis, we used peripheral blood cells reared in metaphase and fixed 
on microscope slides. Blood samples (3.5mL) were collected on Sodium Heparin tubes.  
 
Reagents and materials 
• Vysis SRY Probe LSI SRY Spectrum Orange/Vysis CEP X Spectrum Green Probe 
Kit (Abbott Mol Inc., Chicago, IL, USA, Cat. No. 06N29-020), containing Vysis LSI 
SRY SpectrumOrange/CEP X SpectrumGreen Probes (1 x 20µL) (Cat. No. 30-
191007) and Vysis LSI/WCP Hybridization Buffer (1 x 150µL) (Cat. No. 30-
804824). 
• DAPI II counterstain (2 x 500µL) (Abbott Mol. Inc., Cat. No. 06J50-001). 
• RPMI 1640 Medium (1L) (Thermo Fisher Scientific, Cat. No. 11875085). 
• Fetal bovine serum (FBS) (1L) (Thermo Fisher Scientific, Cat. No. 10106185). 
• Phytohemagglutinin (10mL) (Thermo Fisher Scientific, Cat. No. 10576015). 
• KaryoMAX™ Colcemid™ Solution (10mL) (Thermo Fisher Scientific, Cat. No. 
15212012). 




• NP-40 (50mL) Thermo Fisher Scientific, Cat. No. 85124). 
• Formamide (Thermo Fisher Scientific, Cat. No. 4311320). 
• Potassium chloride (KCl) BioXtra ≥99.0% (500g) (Merck KGaA, Cat. No. P9333). 
• PBS tablets (Phosphate buffered saline) (50 tablets) (Merck KGaA, Cat. No. 
P4417-50TAB). 
• Ficoll 1077 (100mL) (Merck KGaA, Cat. No. 10771-100ML). 
• Methanol (1L) (Merck KGaA, Cat. No. 34860-1L-R). 
• Acetic acid (1L) (Merck KGaA, Cat. No. A6283-1L). 
• Absolute Ethanol (Thermo Fisher Scientific, Cat. No. BP2818100). 
• 100% Acetone (10x 0.5mL) (Merck KGaA, Cat. No. 175862-10X0.5ML). 
• 36-38% Hydrochloric acid (HCl) (100mL) (Merck KGaA, Cat. No. H1758-100ML). 
• Milli-Q ultrapure water (Merck KGaA). 
• Slide and coverslip (Thermo Fisher Scientific, Cat. No. 12373118 and Cat. No. 
12343138). 
• Coplin jars (VWR, Radnor, PA, USA, Cat. No. 470175-194). 
• pH-meter BASIC 20 (Crison instruments S.A, Alella, Spain, Cat. No. Hach 
LPV2000.98.0002). 
• Water baths (Thermo Fisher Scientific, Cat. No. TSGP02). 
• Bunsen lighter (Merck KGaA, Cat. No. Z270318-1EA). 
• Magnetic stirrer hotplate (Velp Scientifica, Usmate, Italy, Cat. No. F20700431). 
• TP2555 Thermal Plate (inTEST Corporation, Mt. Laurel, NJ, USA). 
• Minicentrifuge (Nippon Genetics Europe, Cat. No. NG002R). 
• Centrifuge Sorvall™ Legend™ Micro 17R (Thermo Fisher Scientific, Cat. No. 
75002440). 
• Oven (Sheldon Manufacturing, Inc., Cornelius, OR USA, Cat. No. SHO1). 
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
• Membrane MF-Millipore, 0.45µm (Merck KGaA, Cat. No. HAWP04700). 
• Fluorescence microscope Nikon Eclipse 50i (Nikon Inc, Tokio, Japan). 
 
Procedure for preparing blood cells  
1. Prepare the 1X PBS, KCl 57mM, Carnoy solution and1% HCl solutions (See 
Supplementary data 7) 
2. Place 3.5mL of blood in a falcon tube and add 500µL of 1X PBS. 
3. Slowly add 4mL Ficoll 1077, avoiding the mix. Centrifuge at 700 x g for 30 
minutes. 
4. Harvest the ring with the lymphocytes without touching the Ficoll using a 
sterile pipette tips. Collect in a falcon tube and add 15mL of 1X PBS. 
5. Centrifuge at 900 rpm for 20 minutes. 
6. Discard the supernatant. Resuspend the pellet in 5mL supplemented RPMI 




7. Incubate the lymphocytes at 37°C for 3 days. 
8. Add 50µL colcemid solution (10µg/mL) and place the flask at 37°C for 20 
minutes in the culture oven. 
9. Transfer the lymphocytes to a falcon tube and add 50mL 1X PBS. 
10. Centrifuge at 900 rpm for 15 minutes. 
11. Discard the supernatant, except 500µL for resuspending the pellet. Add 15mL 
KCl 75mM. 
12. Incubate at 37°C for 20 minutes in the water bath. 
13. Centrifuge at 900 rpm for 15 minutes. 
14. Discard the supernatant, except 500µL for resuspending the pellet. Slowly, drop 
by drop, add 2mL Carnoy solution. Faster, add another 8mL. Tap the tube 
continuously for mixing.  
15. Incubate for 10 minutes at room temperature. 
16. Centrifuge at 900 rpm for 15 minutes. 
17. Repeat steps 15 to 17 three more times. In the last step resuspend pellet in 
2mL Carnoy solution. 
At this point metaphases can be stored for 2-3 days at 4°C, or for longer periods 
at -20°C. 
18. Clean the slides as shown in Supplementary data 7. 
19. Collect 500µL metaphases. With the slide over the steam of the water bath at 
100°C, pour three drops of the metaphases. Drops should be poured at a 
distance of 60-70cm.  
20. Dry the slide upon and below the sample with the Bunsen lighter. Place the 
slide in the thermal plate at 45°C until it completely dries. 
21. Leave the preparations at 4°C before use. 
  
Procedure for FISH 
1. Prepare 20X SSC, 2X SSC/0.1% NP-40 wash solution, denaturation solutions, 
0.4X SCC/0.3% NP-40 Wash solution and ethanol solutions at 70%, 85% and 
100%. 
2. Prepare the target and probe mixture 
• Place Coplin jar containing denaturation solution to a water bath at 
73°C.  
• Immerse the slides in the denaturation solution for 5 minutes. 
• Immerse the slides in 70% ethanol for 1 minute, followed by 1 minute in 
ethanol 85% and 1 minute in ethanol 100% to dehydrate. Keep slides in 
100% ethanol until probe mixture is ready. 
• For each target, prepare the following:  
o 7µL LSI/WCP hybridization buffer 
o 1µL probe 




•  Centrifuge tube for 3 seconds, vortex and centrifuge the tube again. 
• Place the tube in the water bath at 73°C for 5 minutes. 
• Add denaturation solution and 70mL of each ethanol dilutions to 
different Coplin jars and bring to room temperature.  
3. Hybridize the probe 
• Prepare a humidified box: Place a humidified paper towel on an airtight 
container at 37°C. 
• Remove the slides from 100% ethanol and place them on a 45 to 50°C 
slide warmer for up to 2 minutes. 
• Apply 10µL of probe mixture and put the coverslip.  
• Place slides in the pre-warmed humidified box and place in the 
incubator at 37°C overnight. 
4. Washing and detection 
• Pour 70mL of 0.4X SCC/0.3% NP-40 solution into a Coplin jar and place 
in a 73°C water bath at least for 30 minutes before use. 
• Pour 70mL of 2X SCC/0.1% NP-40 into a Coplin jar and bring to room 
temperature. 
• Remove the coverslip from the slide and immerse the slide in the 0.4X 
SCC/0.3% NP-40 solution. Agitate slide for 3 seconds and immerse for 2 
minutes. 
• Immerse the slide in the 2X SCC/0.1% NP-40 solution. Agitate slide for 3 
seconds and immerse for 1 minute. 
• Dry slide in darkness. 
• Apply 10µL of DAPI II counterstain and put coverslip. 
5. Visualize results on the fluorescence microscope. 
The optimal visualization of the probe allows viewing the orange and green 
fluorophores. For male specimens with a 46, XY karyotype is one orange signal on the Y 
chromosome and one green signal on the X chromosome. The signal pattern of one 
green signal on each X chromosomes with lack of orange signal is seen in 46, XX 
karyotype specimens.  
 
 
7.9. BIOINFORMATIC ANALYSIS 
 
The sequencing data were analysed using the Ion Reporter software (Thermo 
Fisher Scientific), which comprises a group of bioinformatics tools that simplifies the 
study. Base calling, read filtering, alignment to the human genome and variant filtering 
were done with Ion Reporter Suites. The trimmed reads were aligned using BWA-MEM 
(Burrows-Wheeler Aligner Memory) algorithm followed by Genome Analysis ToolKit 




the Ion PGM system were automatically uploaded from the Torrent Browser to our Ion 
Reporter software for read mapping, annotation and reporting of variants. 
 
Data analysis was automated with a predefined workflow in which annotation 
sources about the biological meaning of variants for priorization were selected, as well 
as the alignment to the human genome (hg19), the analysis of a single sample and 
germline variant detection was set.  
 
Two workflows were applied to each sample. First workflow was done for 
variant calling of single-nucleotide variants (SNV) and small insertions or deletions 
(indels) and a second one was used for copy number variations (CNV). Then, filter 
chains were created based on Ion Reporter Software variant data types.  
 
7.9.1. Variant filtering for point mutations and small indels 
 
To identify the DSD causative variant in each patient we filtered as follows: 
• Variants with insufficient sequence coverage, depth and a Phred-like quality 
score below 20 were excluded. For evaluating the coverage and depth the 
variants were visualized using the Integrative Genomics Viewer (IGV) 
(http://www.broadinstitute.org/igv/). In those cases in which the amplicon was 
not covered or the depth was low (<20x fold) validation by Sanger sequencing 
was done. Phred-like score measures the quality of the identification of the 
bases generated by DNA sequencing or the confidence in the assignment of 
each base call by the sequencer.  Phred-like score >20 means a 99% accurate 
assignment of each base, with a 1% chance of error. Quality metrics of each run 
and library was generated and evaluated. 
• Variants were filtered to include those with a p-value <0.001 and a Minor Allele 
Frequency (MAF) <0.05 in the annotation settings of the Ion Reporter software, 
namely dbSNP, ClinVar and 5000 exomes databases. Moreover, the allele 
frequency was further checked for each ethnic group in 1000 genomes browser 
(http://browser.1000genomes.org/), Exome Aggregation Consortium (ExAC) 
Consortium (http://exac.broadinstitute.org/), Genome Aggregation Database 
(GnomAD) (https://gnomad.broadinstitute.org/) and Exome Sequencing Project 
(ESP) Variant Server (http://evs.gs.washington.edu/EVS/) and variants were 
discounted if they were common. Thus, we filtered to include only rare variants 
with MAF≤0.001. Moreover, we identified repeated variants within our cohort 
that may result from amplification or sequencing errors. These, were also 
discarded if found in more than 4 samples in the same run or in the total 
cohort, as well as if they are found in different phenotypes. Then, gene changes 
in the untranslated or intronic regions were discarded, with the exception of 




genotype/phenotype correlation was done, where the DSD variant is consider 
for further curation if it fits with the clinical presentation of the patient.  
 
7.9.2. Variant filtering for CNV 
 
The detection of CNV is dependent on several parameters. Control samples 
need to be included in the study as CNV will be reported based on their copy number 
relative to these samples. Previously studied samples will be used to make a baseline 
and thus, it is desirable to select those samples with not known CNV in any region 
covered by the panel. The karyotype of the patient is also important because copy 
number on X and Y chromosomes will be determined relative to its presence. 
  
We included 4 samples (GN0038, GN0109, GN0141 and RE0045) to make the 
baseline and used the Confident Germline CNV filter added to filter chains in Ion 
Reporter Software. This filter returns CNV with high confidence levels, between 10 and 
10,000,000. Moreover, we chose a MAPD (Median of the absolute value of all pairwise 
differences) score >0.4 as the cut-off. 
 
7.9.3. Categorization of the variants 
 
Variants were categorized based on the recommendations of the American 
College of Medical Genetics (ACMG) for variant classification and reporting (229) into 5 
categories: Pathogenic, likely pathogenic, VUS (Variant of Unknown Significance), likely 
benign and benign. We used the following rules: 
• Variants previously reported to cause disease in HGMD, OMIM, ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) or PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) were noted as reported, and were 
considered pathogenic if described in one or more unrelated individuals. They 
were reported as likely pathogenic if the same variant had been associated to a 
different DSD-phenotypes or if no functional studies had been done. 
• Variants with MAF ≤0.1% that disrupt gene function, such as nonsense, 
frameshift, splice sites, initiation codons and exon deletion, were classified as 
pathogenic when the mechanism of pathogenicity is consistent with the 
inheritance pattern, previous DSD-associated variants have been described in 
the gene and the variant in a splice site leads to exon skipping or shortening.  
• Novel missense variants with MAF ≤0.1%, with evidence for pathogenicity 
according to in silico programs and that demonstrated to be de novo in patient 
with the disease and no family history were classified as pathogenic.  
• A novel missense variant with MAF≤ 0.1% involving an amino acid or nucleotide 
change known to be pathogenic, but changes to a different amino acid or 




pathogenicity is well known to be caused by altered protein function it was 
classified as pathogenic.   
• Novel missense variants with MAF ≤0.1% in known DSD genes and evidence for 
pathogenicity according to in silico programs were considered as likely 
pathogenic. 
• Novel single variants with MAF ≤0.1% were considered VUS when contradictory 
evidence of pathogenicity according to prediction software. 
• Variants previously reported, but with contradictory evidence in bibliography 
were considered VUS. 
• Variants with an allele frequency >0.1% and synonymous variants that had not 
been previously reported to have a deleterious effect were classified as benign.  
 
In this work, we only present those variants classified as pathogenic, likely 
pathogenic and VUS, as well as likely benign polymorphism previously related to DSD. 
 
7.9.4. Variant effect prediction software tools 
 
The most direct method to identify causal variations in an individual is by 
comparison with known mutations and disease-associated genes, like those referred in 
databases such as the HGMD (230), OMIM (231), ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), UCSC (University of California Santa Cruz 
Genomics Institute) (https://genome.ucsc.edu/), DGV (Database of Genomic Variants) 
(http://dgv.tcag.ca/dgv/app/home) and dbVar (Database of human genomic structural 
Variation) (https://omictools.com/dbvar-tool). This is of utility in well studied diseases 
and can be used to find novel and known mutations in previously identified genes.  
 
The remaining variants that have not been previously described can be 
prioritized. Multiple algorithms have been developed for predicting deleteriousness 
based on different information of the variant including its sequence homology, protein 
structure and evolutionary conservation. Although there are many, we have used the 
following prediction software tools. 
 
7.9.4.1. Interpretation of single-nucleotide variants and small indels.  
 
• PROVEAN (http://provean.jcvi.org/index.php) 
PROVEAN (Protein Variation Effect Analyzer) is an informatics tool developed to 
predict whether a protein sequence variation affects protein function. It introduces a 
delta score based on the reference and variant versions of a protein query sequence 
with respect to sequence homologs collected from the NCBI NR (National Centre for 
Biotechnology Information Non-Redundant) protein database through BLAST (Basic 





The delta score is computed for each supporting sequence and then averaged 
within and across clusters to generate the final score. The protein variant is predicted 
to have a deleterious effect if this score is equal or below the default threshold, set at -
2.5.   
 
• SIFT (http://sift.jcvi.org/) 
SIFT (Sorting Intolerant From Tolerant) predicts whether an amino acid 
substitution affects protein function. It is based on the degree of conservation of 
amino acid residues in sequence alignments derived from closely related sequences, 
collected through PSI-BLAST (Position-Specific Iterative Basic Local Alignment Search 
Tool) and calculates the probability of the amino acid being tolerated based on 
observed alignment. 
 
• Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) 
PolyPhen-2 (Polymorphism Phenotyping v2) is a tool for the prediction of the 
possible impact of an amino acid substitution on the structure and function of a human 
protein using features that comprise the sequence, phylogenetic and structural 
information. 
 
The user can choose between HumDiv and HumVar models. HumDiv dataset 
was compiled from the damaging alleles with known effects on the molecular function 
causing human Mendelian diseases, present in the UniProtKB (UniProt 
Knowledgebase) database. HumVar consists of human disease-causing mutations 
together with common nsSNPs (Non-synonymous SNPs) without involvement in 
disease and therefore treated as non-damaging. Both models were considered in this 
work. 
 
For a variation, PolyPhen-2 calculates the probability that this mutation is 
damaging and is evaluated qualitatively, as benign, possibly damaging, or probably 
damaging. 
 
• MutationTaster (http://www.mutationtaster.org/) 
MutationTaster integrates information from different biomedical databases 
and uses established analysis tools. Analyses comprise evolutionary conservation, 
splice-site changes, loss of protein features and changes that might affect the amount 
of mRNA (Messenger RNA). It employs Bayes classifier to predict the disease-potential 
of an alteration and calculates a probability value to be either a disease mutation or a 
harmless polymorphism. For this prediction, the tool studies the frequencies of known 





We have used the Mutation Taster for the comparison of the proteins for non-
synonymous changes among different species. 
 
• SNPs and GO (http://snps.biofold.org/snps-and-go/snps-and-go.html) 
It is a GO (Gene Ontology) integrated predictor that uses a SVM (Support 
Vector Machine) classifier that takes in input protein sequence, profile and functional 
information to predict if a given variation can be classified as disease-related or 
neutral.   
 
• MutPred (http://mutpred1.mutdb.org/) 
MutPred (Mutation Prediction) is a web application tool developed to classify 
an amino acid substitution as disease-associated or neutral in human. Moreover, it 
predicts the molecular cause of disease of the substitution based upon the gain or loss 
of 14 different structural or functional properties, for example, gain of helical 
propensity.  
 
• PANTHER (http://www.pantherdb.org/) 
The PANTHER (Protein Analysis Through Evolutionary Relationships) system 
classifies protein according to molecular function, biochemical process, pathway and 
family or groups of evolutionarily related proteins. 
 
• VarSome (https://varsome.com/) 
This engine is used as an annotation tool, search instrument for genomic 
variants and also as a platform that enables the sharing of information (232). The 
variant of interest is mapped to a specific genomic location, identifying equal variants, 
the variant type and the coding effect. Variant pathogenicity is given using an 
automatic classifier that evaluates the submitted variants according to the American 
College of Medical Genetics (ACMG) guidelines (229). 
 
7.9.4.2. Interpretation of variants located on the splicing sites 
 
Alternative splicing is a process during gene expression in which particular 
exons of a gene are included or not in the final mRNA from that gene. This process 
results in a single gene coding for multiple proteins, that contain differences in their 
amino acid sequence and therefore, in their biological functions.  
 
We used the Neural Network Splice Site Prediction 
(http://www.fruitfly.org/seq_tools/splice.html) and NetGene2 Server 
(http://www.cbs.dtu.dk/services/NetGene2/) to deduce the effect of the variants 




donor and acceptor sites in the wild type (wt) to the newly altered gene and stablish if 
these structures have suffered any modification. 
 
7.9.4.3. Interpretation of genomic structural variations 
 
The analysis of structural variations was firstly performed with the 
CytoGenomics software v2.7, which applies automated filters based on several 
databases, such as the Database of Genomic Variants (DGV) and polymorphisms of 
Agilent Reference DNA. 
 
The DGV (http://dgv.tcag.ca/dgv/app/home?ref=) provides structural variations 
identified in healthy control samples. It is continuously updated and aiming to 
correlate with phenotypic data. 
 
Structural variations were also compared in dbVar, the NCBI's database of 
human genomic structural variation, ClinVar, which aggregates information about 
genomic variation and its relation to health and UCSC, a collection of organism 
assemblies and annotations. 
 
 
7.10. IN VITRO FUNCTIONAL AND EXPRESSION STUDIES  
 
Likely pathogenic or variants of unknown significance were selected and 
functionally characterized in different cell systems. In order to test the transcriptional 
activity of identified variants, several experiments were carried out including the site-
directed mutagenesis, cloning and purification and the functional characterization of 
the variant. 
 
The in vitro functional studies were developed in the Paediatric Endocrinology, 
Diabetology and Metabolism Department of BioMedical Research in the University 
Hospital Inselspital in Bern (Switzerland) under the guidance of Prof. Dr. med. Christa 
Flück.  
 
7.10.1. Used vectors for the in Vitro functional studies  
 
7.10.1.1. Expression vectors 
 
To assess the impact of the identified variants, we used previously constructed 
mammalian expression vectors by cloning the gene cDNA into the corresponding 





• pCMV: Derived from a high-copy-number pUC-based plasmid. Mammalian 
expression is driven by the human cytomegalovirus (CMV) promoter to 
promote constitutive expression of cloned inserts in a wide variety of cell lines. 
Selection is made possible in bacteria by the ampicillin-resistance gene under 
control of the β-lactamase promoter.  
• pSG5: This ampicillin resistant vector was constructed by combining pKCR2 and 
pBS vectors. The SV40 early promoter and polyadenylation signal promotes 
expression in vivo.  
• pcDNA3: It has a CMV enhancer-promoter for high-level expression and 
ampicillin resistance gene, as well as a pUC origin for selection and 
maintenance in E. coli.  
 
 
Figure 15. Image of the three expression vectors pCMV, pSG5 and pcDNA3 where cDNA from GATA4, 
LHCGR and NR5A1 was inserted.  
 
 
Human wild type (wt) GATA4 cDNA was inserted into the mammalian pCMV 
expression vector. For the LHCGR expression vector we used the HA-tagged (Human 
influenza Hemagglutinin) wt LHCGR_pSG5 kindly gifted by Dr. Adolfo Rivero-Müller 




described (233). Whereas, wt cDNA of NR5A1 in a pcDNA3 vector with an HA-tag 
added at 5‘ by PCR strategy was available from previous work (14). 
 
GATA4, LHCGR and NR5A1 mutants were generated by site-directed 
mutagenesis using specific primers and the QuickChange protocol by Stratagene 
(Agilent technologies Inc., Santa Clara, CA, USA).  
 
7.10.1.2. Promoter reporter vectors 
 
Mammalian expression vectors were tested on different responsive promoters. 
These reporter vectors included a gene described as being regulated by the genes of 
interest (GATA4 or NR5A1) linked to a firefly-luciferase (luc) and inserted in a plasmid. 
The following reporter vectors were used in this work: 





The pGL3 promoter vector is an ampicillin resistant vector which contains an 
SV40 promoter upstream of the luciferase gene for monitoring transcriptional activity 
in transfected eukaryotic cells. CYP11A1 and HSD3B2 genes were inserted in this pGL3 
vector. CYP17A1 was inserted into the reporter plasmid pMG3 luciferase. The 
CYP17A1, CYP11A1 and HSD3B2 luciferase reporter vectors were used in either the co-
transfection of GATA4 or NR5A1 expression vectors. 
 
On the other side, CRE-luc reporter was used in the co-transfection of either 
the wild type LHCGR expression vector, the empty vector (pSG5) or the mutant LHCGR 
vectors. CRE-luc reporter contains the firefly luciferase gene under the control of cAMP 
(Cyclic adenosine monophosphate) response element (CRE), located upstream of a 
promoter. Elevation of the intracellular cAMP level activates cAMP response element 
binding protein (CREB) to bind CRE and induces the expression of luciferase.  
 
The construction and cloning of the promoter luciferase reporter vectors has 
been previously described and were available from earlier work (14, 24, 117). 
 
7.10.1.3. Renilla luciferase vectors 
 
To normalize the transfection efficiency, we added a pRL vector that contains 
wt Renilla luciferase (Rluc). This provides constitutive expression of Renilla luciferase 




mammalian cells, provides an internal control value to which expression of the 
experimental firefly luciferase reporter gene can be normalized.  
 
pRL vectors contain the cDNA encoding Renilla luciferase cloned from the 
Renilla reniformis. We used the pRL vectors with the HSV-thymidine kinase promoter 
(pRL-TK) and the CMV promoter region (pRL-CMV) (Figure 16). Both were isolated from 
an E. coli K host strain and are ampicillin resistant. pRL-TK was used to normalize the 
transfection efficiency of the LHCGR and NR5A1 promoter transactivation assays while 
pRL-CMV was used for the GATA4 functional studies. These vectors were available 
from previous works (14). 
 
 




7.10.2. From Site-directed mutagenesis to plasmid purification 
 
The procedure requires the synthesis of a DNA primer containing the desired 
mutation, complementary to the template DNA, so it can hybridize with the DNA in the 
gene of interest. Then, the single-strand primer is extended using a DNA polymerase, 
which copies the rest of the gene. During PCR, the mutation is incorporated into the 
amplicon, replacing the original sequence. The template DNA is removed using a 
methylation-dependent endonuclease, such as DpnI, and the mutated gene is 
introduced to a host cell (E. coli) as a vector and cloned. Plasmids are isolated 
(Miniprep) from the resulting colonies and both mutants and wild type (wt) were 
checked by DNA sequencing to ensure that they contain the desired mutation or the 
wt DNA. These clones were used for all downstream procedures. They were again 
amplified in E. coli and purified using a maxiprep kit. The purified plasmids were then 






7.10.2.1. Primers design and site-directed mutagenesis 
 
Site-directed mutagenesis is an in vitro method used to make specific and 
intentional changes to the DNA sequence of a gene. Primers containing the change of 
interest were designed using the Agilent tool 
(www.genomics.agilent.com/primerdesignprogram) and ordered to Microsynth AG 
Company (https://www.microsynth.ch/home-ch.html) (Balgach, Switzerland). We 
designed primers (Supplementary data 6) for the following sequence changes: 
• LHCGR: c.757C and c.1660T variants 
• GATA4: c.677T variant 
• NR5A1: c.88A, c.902A and c.71T variants. 
 
Mutant expression vectors (GATA4: c.677T; LHCGR: c.757C and c.1660T; 
NR5A1: c.88A, c.902A and c.71T) were generated by PCR-based site-directed 
mutagenesis (Figure 17) using specific primers and the QuickChange protocol by 








Reagents and material 
• QuikChange II Site-Directed Mutagenesis Kit (30 Rxn) (Agilent Technologies, Inc, 
Cat. No 200524) containing Pfu Ultra High-Fidelity DNA polymerase (2.5 U/µll) 
(80 U), 10× reaction buffer (500µl), DpnI restriction enzyme (10 U/µl) (300 U) 
and dNTP mix (30µl). 
• Primers for each mutant (20µM) (Microsynth AG). 
• Plasmid (GATA4-CMV5 plasmid 128,5ng/µL; LHCGR-pSG5 plasmid 415,4ng/µL; 
NR5A1-pcDNA3 plasmid 206,8ng/µL), obtained from previous works. 
• Bidistilled water.  






Procedure for site-directed mutagenesis 
1. Mutant Strand Synthesis Reaction  
• Prepare the sample reaction by mixing 5µL 10X Buffer, 250ng plasmid, 
1µL forward primer (20µM), 1µL forward primer (20µM), 1µL dNTPs 
(10mM), 1µL Pfu DNA polymerase (2,5U/µL) and bidistilled water up to 
50µL. 
• Place in the T100™ Thermal Cycler and perform as follows:  
o  95°C for 30 seconds. 
o Cycle 12 times: 95°C for 30 seconds, 55°C for 60 seconds and 
68°C for 8 minutes.  
o Hold at 4°C. 
2. DpnI digestion of the amplification product 
• Add 1µL DpnI restriction enzyme to the sample tube. 
Include also a positive and a negative control. Prepare negative control 
with 10X Buffer, plasmid, DpnI and bidistilled water up to 50µL and 
positive control with 2µL plasmid and bidistilled water up to 50µL. 
• Mix by pipetting up and down. 
• Incubate the reaction at 37°C for 1 hour. 
• Proceed to transformation of E. coli cells or store the product at -20°C. 
 
7.10.2.2. Plasmid transformation and purification 
 
Transformation is the process by which foreign DNA is introduced into a host 
cell. Transformation of bacteria with plasmids is widely used due to the bacterial 
capacity of storage and replication but also because plasmids carry both the bacterial 
origin of replication and an antibiotic resistance gene, which is a selective marker in 
bacteria. 
 
Some bacterial strains have been created to be more easily transformed, as 
DH5α which is the most frequently used E. coli strain for routine cloning applications. 
In order to make bacteria capable of internalizing the exogenous DNA, they must be 
made competent. Cells are made competent by treating them with divalent cations, 
such as calcium chloride (CaCl2) or magnesium chloride (MgCl2), which make the 
bacterial wall permeable to DNA, facilitating genetic transformation. 
 
The method for transformation of a DNA construct into a cell is chemical and 
calcium chloride transformation is the most efficient technique. The addition of 
calcium chloride to the cell suspension permits the binding of plasmid DNA to bacterial 
cell membrane, although both are negatively charged, and when heat is provided, 
plasmid DNA passes into the cell. Once plasmid DNA is inside the cell, it will be 




isolate and purify plasmid DNA from genomic DNA. The purified plasmids will be used 
for cell transfection. 
 
We followed the next steps to get the purified plasmid DNA: 
• Transformation of DH5α cells  
• Growth of bacterial culture (small-scale growing) 
• Plasmid DNA purification (Miniprep) 
• Quantification of the recombinant DNA 
• Sequencing to ensure that the plasmid DNA has inserted the change 
• Growth of bacterial culture (large-scale growing) 
• Plasmid DNA purification (Maxiprep) 
• Quantification of the recombinant DNA 
 
7.10.2.2.1. Transformation of E. coli competent cells 
 
We used the transformation storage solution (TSS) buffer method to make 
DH5α cells competent. Competence of cells is induced by the addition of low 
concentrations of Mg2+, which alters the permeability of the membrane, and DMSO, 
acting as a preserving agent. Polyethylene Glycol (PEG) shields the negative charges on 
the DNA and host cell membrane, reducing the repulsion between them. For the 
transformation, we prepared a KCM buffer with both CaCl2 and MgCl2 divalent cations 
for altering the permeability of the bacterial membrane  
 
Reagents and materials 
• DH5α cells (From previous works). 
• LB (Luria-Bertani) broth (Luria/Miller) (1kg), (Carl Roth Gmbh + Co., Karlsruhe, 
Germany, Cat. No. X968.1), containing Tryptone 10g/L, Yeast extract 5g/L, 
Sodium chloride (NaCl) 10g/L. 
• LB Agar (Luria/Miller) (1kg) (Carl Roth Gmbh + Co., Cat. No. X969.1), containing 
Tryptone 10g/L, Yeast extract 5g/L, NaCl 10g/L, Agar 15g/L. 
• Ampicillin, disodium salt (10g) (Carl Roth Gmbh + Co., Cat. No HP62.1). 
• TSS Buffer (See preparation on Supplementary data 7). 
• 5X KCM Buffer (See preparation on Supplementary data 7). 
• Bidistilled water. 
• Orbital shaker (Thermo Fisher Scientific, Cat. No. SHKE420HP). 
• Incubator (Eppendorf AG, Cat. No CO17321001). 
 
Procedure for preparing E. coli competent cells 
1. Prepare LB medium and LB agar plates (Supplementary data 7) 




3. Dilute 0.5mL of the culture into 50mL of fresh LB medium in a 200mL conical 
flask. Grow at 37°C the diluted culture to an OD600 of 0.2–0.5.  
4. Cold the TSS buffer and the microcentrifuge tubes on ice. 
5. Split the culture into two 50mL falcon tubes and incubate on ice for 10 minutes.  
6. Centrifuge cells for 10 minutes at 3000 rpm at 4°C. 
7. Discard the supernatant and resuspend the pellet in chilled TSS buffer. The 
volume of the TSS to use is 10% of the culture volume that was discarded. 
8. Resuspend the culture by vortexing.  
9. Aliquot 200μl into the chilled microcentrifuge tubes. Store at -80°C until use. 
 
Procedure for transformation of E. coli competent cells 
1. Prepare LB medium and LB agar plates (Supplementary data 7). 
2. Pre-warm LB medium and LB plates at 37°C. 
3. Defrost DH5α competent cells on ice. 
4. Prepare DNA mixture by mixing 58µL bidistilled water, 20µL 5X KCM Buffer 
(Supplementary data 7) and 2µL plasmid DNA. 
5. Chill DNA mixture on ice for 10 minutes. 
6. Add 100µL DH5α competent cells to DNA mixture and place on ice for 20 
minutes. 
7. Add 1mL pre-warmed LB medium and incubate at 37°C with shacking for 1 
hour. 
8. Centrifuge for 4 minutes at 200-300 rpm at room temperature. Discard the 
supernatant, except 300µL. 
9. Spread cells with 300µL LB into an LB plate. 
10. Incubate the plate at 37°C for 24 hours. Then store at 4°C until use. 
 
7.10.2.2.2. Growth of bacterial cultures 
 
LB (Luria-Bertani) broth has been widely used for the growth of bacteria in 
molecular applications. These bacterial media are nutrient-rich formulations which 
provide peptides, peptones, vitamins, and trace elements, that permit the fast and 
easy growth of many species, including E. coli. Different formulations have been 
created to vary in the amount of sodium chloride and, therefore, in the osmotic 
conditions for the particular bacterial strain and culture conditions. 
 
We used the Luria-Miller formulation with a high salt content, ideal for 
propagation of E. coli and culturing cells for plasmid preparation. Only those bacterial 
colonies that have incorporated the plasmid and thus the resistance to the antibiotic 
will grow on the LB agar plate. Various colonies of recombinant and wt plasmids were 





Reagents and materials 
• LB broth (Luria/Miller) (1kg), (Carl Roth Gmbh + Co., Cat. No. X968.1), 
containing Tryptone 10g/L, Yeast extract 5g/L, Sodium chloride (NaCl) 10g/L. 
• Ampicillin, disodium salt (10g) (Carl Roth Gmbh + Co., Cat. No HP62.1). 
• Magnesium sulfate (MgSO4) (100g) (Carl Roth Gmbh + Co., Cat. No. 0682.1). 
• Autoclave (JP Selecta group, Abrera, Spain, Cat. No. 4002136). 
• Bidistilled water. 
• Orbital shaker (Thermo Fisher Scientific, Cat. No. SHKE420HP). 
• Magnetic stirrer hotplate (Thermo Fisher Scientific, Cat. No. 13889336). 
 
Procedure for small-scale growing 
1. Prepare LB medium (Supplementary data 7). 
2. Add 12mL LB medium to a 15mL tube. 
3. Add 12µL ampicillin (100mg/mL) to the tube and mix. 
4. Distribute 3mL of the LB medium into 4 tubes of 15mL. 
5. Add 6µL MgSO4 (1M) to each tube. 
6. Collect one single colony and mix it with the culture. Repeat it for the four 
tubes. 
7. Incubate the cell culture at 37°C with constant shaking (250 rpm) for 12-16 
hours. 
Store the bacterial cultures at 4°C until use. 
 
Procedure for large-scale growing 
1. Prepare 500mL LB medium. Mix in a magnetic mixer for 1 hour. 
2. Distribute 100mL to 4 flask and autoclave on liquid cycle at 121°C. 
3. Cool to 60°C for 15 minutes. 
4. Dilute ampicillin (100mg/mL) to 1/1000. Add 100µL to each flask. 
5. Inoculate 200µL of the bacterial growth (obtained at the small-scale growing 
step). Cover with foil. 
6. Incubate at 37°C for 12-16 hours with constant shaking at 230-240 rpm. 
 
7.10.2.2.3. Plasmid DNA purification 
 
We used the NucleoSpin® Plasmid QuickPure kit (Macherey-Nagel GmbH & 
Co.KG, Düren, Germany) which permits to achieve up to 15µg of plasmid DNA and the 
GenElute™ HP Plasmid Maxiprep Kit (Merck KGaA) to isolate large-scale pure plasmid 
DNA.  
 
Plasmid DNA miniprep purification was performed to verify that the mutation 





Reagents and materials 
• NucleoSpin® Plasmid QuickPure kit (50 preps) (Macherey-Nagel GmbH & Co.KG 
Cat. No. 740615.50), containing Resuspension Buffer A1 (15mL), Lysis Buffer A2 
(15mL), Neutralization Buffer A3 (20mL), Wash Buffer AQ (6mL), Elution Buffer 
AE (13mL), RNase A (lyophilized) (6mg), NucleoSpin® Plasmid QuickPure 
Columns (50), Collection Tubes (2mL) (50).  
• GenElute™ HP Plasmid Maxiprep Kit (Merck KGaA, Cat. No. NA0310) containing, 
Column Preparation Solution (225mL), RNase A Solution (2.5mL), Resuspension 
Solution (375mL), Lysis Solution (375mL), Neutralization Solution (375mL), 
Binding Solution (280mL), Wash Solution 1 (375mL), Wash Solution 2 (75mL), 
Elution Buffer (115mL), GenElute HP Maxiprep Filter Syringe (25 units), 
GenElute HP Maxiprep Binding Column (25 units), Collection Tubes 50mL (50 
tubes). 
• Absolute ethanol (Merck KGaA, Cat. No. 1009831000). 
• Centrifuge Sorvall ST 8 (Thermo Fisher Scientific, Cat. No. 75007202). 
• Vortex mixer (Heidolph Instruments GmbH & Co.KG, Cat. No. 541-10000-00). 
• Heating-block (Thermo Fisher Scientific, Cat. No. 88880028). 
 
Procedure for miniprep 
1. Cultivate and harvest bacterial cells 
• Add 2mL of the saturated E. coli LB culture to a tube and centrifuge at 
13000 rpm for 30 seconds at room temperature. Discard the 
supernatant and remove as much liquid as possible. 
2. Cell lysis and clarification of lysate 
• Add 250μL Buffer A1. Resuspend the cell pellet completely by vortexing.  
• Add 250μL Buffer A2. Mix by inverting the tube 6–8 times.  
• Incubate at room temperature for 5 minutes.  
• Add 300μL Buffer A3. Mix by inverting the tube 6–8 times.  
• Centrifuge for 5 minutes at 13000 rpm at room temperature. 
3. Bind DNA 
• Place a NucleoSpin® Plasmid QuickPure Column in a 2mL Collection 
Tube and pipet a maximum of 750μL of the supernatant onto the 
column.  
• Centrifuge for 1 minute at 13000 rpm. Discard flow-through and place 
the NucleoSpin® Plasmid QuickPure Column back into the collection 
tube.  
• Repeat this step to load the remaining lysate. 
4. Wash silica membrane 
• Add 450μL Buffer AQ and centrifuge for 3 minutes at 13000 rpm at 
room temperature. Discard the collection tube and the flow-through. 




• Place the NucleoSpin® Plasmid QuickPure Column in a 1.5mL 
microcentrifuge tube  
• Add 50μL Buffer AE and incubate for 1 minute at room temperature.  
• Centrifuge for 1 minute at 13000 rpm. 
• Pipet the 50µL of plasmid DNA into a new 2mL tube. 
• Store at 4°C until use.NA03 
 
Procedure for maxiprep 
1. Harvest Cells 
• Transfer the bacterial culture to proper centrifuge tubes and centrifuge 
at 4600 rpm for 20 minutes at 4°C. 
• Discard the supernatant. 
2. Resuspend and lyse cells 
• Add 12mL Resuspension/RNase A Solution to the bacterial pellet. 
Resuspend by pipetting up and down. Place to 50mL tubes. 
• Add 12mL Lysis Solution and mix by inverting 6 to 8 times. Let the 
mixture sit for 5 minutes until it becomes clear 
3. Prepare Filter Syringe  
• Prepare a filter syringe by removing the plunger and placing the barrel 
in a rack so that the syringe barrel is upright. 
4. Neutralize and add binding solution 
• Add 12mL Neutralization Solution to the mixture and invert 4 to 6 times.  
• Add 9mL Binding Solution and invert 1 to 2 times. 
• Immediately pour into the barrel of the filter syringe.  
• Allow the lysate to sit for 5minutes.  
5. Prepare Binding Column 
• Place a GenElute HP Maxiprep Binding Column onto the vacuum 
manifold and apply vacuum.  
• Add 12mL of Column Preparation Solution to the column and allow it to 
pass through. 
• Centrifuge for 2 minutes at 3000 x g at 4°C. 
6. Washing 
• Add 12mL of Wash Solution 1 to the column. 
• Centrifuge for 2 minutes at 3000 x g at 4°C. Discard the eluate. 
• Add 12mL of Wash Solution 2 to the column. 
• Centrifuge for 5 minutes at 3000 x g at 4°C.  
7. Elute Plasmid DNA  
• Transfer the binding column to a clean 50mL collection tube. 





• Centrifuge for 5 minutes at 3000 x g at 4°C. Discard the column.  
Store the plasmid DNA at 4°C until use. 
 
7.10.2.2.4. Plasmid DNA quantification 
 
Plasmid DNA quantification was performed after miniprep and maxiprep. We 
used a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific).  
 
7.10.2.2.5. Plasmid DNA sequencing 
 
Microsynth AG Company (https://www.microsynth.ch/home-ch.html) 
performed the Sanger sequencing of the plasmid DNA to ensure that the site-directed 
mutagenesis worked properly and the variant of interest was introduced in the 
plasmid.  
 
7.10.3. Functional characterization of the variants of interest 
 
7.10.3.1. Cell lines and culture 
 
Human placental JEG3 cells (CLS, 300222) and non-steroidogenic human 
embryonic kidney HEK293 cells (ATCC CRL-1573) (http://www.lgcstandards-atcc.org/) 
(Figure 18) were cultured and used for functional assays.  
 
JEG 3 cells are clonally derived lines isolated from human choriocarcionoma 
(Woods strain of the Erwin-Turner tumor) by Kohler et al (234). These cells release 
human chorionic gonadotrophin (hCG) and somatomammotrophin and progesterone 
to media and are able to transform steroid precursors to estrone and estradiol. On the 
contrary, HEK293 cells are derived from human embryonic kidney (235). 
 
JEG3 cells were cultured in MEM (Minimum Essential Medium), supplemented 
with 10% Fetal Bovine serum (Thermo Fisher Scientific), 1% L-glutamin serum (Thermo 
Fisher Scientific) and 1% Penicillin/streptomycin serum (Thermo Fisher Scientific). 
HEK293 cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium), 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and 1% 
sodium pyruvate (Thermo Fisher Scientific) supplemented media. 
 
Reagents and materials 
• JEG3 cells (CLS Cell Lines Service GmbH, Eppelheim, Switzerland, Cat. No. 
300222). 






Figure 18. JEG3 cell lines cultured at low (A) and high density (B). Human embryonic kidney HEK293 cells 
cultured at low (C) and high density (D). 
 
 
• MEM medium (500mL) (Thermo Fisher Scientific, Cat. No. 21090-022). 
• DMEM medium (500mL) (Thermo Fisher Scientific, Cat. No. 41965039). 
• Fetal bovine serum (1L) (Thermo Fisher Scientific, Cat. No. 10106185). 
• Penicillin-Streptomycin (10,000 U/mL) (100mL) (Thermo Fisher Scientific, Cat. 
No. 15140-122). 
• L-Glutamin (100mL) (Thermo Fisher Scientific, Cat. No. 25030081). 
• Sodium pyruvate (C3H3NaO3) (100mM) (100mL) (Thermo Fisher Scientific, Cat. 
No. 11360070). 








• Cell culture hood (Class II cabinet, Bio II Advance, Azbil Telstar, Terrassa, Spain). 
• Incubator (Eppendorf AG, Cat. No CO17321001, Hamburg, Germany). 
• Water bath (JP Selecta group, Abrera, Spain, Cat. No. 032012). 
• Centrifuge Sorvall ST 8 (Thermo Fisher Scientific, Cat. No. 75007202). 
• Vacuum aspiration system (Integra Biosciences™, Hudson, NH, USA, Cat. No. 
158320). 
• Microscope (Carl Zeiss AG, Oberkochen, Germany). 
 
Procedure for thawing frozen cells  
1. Prepare supplemented media (Supplementary data 7). 
2. Remove the cryovial containing the frozen cells from storage and place into a 
37°C water bath. 
3. Pre-warm media at 37°C. 
4. Use a small crystal pipet to transfer the vial content to a flask and dilute with 
14mL of media. 
5. Incubate the culture at 37°C in the incubator at 5% CO2 for 4 days. 
 
Procedure for passaging cells 
1. Pre-warm supplemented media and trypsin-EDTA at 37°C. 
2. Remove and discard the cell culture media from the culture vessel with a 
crystal pipet and vacuum. 
3. Add 2.5mL trypsin-EDTA to the vessel and incubate at 37°C for 5 minutes. 
4. Prepare 2 new culture vessels by adding 14mL media. 
5. Observe the cells under the microscope for detachment.  
6. Add 7.5mL media to the vessel and pipet up and down. 
7. Pipet the appropriate volume into new cell culture vessels so that cell 
suspension is diluted. 
8. Incubate at 37°C in the incubator at 5% CO2 until cells are ready to be 
subcultured. 
 
7.10.3.2. Promoter transactivation experiments 
 
Transfection is the delivery of genetic material into eukaryotic cells to study the 
regulation of the genes, protein expression and function. It can be accomplished using 
various methods and reagents. These methods include physical (i.e. electroporation), 
chemical (i.e. liposome-mediated) or viral-based (i.e. adeno-associated virus) delivery 
systems. Chemical transfection methods are the most widely used methods.  
 
For functional studies, cells were cultured on 12 or 24-well plates and 
transfected with wild type (wt) or mutant vectors and a promoter reporter using either 




2000 Transfection Reagent (Thermo Fisher Scientific). 48h after transfection, cells were 
washed and lysed, before luciferase activity was measured with the Dual-Luciferase® 
Reporter (DLR™) Assay system (Promega AG, Wallisellen, Switzerland) on a Veritas 
microplate Luminometer reader (Turner Bio systems Luminometer and Software by 
Promega). Specific Firefly luciferase readings were standardized against Renilla control 
readings and results were expressed as relative luciferase units.  
 
We used calcium phosphate for the cotransfection of the vectors containing wt 
or mutant GATA4 and LHCGR and promoter reporters. When mixing DNA with calcium 
chloride to a buffered saline solution, a fine precipitate is formed and added to the 
surface of the cells. The cell will take up the precipitate by endocytosis. On the other 
hand, lipofection uses a cationic lipid to form a vesicle with the DNA and easily merge 
with the cell membrane. This liposome transfection was used for the transactivation 
studies of the wt and alterations found in the NR5A1 gene. 
 
Reagents and materials 
• Calcium phosphate transfection Kit (Cat. No. K2780-01, Thermo Fisher 
Scientific), containing Tissue Culture Sterile Water (2 × 12mL), 2X Hepes 
Buffered Saline (HBS) (2 × 12mL) and 2 M Calcium phosphate (CaCl2) (3 × 1mL). 
• Lipofectamine® 2000 Transfection Reagent (1.5mL) (Cat. No. 11668019, 
Thermo Fisher Scientific). 
• MEM medium (500mL) (Thermo Fisher Scientific, Cat. No. 21090-022). 
• DMEM medium (500mL) (Thermo Fisher Scientific, Cat. No. 41965039). 
• Opti-MEM™ I Reduced Serum Medium (500mL) (Thermo Fisher Scientific, Cat. 
No. 31985047).  
• Fetal bovine serum (1L) (Thermo Fisher Scientific, Cat. No. 10106185). 
• Penicillin-Streptomycin (10,000U/mL) (100mL) (Thermo Fisher Scientific, Cat. 
No. 15140-122). 
• L-Glutamin (100mL) (Thermo Fisher Scientific, Cat. No. 25030081). 
• Sodium pyruvate (100mM) (100mL) (Thermo Fisher Scientific, Cat. No. 
11360070). 
• Trypsin-EDTA (0.05%) (100mL) (Thermo Fisher Scientific, Cat. No. 25300-054). 
• Trypan Blue (50mL) (Merck, Cat. No. 93595). 
• Chorionic Gonadotropin, human (1mg) (BioVision, Inc., Milpitas, CA, USA, Cat. 
No. 4778-1000). 
• Cell culture hood (Class II cabinet, Bio II Advance, Azbil Telstar, Terrassa, Spain). 
• Incubator (Eppendorf AG, Cat. No CO17321001, Hamburg, Germany). 
• Water bath (JP Selecta group, Abrera, Spain, Cat. No. 032012).  
• Automated cell counter (Cat. No. 145-0011, Biorad). 






Procedure for calcium phosphate transfection 
• 24 hours before transfection, trypsinize cells and culture to be 50% confluent. 
• Prepare transfection mixture for each variant. To a tube labeled A, add the 
corresponding volume of plasmid DNA (500ng/well), empty vector (750ng/μL), 
promoter luciferase reporter vector (750 ng/well), pRL Renilla Luciferase 
Control Reporter Vector (25ng/well), 15μL 2 M CaCl2 and sterile water up to 
150μL. 
• To a tube labelled B add 150μL 2X HBS. 
• Drop by drop add tube A to tube B.  
• Incubate at RT for 30 minutes. 
• Add 100μL to each well as it corresponds.  
• Incubate for 5 hours at 37°C. 
• Pre-warm medium at 37°C. 
• Remove medium and discard it. Add 1mL new medium to each well. 
• Incubate for 48 hours at 37°C. 
 
Procedure for lipofection 
• 24 hours before transfection, trypsinize cells and culture to be 80% confluent. 
• Prepare DNA/ Opti-MEM™ solution for each variant. To a labeled tube, add the 
corresponding volume of plasmid DNA (125ng/well), empty vector (125ng/μL), 
promoter luciferase reporter vector (500ng/well), pRL Renilla Luciferase 
Control Reporter Vector (25ng/well), and 50μL Opti-MEM™.  
• Prepare lipofectamin/ Opti-MEM™ solution for each well by mixing 5μL 
lipofectamin to 45μL Opti-MEM™. 
• Add 110μL lipofectamin/ Opti-MEM™ solution to each DNA/ Opti-MEM™ 
solution. 
• Incubate the DNA-lipid complex for 5 minutes at room temperature.  
• Trypsinize and culture cells in 1mL medium in 24-well plates.  
• Add 100μL DNA-lipid complex per well as it corresponds.  
• Incubate for 48 hours at 37°C. 
 
7.10.3.2.1. hCG stimulation on LHCGR promoter transactivation 
experiments 
 
Subsequent experiments were performed to assess the cAMP produced by the 
HEK293 cells under both basal and human Chorionic Gonadotropin-stimulated 
conditions after the transfection with the different LHCGR variants.  
 
To determine the cAMP reporter response (CREB) on HEK293 cells transfected 




Gonadotropin 48 hours after transfection had started. We prepared the following 
concentrations: 0ng/mL, 3ng/mL, 30ng/mL, 300ng/mL, 1000ng/mL and 3000ng/mL 
and added 5μL to each corresponding well. We incubated overnight and measured 
luciferase. 
 
7.10.3.2.2. Luciferase assay  
 
The luciferase reporter assay (Figure 19) is commonly used as a tool to study 
gene expression at the transcriptional level. Firefly luciferase enzyme is able to emit 
light via a chemical reaction in which luciferin is converted to oxyluciferin by the 
luciferase enzyme. Some of the energy released by this reaction is in the form of light. 
To perform the reporter assay, the regulatory region of the gene of interest has been 
cloned upstream of the luciferase gene in one expression vector. After transfection 
and cell lysate has been collected, luciferase activity is measured by adding luciferin 
and other necessary cofactors using a luminometer. Since the gene of interest is fused 




Figure 19. Picture of the principles of a dual luciferase reporter assay. Modified from Ohmiya Y, 
Applications of bioluminescence (http://photobiology.info/Ohmiya.html). 
 
 
Reagents and materials 
• Dual-Luciferase® Reporter (DLR™) Assay system (Promega AG, Wallisellen, 




Passive Lysis Buffer (PLB), 5X (30mL), Luciferase Assay Buffer II (10mL), Stop & 
Glo® Substrate (200μl) and Stop & Glo® Buffer (10mL). 
• Rocking Platform Shaker (VWR, Radnor, PA, USA, Cat. No. 10860-662). 
• 96-well plate (Thermo Fisher Scientific, Cat. No. 136101). 
• Veritas microplate Luminometer reader (Promega AG, Cat. No. E4861). 
• Veritas™ Software (Promega AG). 
 
Procedure for Dual luciferase reporter assay  
1. Prepare Passive Lysis Buffer 1X from PLB 5X. Place on ice until use. 
2. Remove media from all the wells. 
3. Add 150µL PLB 1X to the wells. 
4. Place the culture plate on a rocking platform for 15 minutes at room 
temperature. 
At this point plate could be stored at -20°C. 
5. Prepare Stop & Glo solution for each well by mixing 1μL Stop & Glo substrate 
50X with 49μL Stop & Glo Buffer. Place on ice until use. 
6. Prepare LAR II solution for each well by transferring 50μL of the Luciferase 
Assay Buffer II to a 15mL tube. 
7. Pipette up and down the lysate to obtain a homogeneous suspension and add 
50μL to a 96-well plate for luminometer. 
Store the rest of the lysate at -20°C. 
8. Read the plate on the Veritas microplate luminometer reader following 
manufacturer’s instructions. 
 
7.10.3.2.3. Protein expression study  
 
For protein detection and quantification western blot technology was used. 
From a complex mixture of proteins extracted from transfected cells the specific 
protein will be identified through a separation by size, transference to a solid support 
and marking a target protein using primary and secondary antibodies to visualize.  
 
HEK293 cells were transfected with either wt or mutant NR5A1 expression 
vector, which carried a HA-Tag. Cells were lysed and western blot was performed using 
an antibody against HA (Human influenza hemagglutinin)-Tag (Merck KGaA, Cat. No. 
H3663-100UL). Expression of β-actin protein was used as a control. Steroidogenic 
Factor-1 (SF1) expression bands should be visualized at 53KDa and the positive control 








Reagents and materials 
• Protease Inhibitor Cocktail (Merck, Cat. No. 11836153001) (See preparation on 
Supplementary data 7). 
• EDTA (Fluka Analytical, St. Gallen, Switzerland, Cat. No. 3610). 
• Tris (C4H11NO3) (Merck, Cat. No. 8382). 
• Triton X-100 (C14H22O(C2H4O)9) (Merck, Cat. No. T8787-100ML). 
• DC™ protein assay Kit II (Bio-Rad Cat. No. 5000112), containing DC™ Protein 
Assay Reagent A, DC™ Protein Assay Reagent B and DC™ Protein Assay Reagent 
S. 
• Bovine Serum Albumin (1g) (Roth AG, Zürich, Switzerland, Cat. No.80763). 
• Tween 20 (C58H114O26) (50mL) (Merck, Cat. NoP9416). 
• Milk (350g) (Rapilait). 
• β-Mercaptoethanol (C2H6OS) (100mL) (Merck, M6250-100ML).  
• Sodium chloride (NaCl) (1Kg) (Merck, Cat. No. S9888) (mw: 58.4g/mol). 
• Potassium chloride (KCl) (Merck, Cat. No. P9333). 
• Disodium hydrogen phosphate (Na2HPO4) (Merck, Cat. No.  NIST2186II). 
• Potassium dihydrogen phosphate (KH2PO4) (Merck, Cat. No. NIST200B). 
• Tris-MOPS-SDS Running Buffer Powder (5u) (GenScript, Cat. No. Cat. No. 
M00138). 
• Transfer Buffer Powder (10u) (GenScript, Cat. No. Cat. No. M00139). 
• Electrophoresis marker (Bio-Rad, Cat. No. 161-0374). 
• Methanol (CH3OH) (1L) (Merck, Cat. No. 34860-1L-R). 
• Monoclonal Anti-HA antibody produced in mouse (1.0mg/mL) (Merck, Cat. No. 
H3663-100UL). 
• IRDye® 800CW Goat anti-Mouse IgG (Immunoglobulin G) (H + L) (1.0mg/mL), 
(LI-COR Biotechnology GmbH, Bad Homburg, Germany, Cat. No. P/N 926-
32210). 
• IRDye® 680RD Donkey anti-Mouse IgG (H + L) (1.0mg/mL), (LI-COR 
Biotechnology GmbH, Cat. No. P/N 925-68072). 
• Anti-β-Actin antibody, mouse monoclonal (1.0mg/mL) (Merck, Cat. No. A1978-
100UL). 
• 1X Odyssey Blocking Buffer (500mL) (LI-COR Biotechnology GmbH, Cat. No. P/N 
927-40000). 
• Tris-buffered saline with Tween® 20 (TBS-T) (10 tablets) (Merck, Cat. No. 
91414-10TAB). 
• GenScript ExpressPlus™ PAGE Gels (20u) (GenScript, Piscataway, NJ, USA, Cat. 
No. M41212). 
• Centrifuge Sorvall ST 8 (Thermo Fisher Scientific, Cat. No. 75007202). 





• 96-well plate (Thermo Fisher Scientific, Cat. No. 136101). 
• Gel tank (Bio-Rad). 
• Heating-block (Thermo Fisher Scientific, Cat. No. 88880028). 
• Cassette Opener (GenScript, Cat. No. L00674). 
• Blot Absorbent Filter Paper (Bio-Rad). 
• Blotting system fiber pad (Merck, EP1504-8EA). 
• PVDF Western Blotting Membranes (Merck, Cat. No. 3010040001). 
• Rocking Platform Shaker (VWR, Radnor, PA, USA, Cat. No. 10860-662). 
• LI-COR Odyssey Imaging system (LI-COR Biotechnology GmbH). 
• SoftMax® Software (Molecular Devices LLC). 
 
Procedure for Western Blot 
1. Measurement of protein concentration 
• Prepare 1X Lysis Buffer for each well by mixing 15μL 10X Protein 
Inhibiting Cocktail with 135μL Protein Lysis Buffer.  
• Remove media from all the wells. 
• Add 150μL 1X Protein Lysis Buffer to the wells. 
• Homogenize the lysate with a syringe and transfer to 1.5mL tubes. 
• Centrifuge at 13200 rpm for 10 minutes at 4°C. 
• Prepare standards by diluting Lysis Buffer in BSA to obtain 
concentrations that range from 5.6mg/mL to 0.0875mg/mL. 
• Prepare master mix for each well by mixing 0.5μL DC™ Protein Assay 
Reagent S with 24.5μL DC™ Protein Assay Reagent A. 
• Transfer 5μL of the samples, blank and standards to the 96-well plate. 
• Add 25μL master mix to the wells. 
• Add 200μL DC™ Protein Assay Reagent B to the wells. 
• Incubate plate for 20 minutes at room temperature. 
• Read by Softmax at an absorbance of 650nm and calculate protein 
concentration. 
2. Protein denaturation 
• Prepare the protein denaturation mix to have 50μg of total protein by 
mixing protein with 5X β-mercaptoethanol and bidistilled water up to 
50μL. 
• Incubate at 95°C for 10 minutes and spin down 
3. Gel electrophoresis 
• Prepare 1X MOPS and Transfer buffer (Supplementary data 7). 
• Remove the comb of the already prepared gel and place in the gel tank. 
• Fill the gel tank with 1X MOPS buffer 
• Load 24μL of the sample and 5μL of electrophoresis marker. 




• Open the cassette and remove the gel. 
4. Wet transfer 
• In a tray, pre-wet for 10 minutes 4 filter papers and 2 fiber pads. 
• Pre-wet PVDF membrane in methanol for 2 minutes. 
• Prepare the sandwich on the black panel as follows: one fiber pad, two 
filter papers, SDS gel, PVDF membrane, two filter papers and one fiber 
pad. 
• Fill the gel tank with Transfer buffer. 
• Run at 100V for 90 minutes. 
5. Blocking and incubating with antibodies 
• Prepare Blocking buffer, Washing buffer and primary antibody dilution 
buffer (Supplementary data 7).  
• Incubate membrane with 10mL Blocking buffer on a shaker for 2 hours. 
• Add 2μL primary antibody, Anti HA produced in mouse, to 4mL primary 
antibody dilution buffer  
• Immerse the membrane in the primary antibody dilution buffer and 
incubate overnight at 4°C on a shaker. 
• Remove the buffer and wash with washing buffer in the shaker for 5 
minutes. 
• Repeat previous step 3 more times. 
• Dilute 1μL secondary antibody, Goat anti-mouse, in 10mL Blocking 
buffer.  
• Immerse the membrane in the buffer and incubate for 1 hour at RT on 
the shaker. 
• Remove the buffer and wash with washing buffer in the shaker for 5 
minutes. 
• Repeat previous step 3 more times. 
• Incubate membrane with B-actin antibody diluted in 5%BSA for 2 hours 
in a shaker. 
• Remove the buffer and wash with 1X TBS-T in the shaker for 5 minutes. 
• Repeat previous step three more times. 
• Dilute 1μL secondary antibody, Donkey anti-mouse, in 10mL 0.5X 
Odyssey Blocking Buffer. 
• Immerse the membrane in the buffer and incubate for 2 hour at room 
temperature on the shaker. 
• Wash as previously described. 
6. Visualize membrane in the LI-COR Odyssey Imaging system at an absorbance of 






7.10.4. Statistical analysis 
 
Obtained data from the repeated luciferase assays were summarized giving the 
mean±SEM (Standard error of the mean). Data were statistically analysed using 
Student’s t test (Microsoft Excel, Microsoft Corporation, Redmond, WA, USA). Results 


















 Hereafter, I will present the results from the clinical and molecular 
characterization of our DSD cohort. Firstly, a general description of the population is 
made. Subsequent to the validation of the targeted gene panel, I present the genetic 
results obtained either by a gene candidate approach or next generation sequencing 
(NGS). Finally, results from the in vitro studies are shown. 
 
8. GENERAL CHARACTERISTICS OF THE DSD COHORT  
 
A total of 125 independent patients with a DSD diagnosis were analysed in this 
study. We have classified the cohort of patients according to the consensus statement 
on management of intersex disorders published in 2006 (172). The various aetiologies 
of DSD are shown in Supplementary data 2.  
 
Out of the 125 patients that were included, 99 had 46,XY DSD and 24 had 46,XX 
DSD. We also identified a sex chromosome DSD in 2 patients (Supplementary data 2). 
The age of presentation in our series varied from newborn to 41 years and represented 
individuals from 14 populations, which have been grouped into European Caucasian 
(Spain, Switzerland and Rumania) (110 cases, 88.0%), Northern African (Morocco, 
Algeria, Tunisia) (3 cases, 2.4%), Sub-Saharan African (Mauritania, Sierra Leone, 
Madagascar, Equatorial Guinea) (8, 6.4%), Asian (Syria, China, India) (3, 2.4%) and 
American (Mexico) (1, 0.8%). 
 
It is important to note that persons diagnosed with congenital adrenal 
hyperplasia (CAH) due to steroidogenesis defects, such as 21-hydroxylase or 11-
hydroxylase deficiency were not included in this study. We only examined patients 
with non-CAH primary adrenal insufficiency (PAI).  
 
Family members from these 125 individuals were analysed once a genetic 
variant explaining the phenotype of the index case was identified. This comprised 97 
family members that were studied. However, samples of first degree family members 
of 35 probands were not available and segregation studies could not be made.  
 
 
8.1.   46,XY DSD PATIENTS 
 
Based on chromosomal karyotyping and clinical presentation, 99 individuals 
were classified as having 46,XY DSD in which external genitalia were not clearly male or 
female (See Figure 20, page 142). The most common cause at clinical presentation was 
the disorders of testicular development, diagnosed in 47 patients. Testicular 
dysgenesis was suspected in 43 individuals and among the 17 patients with complete 




lack of secondary sex characteristics was mainly reported. Out of them, three 
presented a clitoral hypertrophy, although imaging revealed uterus or vagina. Twenty-
two patients with partial gonadal dysgenesis presented with a wide range of genital 
ambiguity. Four patients were referred without a classified gonadal dysgenesis. On the 
other side, three patients had gonadal regression with male genitalia and non-localized 
gonads after laparoscopy, and one case was reported as an ovotesticular DSD.  
 
On the other side, disorders of androgen synthesis or action were referred in 32 
patients. Six individuals had a suspected androgen biosynthesis defect. Of these, five 
were assigned as males and were born with severe hypospadias, normal testes and in 
two cases curved penis. Four patients out of these were diagnosed based on hCG-
stimulated testosterone to dihydrotestosterone (DHT) ratio. On the other side, one 
patient was reared as female and was virilised at puberty. 
 
Androgen insensitivity syndrome (AIS) was suspected in 21 individuals. Among 
the ten patients with complete AIS (CAIS), four had female genitalia and primary 
amenorrhea during adolescence. Inguinal hernias or palpable gonads were reported in 
3 newborns. Another three cases were suspected to be CAIS after amniocentesis had 
revealed a disagreeing 46,XY karyotype in females. All the infants were born with 
female external genitalia and inguinal gonads. Four PAIS patients presented with 
gynecomastia or different degrees of genital undervirilization, such as micropenis with 
hypospadias in some cases, and hypertrophic erectile organ. Other seven cases were 
not classified as complete or partial due to the absence of clinical information. 
 
Furthermore, we had 5 male patients presenting with precocious puberty, 
adrenarche or bilateral gynecomastia during childhood that led to a suspected LH 
receptor defect. 
 
Among the cases that were classified as other 46,XY DSD, two males were 
reported to have isolated hypospadias and descended scrotal testis while seven 
patients were diagnosed with a non-CAH primary adrenal insufficiency and were 
initially referred to clinician with varying degrees of symptoms such as respiratory 
distress, vomiting and asthenia, hypoaldosteronism, salt wasting and hyponatremia. 
The age of presentation of these ranged between newborn and 3 years. The 
phenotype was not determined in one case. 
 
Additionally, 7 individuals were stated as 46,XY DSD but couldn’t be classified. 
They presented mainly with undervirilized phenotypes, such as cryptorchidism, 







Figure 20. Classification of the 46,XY DSD patients based on the clinical diagnosis. Circles indicate the number of cases. 




8.2   46,XX DSD PATIENTS 
 
We also studied 24 patients with 46,XX DSD (Figure 21). Among the patients 
with disorders of ovarian development, we tested 8 cases with suspected gonadal 
dysgenesis. These, largely presented female genitalia, primary amenorrhea, lack of 
secondary sexual characteristics or hypergonadotropic hypogonadism. One patient 
had bilateral inguinal hernias and neonatal ovaries were shown on probing. Three 
cases with ovotesticular (OT) DSD were included in the cohort. They were reared as 
males and presented with different degrees of genital ambiguity. Laparoscopy 
confirmed the presence of ovotestes in the infants. Moreover, six patients had 
testicular (T) DSD and denoted mainly cryptorchidism, as well as gynecomastia and 
azoospermia in some cases when diagnosed in adulthood. Finally, two out of three 
cases with a suspected Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome had 
primary amenorrhea at puberty, while one subject was diagnosed at childhood. 
Imaging revealed the absence of uterus, vagina and unilateral kidney agenesia in all 
the cases.  
 
The disorder could not be defined in 4 cases. These, were referred with 
different phenotypes such as complete pubertal development and secondary 
amenorrhea, male external and internal genitalia or primary amenorrhea and delayed 
puberty in which maternal virilisation during pregnancy had occurred.  
 
 
Figure 21. Classification of the 46,XX DSD patients based on the clinical diagnosis. Circles indicate the 
number of cases. 
 
 








8.3 SEX CHROMOSOME DSD 
 
Two patients had mixed gonadal dysgenesis. In the newborn case, labioscrotal 
fusion and inguinal hernia were recorded and genitoplasty was required. The second 
patient referred primary amenorrhea as a young adult. On Magnetic Resonance 
Imaging (MRI), a hypoplastic uterus was shown, but gonads were not visualized in any 
case. Karyotype was 45,X0/46,XY in the two subjects. 
 
 
9. ANALYSIS OF THE TARGETED GENE PANEL 
 
At the beginning direct Sanger sequencing was used for the molecular diagnosis 
of DSD patients. In 2015 we developed a customized gene panel and therefore, panel 
validation was required as a first step.   
 
 
9.1. PANEL VALIDATION 
 
9.1.1. Evaluation of quality metrics in each run and library 
 
To validate the performance of the targeted panel sequencing we assessed the 
quality metrics given in each run (Table 7). Considering the 11 runs, the mean number 
of reads was 1123.2 Mbp and the read length was 242.1 bp. We examined the AQ20 
score, which corresponds to the quality level at which the error rate is 1% or less, and 
found that the total number of bases and the mean segment length were 1023.9 Mbp 
and 232.6 bp, respectively, which means that 90.7% and 96% were high quality base 
reads and segments. The mean longest alignment was 487.5pb at AQ20. 
 
Total number of reads varied between 532 Mega and 1.9 Giga base pairs. The 
difference in the number of reads among the runs is given due to the use of Ion 318™ 
Chips instead of Ion 316™ Chips since run 7. The greater capacity of the Ion 318™ Chip 
increased the total number of reads and the mean depth of all the libraries. The 
percentage of aligned bases to the reference sequence was 99% in all the runs, except 






Table 7. Quality metrics given in the 11 runs performed for the sequencing of the DSD cohort. 
 







(%) Metrics at the quality level (AQ20)  Metrics of the libraries in each run 
     
Number of 








Mean depth Uniformity (%) On target (%) Mapped reads      
1 532 M 229 99 99.3 485 M (91.1)1 217 (94.7)1 470  101.4-524.6 86.1-91.1 94.5-96 112109-561952 
2 691 M 223 99 99.3 606 M (87.7)1 211 (94.6)1 460  118.5-431.4 77.3-90.7 92.4-96.2 133276-491692 
3 711 M 217 99 99.4 628 M (88.3)1 208 (95.8)1 460  148.8-354.8 87.4-90.4 94.7-95.9 166327-407373 
4 871 M 241 99 99.5 786 M (90.2)1 232 (96.3)1 488  147.0-345.6 75.1-90.9 91.9-94.6 170072-355568 
5 978 M 243 99 99.5 889 M (90.9)1 234 (96.3)1 510  124.0-413.4 63.97-89.6 93.1-95.2 148919-420999 
6 812 M 238 99 99.4 729 M (89.8)1 231 (97.0)1 506  160.1-302.1 87.6-89.9 81.8-94.4 176079-345955 
7 1.9 G 265 100 99.6 1.75 G (92.11) 258 (97.3)1 552  1200 89.49 92.4 1164105 
8 1.26 G 231 99 99.4 1.14 G (90.5)1 220 (95.2)1 429  196.2-349.2 87.2-90.2 93.8-95.9 211364-380333 
9 1.48 G 259 99 99.5 1.37 G (92.6)1 250 (96.5)1 491  162.8-575.7 86.2-89.6 93.9-96.3 153650-548956 
10 1.64 G 264 99 99.5 1.52 G (92.7)1 256 (96.9)1 525  325.4-485.7 88.4-90.0 95.0-95.7 306575-456078 
11 1.48 G 253 99 99.4 1.36 G (91.9)1 242 (95.6)1 472  370.3 89.8 96 359366 
Mean 1123.2 M 242.1 99.1 99.4 1.02 M (90.7)1 232.6 (96.0)1 487.5  288.3 89.5 94.2 761735.5 




The mean depth analysis of the libraries showed that the occasions a given 
nucleotide in the genome was read varied between 101.4 and 1200. In addition, on 
average 94.2% of the targeted regions were covered and the distribution of the reads 
along targeted regions, or uniformity, was 89.5%. A single DSD library was included in a 
chip along with other disease related libraries in run 7. As the other samples created 
smaller libraries compared to DSD panel, this sample was overexpressed in the chip 
and the total number of bases and mean depth was higher in this run. In run 11, a 
single DSD library was also included but without overexpression of the sample, then 
quality metrics were in the normal range. 
 
In supplementary data 10, run results from the genetically diagnosed patients 
and positive controls are shown as an example of the values. 
 
9.1.2. Analytical validation of the targeted gene panel 
 
We validated the gene sequencing panel by comparing test results against a 
gold standard that establishes the true status of the subject. This validation evaluated 
the ability of our panel to detect a variant in our DSD-cohort. For panel validation 
purposes, we made measures of sensitivity, specificity plus false positive rate, and 
finally, repeatability. Because the performance varies by the type of variant, sensitivity 
and false positives were calculated separately for single variants and small indels or 
CNV (236). 
 
A selection of positive samples with mutation-specific assays for SRY, HSD17B3, 
AR, NR5A1, WT1 and NR0B1 during routine work, were included in the validation 
process. As shown in Table 8, positive controls involved different types of variants and 
were included in all the runs, except in runs 7 and 11 were only one DSD sample was 
included in the sequencing chip together with samples studied for other diseases. 
Moreover, we included 4 samples of healthy individuals, named true negatives. The 
next table (Table 8) summarizes the analytical values obtained in the panel validation. 
 
 
Table 8. Summary of the analytical validation values obtained for the targeted gene panel.  
 
 Single-nucleotide Variants (%) Copy number variations (%) 
Sensitivity 81.8 33.3 
Specificity 100 











Sensitivity is defined as the ability to detect a positive result compared to a 
reference method. Sensitivity was calculated and compared with results obtained by 
Sanger sequencing for point mutations or Multiplex Ligation-dependent Probe 
Amplification (MLPA) for copy number variations (CNV). 
 
For point mutation testing we determined 10 single-nucleotide variants (SNVs) 
and a 4-nucleotide deletion. Among the SNV, 7 were missense changes and 3 were 
deletions or insertions of 1 nucleotide. All the changes detected in positive controls 
were confirmed by gene sequencing panel, except c.182delC in WT1 gene (Table 9), 
showing test sensitivity up to 81.8% (Table 8). The sensitivity yield was also tested for 
chromosome rearrangements. We compared deletions found by MLPA in samples 
POL0285 and GN0041, which was duplicated, with the results determined by NGS. 
Regarding POL0285, the workflow for CNV reported one variant which was the NR0B1 
gene deletion, while for GN0041 individual a single deletion was shown in one of the 
samples but did not correspond to the deletion of the AR exon 2. Then, sensitivity was 
33.3% for the determination of CNV (Table 8). 
 
 
Table 9. Sensitivity test done in positive controls. 
 
Case Run Gene and variant Zygosity Detected variant 
GN0012 Run 8 NR5A1, c.437G>C; p.Gly146Ala Het Yes 
GN0038 Run 2 
HSD17B3, c.845C>T; p.Pro282Leu Het 
Yes 
GN0038 Run 5 Yes 
GN0041 Run 3 AR, c.(1616+1_1617-1)_(1768+1_1767-1)del; 
p.(Arg539_Asp305del) Hemi 
Yes 
GN0041 Run 6 No 
GN0042 Run 4 NR5A1, c.614_615insC; p.Gln206ThrfsTer20 Het Yes 
GN0109 Run 3 
NR5A1, c.910_913delGAGC; 
p.Glu304CysfsTer26 Het Yes 
GN0111 Run 9 NR5A1, c.902G>A; p.Cys301Tyr Het Yes 
GN0119 Run 10 NR5A1, c.437G>C; p.Gly146Ala Hom Yes 
GN0123 Run 10 NR5A1, c.71A>T; p.His24Leu Het Yes 
GN0141 Run 1 SRY, c.391C>T; p.Pro131Ser Hemi Yes 
OT0327 Run 4 
WT1, c.182delC; p.Pro61ArgfsTer28 Het 
No 
OT0327 Run 5 No 
POL0285 Run 6 NR0B1, g.(?_29978097)_(30361290_?)del Hemi Yes 
Sane controls Run 1 - - - 








9.1.2.2. Specificity and false positives 
 
Specificity is defined as the capacity of the method to correctly recognize the 
cases without the disease under study. It is the proportion of true negatives that are 
correctly identified by the test. In our 4-sample validation, we did not identify any DSD-
related variant. Then, specificity was 100% (Table 8, page 146).  
 
However, due to the limited number of healthy subjects that were included, we 
further analysed the false positive rate for the DSD-cohort. A false positive is the error 
in which a test result indicates the presence of a condition, when in reality it is not 
present. Among the 98 point mutations found by NGS that were then tested by Sanger 
sequencing, 13 were not confirmed, so the false positive rate was 13.3% (Table 8).  
 
Validation of false positive rate for CNV was done considering samples 
(GN0034, GN0046 and OT0567) and positive controls (GN0041 and POL0285) in which 
a big deletion or insertion had been detected by NGS and had been confirmed by 
another method. Number of detected variants with the CNV workflow is shown in 
Table 10. The false positive rate for the detection of CNVs was 81.2% (Table 8).  
 
Due to the low sensitivity and high false positive rate found in the CNV 
validation (Table 8), the results obtained in the analysis of these types of mutations 
were poorly reliable. In those cases in which a CNV was suspected a Multiplex Ligation-
dependent Probe Amplification (MLPA), Quantitative Multiplex Polymerase chain 
reaction of Short Fluorescent Fragments (QMPSF) or array-based Comparative 
Genomic Hybridization (aCGH) was performed. 
 
 
Table 10. Rate of false positives determined for copy number variations by NGS. 
 
Case Copy Number Variations False positive rate 
 Detected by NGS False positive 
 
GN0034 1 0  
GN0041 0 0  
GN0041 1 1  
GN0046 1 1  
OT0567 12 11  
POL0285 1 0  









This term refers to the ability to replicate the findings, calculated as the 
percentage of detected variants in a sample included in two separate runs. We did not 
separate the measure of repeatability by type of variant because the ion reporter does 
not distinguish between copy number variations (CNV) and single-nucleotide variants 
(SNV) or small indels when using the workflow for CNV detection without applying the 
confident germline filter. 
 
We considered variants with a coverage depth ≥20x in three different samples 
and determined a mean repeatability of 89.9% (84.7% in GN0038 sample; 90.1% in 
OT0327 and 94.4% in GN0041) (Table 11).  
 
 
Table 11. Detected variants (≥20x) in the three different samples used for the calculation of 
repeatability. 
 
Case Variants  






 1st run 2nd run  Repeated Not repeated    
GN0038 230 228  210 38  84.7 
89.9 GN0041 250 243  241 13  94.9 
OT0327 245 253  236 26  90.1 
 
 
9.1.3. Evaluation of the amplicons 
 
After analysing the coverage data files, we observed a highly variable 
performance of the 874 amplicons in the panel. Besides the not covered regions in 
silico (Supplementary data 9), we evaluated the coverage of the amplicons in each 
sample using IGV (Integrative Genomics Viewer) and found a small number of them to 
which no reads were mapped in most of the studied samples (Supplementary data 11). 
We analysed the location of these amplicons and only those located in exons and 
exons boundaries were further studied via PCR-based Sanger sequencing 
(Supplementary data 12). In total, the surface that could not be read was 9.3%, then 
the design covered 90.7% of the amplicons. Those amplicons with a base coverage 









9.2. VARIANT CALLING AND CHARACTERISTICS OF OBSERVED VARIANTS BY NGS 
 
Before filtering, 27,444 point variants or small indels were observed in the 
entire population in the genes included in the panel (Supplementary data 13). Once 
the filtering was done (p-value <0.001 and MAF <0.05), 4,688 variants were still 
annotated. Of these, 36% were observed recurrently in the cohort and were 
understood as common population variants or as sequencing artefacts. In total, we 
found 34.5 observations on average for each patient. Remaining variants were curated 
based on the ACMG (American College of Medical Genetics) guidelines (229). 
 
Regarding the type of variant, almost 58% (57.9%) were characterized as SNV 
(Single-Nucleotide Variants) or MNV (Multiple Nucleotide Variant) after filtering 
process. Only 10% of the protein changing variants were missense. Small indels were 
also found, mainly frameshift deletions (23.5%). Among the curated variants 29 were 
missense (82.8%), 3 were frameshift deletions (8.5%) and 3 variants were determined 
as nonsense, frameshift insertion and inframe deletion.  
 
In the analysis of the CNVs, 29,885 variants were called and then reduced to 
457 CNV after the application of the confident germline CNV filter. Although the 
number of chromosome rearrangements detected by the customized panel was 
significant, the panel validation showed low sensitivity and high false positive rate for 
the CNV. Big deletions and insertions were only trustworthy when they were not 
repeated among the samples and could be visually confirmed using IGV (Integrative 
Genomics Viewer) and the coverage data files. The 4 samples with CNV that were 
confirmed by aCGH, MLPA or FISH techniques, included the whole and partial deletions 
of LHCGR, SRD5A2 and WT1 genes, as well as the translocation of SRY. Only 3 of the 
CNV had been called by the Confident Germline CNV filter. As done previously, variants 
were annotated and classified following the ACMG criteria.  
 
 
10. MOLECULAR CHARACTERIZATION OF THE DSD COHORT 
 
Firstly, genetic analysis was done in patients presenting a sex development 
anomaly by studying the genes or regions that are most often associated with the 
disease by a candidate gene approach. In a second phase and after the 
implementation of next generation sequencing (NGS) in our laboratory, new patients 








10.1. SINGLE-GENE TESTING  
 
As previously mentioned, gene by gene sequencing was done regularly for the 
genetic diagnosis of DSD patients. In 2015, NGS was implemented in our laboratory 
and single-gene tests, such as Sanger sequencing, MLPA or aCGH, were done 
depending on the judgement on the most likely genetic cause. As shown in Table 12, a 
total of 127 DSD-gene tests were requested for 81 patients, mostly the PCR-based 
sequencing of SRY and AR gene (34 tests, each), followed by the sequencing of the 
coding exons of NR5A1 gene (21 tests).  
 
From the aforementioned requests, only five Sanger sequencing tests were 
done after the targeted gene panel had been validated. Two of these genetic orders 
corresponded to the sequencing of the NR0B1 gene in POL0285 and POL0301 cases, 
presenting with adrenal insufficiency. In the remaining cases LHCGR and AR genes 
were studied due to the suspicion of LH receptor defect (GN0164) or AIS (GN0202, 
GN0177). Due to syndromic features associated with DSD an aCGH was performed in 
case GN0159.  
 
Finally, a plausible molecular finding was done in 36 patients by applying a 
candidate gene approach (36 out of 81, 44.4%) (Table 12). Among these, 13 patients 
had clinical features for an androgen insensitivity syndrome (Table 13, page 154) and 
sequencing of the AR gene was the prior genetic test in most cases. SRY gene missense 
variants or its translocation was found in 7 cases with 46,XX testicular DSD or 46,XY 
gonadal dysgenesis. The two coding exons of the NR0B1 gene were studied in the 7 
cases with an adrenal insufficiency diagnosis and the WT1 gene in the two individuals 
with a suspicion of Frasier syndrome. Two activating alterations were found in the 
luteinizing hormone receptor gene (LHCGR) that lead to precocious puberty in patients 
GN0068 and GN0088 and a deficiency in androgen biosynthesis defect due to a change 
in HSD17B3 in case GN0038. Moreover, variants in NR5A1 were determined in 4 cases 





Table 12. Used approach to analyse each subject and previously studied genes. 
 
Case Previous studies Approach  Case Previous studies Approach  Case Previous studies Approach 
GN0001 FSHR and WNT4 NGS  GN00382 __ CGA  GN0096 __ NGS 
GN0003 SRY NGS  GN0039 
AR, SRD5A2 and 
SRY 
NGS  GN0100 AR, NR5A1 and MLPA4 NGS 
GN0004 - CGA  GN00411 - CGA  GN0101 - CGA 
GN0007 - CGA  GN00421 AR and HSD17B3 CGA/NGS  GN0103 FSHR and LHCGR NGS 
GN0009 - CGA  GN0043 SRY NGS  GN0104 SRY NGS 
GN0011 NR5A1 and SRY NGS  GN0046 AR NGS  GN0108 AR, NR5A1 and SRD5A2 NGS 
GN00121 - NGS  GN0050 NR5A1 and SRY NGS  GN01092 AR and SRY CGA 
GN0013 NR5A1 and SRY NGS  GN0051 SRY and MLPA4 NGS  GN01111 HSD17B3 and SRY CGA 
GN0014 SRY NGS  GN0054 - CGA  GN0112 - CGA 
GN0017 - NGS  GN0055 - CGA  GN0114 AR, NR5A1, SRY and MLPA4 NGS 
GN0018 SRY CGA  GN0056 SRD5A2 and WT1 NGS  GN0118 SRY NGS 
GN0020 SRY NGS  GN0059 SRY NGS  GN01191 - NGS 
GN0023 - CGA  GN0064 SRY NGS  GN0122 - NGS 
GN0024 SRY CGA  GN0066 - NGS  GN01231 AR CGA 
GN0025 - NGS  GN0068 - CGA  GN0124 AR, NR5A1 and SRD5A2 NGS 
GN0026 SRY NGS  GN0070 - NGS  GN0125 - CGA 
GN0027 SRY NGS  GN0075 - NGS  GN0132 - CGA 
GN0028 AR, FMR1 and SRD5A2 NGS  GN0076 - CGA  GN0133 - CGA 
GN0029 - NGS  GN0078 - CGA  GN0138 NR5A1 NGS 
GN0031 AR NGS  GN0080 - CGA  GN0139 - CGA 
GN0033 SRD5A2 NGS  GN0084 SRY and WNT4 NGS  GN01411 - CGA 
GN0034 
AR, HSD17B3, NR5A1 and 
SRD5A2 
NGS  GN0088 - CGA  GN0142 






Table 12. Used approach to analyse each subject and previously studied genes (Continuation). 
Case Previous studies Approach  Case Previous studies Approach  Case Previous studies Approach 
GN0035 - CGA  GN0090 MLPA4 NGS  GN0144 - NGS 
GN0037 - CGA  GN0091 - CGA  GN0145 AR NGS 
GN0146 - CGA  GN0169 - NGS  GN0194 - NGS 
GN0147 AR NGS  GN0171 - NGS  GN0195 - NGS 
GN0148 AR, NR5A1 and SRY NGS  GN0173 - NGS  GN0196 - NGS 
GN0150 AR NGS  GN0174 - NGS  GN0198 - NGS 
GN0151 SRY NGS  GN0175 - NGS  GN0199 - NGS 
GN0152 AR NGS  GN0176 - NGS  GN0200 - NGS 
GN0153 - CGA  GN0177 - CGA  GN0201 - NGS 
GN0154 SRY and MLPA4 NGS  GN0178 - NGS  GN0202 AR NGS 
GN0155 AR, NR5A1 and MLPA4 NGS  GN0179 - NGS  GN0203 - NGS 
GN0156 LHCGR NGS  GN0182 - NGS  GN0204 - NGS 
GN0157 - NGS  GN0183 - NGS  GN0205 - NGS 
GN0158 SRY and MLPA4 NGS  GN0185 - NGS  GN0207 - NGS 
GN0159 - CGA  GN0186 - NGS  OT0567 - NGS 
GN0160 SRY NGS  GN0187 - NGS  POL0274 - CGA 
GN0162 - NGS  GN0189 - NGS  POL0285 - CGA 
GN0163 - NGS  GN0190 - NGS  POL0301 - CGA 
GN0164 LHCGR NGS  GN0191 - NGS  RE0045 AR, NR5A1, RET, SRY, WT1 and MLPA5 NGS 
GN0167 - NGS  GN0192 - NGS     
CGA, candidate gene approach; NGS, next generation sequencing. 1 Sample used as a positive control; 2Relative of the sample used as positive control; 3Sample used as 




Table 13. Genes analysed according to the suspected clinical diagnosis in the single-gene 
approach.  
 
Suspected diagnosis Altered gene Number of cases 
Androgen insensitivity syndrome 
AR 13 46,XY DSD gonadal dysgenesis 
46,XY Ovotesticular DSD 
46,XX Testicular DSD or 46,XX DSD 
SRY 7 
46,XY DSD complete gonadal dysgenesis 
Primary adrenal insufficiency NR0B1 7 
Frasier syndrome WT1 2 
46,XY DSD LH Receptor defect LHCGR 2 
46,XY DSD Androgen biosynthesis defect HSD17B3 1 
46,XY DSD gonadal dysgenesis 
NR5A1 4 
Androgen insensitivity syndrome 
 
 
10.2. GENERAL CHARACTERISTICS OF THE GENETIC FINDINGS 
 
In our cohort 81 rare variants were identified in DSD-associated genes either by 
the candidate gene approach or NGS (Table 14). Of these, 20 were repeated more than 
once, thus we determined 61 single variants in 20 clinically relevant DSD genes.  
 
Variants in the AR gene were the most common. Among the 15 different 
changes (24.6%) found in 16 46,XY DSD individuals, all but one were classified as 
pathogenic, as they had been described in a DSD phenotype or were null variants.  
 
Secondly, we determined 7 pathogenic variants in the NR0B1 gene (11.3%). All 
but 2 had been previously associated to adrenal insufficiency, including missense, 
frameshift causing alterations and big deletions. 
 
NR5A1 gene had the third highest number of variants called. Twenty-one 
patients had a NR5A1 gene change, although only seven were unique (11.3%). Among 
these, 3 were missense and one was a frameshift that had not been described before. 
 
We found five variants in WT1 (8.2%), a gene described in several syndromes in 
which gonadal dysgenesis is associated. We found two known mutations in intron 9 in 
two cases with Frasier syndrome and a partial deletion (from exon 7 to 10) in a male 
infant with cryptorchidism and Wilms’ tumour. Another two missense changes were 











Number of different 
variants 
Type of variant 
AR 16 15 
11 missense,2 frameshift, 1 deletion and 1 
nonsense 
NR0B1 7 7 
2 deletions, 2 frameshifts, 2 nonsense and 1 
missense 
NR5A1 21 7 5 missense and 2 frameshift 
WT1 5 5 2 missense, 2 intronic and 1 deletion 
SRY 8 3 
6 gene translocations, 1 nonsense and 1 
missense 
MAP3K1 1 1 1 missense 
HSD17B3 1 1 1 missense 
CYP17A1 1 1 1 missense 
SRD5A2 3 3 2 missense and 1 deletion 
STAR 2 2 2 missense 
LHCGR 6 6 4 missense, 1 deletion and 1 nonsense 
WWOX 2 2 2 missense 
ESR1 1 1 1 missense 
ESR2 1 1 1 missense 
AMH 1 1 1 missense 
DMRT2 1 1 1 missense 
GATA4 1 1 1 missense 
HSD17B4 1 1 1 frameshift 
MAMLD1 1 1 1 missense 
ZFPM2 1 1 1 missense 
 
 
On the other side, SRY translocations were observed in 6 patients. Otherwise 
nonsense and an unreported missense variant were detected in two more cases 
harbouring a SRY defect. Of interest, a single mutation in the MAP3K1 gene, causing 
gonadal dysgenesis, was detected by NGS. 
 
Mutations in genes causing an androgen biosynthesis defect, such as HSD17B3, 
CYP17A1 and SRD5A2, were observed in 4 patients. All the subjects harboured 
homozygous pathogenic variants, except one patient with two variants in compound 
heterozygosis in the SRD5A2 gene. We also identified two unique not described 
variants in STAR gene. 
 
A total of 6 changes were observed in the LHCGR gene (9.8%). These, were 




variants and a complete gene deletion. We also identified 2 LH receptor novel variants 
in equal number of patients.  
 
We identified another 10 novel candidate variants in 10 patients. Two WWOX 
missense changes detected in our study were either classified as likely pathogenic and 
VUS, due to the results given by the prediction software. Interestingly, we identified 2 
single variants in ESR1 and ESR2 genes, all unreported. As ESR2 variants have been 
described in 46,XX DSD cases, we considered the missense change as probably 
deleterious. The remaining missense changes in AMH, DMRT2, GATA4, HSD17B4, 




10.3. CLASSIFICATION OF GENETIC VARIANTS  
 
Variants were evaluated and classified as previously reported in methodology.  
 
As shown in Table 15, a total of 81 variants, including 61 unique changes, found 
in 72 individuals are reported. Repeated changes are SRY gene translocations in 46,XX 
DSD individuals, or alterations located in AR (c.2323C>T;p.Arg775Cys) and NR5A1 
(c.437G>C;p.Gly146Ala) genes. Results given by the prediction software are shown in 
Table 16 (Page 161). 
 
We classified 54 variants out of 81 as pathogenic or likely pathogenic (66.7%) 
(See Figure 34, page 195). These, were mainly previously reported in association with a 
DSD phenotype (40 out of 54, 74.1%) and were mostly located in the AR and NR0B1 
genes, or were a Y-chromosome translocation confirmed by the detection of SRY 
material. The remaining 14 novel variants classified as pathogenic or likely pathogenic 
were identified in AR, NR5A1, NR0B1 and LHCGR most commonly, but also in ESR2, SRY 
and WWOX genes (1 variant called each). 
 
Moreover, 12 variants of unknown significance were identified in 11 individuals 
(12 out of 81, 14.8%). Of these 11 individuals, one harboured two variants of unknown 
significance and in 3 patients a deleterious variant in an additional gene was found. 
 
Regarding the p.Gly146Ala polymorphism in the NR5A1 gene, it was classified 
as likely benign and was determined in 15 cases. In 4 individuals (GN0147, GN0156, 






Table 15. Classification of the genetic variants identified in this work.  
 
Case Gene Variants Classification Location Zygosity Previously reported* Diagnostic approach 
GN0004 SRY 46,XX (SRY+) Pa - - Fechner PY (1993) CGA 
GN0007 SRY c.289C>T; p.Gln97Ter Pa Exon 1 Hemi Bilbao (1996) CGA 
GN0023 SRY 46,XX (SRY+) Pa - - Fechner PY (1993) CGA 
GN0054 SRY 46,XX (SRY+) Pa - - Fechner PY (1993) CGA 
GN0133 SRY 46,XX (SRY+) Pa - - Fechner PY (1993) CGA 
GN0141 SRY c.391C>T; p.Pro131Ser LP Exon 1 Hemi No CGA 
GN0159 SRY 46,XX.ish der(X)t(X;Y)(p22.3;p11.3)(SRY) Pa - - Yen (1991) CGA 
GN0187 SRY 46,XX.ish der(X)t(X;Y)(p22.3;p11.3)(SRY) Pa - - Yen (1991) NGS 
GN0012 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) NGS 
GN0028 
NR5A1 c.88T>A; p.Cys30Ser Pa Exon 2 Het No 
NGS 
STAR c.361C>T; p.Arg121Trp VUS Exon 4 Het No 
GN0042 
NR5A1 c.614_615insC; p.Gln206ThrfsTer20 Pa Exon 4 Het Camats (2012) 
CGA/NGS 
AMH c.428C>T; p.Thr143Ile VUS Exon 2 Het No 
GN0051 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) NGS 
GN0070 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) NGS 
GN0075 NR5A1 c.250C>T; p.Arg84Cys Pa Exon 4 Het Reuter (2007) NGS 
GN0090 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Hom Wada (2006) NGS 
GN0096 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Hom Wada (2006) NGS 
GN0109 NR5A1 c.910_913delGAGC; p.Glu304CysfsTer26 Pa Exon 5 Het No CGA 
GN0111 NR5A1 c.902G>A; p.Cys301Tyr LP Exon 5 Het No CGA 
GN0118 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) NGS 
GN0119 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Hom Wada (2006) NGS 
GN0123 NR5A1 c.71A>T; p.His24Leu Pa Exon 2 Het No CGA 




Table 15. Classification of the genetic variants identified in this work (Continuation). 
Case Gene Variants Classification Location Zygosity Previously reported* Diagnostic approach 
GN0163 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) NGS 
GN0182 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) NGS 
GN0199 NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) NGS 
GN0078 NR0B1 c.913C>T; p.Gln305Ter Pa Exon 1 Hemi Rodriguez-Estévez (2015) CGA 
GN0091 NR0B1 c.291delC; p.Glu98ArgfsTer166 Pa Exon 1 Hemi Guoying (2012) CGA 
GN0101 NR0B1 g.(?_30327014)_(30361290_?)del Pa - Hemi Guo (1995) CGA 
GN0153 NR0B1 c.528C>G; p.Tyr176Ter Pa Exon 1 Hemi No CGA 
POL0274 NR0B1 c.871T>A; p.Trp291Arg Pa Exon 1 Hemi Yeste (2009) CGA 
POL0285 NR0B1 g.(?_29978097)_(30361290_?)del Pa - Hemi Guo (1995) CGA 
POL0301 NR0B1 c.712_713delAC; p.Thr238LeufsTer60 Pa Exon 1 Hemi No CGA 
GN0009 WT1 c.1447+5G>A Pa Intron 9 Het Bruening (1992) CGA 
GN0132 WT1 c.1447+4C>T Pa Intron 9 Het Barbaux (1997) CGA 
GN0150 WT1 c.223G>A;p.Glu75Lys VUS Exon 1 Het No NGS 
GN0156 
WT1 c.545T>A; p.Met182Lys VUS Exon 2 Het No 
NGS 
NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Hom Wada (2006) 
OT0567 WT1 c.(1099-?_1551+?)del; p.(Asp367?_Leu517?)del Pa - Het Finken (2015) NGS 
GN0011 MAP3K1 c.2291T>G; p.Leu764Arg LP Exon 13 Het Granados (2017) NGS 
GN0020 WWOX c.1096C>G; p.Pro366Ala VUS Exon 9 Het No NGS 
GN0203 WWOX c.184G>A; p.Gly62Arg LP Exon 3 Het No NGS 
GN0198 
ESR1 c.1781C>T;p.Thr594Met VUS Exon 9 Het No 
NGS 
HSD17B4 c.524delC; p.Ala175GlufsTer26 VUS Exon 8 Het No 
GN0207 ESR2 c.661A>G; p.Arg221Gly LP Exon 5 Het No NGS 
GN0142 DMRT2 c.1607C>T; p.Ser536Leu VUS Exon 4 Het No NGS 
GN0155 ZFPM2 c.3077C>T, p.Ala1026Val VUS Exon 8 Het No NGS 




Table 15. Classification of the genetic variants identified in this work (Continuation). 
Case Gene Variants Classification Location Zygosity Previously reported* Diagnostic approach 
GN0018 AR c.2323C>T; p.Arg775Cys Pa Exon 6 Hemi Brown (1990) CGA 
GN0024 AR c.2086G>A; p.Asp696Asn Pa Exon 4 Hemi Ris-Stalpers (1991) CGA 
GN0035 AR c.2522G>A; Arg841His Pa Exon 7 Hemi McPhaul (1992) CGA 
GN0037 AR c.2178C>G; p.Phe726Leu Pa Exon 5 Hemi Quigley (1995) CGA 
GN0041 AR c.(1616+1_1617-1)_(1768+1_1767-1)del; p.(Arg539_Asp305del) Pa Exon 2 Hemi Quigley (1992) CGA 
GN0055 AR c.2710G>A; p.Val904Met Pa Exon 8 Hemi McPhaul (1992) CGA 
GN0076 AR c.2566C>T; p.Arg856Cys Pa Exon 7 Hemi McPhaul (1992) CGA 
GN0080 AR c.298insC; p.His100ProfsTer3 Pa Exon 1 Hemi No CGA 
GN0112 AR c.827delC;p.Pro276HisfsTer20 Pa Exon 1 Hemi No CGA 
GN0125 AR c.865G>T; p.Glu289Ter Pa Exon 1 Hemi Holterhus (2003) CGA 
GN0139 AR c.2642T>G; p.Leu881Arg LP Exon 8 Hemi No CGA 
GN0146 AR c.2473C>A; p.Gln825Lys Pa Exon 7 Hemi Hellmann (2012) CGA 
GN0164 AR c.2270A>G; p.Asn757Ser Pa Exon 5 Hemi Hiort (1996) NGS 
GN0177 AR c.1301C>T; p.Ser434Phe Pa Exon 1 Hemi Holterhus (2005) CGA 
GN0189 AR c.2567G>A; p.Arg856His Pa Exon 7 Hemi Batch (1992) NGS 
GN0194 
AR c.2323C>T; p.Arg775Cys Pa Exon 6 Hemi Brown (1990) 
NGS 
NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) 
GN0046 
SRD5A2 c.377A>G; p.Gln126Arg Pa Exon 2 Het Thigpen (1992) 
NGS 
SRD5A2 c. (-1+1_1-1)_(281+1_280-1)del; p.(Met1_Arg94del). Pa Exon 1 Het Fenichel (2013) 
GN0186 SRD5A2 c.271T>G; Tyr91Asp Pa Exon 1 Hom Wilson (1993) NGS 
GN0034 LHCGR arr [hg19] 2p16.3(48,905,663-48,983,208)x0 Pa - Hom Richard (2011) NGS 
GN0068 LHCGR c.1713G>T; p.Met571Ile Pa Exon 11 Het Kremer (1993) CGA 
GN0088 LHCGR c.1193T>C; p.Met398Thr Pa Exon 11 Het Kraaij (1995) CGA 
GN0147 
LHCGR c.757T>C; p.Ser253Pro Pa Exon 9 Hom No 
NGS 




Table 15. Classification of the genetic variants identified in this work (Continuation). 
Case Gene Variants Classification Location Zygosity Previously reported* Diagnostic approach 
GN0157 
LHCGR c.568C>A; p.Gln190Lys LP Exon 7 Het No 
NGS 
NR5A1 c.437G>C; p.Gly146Ala LB Exon 4 Het Wada (2006) 
GN0171 
LHCGR c.1660C>T; p.Arg554Ter Pa Exon 11 Het Latronico (1996) 
NGS 
GATA4 c.677C>T; p.Pro226Leu VUS Exon 3 Het Martinez de LaPiscina (2018) 
RE0045 CYP17A1 c.1246C>T; p.Arg416Cys Pa Exon 8 Hom Takeda (2001) NGS 
GN0038 HSD17B3 c.845C>T; p.Pro282Leu Pa Exon 11 Hom Andersson (1996) CGA 
GN0185 STAR c.50T>G; p.Met17Arg VUS Exon 1 Het No NGS 
CGA, candidate gene approach; Hemi, hemizygosis; Het, heterozygosis; Homo, homozygosis; LP, likely pathogenic; NGS, next generation sequencing; Pa, pathogenic; VUS, 




Table 16. Results obtained by the different prediction software. 
 





SNPs&go MutPred Panther VarSome 
GN0020 WWOX; p.Pro366Ala N(-2.36) T(0.328) B (0.009)/B(0.004) DC N(8;0.102) <0.50 PsD(324) VUS 
GN0028 
NR5A1; p.Cys30Ser Del(-8.22) Dam(0.000) PrD(0.988)/PrD(0.988) DC D(9;0.965) 1(0.03),2at S32 (0.04) PrD(911) LP 
STAR; p.Arg121Trp Del(-3.98) Dam(0.009) PrD (1.0)/PrD(0.995) DC N(4;0.309) 3(0.04) PsD(324) VUS 
GN0042 AMH; p.Thr143Ile Del(-2.88) Dam(0.035) B (0.411)/B(0.187) P N(5;0.231) <0.50 PrB(103) VUS 
GN0080 AR; p.His100ProfsTer3 N/A N/A N/A DC N/A N/A N/A VUS 
GN0111 NR5A1; p.Cys301Tyr Del(-6.67) Dam(0.0) PrD(1.0)/PrD(1.0) DC Dam(6;0.795) 4(3.7e-03),5(0.02) PrD(797) LP 





GN0139 AR; p.Leu881Arg Del(-4.48) Dam(0.001) PrD 1.0)/PrD(0.897) DC N(1;0.457) 10(0.27),9(0.11) PrD(455) LP 
GN0141 SRY; p.Pro131Ser Del(-7.12) Dam(0.001) PrD(1.0)/PrD(1.0) DC D(8;0.902) <0.50 PrD(912) LP 
GN0142 DMRT2; p.Ser536Leu N(-1.69) Dam(0.002) PsD(0.614)/B(0.038) DC N(8;0.124) <0.50 PsD(324) VUS 
GN0147 LHCGR; p.Ser253Pro N(-2.10) Dam(0.004) PrD(0.999)/PrD(0.986) DC D (9; 0.969) 9(8.9e-04) PsD(361) VUS 
GN0150 WT1; p.Glu75Lys N(-1.58) Dam(0.0) PrD(0.980)/PsD(0.856) DC N(1 0.427) <0.50 Dam(750) VUS 
GN0154 MAMLD1; p.Thr670Ile N(-1.54) Dam(0.042) N/A P N/A <0.50 N/A LB 
GN0155 ZFPM2; p.Ala1026Val N(0.03) T(0.603) B(0.0)/B(0.0) DC N(10;0.253) 11(0.00),5(0.01),12(0.03) N/A VUS 
GN0156 WT1; p.Met182Lys Del(-2.78) Dam(0.0) B(0.140)/B(0.143) DC D(3;0.632) <0.50 PrD(455) VUS 
GN0157 LHCGR; p.Gln190Lys N(-1.22) T(0.162) B(0.282)/B(0.170) DC D(8;0.898) <0.50 PsD(220) VUS 
GN0171 GATA4; p.Pro226Leu Del(-9.67) Dam(0.0) PrD(1.0)/PrD(1.0) DC D(10;0.992) 9(8.2e-03) PrD(1368) VUS 
GN0185 STAR; p.Met17Arg N(-1.74) Dam(0.003) B(0.091)/B(0.037) DC D(6;0.778) 
4(3.3e-03),13(8.3e-04) 
8(0.02),7at Y14 







Table 16. Results obtained by the different prediction software (Continuation) 





SNPs&go MutPred Panther VarSome 
GN0198 
HSD17B4; p.Ala175GlufsTer26 N/A N/A N/A DC N/A N/A  Pa 
ESR1; p.Thr594Met N(-1.23) Dam(0.001) PrD(1.0)/PrD(0.976) P N(7;0.168) <0.50 N/A VUS 





GN0207 ESR2; p.Arg221Gly Del(-5.73) Dam(0.001) B(0.085)/B(0.086) DC D(3;0.627) <0.50 PrD(750) VUS 
POL0301 NR0B1; p.Thr238LeufsTer60 N/A N/A N/A DC N/A N/A N/A Pa 
Score given by each prediction program is given in brackets. Provean, the variant is predicted to be deleterious when the score is equal or below the default score threshold 
(-2.5). SIFT, ranges from 0 to1 and the substitution is predicted to be tolerated if >0.05. Polyphen, divided into HumDiv and HumVar, the score values nearer one are more 
confidently predicted to be deleterious. SNPs and GO, if disease probability is >0.5 the variant is predicted as disease. Mutpred, a g score of 0.50 suggest pathogenicity and 
then, a loss/gain of structural or functional property. Only predictions with a g score >0.50 are shown. (1) Gain of disorder; (2) Loss of catalytic residue; (3) Altered stability; 
(4) Altered disordered interface; (5) Loss of helix; (6) Loss of strand; (7) Loss of allosteric site; (8) Altered metal binding; (9) Altered transmembrane protein; (10) Gain of 
strand; (11) Gain of sheet; (12) Gain of loop; (13) Altered DNA binding; (14) Loss of acetylation; (15) Loss of Pyrrolidone carboxylic acid; (16) Loss of sulfation. Panther, A 
longer preservation time indicates a greater functional impact. B, benign; Class, classification; D, disease; Dam, damaging; DC, disease causing; Del; deleterious; LB, likely 
benign; LP, likely pathogenic; N, neutral; N/A, not available; ND, not determined; P, polymorphism; Pa, pathogenic; PrB, probably benign; PrD, probably damaging; PsD, 
possibly damaging; Pt, preservation time; RI, reliability index; T, tolerated; VUS, variant of unknown significance. Previously reported gene variations classified as pathogenic 





10.4. CLINICAL AND MOLECULAR DESCRIPTION OF THE GENETICALLY 
POSITIVE PATIENTS 
 
I have grouped the patients presenting a genetic finding according to the main 
action of the gene during development. Firstly, I present those cases having a genetic 
variant in a gene related to gonadal determination and development, such as SRY, 
NR5A1, etc. Then, I describe patients with a disorder of sex development due to a 
genetic change in a gene associated to genital or sex differentiation (See 10.4.2, page 
182).  
 
10.4.1. Findings in genes related to gonadal development 
 
10.4.1.1. SRY variants 
 
A total of 8 patients had an alteration in the SRY gene. We detected the 
presence of the SRY gene in six 46,XX testicular DSD individuals, five were detected by 
either PCR or NGS and one by aCGH. PCR-based sequencing revealed another two 
single-nucleotide variants (SNV) in two patients with 46,XY DSD.  
 
10.4.1.1.1. Patients with a SRY gene translocation studied by PCR or 
NGS 
 
The majority of these patients presented with unilateral cryptorchidism or 
small testes at diagnosis, gynecomastia and azoospermia (GN0004, GN0133 and 
GN0187). All the patients had otherwise a normal male phenotype (Supplementary 
data 3). Individual GN0023 was referred at age 2 with ambiguous genitalia due to the 
presence of gonads in inguinal canal that descended after hCG stimulation. On the 
contrary, patient GN0054 presented at 41 years old with elevated FSH levels (FSH: 
31.7U/L; LH: 5.37U/L) and absence of body hair. Echography was normal. Karyotype of 
the patients was 46,XX.  
 
The presence of the SRY gene was studied by PCR in all these samples, except in 
GN0187, which was analysed by NGS. To validate the genetic findings a FISH analysis 
was also performed to determine the situation of the SRY gene. As usual, it was 
translocated to the distal tip of the short arm of the X chromosome [46,XX.ish 
der(X)t(X;Y)(p22.3;p11.3)(SRY)].  
 
10.4.1.1.2. Patients with a SRY gene translocation studied by aCGH 
 
GN0159 male patient was born with hypospadias and unilateral cryptorchidism. 




translocation of the SRY gene (46,XX.ish der (X)t(x,y)(p22.3;p11.3)(SRY+)). 3 months 
later, penis was normal and 2mL testes were present in scrotum. The boy had 
developmental delay, microcephaly and partial agenesis of the corpus callosum. Then, 
Smith Lemli Opitz syndrome was suspected. At 9 years of age, he presented at Tanner 
stage I, augmented penis, right testis in scrotum and left in inguinal canal. Hormonal 
analysis indicated low testosterone with normal gonadotropins values. He was 
referred to dermatology service due to café au lait spots when he was 11 years old. 
Surgery for hypospadias was also performed. One year later, testicular scanner 
showed a right testis of 22.7x7.3mm in size and left testis located in inguinal canal 
(24x7.5mm). At 13 years of age, left orchidopexy was performed and no pubertal signs 
were observed.  
 
We made an aCGH to discard a possible deletion in the short arm of 
chromosome 6 (6p) related to the phenotype of the patient. However, we observed an 
8.12Mb deletion at Xp22.2-22.33, from position 2,709,027 to 10,830,236 (Figure 22). 
This deletion involved 19 genes, including MID1 (OMIM 300552) which has been 
related to Opitz G/BBB syndrome (OMIM 300000), a congenital malformation 
syndrome characterized by hypertelorism, hypospadias, cleft lip, 
laryngotracheoesophageal abnormalities, imperforate anus, developmental delay, and 
cardiac defects (237). Moreover, the imbalance has been described in some of the 
most common CNV databases, such as ISCA (International Standards for Cytogenomic 
Arrays) consortium and DECIPHER (Database of genomic variation and phenotype in 
humans using ensembl resources), as structural variation with pathogenic clinical 
significance. Some of the deleted genes encode proteins that could be responsible for 
the phenotype, even the hypospadias. On the other hand, we showed a 430.7Kb 
Yp11.2-p11.3 region translocation, from 2,654,967 to 3,085,681, comprising SRY, 
RPS4Y1, ZFY and TGIF2LY genes (Figure 22). The presence of the SRY sequence might 
explain the DSD in the GN0159 patient. This SRY translocation was confirmed by FISH 
technique (Figure 23, page 166).  
 
Both alterations suggested a Xp22; Yq11 chromosome translocations. These 
chromosomal abnormalities may be due to a balanced translocation in one of the 
parents’ genomes, therefore we performed a FISH analysis to clarify the origin of the 
CNV. Both parents presented normal hybridization patterns (Figure 23, page 166). 
 
10.4.1.1.3. Patients with single-nucleotide variants in SRY 
 
A missense and a nonsense variant were also identified in 3 individuals of two 
different families by sequencing the SRY gene. Index patient GN0007 was a 16-year-old 
female with a 46,XY karyotype who had not reached puberty. A small uterus was 




bilateral gonadoblastomas. The sister of this index case was an apparently normal 
female with a 46,XY karyotype. Echocardiography revealed a small uterus. 
Supplementary data 3 shows the levels of gonadotropins and gonadal steroids in the 
index case. We found a hemizygous change of cytosine to thymine at location 291 of 
the SRY gene in both sisters. This mutation changes codon 97 from glutamine to a stop 
codon (c.289C>T; p.Gln97Ter) and results in a truncated protein. The father presented 
the variants as a mosaicism, while other male relatives had the wt genotype. This 
mutation has been previously reported by our group (238). 
 
 
Figure 22. aCGH detection of the Xp22; Yq11 translocation in the GN0159 patient. A, Ideogram of 
chromosome X. The area outlined by the dotted box is enlarged on the right. Log2 ratio plot of the 
patient relative to the control. Red dots represent probes with a log2 ratio below -0.5 and the blue dots 
greater than 0.5. The red area is the loss region, the 8.12Mb deletion at Xp22.2-22.33. B, Ideogram of 
chromosome Y. The blue area revealed a gain (430.7kb) at Yp11.2-11.31.  
 
 
Patient GN0141 had her gonads removed at puberty. Surgery showed streak 
gonads with tumoral aspect and gonadoblastoma, as well as remaining of Müllerian 
ducts. Treatment with oestrogens was prescribed and 10 years later, hormonal test 
revealed elevated gonadotrophins with high oestrogens levels. We found a C to T 
change in hemizygosis at position 391 (c.391C>T; p.Pro131Ser). The variant was 
predicted as potentially pathogenic since the wt amino acid and surrounding region is 
highly conserved (Supplementary data 14). Furthermore, another mutation has been 








Figure 23. FISH confirms the Xp22:Yq11 translocation. A and B, representative metaphase spreads of the 
patient. The SRY specific probe (labelled in red) hybridizes to the Xp region of one of the X chromosomes 
(labelled in green, CEP X). Metaphase spreads of normal hybridization patterns of the patient’s father 
(C) and mother (D).  
 
 
10.4.1.2. NR5A1 variants 
 
We found 6 variants in the NR5A1 gene in six cases with a 46,XY karyotype. The 
subjects presented mainly, with ambiguous genitalia but also primary amenorrhea, 
bilateral inguinal masses and virilisation at puberty. Four of the six gene variants were 
point mutations that led to a missense change and 2 were frameshift (1 insertion and 1 
deletion).All were located throughout exons 2 to 5 and four of them were novel. All 
the identified variants were in heterozygosis. Three variants were found in other 
family members (cases GN0075, GN0109 and GN0111), whereas the c.88T>A in 
individual GN0028 appeared to be de novo. Complete family studies could not be done 









10.4.1.2.1. Patients with missense variants in the NR5A1 gene 
 
Case GN0028 was a newborn noted to have curved micropenis with scrotal 
hypospadias and bilateral cryptorchidism, corrected by surgery later. At 10 years of 
age, stimulation test with hCG resulted in a normal rise of testosterone (187.4ng/dL). 
At 12 years, his penis was 7.6cm in size, testes of 5mL were observed and presented a 
pubarche and axilarche stage V. Magnetic Resonance Imaging (MRI) showed testes of 
20x15x15mm and 14x15x35mm corresponding to right and left testis respectively. A 
small cyst was also observed in the right epididymis. At 14 years, biochemical analysis 
revealed elevated serum levels of gonadotropins (LH 11.4U/L, FSH 35.9U/L) and 
testosterone (412.5ng/dL) with low levels of AMH (<0.1ng/mL). At recent follow-up at 
15 years of age, penis was in the normal limit. He still presents high levels of LH and 
FSH with a testosterone of 518ng/dL. MRI demonstrated small cysts in both epididymis 
of 6.4mm and 2.7mm. Asperger syndrome was suspected at the age of 13 years old. 
Family history is remarkable for the following: patient’s mother has unilateral renal 
agenesis, as well as brother, with also vas deferens and left epididymis agenesis. We 
found the novel C to A change in the exon 2 (c.88T>A), which is predicted to result in 
the p.Cys30Ser variants. Both parents were studied and did not carry the variant, thus 
this NR5A1 variant is a de novo change in the patient. Brother was also negative for the 
variant.  
 
Index case of GN0075 family presented micropenis, scrotal hypospadias, 
undescended testis and bifid scrotum at birth (Supplementary data 2). Abdominal 
ultrasound (US) revealed no anomalies. Biochemically, LH and FSH were elevated (2.5 
and 3.7U/L, respectively) with a testosterone of 6750ng/dl during the first month. At 3 
months, four doses of testosterone were prescribed (50mg/dose) with a good 
response of the penis. At 5 years of age, physical examination showed a penis of 2.5cm 
in size, right testis of 2ml and testicular left hydrocele. At age 6, replacement 
testosterone treatment was started. Penis was normal (3cm) and pubic hair increase 
was noted. Interestingly, mother presented with premature menopause, maternal 
uncle with scrotal hypospadias at birth and aunt with menstrual disorders. A 
heterozygous C to T transition located at c.250 of the coding NR5A1 sequence 
predicted to replace an arginine with cysteine at position p.84 (c.250C>T; p.Arg84Cys) 
was found. The same heterozygous variant was also found in the mother, brother, 
maternal uncle, aunt and grandfather (Figure 24). The variant, located in exon 4, was 
described firstly by Reuter et al in a Japanese individual with dysgenetic testes and 
normal adrenal function (240). Since then, it has been reported in several cases with 












Patient GN0123 was noted at birth to have curved penis buried in pubis, 
perineal hypospadias, bifid scrotum and palpable gonads. At 2 years of age, biopsy 
showed testicular tissue without variants and laparoscopy didn’t show Müllerian rests. 
During the following years, hypospadias was corrected and at 10 years of age penis 
was 2.6cm, and both testicles were correctly located. Stimulation test with hCG 
resulted in a normal rise of testosterone. He started treatment for micropenis with 
testosterone (250 mg), which increased phallic size to 3.5 cm and began pubarche. At 
14 years of age, the boy had a fallus of 5.5 cm and testes of 2-3cc. Biochemically, 
gonadotropins were elevated (LH: 15U/L; FSH 55U/L) at a testosterone of 1.8ng/dL 
after HCG stimulation test. ACTH, cortisol and 17-hydroxypreogesterone were in the 
normal range. Intramuscular testosterone treatment was prescribed again for 6 
months. At the age of 15 years, penis was 7cm and testis 2cc. After two months of the 
suspension of the treatment LHRH stimulation test was done and gonadotropins and 
testosterone resulted in a normal rise (Supplementary data 3). The subsequent years, 
a second biopsy revealed the absence of germinal cells and Leydig cells hypoplasia, 
orchidopexy was performed and testosterone treatment was restored. Currently, he 
presents with a penis of 3-4 cm and testis of 2cc. LH and FSH were elevated in the 
presence of a low testosterone (500ng/dL). Apart from the development of his 
external genitalia, he is obese. Direct analysis by Sanger sequencing revealed the novel 
c.71A>T; p.His24Leu change in exon 2. Samples from the parents were not available. 
 
Patient GN0111 presented with primary amenorrhea and obesity at 14 years of 
age. She had a stenotic and enlarged vagina, which was possibly a vaginal pouch. 




and vagina, but ovaries were not ascertained, although streak gonads couldn’t be 
discarded. Biochemical analysis at this time showed increased levels of gonadotropins 
with a slight high testosterone (36.60ng/dL). Stimulation test with hCG resulted in a 
minor rise of testosterone (47.70 and 46.0ng/dL for the 3rd and 5th dose of hCG, 
respectively). Laparoscopy at the age of 15 years revealed a rudimentary uterus and 
streak gonads. Gonadectomy and biopsy showed compatible gonads with non-
functioning testicular parenchyma and normal Fallopian tube. No interesting family 
history was reported. Analysis with the customized panel showed that the patient 
harboured the novel c.902G>A; p.Cys301Tyr change in heterozygosis. Curiously, the 
healthy mother of the patient carried the change in NR5A1 as a mosaicism, while the 
father and brother were negative.  
 
In addition to in silico tests and comparison of the residues against diverse 
species (Supplementary data 14), in vitro functional studies were performed to study 
the transactivation activity of the mutants (See 10.5, page 200). Then, we classified the 
p.Cys30Ser and p.His24Leu as pathogenic, while p.Cys301Tyr was categorized as likely 
pathogenic.  
 
10.4.1.2.2. Patients with frameshift variants 
 
Case GN0042 was a female referred at age 11 because of clitoromegaly, 
bilateral inguinal masses and growth increase. She presented with beginning of 
pubarche and facial hair growth. Pelvic ultrasound (US) showed a vaginal pouch and 
absence of uterus, as well as palpable gonads in inguinal canal (2 and 3ml). 
Biochemical analysis was remarkable with elevated gonadotropins at a testosterone of 
250ng/dL. Gonadectomy and subsequent histology revealed 2 testes of 2.4 and 2.5cm 
with germinal hypoplasia. Oestrogen oral therapy was initiated for the next 9 years 
and then was replaced with patches. This resulted in good breast development and 
sexual hair although mammary regression was observed when the dose was 
decreased. During the following years reconstructive surgery was performed. 
Abdominal US showed a normal bladder and a small structure (26mm) above the 
urethra, indicating a possible prepuberal hypoplasic uterus. No ovaries were 
perceived. At 27 years of age the patient was well developed. Hormonal values were in 
the normal, age-and sex-appropriate range. The c.614_615insC variant in exon 4 leads 
to an amino acid change and to a stop codon 20 residues afterwards 
(p.Gln206ThrfsTer20). This had been previously reported in a 46,XY female with 
ambiguous genitalia (14). Only the mother of the proband was studied and brought no 
variants. 
 
The second frameshift variant was identified in GN0109. This female was seen 




genitalia at birth and pubarche and axilarche at the age of 8 years. At examination, 
female external phenotype, erectile hypertrophic organ with perineal urethra and 
absence of inguinal masses was denoted. Pelvic Magnetic resonance imaging showed a 
rudimentary uterus, and computed tomography (CT) scan revealed uterus and atrophic 
gonads in left inguinal canal. Analysis resulted in elevated LH and FSH levels (37.8 and 
113U/L, respectively) with high levels of testosterone (193ng/dL). At 15 years, 
orchidopexy was performed and biopsy showed muscle tissue with a Sertoli-cell 
phenotypic testicle and epididymis. After surgery patient began treatment with 
oestrogens. The novel c.910_913delGAGC; p.Glu304CysfsTer26 variant was found in 
NR5A1 and was classified as pathogenic due to its null effect. The mother of the 
proband presented the change in heterozygosis and curiously, her sister had hirsutism.  
 
10.4.1.2.3. Identification of the p.Gly146Ala polymorphism in our 
cohort  
 
Since the first description of the rs1110061 SNP by WuQiang et al in 2003 in 
which no dominant negative effect was proven (242), the c.437G>C; p.Gly146Ala 
variant in NR5A1 gene has been reported in several DSD-related phenotypes, such as 
hypogonadotropic hypogonadism, micropenis, cryptorchidism, POI and even in 
diabetes, highlighting its poor role in the development of sex disorders (14) (243). 
Moreover, the allele frequency differs among the populations. Regarding the 1000 
Genomes Project Phase 3 in combined population, the frequency of the minor allele G 
is 0.33, while for ExAC, ESP and gnomAD databases this frequency is lower (0.11, 0.24 
and 0.23, respectively). Studies in East Asia indicated a MAF of the G allele similar to 
the general population (0.323), however, this frequency decreases in Spanish (MAF G 
allele: 0.05). On the contrary, studies in Africa have revealed that the most common 
allele is the guanine (0.831), specifically the frequency of the G in people from Sierra 
Leone is 0.894. The results given in this work emphasize the categorization of this 
change in the NR5A1 gene as a benign polymorphism, due to the high frequency, wide 
range of phenotypes and origin of the patients in which it has been identified.  
 
We have identified the c.437G>C; p.Gly146Ala polymorphism, located in the 
exon 4 of the NR5A1 gene in 15 individuals out of 125 (12%). Out of these patients, 9 
were examined due to ambiguous genitalia and were recorded as phenotypic males 
with micropenis and scrotal hypospadias in some cases. In GN0051, GN0070 and 
GN0163 probands, ultrasound detected testes located either in inguinal canal or in the 
scrotum. On the contrary, a laparoscopy was performed to patient GN0090 and 
bilateral ovotestes were reported. Karyotype was 46,XY in all the probands, except in 
GN0090 and GN0051. Patients GN0096 and GN0158 were both referred at age 3 and a 
46,XX DSD was suspected. Female normal karyotype was set and histology revealed 




curved penis with scrotal hypospadias and cryptorchidism at examination. GN0182 had 
unilateral cryptorchidism, as well as bifid scrotum at birth.  
 
On the other hand, patient GN0012 presented as a newborn with micropenis 
(10mm) and bilateral anorchia. Stimulation test with hCG resulted in no response of 
testosterone, indicating an absence of testicular tissue, which was confirmed later. 
Testicular prostheses were placed at age 7 and increasing doses of testosterone were 
prescribed. Biochemically, he had markedly elevated gonadotropins (LH: 42.3U/L; FSH: 
85U/L) in the presence of low testosterone (55ng/dL). At 15 years of age, he presented 
a mature penis and scrotum, pubarche IV and facial and body hair. During the 
following years, he was well virilised and hormones were in the normal, age-and sex-
appropriate range. Finally, case GN0199 was referred because of micropenis and fused 
labia minora. At examination, non-palpable gonads and a tight vagina were noticed. 
Ultrasound (US) revealed a normal uterus and the absence of gonads. Karyotype was 
46,XY. This male was diagnosed with a complete gonadal dysgenesis.  
 
Patients GN0147, GN0156, GN0157 and GN0194 are clinically characterized 
elsewhere because other causative gene variants have been found along with this 
NR5A1 gene change.  All of them were identified by DSD targeted gene panel 
sequencing, except cases GN0012 and GN0119 in which the variant was found in 
heterozygosis and homozygosis by a candidate gene approach. These two samples 
were included in the panel to search for any other additional disease-causing gene 
variant, however none was found. 
 
10.4.1.3. NR0B1 variants 
 
A total of 7 male patients (GN0078, GN0153, GN0091, POL0301, POL0274, 
POL0285, and GN0101) were evaluated with suspicion of non-congenital adrenal 
hyperplasia (non-CAH) primary adrenal insufficiency (PAI). The molecular analysis of 
the NR0B1 gene was performed by PCR amplification of the 2 coding exons and 
subsequent sequencing. Among them, 2 new gene sequence changes were found in 
exon 1 (c.528C>G and c.712_713delAC). Patients GN0101 and POL0285 showed no 
amplification of the gene and therefore a MLPA was performed. 
 
10.4.1.3.1. Sanger sequencing of the gene 
 
Case GN0078 was diagnosed at 45 days of life due to his brother’s neonatal 
death and the familial background of unexplained deaths of eight male infants in the 
first months of life. Despite the absence of glucocorticoid insufficiency (cortisol: 
17.8μg/dL) or hyperpigmentation the clinical diagnosis led to PAI. A scan of the adrenal 




and fludrocortisone treatment. At 3 years, he presented with high testosterone levels 
(170ng/dL), and later hypogonadotropic hypogonadism. GN0153 was admitted at 
hospital at 11 days of life due to a hyponatremic dehydration and hyperkalaemia with 
compatible PAI. Treatment was given until cortisol, 17-hydroxyprogesterone and 
androgens values were normalized, when hydrocortisone administration was stopped. 
8 months later he was controlled at hospital due to hypoaldosteronism. No interesting 
family background was reported. We identified 2 different point mutations (c.913C>T; 
p.Glu305Ter and c.528C>G; p.Tyr176Ter) in GN0078 and GN0153 cases, which predict 
a truncated protein product and thus the generation of a non-functional protein. 
Moreover, the c.528C>G; p.Tyr176Ter change in exon 1 of the NR0B1 gene has been 
listed before (244), but not in a NR0B1-related disease. As the variant is not present in 
population databases (ExAC) and causes a null effect, we classified it pathogenic, as 
well as the c.914CT;p.Glu305Ter variants (245). Regarding family studies, a cousin of 
the GN0078 patient presenting with adrenal insufficiency harboured the same 
variants. First relatives of GN0153 family were studied and only the mother and 
grandmother of the patient were carriers of the variants.  
 
Patient GN0091 manifested a salt-wasting crisis and hypoglycaemia at 24 hours 
of life. Treatment with hydrocortisone and fludrocortisone was prescribed. At 8 
months, testes and penis measured 1mL and 3.6 cm, respectively. Analytical levels are 
shown on Supplementary data 3. At imaging probes no adrenal glands were observed. 
Remarkably, mother of the patient referred abdominal pain, weakness, 
hyperpigmentation and dysfunctional uterine haemorrhages. Her biochemical levels 
were normal (Na: 131mEq/L; K: 5.8mEq/L; glucose: 68mg/dL and cortisol: 6.1μg/dL). In 
both proband and mother, the c.291delC deletion was found, in hemizygosis and 
heterozygosis, respectively, which is predicted to induce a frameshift variants 
(p.Glu98ArgfsTer166), as described (246).  
 
Another small deletion was detected in the index case of family POL0301. This 
2-year-old boy was examined because of an acute hyponatremia after presenting 
polyuria, polydipsia, asthenia and constipation for two weeks. At examination, testes 
of 0.5mL and normal penis were noticed. Treatment with fludrocortisone was 
prescribed. During hospitalization, cortisol deficiency was reported (Supplementary 
data 3). The patient started with the substitutive therapy. Genetic studies revealed the 
novel c.712_713delAC; p.Thr238LeufsTer60 variants in exon 1 of the NR0B1 gene, 
which has been classified as pathogenic. The mother of the patient is a carrier of the 
mutation. 
 
Patient POL0274 was diagnosed in Mexico of adrenal insufficiency at the age of 
one month and was under treatment with hydrocortisone and fluorohydrocortisone. 




and pubic hair development (9 months). He presented with hyperpigmented genitals, 
hypertrophic penis (5cm), testes of 2mL and pubic hair. Basal hormone analysis 
showed low ACTH levels (<10pg/mL) with elevated testosterone (235.3ng/dL) under 
treatment. Ultrasound and computed tomography (CT) proved the absence of the left 
gland. Biochemical analyses were repeated after treatment stopped and showed 
cortisol levels under 0.1µg/dl at baseline and after ACTH stimulation test, while an 
increase in 17-hydroxiprogesterone (17OHP) was noticed (0.62ng/mL to 1.22ng/mL). 
At the age of 15 months, penis was 6cm and hydrocortisone doses were progressively 
increased with subsequent normalization of ACTH and testosterone values, while 
cessation of genital development. At follow-up (3 years), testosterone levels have been 
maintained at prepubertal levels, with no progression in penile length. The c.871T>A; 
p.Trp291Arg mutation was found. Functional studies performed by Lehmann et al 
demonstrated the pathogenicity of the protein change (247). Mother of the patient 
carried the variant in heterozygosis. 
 
Clinical and genetic characteristics of patients GN0078, GN0091, GN0101, 
POL0285 and POL0274 have been published by our group (245, 248). 
 
10.4.1.3.2. MLPA analysis 
 
We found a complete deletion of NR0B1 gene in two different cases. Case 
POL0285 was diagnosed with adrenal insufficiency at birth and treatment with 
hydrocortisone and fludrocortisone was established. There is no clinical data at this 
time due to loss of follow-up care. At 45 years, he had an acute adrenal insufficiency 
and hypogonadotropic hypogonadism. He presented testes of 2mL, prepubertal penis 
(3cm) and scarce body hair. There was a family background, as his uncle died at age 2 
years. Patient GN0101 was studied due to the severe hypoglycaemia (20mg/dL) he 
presented at 3 years of age. He also had salt wasting. He received gonadotropin 
treatment at pubertal age to induce puberty and at 17 years, testes were 2-3mL and 
penis measured 8cm. 
 
As no product was obtained after PCR-based amplification, a MLPA using the 
SALSA MLPA P185-C1 Intersex Kit was performed and showed a complete deletion of 
the 2 exons that are part of the NR0B1 gene. As shown in Figure 25 both patients lack 
the presence of probes in exon 1 (148 and 234 nucleotide), exon 2 (310 nucleotide) 
and at 17.8kb upstream NR0B1 (454 nucleotide). Moreover, patient GN0101 had a 
bigger deletion as probe at 126.3kb upstream NR0B1 (481 nucleotide) was not 







Figure 25. MLPA analysis data in patient POL0285 (middle panel) and GN0101 (lower panel) against a 
control (upper panel). Arrows indicate the probes for NR0B1 gene.  
 
 
Then, we used fluorescent markers to determine the extension of both 
deletions. As shown in the Figure 26 both patients lack the DXS1083 microsatellite, 
located at chromosome X: 30,361,221-30,361,359 position. Case POL0285 does not 
present the DSX8039 marker too, which is placed at chromosome X: 29,977,924-
29,978,270. Combined with the MLPA assay, we could verify that POL0285 presented a 
contiguous gene deletion affecting NR0B1 and MAGEB1genes (Chromosome X: 
30,261,847-30,270,155). Moreover, in this case the deletion upstream NR0B1 was up 
to 17.8kb, whereas deletion in GN0101 did not affect any other gene. Samples of the 
parents were not available for studying. 
 
 
Figure 26. Analysis of genetic markers nearby NR0B1 gene at Xp21.2. The presence or absence of the 








10.4.1.4. WT1 variants 
 
We identified five different variants in WT1 gene. Of these, 2 occurred in 
isolated DSD with Androgen Insensitivity Sundrome (AIS) and precocious puberty. The 
remaining three happened in WT1-associated syndromes.  
 
10.4.1.4.1. WT1 gene variants in isolated DSD 
 
The GN0150 child presented normal female external genitalia and bilateral 
inguinal hernia when she was 3 years old. Surgery and subsequent histology revealed 
testicular tissue. Karyotype was 46,XY. At that moment uterus was not observed by 
ultrasound. At recent follow-up when she was 10 years old, imaging probe was 
repeated and a small uterus with normal kidneys was shown. Biochemical and 
hormonal studies revealed more or less normal values, compared to male age-
controls, only elevated FSH was remarkable. AR was first studied and was negative, 
then we included the patient in the targeted gene panel analysis. We found the novel 
c. 223G>A; p.Glu75Lys sequence change in heterozygosis, as well as in her healthy 
mother.  
 
Case GN0156 was studied because an increase in genital development and 
pubic hair was noted. At examination (age 7 years) this Indian patient presented 
pubertal genitalia with 10mL testes and a penis of 8cm. At MRI, a pituitary adenoma of 
5x3mm was observed. Clinical analysis at this time indicated elevated basal 
testosterone (406ng/dL) and LH after LHRH stimulating test (25.03U/L). Although a 
precocious puberty was suspected, the genetic study of the LHCGR gene was negative. 
The novel c.545T>A; p.Met182Lys variant in the WT1 gene in heterozygous state was 
detected. As the child was adopted no family history could be recorded. 
 
Both novel variants were classified as of unknown significance due to the 
evaluation of disease-causing potential (Table 16, page 161) and multiple genome 
alignment (Supplementary data 14). Quality values of the NGS run are shown on 
Supplementary data 10.  
 
10.4.1.4.2. WT1-associated syndromes 
 
Two patients were diagnosed with a Frasier syndrome. Case GN0009 was 
admitted when she was 12 years old because of severe headaches, vomiting and 
fatigue for 15 days. Blood pressure was 180/120mmHg and a bilateral papilledema was 
detected by fundoscopy. Imaging probes and subsequent biopsy evidenced a 
nephronophthisis. She began treatment and later, haemodialysis due to renal 




after a few days. Since then, she has been treated with several drugs and receiving 
haemodialysis. At 17 years of age, her pubertal development was delayed with a bone 
age of 10 years. Ultrasound revealed a normal uterus (72mm) but no gonads were 
seen. Karyotype was 46,XY and biochemically, gonadotropins were elevated while 
oestradiol level was undetectable. At this time growth hormone (GH) treatment was 
prescribed because she was 137.4cm tall. One year later it was stopped since growth 
response was poor (1.5cm). At the age of 24 bilateral streak gonads were removed and 
a microscopic gonadoblastoma was reported. The second patient (GN0132) is an 18-
years-old female with gonadal dysgenesis, renal insufficiency and gonadoblastoma. 
One year later, laparotomy was done and gonadal remnants were removed. Caryotype 
was 46,XY and Müllerian remnants including uterus were present. She started 
oestrogenic treatment until she was 33 years old. She had a second renal transplant.  
 
Case GN0009 was a heterozygous carrier of the c.1447+5G>A change, while 
GN0132 carried, also in heterozygosis the c.1447+4C>T change. Both mutations are 
located in intron 9 and produce an alternative splicing of the protein. Only mother of 
GN0009 was studied and did not harbour the mutation. Both alterations have been 
previously associated with Frasier syndrome (251) (17). 
 
Patient OT0567, from Tunisia, presented bilateral cryptorchidism at birth. 
When this male was 2 years old he was diagnosed with a bilateral Wilms’ tumour due 
to a hypertensive crisis. He had no metastasis and began chemotherapy. After 
treatment, progression of masses was observed and was treated with chemotherapy. 
Then, surgery was suggested. Few months later he was referred to a Spanish hospital 
with hypertension and Denys-Drash syndrome was suspected due to proteinuria in 
nephrotic range. In order to discard a WT1 gene mutation a DNA sample was sent to 
our laboratory before surgery. We found a partial WT1 gene deletion in one allele, 
from exon 7 to 10 by NGS. We validated this CNV using the commercial MLPA 
containing probes for WT1 and AMER1 genes. As shown in Figure 27, the peak size of 
the probes in exon 7 (probe at 239 nucleotide), 8 (153 nucleotide), 9 (166 nucleotide) 
and exon 10 (185 nucleotide) are reduced, which indicates the deletion of exons 7 to 
10 in one allele of patient OT0567. The parents of the patient were normal. Partial and 
entire deletion of the WT1 gene has been reported before and related to isolated 
Wilms’ tumour (252), as well as to 46,XY gonadal dysgenesis, Wilms’ tumour and 
gonadoblastoma (253). During surgery to remove bilateral tumours, testes were found 
in abdominal cavity and one was visually noted to be hypoplastic. Gonads were not 





Figure 27. MLPA profile illustrating the presence/absence of LOH in OT0567 family. Upper panel, black 
arrows indicate the probes for exon 7, 8, 9 and 10 of the WT1 gene in a negative control. Middle panel, 
MLPA profile of the index case. The peak size of probes for exon 7 to 10 is reduced. Lower panel, normal 
MLPA profile of the patient’s mother. 
 
 
10.4.1.5. MAP3K1 variants 
 
We identified a MAP3K1 gene variant in a 46,XY patient with complete gonadal 
dysgenesis. Female external genitalia, absence of thelarche and pubarche III were 
noted. This 16-year-old patient (GN0011) was examined due to primary amenorrhea. 
No uterus was visualized at ultrasound. She referred that she had grown during the 
last year when pubarche started. Gonadotropins were elevated (FSH:145U/L; 
LH:45U/L) in the presence of low testosterone (1.0ng/dL) levels (Supplementary data 
3). Bilateral gonadectomy was planned and substitutive oestrogenic treatment would 
be then prescribed. Patient’s father and brother reported delayed pubertal 
development.  
 
Firstly, SRY and NR5A1 genes were amplified and studied by traditional 
sequencing but no change was detected. Then, NGS identified a heterozygous MAP3K1 
c.2291T>G change in exon 13, which is predicted to result in a p.Leu764Arg variants. 
Parents and brother were studied and did not carry the variant, thus is a de novo 




However, no functional studies have been done yet probing that the variants causes 
the clinical features in this type of patients.  
 
10.4.1.6. GATA4 variants 
 
This male patient (GN0171) was noted at birth to have micropenis and bilateral 
cryptorchidism. At 11 years of age he still presented micropenis (3.5cm), testes were 
non-palpable and severe obesity (Body Mass Index (BMI) 36.6, +6.4SD) was observed. 
His gonadotropins were elevated with low testosterone. Karyotype was 46,XY. 
Magnetic resonance imaging showed both testes in inguinal canal. At 14 years, 
replacement testosterone treatment was started with gradual increasing doses. After 
treatment, LH suppression and normalization of FSH was observed. At 18 years, 
azoospermia was found. At recent follow-up at 21 years of age, he presented with 
severe obesity (BMI 44.9, +6.8SD) and short stature (156.1cm). Penis (8cm) was buried 
in subcutaneous fat and left testis was in scrotum (0.5ml). Biochemically, he presented 
normal gonadotropins with a testosterone of 11.8ng/ml under treatment. Ultrasound 
showed an ovoid structure (17mm × 16mm) in right inguinal canal corresponding to 
atrophic testis. Currently, laparoscopy is planned to investigate the right testis and 
biopsy both to assess the malignancy risk. Echocardiography revealed no congenital 
heart disease (CHD). 
 
We found the novel GATA4 c.677C>T nucleotide change, which is predicted to 
replace a proline with leucine at position p.226 (p.Pro226Leu). The same heterozygous 
variant was also found in the healthy mother. The pathogenesis of the GATA4 gene 
variant was studied in vitro (See 10.5, page 200) and although prediction software and 
protein alignment (Supplementary data 14) suggested a deleterious effect, 
transactivation studies showed activation of the CYP17 promoter similar to wild type, 
thus we classified the p.Pro226Leu protein change as a VUS. The clinical and molecular 
characterization of the variant found in the index case of the GN0171 family has been 
described in a publication by our group in 2018 (25). 
 
10.4.1.7. WWOX variants 
 
Sequence variants in the WWOX gene were found in two patients with 46,XY 
DSD, presumably with complete and partial gonadal dysgenesis diagnosis.  
 
GN0020 female went to medical consultation for short stature and absence of 
pubertal development. Physical examination of the patient at the age of 13 years 
revealed little pubic hair, without any other obvious findings. Analytical results found 
normal 17-hydroxiprogesterone and DHEA-S (Dehydroepiandrosterone-sulfate) levels 




(US) showed no gonads. After being diagnosed, she received replacement treatment 
with oestrogens and gonadal remaining was removed. At follow up (17 years), she 
reported normal menses but breast development was unsatisfactory. The second 
patient (GN0203) harbouring a WWOX variant was born in Syria and was referred for 
gonadal dysgenesis evaluation. When this male child was 5 years old he presented 
micropenis with fused scrotum and bilateral cryptorchidism. US confirmed he had 
atrophic testes located in inguinal canal and no female internal genitalia were seen.  
 
Targeted gene panel sequencing found two missense variants in the WWOX 
gene. Subject GN0020 carried the heterozygous c.1096C>G; p.Pro366Ala variants while 
GN0203 harboured, also in heterozygosis, the c.184G>A; p.Gly62Arg change in exon 3 
of the WWOX gene. We were not able to achieve DNA samples of the family.  
 
As none of the variants had been reported, prediction software analysis and 
comparison between different species was done. Allele variant c.1096C>G had not 
been listed before in population frequency studies, however comparison of the protein 
variability across species showed that the proline was slightly conserved 
(Supplementary data 14). Moreover, prediction software results were not certain. On 
the other side, c.184A allele was noted with a frequency below 0.01 (MAF <0.01) in 
1000 Genomes Phase 3, ESP and ExAC, although the protein seemed to be highly 
conserved and the in silico analyses predicted as potentially pathogenic. Then, we 
classified c.1096C>G variants as a VUS and c.184G>A as a likely pathogenic change. 
 
10.4.1.8. Variants in Oestrogen receptor 1 and 2  
 
In total, 2 different variants were identified in two independent individuals by 
NGS in ESR1 and ESR2 genes.  
 
10.4.1.8.1. ESR1 gene 
 
Female GN0198 was referred to clinician due to primary amenorrhea and 
failure of pubertal development at age 17 years. Her female external genitalia were 
normal with thelarche stage II and pubarche III at examination. No ovaries were found 
by magnetic resonance imaging and ultrasound, but a likely uterus remnant was 
observed. Karyotype was 46,XX. Biochemical and hormonal studies at presentation 
revealed elevated gonadotropins and a low oestradiol (<5pg/ml) (compared to female 
age-controls) (Supplementary data 3). Hormone replacement therapy was prescribed. 
She is healthy otherwise. We found a novel heterozygous variants in ESR1 (c.1781C>T; 
p.Thr594Met), which is also carried by her mother. Due to the results given by the 
prediction software, the protein conservation analysis (Supplementary data 14) and 




10.4.1.8.2. ESR2 gene 
 
Case GN0207 was referred to clinician due to primary amenorrhea and pubertal 
development delay at age 14 years. At physical examination, this female presented 
normal external genitalia with Prader scale I and no puberty signs. The karyotype was 
46,XX. Ultrasound was done and prepubertal ovaries and uterus were seen. Hormone 
replacement therapy was planned. Hormonal test revealed a hypergonadotropic 
hypogonadism (Supplementary data 3). Family history is remarkable for the following: 
mother was virilised and drugs were taken during pregnancy. We identified a novel 
variant in exon 5 of ESR2 gene (c.661A>G; p.Arg221Gly) in heterozygosis with a 
population frequency <0.01 and as seen in Supplementary data 14, the arginine 
protein is highly conserved. Additionally, most of the prediction programs catalogue 
the variants as pathogenic. Samples of the parents were not available.  
 
10.4.1.9. DMRT2 variants 
 
One single change was found in the DMRT2 gene. Proband of GN0142 family 
was examined at birth because the obtained result of the karyotype during the 
amniocentesis (46,XY) and the female phenotype was discordant. This “female” 
newborn presented with female external genitalia with a 1-2cm clitoris, urinary 
meatus on base, non-palpable gonads and a bifid scrotum that seems to be poorly 
developed. Uterus and gonads were absent at US. Hormonal analysis when the patient 
was 22 days of life indicated the absence of Sertoli cells due to high levels of FSH 
(35.4U/L) and undetectable AMH levels.  
 
Interestingly, her cousin presented at 15 years with primary amenorrhea, 
undeveloped breast and lack of uterus and ovaries. She underwent laparotomy for 
resection of her male remnant. Vaginoplasty was done and is under hormonal 
oestrogen treatment. She was diagnosed with 46,XY DSD gonadal dysgenesis. 
 
Index case GN0142 was examined on the target gene panel for DSD and found 
a missense variant in exon 4 of the DMRT2 gene (c.1607C>T; p.Ser536Leu). As shown 
below the amino acid in position 532 is not highly conserved (Supplementary data 14) 
and only 4 of the in silico programs we used categorize the genetic change as 
deleterious. Family studies were done in parents, maternal uncle and grandmother, 
and found that only the mother (II.2) is a heterozygous carrier of the c.1607C>T 
change, as well as the index case (Figure 28). The genetic study of the cousin with 
complete gonadal dysgenesis would clarify the possible pathogeny of this variant, 










10.4.1.10. ZFPM2 gene  
 
We found a variant in the ZFPM2 gene in one patient. The GN0155 individual 
was born with ambiguous genitalia and was reared as a female. When the patient was 
3 years old, surgery was done to adequate genitalia to assigned gender and a 
disgenetic testicle was removed. At age 7, the patient had a left inguinal hernia. At 
puberty, the patient was spontaneously masculinized and began expressing male 
identity. At age 20 years, a karyotype study was done and found 46,XY. Due to low 
levels of androgens, treatment with testosterone was prescribed (37 years old). At 
examination, he presented male normal phenotype, obesity and lipomastia. The scan 
showed remains of uterus and structures looking like copus cavernosum in the 
perineum. Testosterone levels were very low when removing treatment (1.9ng/dL). 
 
Targeted gene panel sequencing showed the c. 3077C>T; p.Ala1026Val change 
in heterozygosis in the exon 8 of the ZFPM2 gene. This variant has not been described 
and no data is available in population databases. We classified this novel variant as a 
VUS regarding the incongruent results given by the in silico programs and comparison 
of the protein across species (Supplementary data 14). Moreover, familial studies were 
not performed. 
 
10.4.1.11. MAMLD1 gene 
 
We identified a novel MAMLD1 gene variant in a patient with a gonadal 
dysgenesis and a 46,XX karyotype. Subject GN0154 was examined because of primary 
amenorrhea at age 15. She had normal female external genitalia and thelarche at 







(Supplementary data 3). A small uterus was identified by ultrasound and then 
confirmed by laparoscopy. Fallopian tubes and small ovaries were also observed. 
Histology revealed many immature primordial follicles and follicular atresia. The 
patient began with the oestrogenic treatment at that time and continued together 
with progesterone.  
 
SRY was first studied but no gene amplification was observed. Large 
rearrangements in the NR5A1, CXorf21, NR0B1, WNT4, SOX9, SRY and ZFY genes were 
also discarded by MLPA. Then GN0154 was examined on the target gene panel and 
found in heterozygosis the missense c. 2009C>T; p.Thr670Ile change in exon 5 in the 
MAMLD1 gene. We classified this variant as a VUS. The frequency of the T allele is 
<0.01 and has not been cited in ClinVar. However, the in silico programs disagree and 
comparison of the protein across species didn’t find any similarity between species 
although no protein homologue is found in many of them (Supplementary data 14). 
Unfortunately, family studies were not done and therefore, prediction of disease-
causing effect is more difficult.  
 
This patient was included in an exome sequencing study to analyse additional 
genetic variations in cases with MAMLD1 sequence changes. Flück et al, together with 
our group, identified 14 candidate gene variants that could theoretically contribute to 
the patient’s phenotype (91). 
 
10.4.2. Findings in genes related to genital differentiation 
 
10.4.2.1. AR gene 
 
In our DSD cohort a total of 15 different changes in 16 independent patients 
were identified in the AR gene. Twelve individuals were genetically diagnosed after 
Sanger sequencing, 3 by NGS and one case needed further confirmation due to an 
exon deletion. Mainly, they had been previously reported, except for three, which 
were classified either as pathogenic or likely pathogenic (Table 15, page 157). 
 
10.4.2.1.1. Sanger sequencing of the AR gene 
 
Among the cases with an AR defect, 12 patients were studied by sequencing 
the 8 exons that constitute the AR gene 
 
Three patients (GN0035, GN0125 and GN0139) were examined by the clinician 
during puberty due to the presence of primary amenorrhea. They all had bilateral 




internal genitalia was confirmed by ultrasound in cases GN0125 and GN0139. 
Karyotype was 46,XY in all the three patients.  
 
The suspicion of androgen insensitivity syndrome was set with the finding of an 
AR variant. Patient GN0035 presented the c.2522G>A; p.Arg841His mutation, 
described for the first time by McPhaul et al in 1992 (254), while GN0125 harboured 
the nonsense mutation c.865G>T (p.Glu289Ter) (255). Finally, in GN0139 we identified 
the novel T to G change in position 2642 (c.2642T>G) in exon 8, this p.Leu881Arg 
variants has not been described before but has been classified as likely pathogenic 
because of the results given by the prediction programs and the residue seems to be 
highly conserved across different species (Supplementary data 14). The mother carries 
the variant in heterozygosis.  
 
The other patients were born with female external genitalia and presented 
inguinal hernias or masses located in inguinal canal. Foetal karyotyping was done in 
some individuals for another medical reason, such as phenylketonuria family history in 
case GN0177. Ultrasound (US) was performed and testicular tissue was defined after 
gonadectomy or biopsy. Probands of families GN0055 and GN0076 carried in 
hemizygosis the c.2710G>A; p.Val904Met and c.2566C>T; p.Arg856Cys mutations, 
respectively (254). The mothers of the patients were carriers of the mutations, but 
surprisingly mother of proband GN0055 presented the mutation as a mosaicism. More 
missense mutations were determined in GN0018 (p.Arg775Cys) (256), GN0024 
(p.Asp696Asn) (257) and GN0177 (p.Ser434Phe). Unfortunately, family studies were 
not done in these cases. We also found a novel frameshift variant in proband GN0112, 
a deletion of a cytosine at position c.827 changed the reading frame 
(p.Pro276HisfsTer20) and thus we considered it as pathogenic. This change was also 
found in her healthy mother in heterozygosis. 
 
  Furthermore, patient GN0080 harboured another frameshift variant. This 
female child was examined because of the suspicion of AIS. Karyotyping at 
amniocentesis was 46,XY. At 5 years of age, testicular tissue was reported after 
gonadectomy and US imaging showed absence of uterus and Müllerian ducts. We 
found the novel c.298insC; p.His100ProfsTer3 variants, which was also present in her 
mother but not in her sister or father. As a disruption of the protein is happening, we 
considered the variants as deleterious. 
 
Patient GN0146 had ambiguous genitalia and was intervened when she was 10 
years to remove male gonads and began treatment. At recent follow-up, she is 19 
years old and presents hypertrophic erectile organ and partial labial fusion. No 
Müllerian ducts were observed after imaging examination by ultrasound and Magnetic 




AR gene revealed a c.2473C>A; p.Gln825Lys mutation. This variant had been observed 
before (258, 259). DNA samples of the parents were not available.  
 
Male proband (GN0037) had perineal hypospadias, micropenis and bilateral 
testes located in scrotal folds at age 4. Testosterone was normal, as well as the rest of 
hormones. Karyotype was 46,XY. Enlargement of the pseudoclitoris was performed. At 
last examination (11years), the patient presented the same penis size (3cm). 
Testosterone and dihydrotestosterone values after stimulation slightly augmented 
(Supplementary data 3). The suspected diagnosis of PAIS was definite after the finding 
of the p.Phe726Leu change (260). Mother was a carrier of the same variants. 
 
10.4.2.1.2. Targeted gene panel sequencing 
 
Three more patients were genetically diagnosed with the targeted gene panel. 
All variants were missense and none was novel. 
 
Patient GN0189 was noted to have palpable gonads in labioscrotal folds at 
birth. Otherwise, she presented with female external genitalia. Ultrasound ascertained 
the presence of bilateral testes of approximately 0.3mm. Hormonal values were in the 
age-and sex-range. Karyotype was 46,XY. Ultrasound was repeated at 3 months and a 
vaginal pouch was observed. However, no uterus or ovaries were identified. MRI 
confirmed the absence of uterus and ovaries. Testes (20x9mm and 18x8mm) were 
located in labia majora. The c.2567G>A; p.Arg856His mutation was found in 
hemizygosis. The mother of the patient was also a carrier of the AR change in one 
allele. Batch et al (1992) found and described this variant in a patient with AIS (261). 
Case GN0194 presented at 15 years old with primary amenorrhea. At examination, 
lack of pubarche, axilarche and breast development was observed. She was obese. 
Karyotype was 46,XY. Remarkably, her sister has a similar phenotype, although sample 
was not available. NGS revealed the c.2323C>T; p.Arg775Cys change in hemizygosis 
(256). On the contrary, patient GN0164 was referred to clinician because of 
hypergonadotropic hypogonadism, bilateral gynecomastia, micropenis and testis of 
3mL at 36 years old. Karyotype was 46,XY. In the beginning a Leydig‘s cell hypoplasia 
was suspected and LH receptor gene was studied. However, nothing was found and 
the sample was included in the panel. We found the previously reported mutation 
c.2270A>G; p.Asn757Ser in hemizygosis (262). DNA samples of the parents were not 
available. 
 
10.4.2.1.3. QMPSF methodology for the analysis of AIS 
 
PCR amplification of AR gene exons was done due to the suspicion of androgen 




of exon 2 was not possible and therefore confirmation was needed. This proband had 
bilateral gonadectomy performed at age 3 and was referred to clinician due to a 
suspected androgen insensitivity syndrome when she was 9 years old. She presented a 
46,XY karyotype with normal female phenotype and prepuberal external genitalia. 
Elevated gonadotrophins levels were found, but testosterone and DHEAs were within 
normal range. Abdominal ultrasound (US) was done when the patient was 12 years old 
and revealed the absence of female internal genitalia. Treatment with ethinyl-
oestradiol was prescribed and completely developed secondary sexual characteristics. 
Her older sister presented the same phenotype (Figure 29). 
 
 




Quantitative Multiplex Polymerase Chain Reaction of Short Fluorescent 
(QMPSF) was used to confirm the variation in the gene dose. As shown in Figure 29, we 
identified the deletion of exon 2 in the AR gene (c.(1616+1_1617-1)_(1768+1_1767-
1)del; p.(Arg539_Asp305del)). Electropherogram of the patient showed the different 
peaks of the exons 3 to 8 in the HNF1β, and the complete absence of exon 2 in the AR 
gene. Co-segregation studies in the family revealed that the older sister (II.1) with a 
46,XY karyotype, harboured the same hemizygous deletion while the mother (I.2) was 
heterozygous for the gene dosage variation and the father (I.1) was normal (Figure 30). 
Deletions of the exon 2 in AR gene, as well as partial gene deletions containing exon 2 
or complete deletions of the gene, have been previously described in patients with a 







Figure 30. Results of the QMPSF assay in GN0041 family showing the deletion of exon 2 in AR gene. A, 
complete deletion of exon 2 in AR gene happening in the index patient and in her sister, both diagnosed 
with CAIS. B, the peak at 144pb revealls a heterozygous deletion of exon 2 and a 46,XX karyotype in the 
mother of the index patient. 
 
 
10.4.2.2. SRD5A2 gene  
 
We identified recessive mutations in the SRD5A2 gene in two patients.  
 
Proband individual in family GN0046 was a female in which a bilateral 
gonadectomy was performed during the first years of life after echography had 
revealed the presence of inguinal testes. Immature testes and deferent ducts were 
found. Karyotype was 46,XY. We found a heterozygous A to G transition located at 
c.377 in exon 2 of the coding SRD5A2 sequence, replacing a glutamine with arginine at 
position p.126 (c.377A>G; p.Gln126Arg). The same heterozygous variant was found in 
the healthy father. This change has been reported before (264). Because of the 
autosomal recessive inheritance of the gene we performed a QMPSF test to find a 
gene dosage variants and ensure the phenotype presented by the patient. We 
designed labelled primers for the 5 exons of the gene (Supplementary data 6) and 






p.(Met1_Arg94del)). Both parents were studied and did not carry the deletion, thus 
this variant is a de novo change in the patient (Figure 31). This deletion has been 
previously reported (265). Genetic findings demonstrated that the patient could fit in 
an androgen biosynthesis defect diagnosis due to a 5α reductase deficiency, instead of 
an AIS syndrome as firstly supposed.  
 
 




 Patient GN0186 was referred to clinician because of high stature at age 14 and 
elevated testosterone levels (Supplementary data 3). Two years later, this female 
presented with primary amenorrhea. Karyotype was 46,XY. At medical examination, an 
underdeveloped breast, pubarche at Tanner stage 4, hypertrophic erectile organ and 
two palpable masses in inguinal canal were noticed. Pelvic MRI showed two structures 
suggestive of testes in inguinal canal and a rudimentary vagina of 1cm. Biochemically, 
she presented normal gonadotropins with a testosterone of 4ng/dL and high AMH 
(471ng/mL) levels. NGS revealed the c. 271T>G> p.Tyr91Asp change in homozygosis in 
the exon 1 of the SRD5A2 gene. Both healthy parents were studied and carried the 
variant in heterozygosis. This variant has been associated to steroid 5 alpha-reductase 
type 2 deficiency (266).  
 
10.4.2.3. LHCGR gene 
 
We found 6 cases harbouring different variants in LHCGR gene, 5 were 
missense variants and one patient presented a whole gene deletion. Among them, 3 
patients were referred to clinician due to a suspicion of precocious puberty and 
activating mutations were therefore found. In contrast, inactivating variants were 






10.4.2.3.1. Gene sequencing in patients with precocious puberty  
 
The first case (GN0068) presented precocious puberty at 3.5 years and family 
history of the disease. Patient GN0088 was also noticed at age 3 to have pubarche, 
penis and testes growth and high stature. 6 months later, he was 112cm tall, had 6mL 
testes and pubertal penis. Magnetic Resonance Imaging (MRI) showed a doubtful 
image of a pituitary adenoma. Gonadotropins and testosterone were elevated after 
leuprolide. Few months later, testes were 6 to 8mL and he had grown 3cm in 2 
months. He began treatment with triptorelin for 28 days. MRI was repeated and 
adenoma was discarded. At 4.5 years of age began treatment with ketoconazole. 
When he was 5 years old, pubarche started to diminish and no axilarche was noticed. 
Penis was 2.5cm and testes 8mL. Treatment with triptorelin was stopped and the dose 
of ketoconazole was elevated. Candidate gene sequencing revealed the heterozygous 
c.1713G>T; p.Met571Ile and c.1193T>C; p.Met398Thr in the LHCGR gene in cases 
GN0068 and GN0088, respectively. The father of patient GN0068 was also a carrier of 
the mutation, however no clinical information was provided. On the contrary, genetic 
study of the parents of patient GN0088 showed that the change was de novo. These 
two mutations have been previously described in the same phenotype (267, 268).  
 
Index case GN0157 was born in Equatorial Guinea and was referred to clinician 
due to the presence of adrenarche when he was 6 years old. Genital development was 
Tanner 2 and testicular volume 2-3mL. One year later, growth speed was realized as 
well as acne and body odour. Testes were 1-2mL. At this stage pathology of the 
adrenal gland was discarded and abdominal scanner was normal. At 9 years of age, he 
was at Tanner 3 and testes were 3mL. Genetic study showed the heterozygous 
cytosine to adenine change in position c.568 (c.568C>A; p.Gln190Lys). This variant has 
not been described before and the protein region is highly conserved (Supplementary 
data 14). We classified the variants as likely pathogenic. Family studies showed that 
the father is a carrier of the variant.  
 
10.4.2.3.2. NGS and aCGH to study other phenotypes caused by a 
LHCGR gene variant 
 
We detected variants in LHCGR gene in another 3 individuals presenting with 
different phenotypes. Patient GN0147 was born as a female in Algeria and at 7 years of 
age had surgery because of a right inguinal hernia. Histology revealed it was a normal 
teste. She was referred to clinician in her birth country due to primary amenorrhea 
and provided reports with ovarian and uterine agenesis. Thelarche was spontaneous 
when she was 13-14 years old. The patient always had male identity. At 24 years of 
age, the patient presented left inguinal hernia which was a normal teste. When he 




hypergonadotropic hypogonadism was observed (T: 0ng/mL after gonadectomies) and 
US revealed vaginal outline, without uterus and annexes. At 35 years of age, patient 
presented ambiguous external phenotype, thelarche II-III, female external genitalia, 
buried erectile organ and an opening for urethra and vagina. Hormonal analysis still 
indicated a hypergonadotropic hypogonadism (Supplementary data 3). Due to the 
suspicion of AIS, AR gene was studied first but no variants were found. We found by 
NGS the c.757T>C; p.Ser253Pro variant in LHCGR in a homozygous state. Prediction 
software programs and comparison of the proteins revealed that the region is highly 
conserved (Supplementary data 14). Therefore, the identified LHCGR gene variant was 
predicted as pathogenic. This prediction was confirmed by testing the transcriptional 
activity of the variants in vitro. 
 
Patient GN0171 has been described before due to the presence of a novel 
GATA4 gene VUS variant. We also found in LHCGR the reported 
c.1660C>T;p.Arg554Ter substitution in heterozygosis (269). The mother of the patient 
did not present this change. The deleterious effect of the alteration was confirmed in 
the expression studies we performed (See 10.5, page 200). 
 
A last patient was diagnosed with a LH receptor defect by the customized gene 
panel and validated then by aCGH. Patient GN0034 was noted to have bilateral 
inguinal hernia at 8 months of age. Her phenotype was female with normal external 
genitalia. After herniorrhaphy, testicular tissue was found. Absence of upper vagina 
and uterus was noticed. Her testosterone levels were undetectable with normal levels 
of gonadotropins (LH: 2mU/mL and FSH: 1mU/mL) (Supplementary data 3). AIS was 
suspected and karyotype was confirmed to be 46,XY. At 4 years of age, an 
echocardiography demonstrated the lack of uterus and ovaries. At 9 years old, 
biochemical and hormonal studies revealed high levels of testosterone with 
undetectable LH. After puberty gonadotropins, testosterone (60ng/dL) and 
dihydrotestosterone (0.4ng/mL) increased. After gonadectomy, the patient began 
treatment with oestradiol, and two years later at medical consultation (15 years old) 
normal pubarche and thelarche was noticed. AR gene was first studied by Sanger 
sequencing and then, NR5A1, HSD17B3 and SRD5A2 were discarded. Finally, it was 
analysed by the customized gene panel where we found that the LHCGR gene had not 
been covered. PCR of all the exons was done with no amplification of the regions. We 
made an aCGH and found a 77.45kb deletion in the short arm of chromosome 2 
(2p16.3) from base pairs 48,905,663 to 48,983,208 (Figure 32). Genes located in this 
region included LHCGR, among others as GTF2A1L (General Transcription Factor IIA 
Subunit 1 Like) or STON-GTF1A1L. The absence of the entire LHCGR gene has been 
previously reported by Richard et al in 2011 (270). Unfortunately, DNA samples from 










10.4.2.4. CYP17A1 gene 
 
We found a unique variant in the CYP17A1 gene in the RE0045 family. This 
index female patient presented at puberty with primary amenorrhea and lack of 
pubertal development. Karyotype was 46,XY. She had presented high blood pressure 
since childhood. At 17 years old, she was diagnosed with a bilateral 
pheochromocytoma and a left adrenalectomy was performed later that year. Histology 
revealed a left adrenal gland of 25g and 5.5x 5cm in size and indicated an adrenal 
cortical and medullar hyperplasia. After surgery blood pressure was normalized and 
urinary catecholamines values descended and have been maintained normal. In order 
to discard a medullary thyroid carcinoma, and then a Multiple Endocrine Neoplasia 
type II (MEN2), basal calcitonin levels and the response to pentagastrin stimulation 
studies were performed every year. In 1999, at the age of 19 pentagastrin test is 
considered pathologic and a total thyroidectomy is done. The consequent pathological 
anatomy is compatible with the hyperplasia of parafollicular C cells of the thyroid 
gland. Since then, patient has been receiving thyroid hormone replacement therapy 
and during the following years has presented normal urine values of noradrenaline and 
normetanephrine. An abdominal CT scan was performed when the patient was 25 
years old, which revealed a normal right adrenal gland and left adrenal nodule of 
8mm, suggesting an atrophic kidney. At 32 years old, she was gonadectomised and 
biopsy showed immature testes with Leydig’s cell hyperplasia. No uterus was 
observed. The genetic study of RET (REarranged during Transfection) protooncogene 
(OMIM 164761) was negative. Alterations in NR5A1, AR and WT1 had been previously 
ruled out.  
 
Remarkably, the older sister (II.1) of the index case was referred to clinician at 
age 17 with primary amenorrhea and absence of pubertal development due to a 
hypergonadotrophic hypogonadism. Karyotype was 46,XX. She had uterine corpus 
agenesis and cervix hypoplasia and was therefore treated with oestrogens. At 28 years 
of age, she was noted to have elevated blood pressure. Left and right side 




the presence of bilateral adrenal hyperplasia. MEN2 was discarded. Genetic analysis of 
WT1 and RET genes were negative.  
 
DSD targeted gene panel sequencing identified a homozygous CYP17A1 
c.1246C>T (p.Arg416Cys) nucleotide change in the index case (II.2). This variant has 
been previously listed by Takeda et al in 2001 in a patient presenting a defect in 
17alpha-hydroxylase (271). The patient’s affected sister (11.1) had the same variant in 
homozygous state. Mother (I.1), younger sister (II.3) and her 15 years old-twin 
daughters (III.1 and III.2) were carriers of the same heterozygous CYP17A1 variant 
(Figure 33). Sample of the father was not available. 
 
 




10.4.2.5. HSD17B3 gene 
 
 We only found one mutation in the HSD17B3 gene, encoding for 17-beta 
hydroxysteroid dehydrogenase 3. The proband (GN0038) was born with female 
external genitalia and was assigned female at birth, although foetal karyotyping was 
performed because of parent’s consanguinity and indicated a 46,XY karyotype. When 
the individual was 10 years old, voice and changes in external genitalia were noticed. 
At examination, she presented hypertrophic clitoris and palpable gonads at inguinal 
canal which Magnetic Resonance Imaging (MRI) confirmed as possible testes. Vagina 
was small (2cm). Laparoscopy showed the absence of female genitalia. Later, 
clitoroplasty was performed and gonadectomy of both testes. She began treatment.  
  
Sanger sequencing study was done and revealed a C to T change in position 
c.845 (c.845C>T) with produced a proline to leucine modification at the protein level 




reported by Andersson et al in 1996 (130). The mother of the patient was a carrier of 
the same variants while father could not be analysed.  
 
10.4.2.6. STAR gene 
  
Two missense variants were found in the STAR gene in patients GN0185 and 
GN0028.  
 
The GN0185 newborn was referred after birth because of ambiguous genitalia 
(Supplementary data 2). This “female” presented with a small penis (1.5cm) and a 
midshaft hypospadias. Labia majora were well feminized but vagina was blind. Right 
gonad was palpable in inguinal canal. Karyotype was 46,XY. A small vagina and 
hypoplastic uterus displaced to the left (2x0.8x0.8) were identified by MRI. 
Laparoscopy showed a normal vagina in size and a small uterus which continuous to 
the right with a fallopian tube ending in a testis in inguinal canal, and to the left the 
fallopian tube encloses a small streak gonad. Hormonal studies at presentation 
revealed more or less normal values (compared to male age-controls), only elevated 
17-hydroxiprogesterone and progesterone was remarkable (Supplementary data 3). 
One year later, both gonads were removed and showed a left streak ovary and a right 
dysgenetic teste. Clitoroplasty and vaginoplasty was also done. At recent follow up, 
she presented a slight pubertal development (11 years old) and the induction of 
puberty is planned. We identified a heterozygous guanine to timine nucleotide change 
at position 50 (c.50T>G; p.Met17Arg) in exon 1 of the STAR gene by NGS. Moreover, 
the father of the patient presented the same change in heterozygosis.  
 
Regarding the STAR gene variant observed in patient GN0028, see 10.4.3. 
 
10.4.3. Identification of additional gene variants 
 
A total of 4 patients had more than one variant in a DSD-related gene (Table 
17). Three of these patients had a 46,XY karyotype while the other (GN0198) had 
46,XX. Interestingly, two individuals (GN0028, GN0042) had a pathogenic variant in 
NR5A1 in combination with changes in genes acting in gonadal differentiation. On the 
other side, subject GN0171 harboured a pathogenic LHCGR gene mutation and a novel 
missense variant in GATA4. 
 
Regarding GN0028 male, targeted gene panel sequencing revealed a second 
variant in addition to the NR5A1 gene change. The novel, heterozygous C to T change 
at position 361 (c.361C>T; p.Arg121Trp) of the STAR gene was found in the patient and 
his father. As no STAR gene variants related to an isolated DSD phenotype have been 




prediction tools and amino acid conservation studies estimated as deleterious 
(Supplementary data 14). Patient (GN0042) had a known variant in NR5A1, but we also 
found the heterozygous c.428C>T; p.Thr143Ile VUS variant in the testis development 
gene AMH. The mother of the patient did not harbour the sequence changes. Although 
prediction software and conservation studies lead to a non-pathogenic effect 
(Supplementary data 14), it is well known that SF1 regulates in Sertoli cells the 
expression of AMH gene and would fit with the phenotype found in this subject.  
 
 
Table 17. Individuals with additional variants identified by NGS.  
 
Family Gene Variant Classification 
GN0028 
NR5A1 C.88T>A; p.Cys30Ser Pathogenic 






AMH c.428C>T; p.Thr143Ile VUS 
GN0171 
LHCGR c.1660C>T; p.Arg554Ter Pathogenic 
GATA4 c.677C>T; p.Pro226Leu VUS 
GN0198 
ESR1 c.1781C>T; p.Thr594Met VUS 
HSD17B4 c.524delC; p.Ala175GlufsTer26 VUS 
VUS, variant of unknown significance. 
 
 
Patients GN0171 has been previously described (See 10.4.1.6, page 178). 
 
Among the patients with a 46,XX DSD, only GN0198 was found to have two 
variants of unknown significance in ESR1 and HSD17B4 gene. NGS showed in patient 
GN0198 the deletion of a cytosine in position c.524 (c.524delC) which leads to the 
substitution of an alanine and a change in the reading frame of the protein 
(p.Ala175GlufsTer26) in heterozygosis in HSD17B4 gene. The mother of the patient is a 
carrier of this variant, located in exon 8 of the gene. GN0198 case also harboured a 
novel VUS variant in ESR1. We classified the variant as a VUS. Despite the effect that 
this change could cause in the length of the protein, no mutations have been related 
to 46,XX gonadal dysgenesis up to date. HSD17B4 gene variants have been described 
in D-bifunctional protein deficiency and Perrault syndrome, a condition that alters 
hearing loss and causes abnormalities in ovaries. Two alterations have been associated 
to premature ovarian failure too (225). 
 
10.4.4. Family studies and familial cases of DSD 
 
We were able to achieve at least one first degree family member of 37 patients 





Nine families among the familial cases described in our cohort presented an 
alteration in a DSD-related gene, however we could only study 5 families (Table 18). 
The two siblings in family GN0007 had gonadal dysgenesis and a hemizygous nonsense 
variant in the SRY gene. Moreover, the same pathogenic mutation in the AR was 
identified in the sister of index case GN0041, who presented identical phenotype. 
Regarding GN0075 family, 3 affected members harboured a reported variant in NR5A1. 
An activating mutation in the LHCGR gene was found in the GN0068 proband and his 
father, with family history of precocious puberty. Finally, the two affected siblings with 
gonadal dysgenesis in family RE0045 presented a homozygous missense mutation in 
CYP17A1 gene. Although other familial cases of DSD were referred to the clinician, we 
were not able to study the affected family members (GN0078, GN0142, GN0177 and 
GN0186). A summary of the genetic findings in the affected and non-affected family 
members is shown in Supplementary data 15.  
 
In other familial cases, no DSD-related variant was found.  
 
 
Table 18. Analysed familial cases with a genetically positive variant 
 
Case Gene variant Affected family members 




Index case and sister 
GN0068 LHCGR, c.1713G>T; p.Met571Ile Index case and father 
GN0075 NR5A1, c.250C>T; p.Arg84Cys 
Index case, mother, aunt 
and uncle 
RE0045 CYP17A1, c.1246C>T; p.Arg416Cys Index case and sister 
 
 
10.4.5. Yield of identified variants  
 
Sequencing was carried out in the total DSD cohort (125 independent patients). 
At the beginning genetic analysis was done by a candidate gene approach. After the 
implementation of NGS in 2015, patients referred with a DSD were analized using a 
targeted gene panel as well as previous patients with negative results. In total, 89 
patients were analysed by targeted panel (Figure 34). 
 
Totally, we made a DSD-associated genetic finding in 53 patients (41.6%). 
Among these positive cases, 36 (69.2%) were identified by a candidate gene approach 
by PCR-based sequencing, aCGH, QMPSF or MLPA technique. The DSD panel provided 
a molecular diagnosis in 17 out of 89 patients (19.1%) tested by NGS with an unknown 




the total observations, clinically relevant rare variants were reported if the filtering 
process classified them as pathogenic or likely pathogenic (229), the variant was 




Figure 34. Schematic representation of the molecular study in the DSD cohort. Number of patients is 
given in cicles.  
 
 
The diagnostic yield for this panel is therefore 17/89 for all samples. This yield is 
increased up to 22.0% for 46,XY DSD (15/68) while it only provided a molecular 
diagnosis in 10.5% of 46,XX DSD individuals (2/19). Variants of unknown significance 
were found in 11 patients (12.3%) and then, diagnosis could not be confirmed because 
of the ambiguity around the variant.  
 
Several variants were identified in the remaining 61 patients, but none showed 
consistency with the phenotype or inheritance mode of the individuals. In these cases, 




patients in whom the Gly146Ala protein change in the NR5A1 gene was observed. 
Although these cases are not discussed in this work they are being further studied.  
 
10.4.6. Clinical diagnosis after molecular studies 
 
 After molecular analysis, initial diagnosis changed in some patients in which a 
pathogenic or likely pathogenic variant was identified.  
 
Disorders of testicular development were suspected in 47 probands. In 4 out of 
17 of those with a complete gonadal dysgenesis this was supported by the identified 
gene variant. On the other side, 22 patients presented with a suspected partial 
gonadal dysgenesis and only two cases were found to be genetically consistent. An AR 
gene variant was found in another index case. Two patients referred as gonadal 
dysgenesis were then reassigned to the androgen biosynthesis defect group due to the 
detection of SRD5A2 and CYP21A2 gene variants (Table 19), while in another case 
diagnosis was reinforced. The only case with an ovotesticular suspicion presented an 
AR variant and was therefore classified as AIS, however, none of the patients with 
gonadal regression harboured a gene variant. Twenty-one patients were categorised 
as AIS (Complete, partial or AIS), however an AR defect was only found in 12 of these 
cases and 4 had another variant. Disorders of androgen synthesis were confirmed in 
one patient with a HSD17B3 deficiency suspicion and in three patients with luteinizing 
hormone defects and activating mutations in LHCGR gene. Regarding the group 
classified as others, adrenal insufficiencies were confirmed with the detection of 
NR0B1 gene changes, as well as 3 out of 4 pathologies related to the WT1 gene (Denys-
Drash and Frasier syndrome). Among those individuals with a clinical suspicion of 
anorchia, cryptorchidism or 46,XY DSD, the genetic aetiology was set in 4 out of seven 
patients leading diagnosis to AIS in the case of anorchia suspicion, and three cases of 
46,XY DSD to gonadal dysgenesis and LH-receptor defect. Overall, a genetic alteration 
was determined in 21.7% of those with a suspected disorder of testicular development 
(Table 20, page 198), 70.3% of those with a disorder of androgen synthesis or action 
and 62.5% of those classified as others. 
 
All the individuals with a suspected 46,XX testicular DSD were genetically 
confirmed. Furthermore, two patients with a primary cause of 46,XX DSD had a SRY 
translocation and a likely deleterious change in ESR2 gene and were reassigned to 
46,XX testicular DSD and ovarian dysgenesis, respectively. The remaining cases with a 
46,XX karyotype and gonadal dysgenesis, Mayer-Rokitansky-Küster-Hauser (MRKH) 
syndrome or OT DSD were not confirmed. Overall, 36.8% of patients referred with a 






Table 19. Classification of our DSD cohort at clinical diagnosis and after molecular study in 
accordance to the Consensus statement on intersex disorder (172). Number of patients with a 
















Disorders of testicular development 
Complete gonadal dysgenesis 17 19  
Partial gonadal dysgenesis 22 23  
Gonadal dysgenesis 4 1  
Gonadal regression 3 3  
Ovotesticular DSD 1 0  
Total 47 46 10 (21.7) 
Disorders in androgen synthesis and action 
Androgen biosynthesis defect 6 9  
Defects in androgen action 21 21  
LH receptor defects 5 7  
Total 32 37 26 (70.3) 
Others 
Frasier and Denys-Drash syndromes 4 4  
Severe hypospadias 2 2  
Primary adrenal insufficiency 7 7  
Unknown 7 3  
Total 20 16 10 (62.5) 








Disorders of ovarian development 
Ovotesticular DSD 3 3  
Testicular DSD 6 6  
Gonadal dysgenesis 8 8  
Total 17 17 6 (35.3) 
Androgen excess 
Total 0 0 0 (0) 
Others 
MRKH syndrome 3 3  
Unknown 4 4  
Total 7 7 0 (0) 







 45X/46,XY, mixed gonadal 
dysgenesis 
2 2 0 (0%) 
Total Sex chromosome DSD 2 2 0 (0%) 
 Total DSD 125 125 53 (42.4%) 









Affected gene Results reported 
Diagnosis after molecular 
study 
GN0004 46,XX T DSD SRY Consistent with clinical features 46,XX T DSD 
GN0007 46,XY DSD CGD SRY Confirmed diagnosis 46,XY DSD CGD 
GN0009 Frasier syndr WT1 Consistent with diagnosis Frasier syndr 
GN0011 46,XY DSD CGD MAP3K1 Confirmed diagnosis 46,XY DSD CGD 
GN0018 46,XY DSD PGD AR Consistent with clinical features 46,XY DSD CAIS 
GN0023 46,XX T DSD SRY Consistent with clinical features 46,XX T DSD 
GN0024 46,XY DSD AR Consistent with clinical features 46,XY DSD PAIS 
GN0028 46,XY DSD NR5A1 Consistent with diagnosis 46,XY DSD PGD 
GN0034 46,XY DSD AIS LHCGR Consistent with clinical features 46,XY DSD LH RD 
GN0035 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0037 46,XY DSD PAIS AR Consistent with clinical features 46,XY DSD PAIS 
GN0038 46,XY DSD ABD HSD17B3 Confirmed diagnosis 46,XY DSD ABD 
GN0041 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0042 46,XY DSD AIS NR5A1 Consistent with clinical features 46,XY DSD CGD 
GN0046 46,XY DSD AIS SRD5A2 Consistent with clinical features 46,XY DSD ABD 
SRD5A2 
GN0054 46,XX T DSD SRY Consistent with clinical features 46,XX T DSD 
GN0055 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0068 46,XY DSD LH RD LHCGR Supports diagnosis 46,XY DSD LH RD 
GN0075 46,XY DSD NR5A1 Consistent with clinical features 46,XY DSD PGD 
GN0076 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0078 PAI NR0B1 Confirmed diagnosis PAI 
GN0080 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0088 46,XY DSD LH RD LHCGR Supports diagnosis 46,XY DSD LH RD 
GN0091 PAI NR0B1 Consistent with diagnosis PAI 
GN0101 PAI NR0B1 Supports diagnosis PAI 
GN0109 46,XY DSD GD NR5A1 Confirmed diagnosis 46,XY DSD CGD 
GN0111 46,XY DSD CGD NR5A1 Confirmed diagnosis 46,XY DSD CGD 
GN0112 46,XY OT DSD AR Consistent with clinical features 46,XY DSD CAIS 
GN0123 46,XY DSD PGD NR5A1 Consistent with diagnosis 46,XY DSD PGD 
GN0125 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0132 Frasier syndr WT1 Consistent with diagnosis Frasier syndr 
GN0133 46,XX T DSD SRY Consistent with clinical features 46,XX T DSD 
GN0139 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0141 46,XY DSD CGD SRY Confirmed diagnosis 46,XY DSD CGD 
GN0146 46,XY DSD PAIS AR Confirmed diagnosis 46,XY DSD PAIS 
GN0147 46,XY DSD AIS LHCGR Consistent with clinical features 46,XY DSD LH RD 
GN0153 PAI NR0B1 Confirmed diagnosis PAI 
GN0157 46,XY DSD LH RD LHCGR Supports diagnosis 46,XY DSD LH RD 
GN0159 46,XX T DSD SRY Confirmed diagnosis 46,XX T DSD 
GN0164 46,XY DSD LH RD AR Consistent with clinical features 46,XY DSD AIS 
GN0171 46,XY DSD LHCGR Consistent with clinical features 46,XY DSD LH RD 










Affected gene Results reported 
Diagnosis after molecular 
study 
GN0177 46,XY DSD CAIS AR Consistent with clinical features 46,XY DSD CAIS 
GN0186 46,XY DSD GD SRD5A2 Supports diagnosis 46,XY DSD ABD 
GN0187 46,XX T DSD SRY Confirmed diagnosis 46,XX T DSD 
GN0189 46,XY DSD CAIS AR Confirmed diagnosis 46,XY DSD CAIS 
GN0194 46,XY DSD AIS AR Confirmed diagnosis 46,XY DSD AIS 
GN0203 46,XY DSD PGD WWOX Consistent with clinical features 46,XY DSD PGD 
GN0207 46,XX DSD ESR2 Consistent with clinical features 46,XX DSD 
OT0567 Denys-Drash syndr WT1 Consistent with diagnosis Denys-Drash syndr 
POL0274 PAI NR0B1 Consistent with clinical features PAI 
POL0285 PAI NR0B1 Confirmed diagnosis PAI 
POL0301 PAI NR0B1 Confirmed diagnosis PAI 
RE0045 46,XY DSD GD CYP17A1 Consistent with clinical features 46,XY DSD ABD 
ABD, androgen biosynthesis defect; AIS, androgen insensitivity syndrome; CAIS, complete androgen 
insensitivity syndrome; CGD, complete gonadal dysgenesis; DSD, disorder of sexual development; GD, 
gonadal dysgenesis; OT, ovotesticular; PAI, Primary adrenal insufficiency; PAIS, partial androgen 




Due to the uncertainty around the pathogenicity of VUS variants initial clinical 
diagnosis could not be confirmed in such patients (Table 21).  
 
 
Table 21. Detail of the patients with a variant of unknown significance (VUS). 
 
Case Suspected clinical diagnosis Affected gene Results reported 
GN0020 46,XY DSD GD WWOX Consistent with clinical features 
GN0028 46,XY DSD STAR Variant found in addition to NR5A1 
GN0042 46,XY DSD AIS AMH Variant found in addition to NR5A1 
GN0142 46,XY DSD GD DMTR2 Consistent with clinical features 
GN0150 46,XY DSD AIS WT1 Consistent with clinical features, not with diagnosis 
GN0154 46,XX DSD GD MAMLD1 Conflicting evidence 
GN0155 46,XY DSD AIS ZFPM2 Consistent with clinical features, not with diagnosis 
GN0156 46,XY DSD LH RD WT1 Conflicting evidence 
GN0171 46,XY DSD GATA4 Variant found in addition to LHCGR 
GN0185 46,XY DSD GD STAR Consistent with clinical features 
GN0198 46,XX DSD 
HSD17B4 Consistent with clinical features 
ESR1 Consistent with clinical features 





10.5. IN VITRO FUNCTIONAL STUDIES 
 
Transcriptional activity of different variants located in GATA4, NR5A1 and 
LHCGR genes was tested to elucidate its potential pathogenic role in the development 
of the disease. 
 
10.5.1. Functional characterization of the GATA4 transcription factor 
 
In the literature, a single GATA4 variant found in a patient with DSD and CHD 
(congenital heart defect) has been characterized before (27). The p.Gly221Arg variant, 
located in the N-terminal zinc finger domain of GATA4, had impaired transactivation 
activity on the AMH promoter.  
 
Priorization of variants detected by NGS in our cohort revealed a novel GATA4 
gene variant in heterozygosis in patient GN0171. In silico programs predicted the gene 
variant c.677C>T; p.Pro226Leu as likely pathogenic and comparison of the amino acid 
among different species indicated that the region is highly conserved. This suggested 
the importance of the residue in the protein. Then, we decided to study the impact of 
the Pro226Leu variant in the transactivation capacity of GATA4 in vitro, and compared 
to the Gly221Arg mutant.  
 
10.5.1.1. Transactivation capacity of GATA4 in JEG3 cells 
 
Previously, co-transfection of the GATA4 expression construct and the AMH 
and SRY-reporter genes promoters had been carried out in different cell models (25) 
but only JEG3 cells transfected with CYP17 promoter revealed consistent results. 
Functional activity was tested by studying transactivation of wt and mutant GATA4 on 
the CYP17A1 promoter in JEG3 cell systems (Figure 35). 
 
Transfection of human placental JEG3 cells with wt and GATA4 mutant together 
with the CYP17A1 promoter reporter construct indicated that the Pro226Leu variant 
activated the CYP17 promoter similar to wt, while Gly221Arg mutant lost 
transcriptional activity.  
 







Figure 35. Transcriptional activity of GATA4 variants on the CYP17A1 promoter. JEG3 cells were 
transfected with a CYP17 promoter luciferase reporter construct, and the activity of wild type (wt) and 
mutant GATA4 to transactivate the promoter was tested using the Promega Dual Luciferase readout 
system. Results are shown as the mean ± SEM of four independent experiments, all performed in 
duplicate. **p-Value ≤ 0.01. RLU, relative light units; wt, wild type. 
 
 
10.5.2. Functional characterization of the novel NR5A1 variants 
 
Many patients with NR5A1 variants have been studied widely, although no 
clear genotype-phenotype correlation has been found already. We describe 3 novel 
NR5A1 variants (c.71A>T; p.His24Leu, c.88T>A; p.Cys30Ser and c.902G>A; p.Cys301Tyr) 
found in three 46,XY DSD patients. Comparison of the residues against multiple species 
indicated its high conservation and in silico programs predicted them as likely 
pathogenic.  
 
10.5.2.1. Promoter transactivation studies 
 
To study the impact of the three changes to the transactivation faculty of SF1 in 
vitro, HEK293 cells were cotransfected with wt or mutant NR5A1 expression construct 
and a responsive CYP17A1, HSD17B3 and CYP11A1 reporter genes. 
 
As shown in Figure 36, all NR5A1 mutants led to a significant reduced 
transactivation of the CYP17A1 promoter. These results were confirmed for the 
His24Leu and Cys30Ser mutants when transactivating the constructs with the CYP11A1 
and HSD17B3 promoter stimulation similar to the CYP17A1 promoter. However, for 







Figure 36. Functional studies of the 3 novel NR5A1 variants. The ability of wt and mutant NR5A1 to 
activate promoter luciferase reporter constructs was tested in HEK293 cells (A-C). Cells were transiently 
transfected with NR5A1 expression vectors and promoter reporter contructs CYP17A1 (A), HSD17B3 (B) 
and CYP11A1 (C). Results are shown as the mean±SEM of five independent experiments, all performed 
in duplicate. D, Western blot showing expression of wt and mutant SF1 proteins. HA antibody 
recognized Hemagglutinin-tagged SF1 in the western blot (band at 53 KDa). B-actin was used as a 
control (band at 42 KDa). **p-Value ≤ 0.01. Ha, hemagglutinin; RLU, relative light units; Ve, empty 
vector; wt, wild type. 
 
 
10.5.2.2. Protein expression of NR5A1 variants 
 
Expression of NR5A1 variants in HEK293 cells was assessed by a western blot. 
Cells were cotransfected with the NR5A1 expression vectors containing a HA-tag, then 
the western blot was performed using an antibody against HA. As shown in Figure 32, 
we found no difference for SF1 protein expression for the tested variants compared to 
wt. 
 
10.5.3. Signal transduction of the LHCGR gene variants 
 
We analysed in vitro two possible LHCGR variants found in patients GN0147 
and GN0171. The novel missense c.757T>C variant, replacing a serine with proline at 
position p.253 was found in homozygous state in patient GN0147, while the 
c.1160C>T;p.Arg554Ter gene variant appeared in heterozygosis in GN0171 case. 
Although this last variant had been reported previously (269), functional impact was 





HEK293 cells were transfected with either wt or mutant pSG5 plasmids and a 
luciferase reporter gene to evaluate the functional impact. As the LHCGR couples to Gs 
alpha subunit to mediate its functions, we assayed the measure of the second 
messenger cAMP. We used a reporter gene system of the cAMP response element 
fused to firefly luciferase (CRE-luc) and cells were then analysed for their 
responsiveness to different hCG doses (0ng/ml to 100,000ng/ml). The generation of 
cAMP directly correlates with the activation of the CRE-luc reporter system. 
  
We found that cells transfected with HA-tag and expression vector showed no 
cAMP generation in response to the increasing tested concentrations of hCG, unlike 
the cells expressing the wt LHCGR receptor (Figure 37). 
 
 
Figure 37. cAMP generation by the wt and the two distinct LHCGR mutants. HEK293 cells were 
transfected with a pSG5 plasmid carrying either a HA-tagged wt or a HA-tagged mutant (Arg554Ter and 
Ser253Pro). Cells were stimulated with hCG at different doses and the generation of cAMP was tested 
using the Promega Dual Luciferase readout system. Each data point represents the mean±SEM of three 
independent experiments, carried out in duplicates. cAMP, cyclic adenosine monophosphate; hCG, 



















In 2006, at the Chicago consensus conference a new term to include the 
confusing intersex, sex reversal, hermaphroditism and pseudohermafroditism words 
was created. Such term, DSD, encompasses a range of conditions and avoids mistakes 
with terms like gender dysphoria or transgender. When genetically caused, reaching a 
molecular diagnosis supports the management of the patient concerning to gender 
development, gonadal and adrenal function or other long-term consequences. Since 
the development of High-throughput screening (HTS) technologies, the understanding 
of the genetic basis of rare human disorders, including DSD, has increased. 
 
The main objective of this work was the clinical characterization and the 
molecular diagnosis of an extent cohort of patients with a disorder of sex development 
either by a candidate gene approach or using next generation sequencing 
technologies. A targeted gene panel was designed to include genes associated with 
gonadal development and differentiation, as well as hypogonadism. Hereafter I discuss 
about the capacity of the customized gene panel as a disgnostic tool. Then, I analyse 
the phenotype-genotype correlations and the results of the in silico and in vitro 
functional studies of the sequence variants found in NR5A1, LHCGR and GATA4.  
 
DSDs represent a major paediatric concern and a difficult clinical management 
that might be associated with infertility or cancer. The correct diagnosis of DSD is 
challenging and may be requested due to a family history of DSD or a phenonotypic 
presentation suggesting the disorder. Clinical care requires a multidisciplinary team 
that includes endocrinology, either paediatric or adult since diagnosis ranges from 
prenatal to adolescent or adults, urology or gynaecology, radiology, pathology in some 
cases and genetics (174). An important part of the evaluation of the DSD patients is the 
bioquemical analysis.  
 
Although steroid hormone testing has been used in the past as the first 
approach to guide the diagnosis, currently is combined with molecular genetic 
analyses. Hormonal analyses in blood or urine provide differences in the phenotypic 
expression and offer a fast differential diagnostic orientation. For example, in 
congenital adrenal hyperplasia it has shown to have a good phenotype-genotype 
correlation as the quantification of numerous steroid detects rare forms of steroid 
synthesis disorders. The bioquemical analysis is important for the initial diagnosis of 
DSD but is also critical to ensure the greatest development at puberty and at hormone 
replacement treatments (272). It is important to note that in DSDs the homone data 
interpretation needs to considerate the clinical presentation of the patients and has to 
be age- and sex- related. In healthy infants, a transient postnatal activation of the 
hypothalamic-pituitary gonadal axis occurs. This mini-puberty period represents an 
important diagnostic tool in clinical diagnosis of infants with a suspected disorder of 




Between the first week and the three months of life, gonadotropins rise and show an 
obvious sexual dimorphism. In males, predominant levels of LH elevate serum 
concentrations of testosterone, AMH and inhibin B, while in females FSH gives rise to 
oestradiol. The following months, concentrations decrease to prepubertal levels. Up to 
date, little evidence existed on the referenced ranges at this mini-puberty period 
which difficulted the evaluation of a child with DSD. Now, these ranges have been 
established (273).  
 
The molecular diagnosis provides guidance for clinical management and further 
risk, however achieving a genetic diagnosis is difficult due to the wide range of 
phenotypes that are encompassed in this group of anomalies, the poor genotype-
phenotype correlation and the limited knowledge of the pathogenesis that lead to 
DSD. Currently, 50% of 46,XY DSD patients do not receive a genetic diagnosis (12, 226), 
although other factors such as environment or epigenetic changes need to be consider 
also (140). For the elucidation of the genetic causes in DSD, the multiciscilinary team 
and current technologies should determine firstly the chromosomal sex of the 
individual. Depending on this, the case will be assigned to one of the three major DSD 
subclasses established in the Chicago Consensus (174) and together with clinical 
description, molecular diagnosis will be requested by using the most adequeate 
molecular testing.  
 
However it is ofter challenging to appropriately classify a DSD patient due to 
the difficulty to make a correct diagnosis. In this study, this was emphasized by the fact 
that as a multicentre study, clinical and hormonal data that we obtained from the 
included patients was highly variable or insufficient. In these cases, the molecular 
analysis prior to the implementation of NGS led to a poor specific gene study. On the 
other side, the analysis of these patients, classified as of unknown origin with the 
targeted gene panel pointed to a more clear DSD classification. In the group of 
unknown 46,XY DSD, 4 patients were reassigned to disorders of androgen synthesis or 
action after the identification of an AR and LHCGR gene variant and to disorders of 
testicular development due to alterations in NR5A1. Nevertheless, a scarce clinical 
description of the DSD patient drives to a more complicated management of the 
variants of unknown significance. An individual in the unknown 46,XX DSD cohort 
presented a sequence variant in ESR2 but was not further classified because 
prepubertal ovaries and not dysgenetic had not been reported in the patient. Others 
have illustrated the requirement of a more detailed biochemical and clinical data for a 
better understanding of the DSDs (274). To avoid these differences in the clinical 
descriptions of the patients presenting a DSD, standardized guidelines could be used, 
such as the External Genitalia Score (275) or recommendations already published as 




illustrated the requirement of a more detailed biochemical and clinical data for a 
better understanding of the DSDs (274).  
 
 
11. EVALUATION OF THE TARGETED GENE SEQUENCING PANEL 
 
We evaluated the performance of the customized panel as a diagnostic gene 
sequencing tool. We observed that 94.2% of the reads were aligned to the reference 
genome with a mean depth of 288.3 reads on targeted regions. Although the expected 
coverage for the targeted regions was 98.55% according to the Ion Ampliseq Designer 
tool, we observed that the coverage depth was variable among the different genomic 
regions. For the 48 DSD-related genes we found that 9.3% of the amplicons included in 
the panel were not covered in most of the samples or were covered by less than 20 
reads, an acceptable level for diagnostic use. An example of the latter is the complex 
sequencing of the CYP21A2 gene due to the high sequence homology with the 
CYP21A1P pseudogene.  
 
Coverage and targeting efficiency is positively comparable with other studies, 
using the same and other competing platform (12, 218) Current sequencing platforms, 
such as Ion Torrent or Illumina use short reads (<400pb) for mapping to the reference 
genome, which reduces costs and fastens the sequencing but fails to uniquely target 
the interesting region, Further analysis was done to study those regions without 
mapped or low amplified regions that were located within exons or exon boundaries. 
 
We also included previously sequenced samples to validate the assay quality. 
Panel sequencing did not detect a single one-nucleotide deletion in the first exon of 
the WT1 gene, located within an amplicon that failed to be read in all the samples. 
Therefore, sensitivity was set at 81.8%. Although others have included known point 
variants to ascertain the performance of the panel, the type of variant is not reported 
and comparison couldn’t be made.   
 
CNV were not completely analysed in this study. The customized gene panel 
failed to detect those rearrangements in patients included as positive controls, 
therefore few copy number gains or losses were broaden validated. Up to date, the 
detection of CNV is challenging when using gene panels and although a workflow can 
be standardized for its use with the Ion Torrent technology, a major expertise is 
required. For example, it is essential to include control samples without known CNV, as 
rearrangements will be reported based on their copy number gain or loss relative to 
the control samples. Four samples from patients with known point mutations in which 
commercial MLPA had ruled out a CNV were used as controls. However, the presence 




exhaustive genetic panel including CNV may improve from 9.1% to 29.8% the disease 
aetiology, as based on previous reports (28, 222, 276, 277). A specific defect of the Ion 
Torrent sequencing platform is given by the errors in the number of bases called when 
a nucleotide or a group of nucleotides are repeated more than once in a sequence 
(homopolymer errors) (278). Subsequently, alignment is misguided and false small 
deletions and insertions are called, increasing the false positives and hiding real indels. 
 
Even though the limitations related to the current next generation sequencing 
technologies or to the Ion Torrent platforms exclusively, we have shown that targeted 




12. CLINICAL AND MOLECULAR CHARACTERISTICS OF THE DSD COHORT 
 
For this study we have analysed DNA from 125 patients and 37 family members 
from DSD patients. Targeted gene panel sequencing together with single gene testing 
provided a genetic diagnosis in 42.4% of these individuals. 
 
Among the studied patients, 36 were genetically identified by a candidate gene 
approach and 89 underwent diagnostic testing for DSD using a 48-gene NGS panel. 
This panel was used for all the samples since 2015, unless a specific gene sequencing 
or aCGH analysis was requested based on the clinical features of the patient. The 
diagnostic yield of this targeted gene panel was shown to be 17/89 (19.1%) for all 
DSDs. Our detection rate is lower to those in previous studies (12, 81, 93, 217, 219, 
220, 279) but similar to that obtained by Fan Y et al (20.7%) (218). The molecular 
analysis in our cohort showed a total of 47 pathogenic and 7 likely pathogenic variants 
in known DSD genes. Among them, 14 were previously unreported, in addition to the 
12 VUS variants that were also identified. 
 
As in other publications, a separate analysis of the 46,XY DSD from the whole 
cohort results in an improved yield to 15/68 (22.05%). It is important to note that prior 
to the design and implementation of the customized gene panel, a big proportion of 
our DSD cohort had undergone genetic pre-screening (64.8%) in our laboratory, which 
definitely affects our overall diagnostic rate. We suppose that if we had applied the 
gene panel as the first diagnostic approach, we could expect our panel to provide a 
greater diagnostic percentage. On the other side, reaching a diagnosis essentially 
depends on the genes included in the panel. Our panel was designed in 2015 and the 
48 genes were selected due to published evidence of their role in DSD. Evidence has 
shown that a higher number of genes do not correlate with a better diagnostic rate. 




population by analysing 30 genes (219) and Kim et al reached a 29.5% including 67 
genes (93). Comparison of the genes in our panel against published genes in other 
customized panels showed a percentage of common genes from 17.8% (217), 60.9% 
(12) to 86.6% (219). This may highlight the importance of the selected patients to be 
analysed through the panel, rather than the genes included in the panel, as the major 
influence in the diagnostic rate.  
 
Sanger sequencing or testing with a MLPA or aCGH was done depending on the 
clinician’s judgement and following clinical examination. Disease-causative variants 
were detected in 36 out of the 81 DSD (44.4%) patients studied for a single test. The 
detection yield of single gene test is dependent on the first selected gene, limited to 
the phenotype of the patient and therefore to the clinical information given by the 
clinician. Those patients presenting a DSD with a clear phenotype-genotype correlation 
were successful after a single gene was sequenced, such as SRY in 46,XX testicular DSD 
or AR in AIS suspicion. Patients in which 3 or more genes (or MLPA) were studied had 
been mainly classified as 46,XY DSD with complete or partial gonadal dysgenesis, 
which highlights the heterogeneous molecular mechanisms underlying 46,XY DSD. 
 
We conclude that our gene panel is not useful for the molecular diagnosis of 
46,XX DSD, at least until the detection of CNVs is upgraded. Among previous studies 
including 46,XX DSD in their cohorts, massive parallel sequencing led to a diagnostic 
rate in these patients up to 25% (12, 93, 217-219).  
 
This is one of the largest cohorts of DSD patients analysed for a molecular 
diagnosis worldwide. To the best of our knowledge this is the first study in which 
patients with 45X0/46,XY karyotypes and mixed gonadal dysgenesis are included in a 
targeted gene panel to search for additional variations that explain the phenotype. 
Altogether this study demonstrated that 42.4% of DSD patients harboured pathogenic 
or likely pathogenic variants and positively increased the diagnostic yield reached by 
Fan Y et al who analysed 32 patients using a gene sequencing approach and a 
customized Ion Ampliseq panel (218). Currently, we are working to improve the 
detection of CNV with the gene panel. An increase in the number of control samples 
will optimize the workflow and expand the number of patients with a molecular 
diagnosis. The analysis of both point and big rearrangement in a single run by NGS 
would improve the use of the technique in a cost-effective mode. Otherwise, a range 
of methods have been developed to detect these type of genetic variants, such as 
MLPA or aCGH, and will be performed in those patients with negative genetic results in 
the near future.  
 
In our series, patients with 46,XY DSD (99, 79.2%) were more common than 




diagnostic rate was observed in patients with 46,XY DSD (46.5%), specifically in 
disorders of androgen synthesis and action (70.3%), in which described AR changes 
were found in several individuals with identical phenotypes (254-257, 260-262, 280).  
 
As in other populations (140), defects in AR were the most common cause of 
46,XY DSD in our cohort. We observed three novel AR variants (His100ProfsTer3, 
Pro276HisfsTer20, Leu881Arg). The two frameshift variants are likely to have no 
variable expressivity, and then result in a CAIS phenotype. In contrast, Leu881Arg, 
located in the ligand-binding domain of the receptor is expected to impair androgen 
binding capacity. In the same codon, another changes support this hypothesis (281, 
282) and together with the results shown by in silico analyses, it is believed to be the 
cause of the phenotype in our patient. Moreover, Gln825Lys variant, reported in males 
with gynecomastia and infertility (259) was identified in a case with different clinical 
features. However, previously done ligand-binding experiments showed a slight 
impairment of the mutated AR protein function (258), which could also explain the 
phenotype in our patient.  
 
Sequence changes in enzymes involved in steroidogenesis were also detected. 
We identified two novel VUS in STAR gene in two cases with discarded adrenal 
hyperplasia. Up to date, inactivating STAR variants led to lipoic congenital adrenal 
hyperplasia, resulting in adrenal insufficiency and 46,XY DSD, an autosomal recessive 
disease. Although a non-severe phenotype is expected from missense changes located 
outside exon 5 to 7 (283), we could hypothesize that heterozygous gene variants, in 
addition to a second hit, might exclusively affect foetal testicular synthesis without 
driving to an adrenal steroid deficiency. Indeed, patient GN0028 harboured a 
heterozygous variant in NR5A1 together with an unknown significance change in STAR 
gene.  
 
Further reported mutations were detected in SRD5A2, HSD17B3 and CYP17A1 
genes. A number of studies have associated the Gln126Arg change in SRD5A2 to 
severe phenotype of the enzyme deficiency in different individuals (264, 284-287), 
even in compound heterozygosity in four Brazilian patients (288). The deletion of exon 
1 in GN0046 was also found in an 46,XY athlete with blind vagina and lack of Müllerian 
ducts (265). Last variants in SRD5A2 gene (Tyr91Asp) and in HSD17B3 (Pro282Leu) 
were detected in homozygous state and patients were referred with identical 
phenotypes to those described before (130, 289). Finally, Arg416Cys in CYP17A1 was 
identified in a patient with 46,XY karyotype, primary amenorrhea, infantilism and 
hypertension. Her older sister, with similar clinical features and 46,XX karyotype also 
presented the mutation. Functional comparison of the wild type and transfected cells 




delay and hypertension. Additionally, both sisters were diagnosed of 
pheochromocytoma in their early adulthood. 
 
Nearly 20% of the 46,XY DSD with gonadal dysgenesis are thought to have an 
inactivating variants in the SRY gene (177). However, we only found two patients with 
hemizygous variants in SRY, which represents the 5.7% of the initially suspected cases 
with 46,XY gonadal dysgenesis. Together with the previously described Gln97Ter 
variants in the HMG domain of SRY in two siblings (238), we also observed the novel 
and deleterious Pro131Ser variant in a female with complete gonadal dysgenesis. 
Interestingly, a Proline to Arginine residue change had been described in the same 
position (239). On the other side, cases of sporadic and familial 46,XY DSD have been 
related to deleterious variants in MAP3K1, a key component of the testis-specific 
development (81, 82, 290). Eggers et al identified 11 patients with 6 different MAP3K1 
variants and extended the phenotype to include hypospadias and undervirilization, to 
the previous individuals presenting partial and complete gonadal dysgenesis (12). 
Here, we report one 46,XY gonadal dysgenesis case with a previously reported variant 
in an individual with similar clinical features, such as female external genitalia, both 
Müllerian and Wolffian remnants and elevated gonadotropins (82).  
 
WT1 is another early developmental gene identified in 46,XY DSD patients with 
and without additional syndromes. Historically thought to cause Denys-Drash or 
Frasier Syndromes, gene alterations in WT1 encompass a range of clinical phenotypes 
that may correlate or not with the type of variants and its location (291). Indeed, 
recent publications have reported WT1 variants in infants with undervirilized 
phenotypes, such as hypospadias (38, 291, 292), ambiguous genitalia (219) with and 
without associated nephropathy, and ovarian failure (19).  
 
In this study we found WT1 sequence variants in 5 patients with different 
phenotypes, including two novel missense changes in isolated forms of 46,XY DSDs. 
The novel Glu75Lys was found in a 3 year old female with immature testes at image 
and no signs of kidney abnormality. However, both gonadoblastoma and/or kidney 
disease may be developed later in life (291), therefore patient should be closely 
followed-up. Although the mother of the patient was a carrier of the same 
heterozygous variants, incomplete penetrance associated to Denys-Drash syndrome 
has been previously described (293). The second novel change (Met182Lys) was found 
in patient GN0156, an infant with precocious puberty. This suggests a greater 
phenotypic variability than previously thought, however further in vitro studies are 
needed.  
 
Regarding the two syndromes associated with genital malformations and 




Frasier syndrome which had been previously described (17, 251). Denys-Drash and 
Frasier syndromes are characterized by complete or partial gonadal dysgenesis in XY 
individuals and nephropathy. The difference among these pathologies is the presence 
of Wilms’ tumour in Denys-Drash and gonadoblastoma or streak gonads in Frasier 
Syndrome. However, since a complete WT1 gene deletion was found in a newborn 
with gonadal dysgenesis, gonadoblastoma and bilateral Wilms’ tumour (253), the 
variable phenotype associated to the gene was amplified and enhanced the earlier 
suggestion that both syndromes are part of the same clinical phenotype (294). In our 
cohort we found a partial gene deletion, from exon 7 to 10, in a male with bilateral 
Wilms’ tumour and cryptorchidism as the only genital malformation, although 
hypoplastic testes were visually noted. Nephropathy was not described, but 
proteinuria was present before surgery. Hence, we support the idea of Frasier and 
Denys-Drash syndromes as part of a wider phenotypic picture, instead of isolated 
syndromes, in which milder phenotypes are included, such as less severe kidney 
anomalies or its absence. 
 
Seven individuals in our cohort with X-linked Adrenal hypoplasia congenita 
(AHC) were found to have hemizygous missense, nonsense and frameshift changes or 
complete gene deletions in NR0B1. Clinical features of the disease include salt-losing 
adrenal insufficiency, hypogonadotropic hypogonadism and infertility in both sexes, 
while boys may also refer early puberty and glucocorticoid or mineralocorticoid 
deficiency. In our study patients principally manifested typical symptoms of salt-
wasting crisis involving dehydration, low sodium levels and hypoglycaemia either with 
or without skin pigmentation. Abnormal sexual development was only described in 
POL0274, while two other cases (GN0101 and POL0285) referred hypogonadotropic 
hypogonadism, when aged 17 and 45 years, respectively. DAX1 and SF1 are the major 
factors involved in adrenal and reproductive development and function. Most of the 
different mutations in NR0B1 are associated with the loss-of-function in the ligand-
binding domain or a stop variant that translates to a shorter protein (295).  
 
In the present study we identified two novel variants located in the DNA-
binding domain that are susceptible to form shorter protein structures and explain the 
primary adrenal insufficiency (PAI) observed in these patients. In the newborn males, 
the condition presents with clinical features that are vaguely different from the salt-
wasting form of 21-hydroxylase deficiency. An accurate hormonal and molecular 
diagnosis has significant consequences for precise prescription of the treatment and 
genetic screening affects other family members, indeed the risk of symptoms related 
to adrenal insufficiency in brothers and males in the maternal family need to be 
consider (295). In our study, patient GN0078 presented a positive family history of 
unexpected early death in males, and thus had an effect on the early diagnosis of the 




family background but was genetically diagnosed in his adulthood when he presented 
with hypogonadotropic hypogonadism. Similar to GN0101, a complete NR0B1 gene 
deletion was found in this patient. Guo et al firstly described in 1995 a complete gene 
deletion in two isolated cases presenting with PAI and mental retardation (249), since 
then many others have been reported encompassing similar phenotypes to that of our 
patients (296).  
 
In human, WWOX gene germline mutations have been shown to be associated 
with sex differentiation, but also with spinocerebellar ataxia and WOREE syndrome, 
characterized by epileptic encephalopathy (WWOX-related epileptic encephalopathy) 
(297). We identified two missense variants in two patients referred to clinician for 
46,XY gonadal dysgenesis suspicion. Gly62 residue, in exon 3, situated in the second 
WW domain of the protein, is involved in protein interactions and therefore the 
observed change in patient GN0203 may impair this function. In contrast, Pro366 
amino acid is located in the carboxi-terminal of the encoded protein. Although a milder 
effect would be suspected, the phenotype observed in patient GN0020 is more severe 
than in subject GN0203. Further molecular analyses are needed to assess the 
implications of WWOX in 46,XY gonadal dysgenesis.  
 
More recently, heterozygous and homozygous missense changes in ZFPM2 
have been noticed in patients with partial and complete gonadal dysgenesis (67). We 
identified one variant (Ala1026Val) in heterozygosis in GN0155 patient, who had 
ambiguous genitalia at birth and surgery for a dysgenetic gonad at age 2 years. More 
analyses are required to test this unreported variants. Other studies have identified 9p 
deletions, including DMRT1 and DMRT2 genes in phenotypic females with Y-
chromosome showing gonadal dysgenesis or ambiguous genitalia (75). To the best of 
our knowledge this is the first DMRT2 missense variants found in a 46,XY DSD, 
however its deleterious effect would be probed when the cousin of this patient, also 
presenting complete gonadal dysgenesis, is analysed.  
 
Regarding the 46,XX DSD cohort, we were able to reach a genetic diagnosis in 7 
out of 24 cases (29.2%). The majority of the cases were reported to have a testicular 
DSD and translocation of the SRY gene had been studied prior to gene panel 
sequencing. We only detected one more patient carrying SRY by NGS.  
 
Testicular DSD is caused by the translocation of the SRY gene in the 90% of the 
cases. This type of rearrangements are rare, but about 50 cases have been described 
and happen throughout the aberrant exchange between homologous sequences 
(PAR1) on Xp and Yq during meiosis in the spermatocyte. The phenotype of males with 
Xp:Yq translocations depends on the extend of the Xp deletion. They can present short 




ichthyosis and hypogonadotropic hypogonadism in combination with anosmia 
(Kallman syndrome) when the deletion is large.  
 
Otherwise, copy number gains and deletions, such as activating variants in 
SOX3 driving to testis development  or loss-of-function variants in RSPO1, an ovary-
specific signalling gene (98) (192), contribute to the pathogenesis of the disorders of 
ovarian development. However, the use of CGHa does not increase the molecular 
diagnosis of these patients. Kim GJ et al identified SOX9 upstream duplications in three 
out of nineteen 46,XX DSD individuals (15.8%) (298). Indeed, two ovotesticular 
patients (GN0090 and GN0158) had undergone for Copy Number Variations (CNV) 
detection with a commercial MLPA but rearrangements were not found. The analysis 
of CNV in four patients with SRY-negative 46,XX testicular DSD revealed loss of 
heterozygosity in 13 regions not known to be associated with testicular development 
(299). Similar analysis in 46,XX DSD will emphasize the role of CNV in the pathogenesis 
of the disease. However, disorders other than congenital adrenal hyperplasia (CAH), 
constitute small groups among 46,XX DSD and obtaining a significant number of 
patients is challenging.  
 
46,XX DSDs account for approximately the 25% of all DSDs, with CAH due to 21-
hydroxylase deficiency being the most usual cause (95%) (300). It is diagnosed during 
routine newborn screening by detecting baseline and stimulated 17-hydroxy 
progesterone values at birth. Such screening programs prevent the incorrect gender 
assignment in females with severe virilization and identify male infants with the salt-
wasting type of classic CAH and normal external genitalia to prevent adrenal crisis. 
However, individuals with CAH were not included in this study due to the difficulty to 
correctly sequence the gene, as other studies did (12, 218). Patients would have been 
examined separately for CYP21A1 defects if CAH was suspected. Recent 
recommendations from the DSDnet state that all neonates should have a complete 
steroid analysis to prevent emergencies due to severe adrenal insufficiency (174).  
 
Still, relatively few genes have been implicated in the development of ovaries 
compared to testicular formation, and this unknowledge may be the reason for the 
46,XX DSD cases that remain unsolved. Downstream targets of WNT4 and RSPO1, as 
well as their coactivators seem to be good candidate genes. LGR4 (Leucine-rich repeat-
containing G protein-coupled receptor) for example, codifies for a receptor of R-
spondin and mediates WNT4/β-catenin signalling while Lgr4-null mice models have 
shown female-to-male sex reversal (301).  
 
On the other side, traditional and whole exome sequencing have recently 
identified rare missense heterozygous changes in ESR2 in two young 46,XX girls with 




Although Esr2 deficient murine models resulted in different phenotypes that 
suggested its role in fertility in both sexes but not in sexual differentiation (160, 302), 
loss-of-function mutations have been described in 46,XY DSD (160, 303). Our targeted-
gene panel identified a missense change in a highly conserved residue located in the 
fifth coding exon of ESR2 in a teenage 46,XX girl. The 14-year old patient presented 
with puberty delay and primary amenorrhea, infantile uterus and prepubertal ovaries. 
Estradiol levels were low at <5pg/ml. No other relevant changes were shown in genes 
linked to ESR signalling or gonadal development. ESR2 is expressed in the foetal ovary 
and in the Granulosa cells of the small and preovulatory follicles and as reported, 
negative effect on the receptor led to complete ovarian insufficiency (160). Due to the 
location of the 221 residue on the DNA-binding domain (DBD) (160), we could 
hypothesize that those previously reported variants located in the ligand-binding 
domain (LBD) of the ESR-β cause a more severe phenotype such as absence of ovaries 
and bilateral cystic lesions. In our case, patient had prepubertal ovaries and although 
hormone replacement therapy had been planned, proper gonadal development needs 
to be followed-up. This is the third ESR2 change implicated in the pathogenesis of 
46,XX DSD, which further agrees with its involvement on the female gonadal progress.  
 
Regarding ESR1, loss-of-function gene variants cause oestrogen resistance, a 
syndrome characterized by primary amenorrhea with no breast development, 
polycystic ovaries and infantile uterus in women and delayed bone age, osteoporosis, 
continuous growth and elevated oestrogens levels in both sexes (161). To date, few 
patients with ESR1 mutations have been reported in DSD patients, 1 in males and 4 in 
females (38, 304). Our 46,XX patient presented with a different phenotype compared 
to the Mayer-Rokitansky-Küster-Hauser type 1 cases described by Brucker et al in 2017 
(304). Female KO mice have no pubertal mammary gland development and hypoplastic 
uterus, then the clinical phenotype of patient GN0198 recapitulates the murine model 
(162). This young female presented with non-visible ovaries at the referral time but 
later cystic development is not discarded after treatment has started. On the other 
side, this patient harboured another variant in HSD17B4 gene, which function is 
unknown in isolated DSD, but could modulate the role of ESR1. 
 
Finally, a rare variant in MAMLD1 was found in a 46,XX DSD. The importance of 
MAMLD1 in sexual development is unknown. Although it is expressed in testes and 
ovaries during foetal life and in testicular and adrenal tissue in adults (87, 91), the poor 
genotype-phenotype correlation led to the search of further variants that explained 
the clinical broad range. A recent WES analysis in our patient revealed 5 genes related 
to female gonadal development and 46,XX DSD, such as MAML3 (91). The 
identification of multiple variants in a patient suggests the partial contribution of each 
one and complicates the functional testing of their effect on the pathogenesis. 




using bioinformatic tools and recent literature in the field, emphasizing the network 
analysis as a tool to understand complex genetic data. This study underlined that the 
different clinical features observed in DSD cases might happen due to a group of 
genetic variants that contribute to sexual development. 
 
In the present study no sequence variants were detected in 72 out of 125 
patients. Besides the limitation of targeted gene panel sequencing to detect CNVs, the 
analysis of deep intronic sequences is also missing with this technology. Genetic 
studies in DSD have been focused towards the coding regions of the genome, however 
it is thought that defects in the transcriptional regulation of either well-known genes 
or yet to be discovered genes resulting from non-coding regions explain a part of the 
DSD unsolved cases.  
 
In fact, several non-coding defects affecting regulatory elements and the 
expression of its target genes have been implicated in DSD (194). For example, 
interesting regulatory mechanisms have been added to the pathogenesis of AIS and 
have highlighted the significance of non-coding regions in the development of AIS. An 
identified variant in the 5’UTR of the AR gene created an open reading frame (ORF) 
that modified the transcript and reduced the translation levels of the downstream 
gene. The expression of the short protein reduced the AR levels, while the mRNA levels 
remained unchanged (141). Although an intronic variant had been previously identified 
(140), later in 2016 a deep intronic variant (c.2450-118A>G) creating a de novo 5’ splice 
site and two aberrant transcripts was identified by WGS. It was shown that despite 
total mRNA levels were normal, the stability of the protein was compromised and the 
AR was undetectable (305). In our cohort, 3 patients with a clinical suspicion of AIS did 
not reveal a coding AR mutation. Our customized panel was designed to span only 
25pb of the exon-intron boundaries. Although enough to detect disease-causing 
intronic variants in patient with a Frasier syndrome suspicion, most diagnostic 
approaches using gene panels, as well as whole exome sequencing leave a majority of 
cases unsolved. As we don’t use an alternative method to study introns we might miss 
diagnostic variants that fall within these regions. The analyses of patients with such 
disorders using genome sequencing will further increase the importance of intronic 
regions in the pathogenesis of DSD.  
 
As stated before, the number of genes in the panel does not necessarily 
correlate with a better diagnostic rate. However, the limited number of genes (48 
genes) strongly contrast with the 62 and 61 genes known to be involved in 46,XY DSD 
and 46,XX DSD, respectively (174). Although new primers can be added to the 
customized panel, the rapid advance in knowledge about the molecular pathogenesis 




of the updating. Sequencing the complete exome appears to be the best cost-eficiency 
method then.  
 
Investigation by WES or WGS sequencing allows a targeted approach first and 
the later extension to candidate genes. Indeed, the use of WES has allowed the 
discovery of genes previously not associated to DSD in humans, such as ZFPM2 and 
SOX8 (53, 67). Nevertheless, the further candidate gene detection needs critical 
evaluation. The addition of genes without a clear phenotype correlation may only 
result in an increase of VUS and accidental findings, without a significant improve of 
the diagnostic rate. Certainly, a challenge associated with the implementation of High-
throughput screening (HTS) is the detection of VUS. These may be in genes known to 
be related to the phenotype but without sufficient evidence to confirm the 
pathogenicity, affecting sequence changes in candidate genes or in well-known genes 
not associated to the field of study (306). In our cohort, segregation studies were not 
performed in some patients with VUS, complicating further categorization of the 
variant and molecular diagnosis. Although previous analysis of singletons and trios in a 
large cohort of DSD cases through NGS suggested that the sequencing of the family 
members is not essential, more single patients had gene variants classified as VUS 
compared to trios (12). 
 
No sequence variants were found in the two patients with a mixed gonadal 
dysgenesis and a 45,X0/46,XY karyotype. MGD has been associated with Yp 
chromosome microdeletions, detected with either sequence tagged site based PCRs or 
cytogenetic techniques, depending on the size of the missing segment. Besides the 
inconveniency of detecting microdeletions in the SRY gene with the gene panel, one 
out of 3 individuals with a 45,X0/46,XY karyotype and an apparently normal Y 
chromosome may have microdeletions (307). Moreover, in 6 out of 15 patients with a 
45,X0/46,XY karyotype or its variants and a MGD phenotype microdeletions were 
found inside the AZF region in Yq11.  
 
The importance of a good clinical description or diagnosis prior to the 
molecular testing is being questioned. DSD present with variable clinical appearance 
and hormonal criteria, interfering with the direct causative gene prediction for a 
concrete phenotype. NGS replaced traditional sequencing allowing the analysis of 
more than one gene at the time and nowadays the technical cost of targeted panel 
sequencing is equal to the multiple-exon sequencing of a gene. Traditionally, certain 
phenotypes were assumed to reliably predict a disruptive change in a DSD-related 
gene, such as sequence variants in AR. However, as mentioned before variants in non-
coding or 5’UTR of the AR or other genes regulating the AR pathway are now highly 
suspected to cause AIS (141). In our experience, we have found DSD patients are either 




our customized panel as a fast and less costly method to reach a molecular diagnosis, 
together with a CNV detection method, when patients are affected with a DSD of 
unknown basis. Additionally, highlights the importance of the molecular analysis for 
clinical management. Recently COST Action authors remembered that genetic 
diagnosis cannot always predict the functional consequences for a particular DSD 
patient, which are important aspects for individualized management (174). For 
instance, the range of phenotypes encompassing LHCGR or NR5A1 gene variants in our 
cohort drives to different managing of the patient.  
 
Finally, not all DSD cases are explained by a genetic variant. The role of 
environment is evident in the development of genitalia as well as the epigenetic 
changes that disrupt gene expression in DSDs arising in foetal stage (140). On one 
hand, oestrogenic and anti-androgenic complexes are responsible of the defects of the 
urethral closure in humans and the elevated exposure to these compounds explains 
the increasing incidence of hypospadias in developed countries. Indeed, only 30% of 
hypospadias cases have a clear genetic cause (183). Exposure to infectious diseases, 
such as rubella has also sustained the development of ovarian dysgenesis in some 
individuals (197). Finally, the impact of histone modifications observed in gonad 
development and the possibility to produce DSD is still challenging. Up to date, the 
understanding of epigenetic modifications activating or inhibiting gene expression 
came from in vitro analyses (308), although its role in specific processes such as 
gonadal development keeps being challenging. Recent tools, such as the ChIP-seq 
(Chromatin Immunoprecipitation Sequencing) allow the investigation of the binding 
pattern of chromatin-associated proteins in the genome and have led to the 
hypothesis that a mixture of posttranscriptional modifications, including methylation, 
acetylation, phosphorylation and ubiquitination are required to obtain an effect on 
gene expression (216). These advances may provide insight into the development of 
DSD.  
 
New screening technologies have demonstrated that the phenotype of some 
individuals with DSD results from the oligogenic inheritance of gene variations. Recent 
publications suggested that the range of DSD phenotypes associated with NR5A1 may 
occur due to the inheritance of heterozygous NR5A1 gene variants and further hits in 
other genes involved in the sex development pathway or other cofactors (224). Since 
Mazen et al reported a heterozygous NR5A1 change in combination with a MAP3K1 
gene variants in a patient with 46,XY gonadal dysgenesis (309), other studies have 
reinforced the complicated phenotype–genotype correlation observed in this patients 
(310). Indeed, we found oligogenic inheritance of a heterozygous variant in NR5A1 in 
combination with a VUS in testis differentiation genes AMH and STAR in two of our 
patients. Both genes are upregulated by the transcription factor in the early human 





Oligogenic inheritance has been discovered in other DSDs. Eggers et al found 
segregating variants in a testis development gene and a VUS in a CHH (congenital 
hypogonadotrophic hypogonadism) gene in 3 patients with severe hypospadias (12). 
More recently, the contribution of multiple genetic variants to MAMLD1-associated 
46,XY and 46,XX DSD phenotypes has been published (91). Similarly we found in a 
46,XY DSD patient with a mild phenotype, a heterozygote variant in LHCGR together 
with a GATA4 gene change. Although the GATA4 variants did not affect the CYP17 
promoter activity, it has been suggested that the combination of individually non-
deleterious variants contributes to the DSD phenotype (224). Moreover, several 
GATA4 sites are present in the 5’UTR of LHCGR, which indicates that GATA4 could 
regulate this gene. We propose that GATA4 may also show oligogenic involvement in 
DSD. Finally, we found in a 46,XX DSD patient a heterozygous ESR1 variants in 
combination with an additional variant in gonadal differentiation gene HSD17B4. 
Although few variants have been identified in ESR1, an autosomal recessive 
inheritance mode is suspected, and then we propose that defects in both genes cause 
the phenotype of this patient.  
 
 
13. ANALYSIS OF RARE VARIANTS IN GATA4, NR5A1 AND LHCGR AND FUNCTIONAL 
STUDIES 
 
The molecular testing of our DSD cohort showed also a VUS in GATA4, as well 
as 6 changes in the NR5A1 gene and 6 in LHCGR. In those novel variants, further 
studies were performed to test the transcriptional activity of the variants. 
 
 
13.1. VARIANTS IN GATA4 AND IN VITRO STUDIES 
 
In 2018, we published the characterization of p.Pro226Leu GATA4 sequence 
variant together with another two variants (p.Cys238Arg and pTrp228Cys) found by 
other research groups (25). The three missense changes were found in heterozygosis 
in three individuals with a 46,XY DSD phenotype with and without congenital heart 
disease (CHD). GATA4 mutations associated with cardiac defects are distributed 
throughout the gene and its contribution to the pathogenesis of the disease was 
assessed when mutants decrease the ability to transactivate target genes or fail to 
interact with proteins involved in heart development (312). Moreover, it is known that 
common variants in a region of GATA4 3’UTR change posttranscriptional gene 





In contrast, functional characterization of GATA4 variants with respect to the 
46,XY DSD phenotype has only been performed for the p.Gly221Arg mutation so far 
(27). In vitro studies revealed that p.Gly221Arg lacked DNA binding, had impaired 
transactivation activity on the AMH promoter, and failed to bind cofactor FOG2. 
Functional testing of three GATA4 variants identified in 46,XY DSD individuals of our 
study showed no effect on transactivation activity on the CYP17 promoter for GATA4 
variants p.Pro226Leu and p.Trp228Cys but similar disruptive effect for the missense 
mutation p.Cys238Arg.  
 
The few GATA4 missense mutations found in 46,XY DSD individuals with or 
without CHD are all located in the N-terminal zinc finger domain, responsible for DNA 
binding and interaction with cofactors (314). Although the three variants are located in 
the N-terminal zinc finger domain of GATA4, only Cys238 is close to Zn binding sites. 
The Gly221 also close to such sites, is not directly involved in Zn binding but is situated 
next to Cys220 which binds the Zn atom, and thus, the mutation Gly221Arg disrupts 
the Zn binding, leading to a non-functional GATA4. The Cys238 binds Zn and its change 
to arginine leads to loss of Zn binding. 
 
GATA4 regulates the expression of multiple genes coding for hormones or 
components of the steroidogenic pathway during testis development and function, 
such as NR5A1. GATA4 interacts with NR5A1 in Sertoli cell cultures to regulate the 
expression of AMH, and therefore, it has been reported that mutations in NR5A1 cause 
46,XY DSD due to lack of interaction with GATA (23). In families with GATA4 mutations 
and isolated CHD no gonadal involvement is mostly detected, possibly because some 
of the variants retain some DNA-binding activity and exhibit different degrees of 
transcriptional activation on gonadal promoters and thus, remain able to synergize 
with NR5A1. The p.Cys238Arg mutation was found in a patient with a complex CHD, 
genital ambiguity, and persistent Müllerian ducts, which led to female gender 
assignment. We proposed that p.Cys238Arg mutation in GATA4 lacks activity to bind 
DNA reducing the transactivation of AMH critically. 
  
On the contrary, variants p.Pro226Leu and p.Trp228Cys were found in 
individuals with less severe 46,XY DSD phenotype. They were raised as males, and had 
no evidence of heart anomalies. Indeed, Harrison et al (26) screened patients with 
46,XY DSD using an aCGH and found an infant presenting a deletion of 0.22 Mb 
upstream GATA4. Same deletion was found in his healthy mother and his maternal 
grandmother, who had CHD. The authors proposed that the identified deletion do not 
affect the coding sequence of GATA4, and may, therefore, not manifest with CHD, but 
rather disrupt regulatory elements controlling gene expression essential in the 
developing gonad (28). Thus, the phenotypic variability could be explained by genetic 




degrees. Structural changes caused by both the p.Pro226Leu and pTrp228Cys 
variations were not predicted to be disruptive and GATA4 structure was not altered. 
However, the changes were in the DNA interaction sites and it is expected that both 
p.Pro226Leu and p.Trp228Cys variants could have altered binding and activation of 
some of GATA4 interaction partners and could also bind to other promoters and 
potentially change the transcription of several other genes. In fact, NGS revealed 
segregating genetic variants in two other genes in these two patients with a 46,XY DSD 
phenotype without CHD. In the GN0171 patient a heterozygote mutation in LHCGR 
gene was found together with the GATA4 variant. Looking at the 5ʹUTR of LHCGR, 
several GATA sites are present suggesting that GATA4 may regulate this gene. 
Therefore, combined heterozygosity for GATA4 and LHCGR variants in our patient may 
explain the 46,XY DSD phenotype. The other case harboured an additional 
heterozygote variant in LRP4 gene, related to the Cenani–Lenz syndactyly syndrome 
(OMIM 212780) and disruption of canonical WNT/beta-catenin signalling, important in 
sexual development (25). 
 
As in other DSD-related genes, phenotypical variability with same heterozygous 
GATA4 mutation (p.Gly221Arg and p.Trp228Cys) observed within same family 
manifesting with either 46,XY DSD or CHD only, indicates that there might be 
incomplete penetrance or variable sensitivity (27) (25). Interestingly, the same 
observation was made in mice heterozygote for a Gata4 deletion (316). Oligogenic 
mechanisms may also be considered.  
 
 
13.2. SEQUENCE VARIANTS IN NR5A1 GENE AND FURTHER ANALYSES 
 
We found six variants in the NR5A1 gene, all were detected in heterozygosis 
and were mainly single-nucleotide variants. A broad range of phenotypes, from 
hypospadias to severe forms of 46,XY DSD and primary ovarian insufficiency (POI) in 
46,XX DSD have been widely described in individuals harbouring heterozygous NR5A1 
variants (14). Clinical picture of these 46,XY patients varied from ambiguous genitalia 
with micropenis and cryptorchidism to female external genitalia with Müllerian 
remnants. Hormonal levels were also variable and although adrenal insufficiency has 
been associated with NR5A1 mutations, it was not suspected in our patients.  
 
The first three mutations (His24Leu, Cys30Ser and Arg84Cys) are located in the 
DNA- binding domain (DBD) region of the protein. While His24 and Cys30 amino acids 
are involved in the binding of the major groove of DNA to promoters, Arg84 is placed 
in the A box which stabilizes the binding of the protein to DNA (14). The latter, was 
found in a patient presenting with ambiguous genitalia at birth and has been observed 




the mutation showed decreased DNA binding and reduced transactivation activity 
(240). Variants His24Leu and Cys30Ser in NR5A1 gene are described here for the first 
time. However, other mutations in the same codons (His24Tyr and Cys30Trp) were 
reported in Spanish and Turkish girls who presented with bilateral inguinal hernia and 
female or ambiguous genitalia, respectively (14). We found that these SF1 mutations in 
the DNA binding domain (DBD) showed impaired transactivation activity when studied 
in the three different promoters. Gln206ThrfsTer20, located in the hinge region will 
result in a truncated protein without ligand binding domain (LBD). The same variant in 
a Spanish girl with similar phenotype had been reported (14). We found two more 
novel gene variants (Glu304CysfsTer26 and Cys301Tyr) located in the LBD region, 
which modulates the activity of the protein through the binding of cofactors to the AF2 
domain in the C-terminal. Several studies have shown that variants in the DBD may 
correlate with higher protein impact compared to changes in the LBD region, where 
effects vary depending on their location and the recognition of the ligand (14, 310). 
Similar results were observed in our cohort, since the in vitro promoter transactivation 
assay showed a more variable result when analysing Cys301Tyr. However, in this 
study, we found that patients GN0109 and GN0111 presented with a more severe 
phenotype compared to those with a sequence variant in the DBD region, which 
highlights the poor correlation between functional testing and clinical features. In the 
case of Glu304CysfsTer26 mutation, a premature stop was created and the truncated 
protein lacked the AF2 region, leading to a loss of protein function. 
 
A clear genotype-phenotype correlation was not seen in patients bearing 
NR5A1 mutations and certainly, family members harbouring the same gene variant 
may present with variable phenotypes (14). In one case (GN0075), family history 
showed premature menopause or menstrual anomalies and severe hypospadias in 
some relatives having heterozygous NR5A1 variants. By contrast, clinically normal 
carriers of the Cys301Tyr and Glu304CysfsTer26 variants were also observed, as 
similarly reported before (14). Additional mutations in NR5A1 or in other genes 
implied in the sexual development have been proposed as a hypothesis to explain this 
phenotypic variability. In 2016, Mazen and colleagues found a known Arg313Cys 
NR5A1 mutation in compound heterozygous state with a MAP3K1 variant, suggesting 
that a digenic inheritance model could explain the phenotypic heterogeneity observed 
in 46,XY cases with gonadal dysgenesis (309). Since then, other NGS analyses of DSD 
patients have reported a second rare variant in 46,XY patients (224) (310). Similarly, 
we analysed the data for additional variants and found the Arg121Trp STAR change in 
patient GN0028 and Thr143Ile variant in AMH gene in GN0042. SF1 transcription factor 
regulates the synthesis of StAR in Leydig cells, causing virilisation of external genitalia 
as well as testicular descent, while in Sertoli cells it upregulates AMH, leading to the 
regression of Müllerian structures (317). Both patients presented with clinical features 




patient’s healthy father. An extensive study of the contribution of these second 
variants found in this study would provide further insight into the variable genotype-
phenotype correlation found in DSD patients harboring a heterozygous NR5A1 gene 
variant.  
 
The contribution of the Gly196Ala polymorphism has also been suggested to 
explain the phenotypic variability, as some of the described mutations in NR5A1 are in 
compound heterozygous state with this SNP (318). We did not detect the Gly196Ala 
change in none of the NR5A1 positive patients, however we found it in four patients 
presenting another deleterious variants in AR and LHCGR, which may suggests its 
benign role in the pathogenesis of DSD. Although functional analyses of the 
polymorphism demonstrated its null ability to activate transcription (240) we cannot 
discard an adding effect to the pathogenesis of the disease. 
 
 
13.3. VARIANTS IN LHCGR GENE AND IN VITRO STUDIES 
 
Clinical characteristics of patients harbouring sequence variants in LHCGR 
depend on the activating or inactivating effect driven by the change. Based on the 
inactivation degree of the receptor, consequences of the inactivating variants range 
from a 46,XY DSD with female phenotype (Leydig Cell Hypoplasia, LCH type 1) to an 
undervirilized male with hypospadias and micropenis (LCH type 2) (319) or primary 
amenorrhea in females. Although LCH is thought to be a recessive inheritance disease, 
we identified the Arg554Ter change in LHCGR gene in a patient with incomplete 
masculinization of external genitalia. This nonsense variant is located in the third 
intracellular loop of the LH receptor and Latronico et al also found it in three affected 
siblings with female external genitalia (269). Subsequently, we tested the ability of Wt 
LHCGR and Arg554Ter mutant to mediate cAMP production in respond to increasing 
concentrations of hCG and found no second messenger generation when cells 
expressed the mutant LHCGR. The premature interruption of the translation process 
removes a large part of the receptor and thus, the hormonal signal is not transduced 
properly. Because heterozygous parents of other described patients were 
phenotypically normal (269) we could conclude that a non-functioning allele causes no 
DSD in either sex, but its combined heterozygosity with the GATA4 change might 
explain the phenotype of this concrete case (75). Moreover, other inactivating 
missense variants and deletions have been identified throughout the whole gene, 
which cause the mutant LHCGR unresponsive to hormones and result in female 
external phenotype, as in two of our cases. Patients GN0034 and GN0147, with typical 
clinical and hormonal phenotype of LCH, presented a complete gene deletion and a 
novel missense variant in the extracellular domain of the protein, respectively. This 




hormone on the surface formed by leucine-rich repeats and the beginning of signal 
transduction (320). Functional analyses of the mutations located in this region have 
resulted in receptor intracellular retention with little surface expression and slight or 
no hormone stimulation measure (321). Accordingly, transfected cells with the 
Ser253Pro mutant significantly reduced cAMP accumulation after hCG stimulation and 
elucidates the severe Leydig cell hypoplasia observed in this patient. Patient GN0034 
presented a large deletion in chromosome 2 affecting exons 1 to 10 of the gene and 
therefore inducing the total loss-of-function of the gene. Indeed, the deletion removed 
GTF2A1L and STON-GTF2A1L genes, encoding a germ cell specific subunit of the TFIIA 
transcription factor involved in the interaction between TATA-binding protein and DNA 
and essential in testis biology and spermatogenesis (322). The lack of the entire LHCGR 
gene had been previously reported by Richard et al (270) in a newborn with sexual 
ambiguity described as labial fusion, a genital tubercle with hypospadias and inguinal 
gonads. We therefore expand the phenotype of patients presenting with a whole gene 
deletion. 
 
On the other side, male-limited precocious puberty is an autosomal dominant 
disease characterized by the LH-independent activation that increases testosterone 
synthesis. Heterozygous activating mutations in the LHCGR change the normal 
configuration of the receptor and activate G protein-coupled receptor (267). Patients 
commonly present early signs of puberty by the age of 4 years and elevated serum 
testosterone levels despite low LH (323). In early reported patients, either in familial or 
sporadic cases, mutations were located in exon 11, encoding for the signal 
transduction region, but now they are sited in other exons. For instance, we identified 
the novel and probably deleterious Gln190Lys variants in exon 7 in GN0157 case, 
affected with pubic hair development, accelerated growth and a slight testicular 
enlargement without penile growth. Adrenal tumors and aromatase deficiency were 
excluded. Testosterone level was within normal range at referral and LH was 
undetectable. We can speculate that the different clinical aspects are related to the 
location of the c.568C>A (p.Gln190Lys) variant in the LHCGR gene.  
 
Previous studies had compared clinical and hormonal data of unrelated 
patients with gonadotropin-independent precocious puberty harboring the same 
variant in one and two alleles and no differences were observed (324). However 
functional studies would clarify if the variant is likely to cause the precocious puberty 
in this boy. Genetic analysis in the parents confirmed that the father is a carrier, 
however no clinical data was available to verify the pathogenicity of the alteration. As 
known, females with activating LHCGR mutations have no manifestations (325). In 
patients with precocious puberty, sporadic or with family background, genetic analyses 
as well as clinical and hormonal investigations are valuable for diagnosis. In GN0068 




father. In contrast, GN0088 was a sporadic case and the Met398Thr mutation 
appeared de novo. Both mutations had been reported in similar phenotypes by Kremer 
et al in 1993 (267) and Kraaij in 1995 (268) in exon 11 of LHCGR gene. This two 
activating mutations, placed in the third intracellular loop and involved in G-protein 
interaction, change the sixth and second transmembrane segments of the protein. In 
vitro experiments showed LH- or hCG-independent increased production of cAMP 
levels in HEK293 cells and elevated production of basal steroids in tumor Leydig cells of 
a murine model (268).  
 
In conclusion, we have reported the clinical and molecular characteristics of 
125 patients with a DSD diagnose. We have extended the number of gene variants 
identified to date in sex development and contributed to the idea of either incomplete 
penetrance or oligogenic mechanisms that explain the phenotypical variability 
observed in these individuals. However, further research is needed and the application 
of other molecular approaches, such as exome and/or genome sequencing would 

















1. The molecular analysis of DSD-related genes identifies a causative genetic 
variant in the 40.2% of the patients analysed in this cohort. 
 
2. The molecular analysis using a targeted gene panel is useful for the detection of 
single-nucleotide variants, mostly in 46,XY DSD patients. Indeed we made a 
molecular diagnosis in 22% of 46,XY DSD compared to the 10.5% of the 46,XX 
DSD individuals. However, further improvements are necessary to detect copy 
number variations with this technology. 
 
3. We observed that disorders of sex development are highly heterogeneous. 
This, difficults the clinical diagnosis and highlights the need of a genetic study 
to validate the initial suspicion. Still, little correlation has been found between 
the phenotype of an individual and the genetic variant that is identified. 
 
4. Clinical and biochemical data guide the genetic analysis when using a single-
gene sequencing approach. Next generation sequencing provides a molecular 
diagnosis when there is incomplete analitical information on the patients. 
 
5. Incomplete penetrance or oligogenic mechanisms might explain the 
phenotypical variability observed in patients with identical gene variants or 
within same family. 
 
6. Next generation sequencing techniques have expanded the number of genes 
and pathways that are involved in sex determination and gonadal 
development. We propose the use of a targeted gene panel as the first layer of 
the molecular diagnosis and the sequencing of the whole exome (WES) or 
whole genome (WGS) for additional analysis. The study of chromosomal 
rearrangements and intronic regions is also necessary.  
 
7. Functional analysis are necessary to validate the pathogenicity of the novel 
genetic changes that are identified either through the gene-by- gene approach 
or next generation sequencing. Accordingly, we found that only variants 
located in the DNA binding domain of the SF1 protein significantly reduced 
transactivation activity of the promoters, as well as the two gene alterations in 
LHCGR. However, in patients harbouring heterozygote NR5A1 and LHCGR 
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Supplementary data 1. Expected clinical and biochemical features of the different DSD. Modified from Guerrero- Fernandez et al (227). 
 
  Gonads 
Internal genitalia 
External genitalia Bioquemical defect 
























Gonadal dysgenesis Dysgenetic Complete: absent; Partial: hypoplastic 
Complete: present; 
Partial: absent 
Complete: female; Partial: 
variable virilization 
Low T1,2, low AMH 46,XY OT DSD Dysgenetic (Same gonad) 
Hypoplastic (+/-) 
Absent 
Partial variable virilization 























Female, ambiguous, rarely 
male. In puberty, virilization 
signs 
Low T, N/high AMH, N ACTH2. 
T/Andros <1  
HSD3B2 def Male with undervirilization 
Low T, N/high AMH, high 
ACTH2  
CYP17A1 def 
Present (Normal or 
hypoplastic) Female or ambiguous 





vagina) Variable virilization N T and AMH. T/DHT>30
2 
AIS Complete: absent; Partial: hypoplastic 
Complete: female; Partial: 
variable N/High T, AMH and LH 
LH receptor defects 
Present 
Ambiguous genitalia to normal 
female High LH, low T
1,2  























t  46,XX OT DSD Dysgenetic (Same gonad) Variable, normally absent Variable. Mostly present  Ambiguous, male or female HyperH, AMH in male range
4. 
Higher T levels2. 
46,XX Testicular DSD Atropic testes Present Absent Male, sometimes with ambiguous genitalia HyperH, low T, high FSH and 
LH. 

















 CYP21A2 def 
Ovaries Absent or scarce 
Ambiguous genitalia 
High 17OHP. SW in the classic 
form. 
CYP11B1 def High 17OHP, DOC, 11-desoxicortisol  
 POR def Ambiguous genitalia to normal female 
High 17OHP, T, prog, 
corticosterone 
HSD3B2 def Female, sometimes scarce virilization 
High 17OHP and 17OH-preg. 
SW syndrome 









45,XO/46,XY MGD Dysgenetic, streak or normal Hypoplastic (Unilateral) Hypoplastic (Unilateral) 
Partial virilization (Variable) 
HyperH, T and AMH4 
46,XX/46,XY mosaicism Testis and ovary (same gonad/two gonads Variable Variable HyperH, T and AMH
4  
Turner syndr3  Dysgenetic  Absent Present Female  HyperH, depending on the gonadal dysgenesis 
Klinefelter syndr3 Small testes 
Present  Absent Male  
HyperH, higher FSH than LH. 
47,XYY karyotype Testes   Normal testicular function 
ACTH, adrenocorticotropic hormone; AIS, Androgen insensitivity síndrome; AMH, anti-Müllerian hormone; Andros, androstenedione; Cyb5, cytochrome b5; CYP11A1, 20-22 desmolasa; CYP11B1, 
11-Beta hydroxilase; CYP17A1, 17α-hydroxylase and 17,20-lyase; CYP21A2, 21-hydroxilase; DHT, dihydrotestosterone; Def, deficiency; DOC, 11-desoxicorticoesterona; E, oestradiol; HSD3B2, 3-
Beta Hydroxysteroid dehydrogenase; HSD17B3, 17-Beta Hydroxysteroid dehydrogenase; HyperH, hypergonadotropic hypogonadism; FSH, Follicle Stimulating Hormone;  LH, Luteinizing hormone; 
MGD, mixed gonadal dysgenesis; N, normal; OT, ovotesticular; PMDS, Persisten Müllerian Duct defect; POR, Cytochrome P450 Oxidoreductase; Prog, progesterone; Syndr, síndrome; SW, salt 
















Clinical phenotype of the patients and relatives 
Clinical phenotype Müllerian ducts 
Gonadectomy 
(age) Histology 





17y, primary amenorrhea, pubertal delay, lack of breast development. US: 
absence of ovaries and uterus. Begins treatment with estrogens. 24y, normal 
feminization, lack of menarche. US: absence of ovaries and uterus. 
Other features: Sister presenting same phenotype, after treatment lack of 
breast development 
No No  
GN0003 46,XX/F MRKH II syndrome 
Vaginal 
agenesis 
8y, vaginal and uterine agenesis, confirmed by laparoscopy. 15y, MRI: left 






gynecomastia 13y, bilateral gynecomastia, unilateral cryptorchidism. 26y, azoospermia. No No  




16y, female external genitalia with normal vagina and small cervix. Non-
palpable gonads. 17y, gonadectomy: hypoplastic uterus, streak gonads 
(4cm). 
Other features: Sister with possible 46,XY DSD GD. 
Yes Yes (17y) 
Ovarian stroma with 
Sertoli and Granulosa 




GN0009 46,XY/F Frasier syndrome 
Delayed 
puberty 
12y, headaches, vomiting and fatigue, high blood pressure. Fundoscopy: 
bilateral papilledema. US: glomerulopathy. Biopsy: confirmed the 
nephronophtisis. Began treatment. 13y, hemodialysis. Renal transplant but 
kidney rejection. 17y, infantile external genitalia without breast development 
and pubarche. US: normal uterus, non-visible gonads. GH treatment was 
prescribed. 24y, gonadectomy. 
Yes Yes (24y) Streak gonads. Gonadoblastoma 




16y, absence of menarche and thelarche. Normal female external genitalia 
and hypergonadotropic hypogonadism. US: non-visible uterus, normal vagina 
and bilateral gonads. Laparoscopy: hypoplastic uterus and streak gonads. 
Gonadectomy. 
Other features: Father and brother with delayed puberty. 
Yes Yes (16y) 
Gonadoblastoma 










1y, no response to hCG stimulation test. Laparoscopy: absence of female 
gonads and testicular tissue.7-8y, testicular prostheses (5cc).11y, begins 
treatment with testosterone. 15y, mature penis and scrotum, pubarche IV, 
facial and body hair. Adrenal insufficiency discarded. 17y, changed treatment 










18y, primary amenorrhea and delayed puberty. Female external genitalia. 
US: vagina (7cm), streak left gonad. Laparoscopy: rudimentary uterus, large 
fallopian tubes and streak gonads. 
Other features: marfanoid habitus. 












13y, delayed development of secondary sexual characteristics. US: vagina 
and small uterus in the right side (3.8x1.4x1.8cm), small gonad (1.7cm) next 
to bladder. CT scan: rudimentary uterus after bladder, two rounded images 
suggesting vas deferens previous to inguinal canals, no image corresponded 
to inguinal testes. Gonadectomy of streak gonads.  
Other features: sister presenting with primary amenorrhea and female 
external genitalia (16y). US: small hypoplastic uterus, well defined ovaries. 
46,XY. Laparoscopy: right streak gonad and left gonad (3.5cm), hypoplastic 
uterus and no wolff remnants. Histology: Right streak gonad with ovarian 
stroma, Sertoli and Leydig cells; left gonad: disgerminoma 
Yes Yes (13y) 
Streak gonads. 
Ovarian stroma and 
seminiferous tubules 
with Sertoli cells. 
Absence of germ 







At birth micropenis, bilateral cryptorchidism and hypoplastic scrotum. 12mo, 
micropenis, non-palpable testes, atrophic scrotum and hypergonadotropic 
hypogonadism. No response of testosterone to hCG stimulation test. 
Laparoscopy. 
Other features: psychomotor retardation, parental consanguinity. 
No No Atrophic seminiferous tubes 




5y, surgery for bilateral inguinal hernia. US: non-visualized uterus and 
ovaries. 6y, gonadectomy No Yes (6y) 
Immature testicular 
tissue 




13y, pubertal development delay and little pubic hair. US: absence of gonads. 
17y, undeveloped breast, normal menses on treatment. 
Other features: short stature. 
ND Yes (ND) ND 









GN0024 46,XY/F 46,XY DSD Anorchia At birth, female external genitalia and bilateral inguinal hernia. US: inguinal testes, no uterus or ovaries. No No  
GN0025 46,XY/F 46,XY DSD CGD 
Primary 
amenorrhea 
17y, primary amenorrhea, undeveloped external genitalia and 
hypergonadotropic hypogonadism. US: hypoplastic uterus (35x7mm) and no 
gonadal remnants. Gonadectomy: atrophic uterus, streak gonads. 26y, US: 
uterus 36x22x17mm.  
Other features: Sister with CGD. Family history positive for short stature 
(mother 149 cm, father 162.6 cm). 




GN0026 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, US: short vagina, images suggesting inguinal gonads (10x6mm), no 
uterus. 
Other features: disorder of intermediary metabolism. 
No No  
GN0027 46,XY/F 46,XY DSD CGD 
Primary 
amenorrhea 
15y, primary amenorrhea, female normal external genitalia and delayed 
puberty. US: Small gonads, uterus and cervix. 
Other features: sister presenting with MGD. 
Yes No  
GN0028 46,XY/M 46,XY DSD  Ambiguous genitalia 
At birth curved micropenis with scrotal hypospadias and bilateral 
cryptorchidism. Surgery. 12y, penis (7.6cm and 10cm diameter), testes (5ml), 
pubarche and axilarche V and acne. US: Right testis of 15x15x28mm, vol 
3.2cc, and left testis 14x15x35mm, vol 3.9cc, small cysts in right epididymis 
6.4mm. From 12y 10 15y, phenotype remained without significant changes.  
15y, US: Right testis of 12x17x28mm, vol 3.2cc, and left testis 9x21x31mm, 
vol 3.3cc, small cysts in both epididymis 6.4mm and 2.7mm. 
Other features: 13y, Fragile X syndrome study, FMR1 gene was normal.15y, 
Asperger syndrome. Mother and brother with unilateral renal agenesis, 
brother also presenting with vas deferens and epididymis agenesis. 
No No  
GN0029 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, bilateral cryptorchidism, hypospadias and horseshoe kidney. 
Orchidopexy was done without good results. 15y, atrophic right testis, 
undescended left testis and curved penis.  
Other features: Horseshoe kidney 
No No  
GN0031 46,XX/F 46,XX DSD GD 
Ambiguous 
genitalia 
16d, hyperpigmented genitalia, hypertrophic labia minora and bilateral 
inguinal hernia with palpable masses. US: bilateral inguinal hernia with 
neonatal ovaries. Surgery was planned. 




GN0033 46,XY/M 46,XY DSD PGD Micropenis 3mo, micropenis and cryptorchidism. 12y, small penis (4cm) and testes (2ml). No No  




8mo, normal female external genitalia, bilateral inguinal hernia, absence of 
upper vagina and uterus. Surgery. 4y, US: absence of uterus and gonads. 13y, 
gonadectomy. Begins treatment with estradiol. 15y, thelarche IV and 
pubarche V. 
No Yes (13y) Testicular tissue 
GN0035 46,XY/F 46,XY DSD CAIS 
Primary 
amenorrhea 
13y, primary amenorrhea, hypertrophic clitoris, bilateral inguinal gonads, 
breast development begins. 16y, gonadectomy. 22y, vaginoplasty. 42y, 
hypertrophic clitoris (1.5-2cm). 
Other features: Obesity (BMI 39) 
No Yes (16y) ND 
GN0037 46,XY/M 46,XY DSD PAIS 
Ambiguous 
genitalia 
At birth, micropenis with perineal hypospadias, cryptorchidism and palpable 












At birth, female external genitalia. 10y, change in voice. 11y, hypertrophy of 
the clitoris, vagina (2cm) palpable gonads in inguinal canal and hirsutism. 
MRI: absence of female genitalia, possible gonads in inguinal canal. 
Laparoscopy: absence of female genitalia. Clitoroplasty and gonadectomy. 
No Yes (12y) 
Testicular 
parenchyma with 
Sertoli and preSertoli 
cels. Basal 
spermatogoonias. 
Leydig mature cells 
(both). 
GN0039 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, scrotal gonads, scrotal hypospadias and bilateral inguinal hernia. US: 
Gonads with epididymis suggesting testes (right: 1.2x0.6x0.6; left testis: 
1.2x0.7x0.8). 
Other features: Heart murmur 
No No  
GN0041 46,XY/F 46,XY DSD CAIS 
Suspicion of 
AIS 
9y, female external genitalia, thelarche and pubarche Tanner I. 12y, US: 
absence of internal genitalia. 
Other features: Older sister presenting the same phenotype 
No Yes (3y) ND 





11y, bilateral inguinal hernia, palpable gonads (2cc, 3cc), clitoromegaly and 
pubarche. Growth rate increase. US: vaginal pouch and non-visible uterus. 
Clitoroplasty. 20y, good breast development after estrogen treatment. 25y, 
US: prepubertal hypoplastic uterus, no ovaries. 
Yes Yes (10y) Hypoplastic testes 
GN0043 46,XY/M 46,XY DSD PAIS 
Ambiguous 
genitalia 
At birth (33w +3), micropenis with hypospadias, bilateral cryptorchidism and 
non-palpable testes in inguinal canal. Bilateral inguinal hernia. US: testes in 
inguinal canal (8mm), no uterus. 




Other features: Respiratory distress, anemia, hyperlactiacidemia 
GN0046 46,XY/F 46,XY DSD AIS 
Vaginal 
agenesis 
At birth, bilateral inguinal hernia and vaginal agenesis. US: images 
corresponding to testes. 16mo, bilateral gonadectomy. 10y, begins estrogen 
treatment. 15y, normal female external genitalia, vagina of 3cm. 16y, 
vaginoplasty. 17y, thelarche V. 
Other features: Obesity. 
No Yes (16m) 
Infantile testes, vas 
deferens, no 
intersticial cells. 
GN0050 46,XY/F 46,XY DSD CGD 
Turner 
phenotype 
3y, presenting with some slight Turner features and normal female external 
genitalia. Laparoscopy: streak right gonad suspecting dysgenetic testes, 
normal fallopian tube and small uterus. 
Other features: Low hairline, auditory pavilions with low implantation 
Yes Yes (3y) ND 
GN0051 46,XX/M 46,XX DSD Ambiguous genitalia 
6y, micropenis with scrotal hypospadias, bilateral cryptorchidism, palpable 
right testis in inguinal canal and bifid scrotum. US: abdominal left testis 
(9.5x3.8mm) and right in inguinal canal, no Müllerian structures were 
visualized. Orchidopexy and biopsy. Congenital adrenal hyperplasia was 
discarded. 
Other features: Patient from Mauritania. 
Yes No 
Infantile ovary with 
follicular cysts, 
fallopian tube, 







lack of body 
hair 
41y, weakness, absence of body hair, hypergonadotropic hypogonadism. 
Begins treatment with testosterone.  No No  
GN0055 46,XY/F 46,XY DSD CAIS 
Right inguinal 
hernia 
At birth, right inguinal hernia. Gonadectomy. 13y, US: non-visible uterus, 
vaginal pouch (2cm), 2 possible testes (17.8 and 13.8 mm).14y, 
gonadectomy. 
No Yes (1m; 14y) 
Testicular dysgenetic 
tissue, seminiferous 
tubules with plenty 
Sertoli cels. Leydig 
cell hyperplasia. 





1mo, micropenis with perineal hypospadias, cryptorchidism and Prader III. 
Laparoscopy: intra-abdominal small gonads, vas deferens and prostatic 
utricle are visualized. Wilms' tumor. 
No No  
GN0059 46,XY/F 46,XY DSD CGD 
Ambiguous 
genitalia 
At birth, micropenis, non-palpable testes and atrophic scrotum. US: normal 
vagina, non-visible gonads and uterus. 7d, US: non-visible gonads and uterus. 
1mo, hCG test with no increase of testosterone. 6mo, laparoscopy. 18mo, 
feminizing genitoplasty. 
Yes Yes (6m) 
Epididimus and 
fallopian tube is 
identified, germ cells. 




CGD karyotype Other features: Down syndrome 
GN0066 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, unilateral cryptorchidism, bifid scrotum and scrotal hypospadias. US: 
inguinal left testis (9.2x5.5x5.1mm). 7y, after surgery and treatment, 
presents a 3cm penis. Biochemical analysis is normal. 8y, precocious 
adrenarche. 
Other features: 8y, hearing loss 
No No  
GN0068 46,XY/M 46,XY DSD LH RD 
Precocious 
puberty 3y, precocious puberty and family background. ND No  
GN0070 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
9y, penis (2 cm) with scrotal hypospadias and bilateral inguinal testes.  US: 
Images corresponding to testes in inguinal canal (right: 15.6x8.7x6.7mm, 
0.5cc; left 17x8.5x8, 0.6cc). 
Other features: Patient from Madagascar. 
No No  
GN0075 46,XY/M 46,XY DSD  Ambiguous genitalia 
At birth, micropenis with scrotal hypospadias, undescended testes and bifid 
scrotum. 5y, normal penis (2.5cm) after testosterone treatment, scrotal right 
testis (2ml), and hydrocele in left testis. 6y, smaller penis and both testes in 
scrotum. 7y, small penis (2.5cm). 
Other features: Mother and aunt with precocious menopause and uncle with 
scrotal hypospadias. 
No No  
GN0076 46,XY/F 46,XY DSD CAIS 
Unilateral 
mass in labia 
majora 
8d, palpable gonad in labia majora. US: 2 visible gonads similar to testes, no 
uterus. No No  
GN0078 46,XY/M Adrenal Insufficiency 
Adrenal 
Insufficiency 
Familial background. 45d, scan: Hypoplastic adrenal glands. 
Other features: Glycemia NA; Na 107mEq/L; K 6mEq/L; Aldosterone 14ng/dL; 
PRA 66ng/mL/H. Cousin presenting with adrenal insufficicency. 
- - - 
GN0080 46,XY/F 46,XY DSD CAIS Suspected AIS 5y, gonadectomy. 6y, US: Absence of uterus and fallopian tubes No Yes (5y) Male gonads 
GN0084 46,XX/F MRKH II syndrome 
Primary 
amenorrhea 
16y, primary amenorrhea, MRKH type II phenotype, uterine, vaginal and 
kidney agenesis, ectopic ovaries, hyperandrogenism. 18y, US: left normal 
gonad, absence of right gonad, uterus and fallopian tubes. MRI: unique pelvic 
kidney (11x74mm), visible ovaries in pelvic region (60x25mm and 43x22mm). 
No hearing loss. 
Other features: kidney agenesis. 
No No  




LH RD puberty and begins treatment. 5y, pubarche is diminishing, testes 8mL and penis 
25x60mm. 
GN0090 46,XX/M 46,XX OT DSD 
Ambiguous 
genitalia 
6y, curved penis (2cm) with scrotal hypospadias, bifid scrotum, right inguinal 
hernia, right gonad (<1ml)  in inguinal canal. US: absence of female internal 
genitalia, right gonad (10.7mm) in inguinal canal and intra-abdominal left 
gonad (9.7mm). Laparoscopy: bilateral ovotestes located in inguinal canal 
and in iliac fosse, attached by tubes and atrophic uterus. Absence of lower 
portion of uterus or vagina. 
Other features: Patient from Mauritania. 
No No Bilateral ovotestes 
GN0091 46,XY/M Adrenal Insufficiency 
Respiratory 
distress 
At birth, respiratory distress, hyperpigmentation, hypoglycemia. Testes 1ml 
and penis 3.6cm. MRI: non-visualized adrenals. 
Other features: Glycemia 39mg/dL; Na 126mEq/L; K 6.2mEq/L; Aldosterone 
49ng/dL; PRA >21.3ng/mL/H. 
- - - 
GN0096 46,XX/M 46,XX OT DSD 
Ambiguous 
genitalia 
3y, rudimentary penis (<0.5cm), palpable right gonad (0.5-1ml) in scrotum, 
non-palpable left gonad and pubarche I. US: inguinal bilateral gonads (1ml), 
absence of female internal genitalia. 4y, bilateral orchidopexy and 
laparoscopy. 
Other features: Patient from Mauritania 
No No 
Ovarian tissue (left), 
testicular and ovarian 
tissue (right) 
GN0100 46,XY/F 46,XY DSD CGD 
Primary 
amenorrhea 
16y, primary amenorrhea and lack of secondary sex characteristics. US: 
structure at the vaginal location, non-visible uterus and ovaries. MRI: visible 
right gonad (1cm), no uterus. 17y, normal external genitalia.  Laparoscopy: 
streak gonads and absence of uterus. Begins treatment with estradiol. 
Yes Yes (17y) 
Fallopian tubes and 
ovarian tissue. No 
testicular tissue. 




3y, primary renal insuficiency. Hypoglycemia, vomiting, asthenia. 17y, testes 
4mL and penis 8cm. 
Other features: Glycemia 28mg/dL; Na 119mEq/L; K 6.8mEq/L; Aldosterone 
11ng/dL; PRA NA. 
- - - 
GN0103 46,XY/M 46,XY DSD Ambiguous genitalia 
At birth, hypoplastic penis and bilateral cryptorchidism. US: inguinal testes. 
6mo, after testosterone treatment penis increased to 5cm and 1.2cm in 
diameter. US: inguinal both testes. Presents pericentric inversion of chr. 9 
(inv[9][p11q13]). 
No No  
GN0104 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, micropenis buried in fat with scrotal hypospadias, bilateral 
cryptorchidism and well developed scrotal sacks. Palpable testes in inguinal 
canal, confirmed by US. 22mo, surgery for hypospadias. 




GN0108 46,XY/F 46,XY DSD CAIS 
Discordant 
karyotype 
At birth, female external genitalia. 3y, US: absence of uterus, no gonads in 
inguinal canal.12y, US: absence of uterus. 13y, MRI: blind short vagina 
(14.2mm), absence of uterus or annexes, near to left iliac vasses presence of 
soft structure that could correspond to undescended teste, no structures in 
inguinal region. 
No No  
GN0109 46,XY/F 46,XY DSD GD 
Virilization at 
puberty 
14y, primary amenorrhea, previously virilized (8-9y) and increased body and 
face hair. Erectile hypertrophic organ with perineal urethra and scrotal rests. 
US: rudimentary uterus and two images in left inguinal canal suggesting 
atrophic testes. MRI: endocervical cavity, next to another cystic cavity 
corresponding to cervix without ovaries. 15y, orchidopexy. Begins treatment. 
Yes Yes (15y) Testes with Sertoli cells and epididymis. 




14y, primary amenorrhea, stenotic and enlarged vagina. US: non-visible 
uterus and gonads. MRI: rudimentary uterus and vagina, ovaries not 
identified. 15y, Laparoscopy: rudimentary uterus, streak gonads. 
Other features: Obesity. 




GN0112 46,XY/F 46,XY OT DSD 
Discordant 
karyotype 
Male karyotype in amniocentesis. At birth, female external genitalia and 
bilateral inguinal gonads. 1d, US: hypoplastic uterus (2cm), normal vagina 
and inguinal gonads (right: 1x0.8x0.4c, left: 1.1x0.5x0.6cm). 
Yes No  
GN0114 46,XY/F 46,XY DSD CGD Suspected GD 
Absence of uterus and streak gonads. 
Other features: Niece presenting with same phenotype No Yes  (17y) Absence of germ cells 
GN0118 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
2y, curved penis with scrotal hypospadias, normal testes, rectal 
malformation. MRI: absence of uterus and ovaries. 
Other features: Anal agenesis, iron deficiency. Patient from Mauritania 
No No  
GN0119 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
6y, curved penis (4.4-4.5cm) with scrotal hypospadias, cryptorchidism and 
bifid scrotum. US: Right testis (15x9mm) in scrotum, left testis (13x6mm) in 
inguinal canal. 
Other features: Patient from Equatorial Guinea. 








2y, curved penis (3.1cm) with scrotal hypospadias and testes (0,5-1ml). Peno-
scrotal transposition. 5y, penis 5cm, and testes volume 0.5ml. No No  
GN0123 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, micropenis with perineal hypospadias, palpable gonads and atrophic 
bifid scrotum. 2y, laparoscopy: absence of Müllerian ducts. 10y, small penis 
(2.6cm), right testis in scrotum and left in inguinal canal. 14y, penis (5.5cm) 
No No 
2y, normal testicular 
tissue. 10y, absence 




with both testes in scrotum (2-3cc). 17y, biopsy. 38y, penis 3-4cm, testes 2cc. 
Other features: Obesity. 
Leydig cell 
hypoplasia. 
GN0124 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, curved penis (2.8cm) with scrotal hypospadias, palpable inguinal 
gonads and bifid scrotum. US: Left inguinal hernia, inguinal testes (left: 
1.6x1cm; right: 1.5x0.7). Absence of Müllerian ducts. 
Other features: Horseshoe Kidney. 
No No  
GN0125 46,XY/F 46,XY DSD CAIS 
Primary 
amenorrhea 
17y, primary amenorrhea, vaginal pouch, absence of uterus and annexes, 
confirmed by US. Patient refers that she presented bilateral inguinal hernia 
at birth, corrected by surgery (5y). 20y, laparoscopy: testicular gonads, no 
uterus and fallopian tubes 
No Yes (20y) Testicular tissue 
GN0132 46,XY/F Frasier syndrome 
Suspected GD, 
gonadoblasto
ma and renal 
insuficiency 
18y, gonadal dysgenesis and renal insufficiency. 19y, laparoscopy: Müllerian 
ducts. 
Other features: Renal insufficiency, obesity 
Yes Yes (19y) Gonadoblastoma 
GN0133 46,XX/M 46,XX T DSD Incongruent karyotype 
39y, male external phenotype with gynecomastia, unilateral cryptorchidism, 
azoospermia and hypergonadotropic hypogonadism. US: Right testis (30mm) 
with cyst (5.5mm), inguinal left testis.  
No No  
GN0138 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
At birth, micropenis (30mm and 40mm of diameter) with scrotal hypospadias 
and undescended testes. US: visible uterus (3.5cm), non-visible gonads. Yes No  
GN0139 46,XY/F 46,XY DSD CAIS 
Primary 
amenorrhea 
16y, primary amenorrhea, female external genitalia and vaginal pouch (2cm). 
Bilateral inguinal hernia at 2 months of age. US: non-visible right gonad, left 
gonad (1cm). 
No Yes (15y) Testicular tissue 




15y, gonadal exeresis: streak gonad with tumoral aspect and 
gonadoblastoma. Müllerian remnants. Yes Yes (15y) Gonadoblastoma 
GN0142 46,XY/F 46,XY DSD CGD 
Incongruent 
karyotype 
At birth, female external genitalia, clitoris 1-2cm with urinary meatus on 
base, non-palpable gonads in inguinal canal and undeveloped bifid scrotum. 
US: Absence of uterus and gonads. Gonadectomy is planned. 
Other features: Cousin diagnosed with 46,XY DSD gonadal dysgenesis (15y) 
No No  
GN0144 46,XY/M 46,XY DSD PGD Hypospadias 
At birth, male external genitalia, hypospadias and scrotal testes. 2y, surgery 
for hypospadias. 5y, small testes and unilateral cryptorchidism. US: left testis 
in scrotum and right testis in inguinal canal. 
Other features: Hypothyroidism. 




GN0145 46,XY/M 46,XY DSD PAIS 
Sexual 
reassignment 
20y, small penis (3.5cm) and testes (20cc). Request for sexual reassignment. 
Other features: 20y, identified as female since childhood. No No  
GN0146 46,XY/F 46,XY DSD PAIS Suspected AIS 
10y, gonadectomy. 14y, US: no uterus and gonads. 19y, hypertrophic erectile 
organ, partial labial fusión and non-palpable masses. No Yes (10y) Testicular tissue 
GN0147 46,XY/F 46,XY DSD AIS 
Primary 
amenorrhea 
7y, right inguinal hernia. At puberty, primary amenorrhea, clinical history 
from Algeria reporting ovarian and uterine agenesis, genitalia not described. 
13-14y, thelarche. 24y, left inguinal hernia. 30y, in Melilla, 
hypergonadotropic hypogonadism with testosterone 0ng/ml after 
gonadectomies, never had treatment. US: vaginal outline, non-visible uterus 
and annexes. 35y, female external genitalia, no facial hair, thelarche II-III, 
erectile organ is buried, one opening for urethra and vagina. 
Other features: Patient from Algeria. 
No Yes (7 and 24y) 7y, normal testes. 24y, normal testes 
GN0148 46,XY/F 46,XY DSD CGD 
Primary 
amenorrhea 
3y and 5y, surgery for bilateral inguinal hernia. 14y, primary amenorrhea. 
17y, pubarche. 20y, female external genitalia, rudimentary cervix. US: 
hypoplastic uterus (2.5cm), non-visible gonads, streak annexes. Confirmed by 
laparoscopy. 25y, refers menses under treatment. 
Other features: Father with inguinal hernia (not intervened), sister with 
intervened bilateral inguinal hernias 
Yes No Normal uterine tubes 




3y, female external genitalia with bilateral inguinal hernia. Gonadectomy. US: 
non-visible gonads and uterus. 9y, US: small uterus (7x10x24mm) and normal 
kidneys. 
Yes Yes (3y) 
Immature testes 
presenting with 
Sertoli cells and 
spermatogonias 
GN0151 46,XX/F 46,XX DSD GD Suspected GD 
16y, hypergonadotropic hypogonadism. US: hypoplastic uterus and annexes 
(17 and 18mm). 21y, US: uterus (57x32x22) and non-visible annexes. Bilateral 
mammoplastia. 
Yes No  
GN0152 46,XY/F 46,XY DSD PGD 
Ambiguous 
genitalia 
5mo, scrotal hypospadias, unilateral cryptorchidism and a vaginal pouch. 
Laparoscopy: Right testis in inguinal canal, no Müllerian ducts.19mo, 
micropenis with scrotal hypospadias, normal labia majora without minor 
labia and bilateral inguinal gonads. US: right gonad (0.4cc), left gonad (0.3cc). 
Other features: Ventricular hypertrophy, at 16m normal. Growth delay, 
hypothyroidism, delayed psychomotor development with macrocephaly. 2y, 




tubes, Sertoli cells 
and few 
spermatogonias. 
GN0153 46,XY/M Adrenal Insufficiency 
Hypoaldostero
nism 
8mo, hypoaldosteronism, hyponatremic dehydration and hyperkalemia. 




Actually under fludrocortisone treatment. 
GN0154 46,XX/F 46,XX DSD GD  
Primary 
amenorrhea 
15y, primary amenorrhea, female external genitalia, thelarche II-III and 
hypergonadotropic hypogonadism. US: small uterus, non-visible gonads. 
Laparoscopy: small uterus, fallopian tubes and 2 small ovaries. 
Other features: Childish habitus, short neck, lots of nevus 
Yes No 
Ovarian structure 
with  immature 
primordial follicles 
and follicular atresia 
GN0155 46,XY/F 46,XY DSD AIS 
Ambiguous 
genitalia 
At birth, clitoral hypertrophy. 2y, clitoroplasty and gonadectomy. 7y, left 
inguinal hernia. At puberty, virilization and male role. 20y, gender 
reassignment. 37y, male phenotype, low androgens levels and begins 
treatment. Scan: uterus remnants, other structure like corpus cavernosum in 
the perineum. 
Other features: 37y, obesity. 
No Yes (2y) Testicular disgenetic gonad 





7y, development of genitalia. Penis 8cm length and adult diameter, testes 
10mL, pubarche II. 
Other features: Pituitary adenoma, hearing loss. Indian origin. 
No No  
GN0157 46,XY/M 46,XY DSD LH RD Adrenarche 
6y, precocious puberty, genital development P2, testicular volume 2-3ml. 7y, 
absence of other pubertal signs, pubarche with normal testes, changes in 
body odor, acne. US: normal. 9y, genital development T3, testicular volume 
3ml. US: normal testes located in scrotum.  
Other features: Patient from Equatorial Guinea. 
No No  
GN0158 46,XX/M 46,XX  OT DSD 
Ambiguous 
genitalia 
3y, curved penis with scrotal hypospadias, bilateral cryptorchidism and 
atrophic scrotum. Non-palpable testes. US: prepubertal uterus, images 
suggesting ovaries. Biopsy. 
Other features: Patient from Sierra Leone. 
No No 
Ovarian tissue (left), 








At birth, curved penis with scrotal hypospadias and unilateral cryptorchidism. 
FISH: Confirmed SRY translocation. 3mo, normal penis and testes (2ml). 9y, 
augmented penis (6.3cm circumference x3.8cm length), normal right testis 
and left in inguinal canal. 11y, surgery for hypospadias. 12y, US: right testis 
(22.7x7.3mm), left in inguinal canal (24x7.5mm). 13y, left orchidopexy. Right 
testis 3ml and left 5ml in size, lack of pubarche and axilarche. 
Other features: 3mo, Smith Lemli Opitz syndrome suspected. Psychomotor 
delay. 11y, cafe au lait spots, microcephaly, corpus callosum agenesia. 
No No  




karyotype Other features: 5mo, occipital plagiocephaly, delayed motor development, 
bilateral congenital cataracts. 
GN0162 46,XY/M Scrotal hypospadias 
Scrotal 
hypospadias 
16mo, curved penis (3.8cm) with scrotal hypospadias and normal testes. 








11mo, distal hypospadias, surgery. 10y, micropenis (3.6cm) buried in fat, 
testes (3mL) in scrotum. After testosterone (for 19 days), right testis (2-3ml), 
left testis (4ml), penis (5.2cm length and 6cm diameter), no pubarche. After 
treatment (for 1 month), testes 5ml, penis 5cm and 6.4 cm diameter, 
pubarche III. 12y, penis (5.2cm and normal diameter) buried in fat, testes 
10ml and 12ml, pubarche III. 13y, penis (9cm and 8.9cm diameter), 
testes>25ml, pubarcheIII-IV. 14y, US: intraescrotal testes with normal size 
and morphology. Surgery for hypospadias 5 times. 
No No  
GN0164 46,XY/M 46,XY DSD LH RD 
Bilateral 
gynecomastia 
36y, bilateral gynecomastia, micropenis, small testes (3mm) and 






Hypospadias At birth, normal penis with distal hypospadias and testes in scrotum (1-2mL). No No  
GN0169 46,XY/M 46,XY DSD PGD Hypospadias 
At birth, curved penis with scrotal hypospadias, undescended testes, bilateral 
inguinal hernia and bifid scrotum. Orchidopexy. 8y, US: testes (0.7ml and 
0.3ml) in scrotum. 
No No  
GN0171 46,XY/M 46,XY DSD Ambiguous genitalia 
At birth, micropenis. 11y, micropenis (3.5 cm), non-palpable testes. MRI: 
testes in inguinal canal. 14y, begins increasing doses of testosterone therapy. 
18y, azoospermia. 21y, penis (8cm) buried in subcutaneous fat, left testis in 
scrotum (0.5ml). US: ovoid structure (17x16mm) in right inguinal canal, 
corresponding to atrophic testes. Laparoscopy and biopsy are planned. 
Other features: 11y, Obesity (BMI 36.6, +6.4SD) and short stature. 21y, 
obesity (BMI 44.9,+6.8SD), short stature (156.1 cm), 







At birth, micropenis, hypoplastic scrotum with non-palpable gonads. 3mo, 
micropenis (1cm), developed scrotum. US: non-visible gonads. Begins 
treatment with testosterone. 5mo, penis (2.3cm).  Continues treatment with 
testosterone. 9mo, penis (3cm). 1y, MRI: absence of gonads. 16mo, penis 
(4cm) and developed scrotum. 











2mo, curved micropenis (1,8-2cm) with scrotal hypospadias and palpable 
small testes (0,5ml) in scrotum. 
Other features: Hypothyroidism. 
No No  
GN0175 46,XX/F 46,XX DSD Secondary amenorrhea 
16y, complete pubertal development with secondary amenorrhea. Patient 
refers menarche at age 13. Normal internal genitalia. US: normal uterus 
(5,3cm), gonads (9-10cm). 
Other features: Ventricular septal defect. 








At birth, hypospadias, palpable scrotal testes and bifid scrotum. US: non-
visible Müllerian ducts. No No  
GN0177 46,XY/F 46,XY DSD CAIS 
Discordant 
karyotype 
Male karyotype in amniocentesis. At birth, female external genitalia. 6d, US: 
bilateral inguinal gonads corresponding to testes. 13d, biopsy. 
Other features: Brother affected with phenylketonuria, she is a carrier of the 




cells, no Leydig cells 
(both) 
GN0178 46,XY/M 46,XY DSD PGD Micropenis 
3mo, micropenis, good response to treatment. 6y, penis 2,5cm and normal 
diameter. 9y, normal penis, testes (2ml) and hypoplastic scrotum.10y, 
smaller penis (2cm), testes (2ml) and hypoplastic scrotum.  
Other features: 8y, Autoimmune thyroiditis. 
No No  







At birth, left scrotal hypoplasia, bifid scrotum and left renal agenesis. 4y, 
orchidopexy. 11y, male phenotype, penis 3.5-4cm, testes (right 4ml, left 
2ml), bifid scrotum, bilateral gynecomastia and pubarche I. 
Other features: Lipomeningocele. Chinese origin. 
No No  




Undescended right testis. 12y, surgery. 14y, hormonal treatment to induce 
puberty. 20y, testes of 10 and 12ml in scrotum.21y, testes of 12ml in size, 
normal penis. 
Other features: Delay of psychomotor development, mental retardation, lack 
of GH. Father with schizophrenia. 
No No  
GN0185 46,XY/F 46,XY DSD GD 
Ambiguous 
genitalia 
At birth, penis (1.5cm) with hypospadias, two individualized labia majora 
with blind vagina and palpable right gonad in inguinal canal. US: Presence of Yes Yes (1y) 





uterus and vagina, non-visible ovaries. MRI: hypertrophic clitoris, normal 
vagina, hypoplastic uterus (2x0.8x0.8), non-visible gonads. 1y, laparoscopy: 
hypoplastic uterus which continues to fallopian tubes, right one reaches 
testis in inguinal canal and left tube encloses streak abdominal gonad. 
Vaginoplasty and clitoroplasty. 11y, thelarche MI, pubarche P1. 
testis (right). 




14y, high stature. 16y, primary amenorrhea, pubarche P4, undeveloped 
mammals, hypertrophic erectile organ, palpable gonads (2cm) in inguinal 
canal. MRI: inguinal bilateral testes. 
Other features: High stature. Brother with gynecomastia. 





Azoospermia 34y, male phenotype, azoospermia. US: small testes (right 17x8mm, left 21x10mm).  No No  




At birth, female external genitalia, normal clitoris and palpable male gonads 
in labioscrotal folds. 3mo, US: vaginal pouch, bilateral testes (0.3cc), without 
uterus and ovaries. MRI, testes in labioscrotal folds (20x9 and 18x8mm). 
No No  
GN0190 46,XX/F 46,XX DSD GD 
Primary 
amenorrhea 
14y, primary amenorrhea, infantile female phenotype, thelarche M2, 
pubarche P1 and hypergonadotropic hypogonadism. Normal vagina. 15y, US: 
infantile uterus and left streak gonad. MRI: small uterus, normal vagina, no 
ovaries. 
Other features: Small stature. Aunt of the mother presented precocious 
menopause (15y). 






At birth, inguinal hernia, labioscrotal fusion, labioescrotal and inguinal 
gonads. Prader IV. MRI: visualized hypoplastic uterus and upper vagina, 
absence of ovaries. 1y, gonadectomy, vaginoplasty and clitoroplasty. 11y, 
pubertal signs. 







19y, amenorrhea. MRI: hypoplastic uterus, absence of gonads and lower 
vagina. 
Other features: 19y, short stature, multiple nevus, Turner phenotype. 
Yes No  
GN0194 46,XY/F 46,XY DSD AIS 
Primary 
amenorrhea 
15y, primary amenorrhea. 44y, absence of developed breast, pubic and 
axillary hair. Patient refers that at the age of 30y, doctor said she had 
infantile uterus and ovaries. 
Other features: Abdominal obesity. Sister (30y) with primary amenorrhea, 
absence of development breast and absence of pubic and axillary hair. 




GN0195 46,XY/M Hypospadias Hyspospadias 2y, Hypospadias No No  
GN0196 46,XY/F 46,XY DSD CGD 
Ambiguous 
genitalia 
At birth, micropenis (2x1.5) with vaginal opening and bifid scrotum looking 
like labia majora without hyperpigmentation. Non-palpable gonads. 12d, US: 
normal uterus (3.5cm), in intra-abdominal location an ovoid structure 
(11.8mm) suggesting right testis. 
Yes No  
GN0198 46,XX/F 46,XX DSD GD 
Primary 
amenorrhea 
17, primary amenorrhea, delayed puberty and hypergonadotropic 
hypogonadism. US and MRI: non-visible ovaries and uterus No No  
GN0199 46,XY/M 46,XY DSD CGD Micropenis 
7d, micropenis with fused labia minora, non-palpable gonads, tight vagina. 
US: normal uterus, absence of gonads. Yes No  
GN0200 46,XY/M 46,XY DSD PGD 
Obesity, 
micropenis 
At birth, hypospadias. 8mo, micropenis. 2y, surgery for hypospadias. 10y, 
normal male phenotype, penis buried in fat, testes in scrotrum (2-3ml). 
Other features: Obesity. 
No No  
GN0201 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
15d, micropenis (2.5cm), non-palpable testes and hypoplastic scrotum. 2mo, 
micropenis and bilateral crytorchidism. US: absence of gonads. 8mo, good 
response to the treatment with testosterone. 10mo, right orchidopexy. 3y, 
left orchidopexy. 6y, surgery for hypospadias. 7y, normal penis and testes (1-
1.5ml) 
No No  
GN0202 46,XY/F 46,XY DSD CGD 
Primary 
amenorrhea 
15y, primary amenorrhea, female external genitalia, pubertal delay and 
hypergonadotropic hypogonadism. 17y, MRI: normal vagina, rudimentary 
uterus, left ovary (<1cm) and absence of right gonad. 
Other features: 15y, Obesity (IMC 37,52). 18y gender dysphoria 
Yes No  
GN0203 46,XY/M 46,XY DSD PGD 
Ambiguous 
genitalia 
5y, micropenis with fused scrotum and bilateral cryptorchidism. US: atrophic 
testes in inguinal canal. 
Other features: Born in Syria 
No No  
GN0204 46,XX/F 46,XX DSD GD 
Primary 
amenorrhea 
17y, primary amenorrhea, normal female external genitalia and 
hypergonadotropic hypogonadism, US: small uterus, inconsistent findings for 
gonads. 
Yes No  
GN0205 46,XX/F MRKH II syndrome  
Vaginal 
agenesis 
16y, primary amenorrhea, agenesia of vagina, uterus and left kidney. MRI: 
absence of cervix, uterus and upper vagina. No No  




14y, primary amenorrhea and delayed puberty. US: prepubertal ovaries and 
uterus.  
Other features: Mother was virilized during pregnancy 
Yes No  







chemotherapy. Proteinuria. At surgery, found hypoplastic testes. 
Other features: Patient from Tunisia. 





1mo, adrenal insufficiency. 9mo, hyperpigmented genitals, hypertrophic 
penis (5cm) and testes 2mL, pubic hair. CT: lack of left gland. 15mo, penis 
6cm. 
Other features: Patient from Mexiko 
- - - 
POL0285 46,XY/M Adrenal Insufficiency Salt wasting 
At birth, salt wasting, hyperpigmentation. 45y, pubertal failure, 
hypogonadotropic hypogonadism. Family background.. - - - 
POL0301 46,XY/M Adrenal Insufficiency 
Acute 
hyponatremia 
2y, acute hyponatremia. Normal penis, testes (0.5mL) and no 
hyperpigmentation. 
Other features: Glycemia 70mg/dL; Na 119mEq/L; K 4.6mEq/L; Aldosterone 
0.15ng/dL; PRA NA. 
- - - 
RE0045 46,XY/F 46,XY DSD GD 
Primary 
amenorrhea 
14y, primary amenorrhea, delayed puberty and hypergonadotrophic 
hypogonadism. 32y, gonadal biopsy revealed immature testes. 
Other features: 17y, diagnosed with bilateral pheochromocytoma. Atrophic 
kidney. Sister presenting with 46,XX DSD gonadal dysgenesis. 
Yes Yes (32y) Immature testes with Leydig cells hyperplasia 
AIS, androgen insensitivity syndrome; CAIS, complete androgen insensitivity syndrome; CGD, complete gonadal dysgenesis; CT, computed tomography; D, days; DSD, disorder of sex 
development; F, female; GD, gonadal dysgenesis; M, male; MGD, mixed gonadal dysgenesis; Mo, months; MRI, magnetic resonance imaging; MRKH, Mayer-Rokitansky-Küster-Hauser; 
N, normal; ND, not determined; OT, ovotesticular; PAIS, partial androgen insensitivity syndrome; PGD, partial gonadal dysgenesis; PRA, plasma renin activity; RD, receptor defect; US, 





Supplementary data 3. Biochemical data of the patients included in the genetic analysis. Out of range values are given in bold. 
 
Biochemical data 
Case Karyotype Age at evaluation 



























17y          65.9/108* 37/150*    
24y          92 41 71   
GN0003 46,XX ND               
GN0004 46,XX 13y     1.8 867   320 23.9 21.5 21   
GN0007 46,XY 16y     1.5    29 41.4 10.7 26.5   
GN0009 46,XY 17y          10.4 144 <10   
GN0011 46,XY 16y    0.5 2.5 183 2.6 5.1 1 145 45 12   
GN0012 46,XY 
At birth <25        34.7      
8y      1295   <10 24.8 <0.5    
11y         12 86 20    
13y         55 85 42.3    
15y        7 87.8/281* 97.9 14.8    
17y         856.2 22.3 12.2    
19y         381 64.6 34.6    
21y         532 69.3 33.5    
24y         783 0.3 <0.1    
26y        16.6 348 27.5 10.2    
27y         899 0.3 0.2    
GN0013 46,XY 18y         2540 109 50.3 12.2   
GN0014 46,XY 13y      2600   16 50 35 <10   
GN0017 46,XY 12m 29 10.7       40/30* 41.7/4* 19.1/8.7*    
GN0018 46,XY ND               
GN0020 46,XY 13y     N* N*      <5   
GN0023 46,XX ND               
GN0024 46,XY 
1m       1.4  73    0.5 11 
2m       1.5  54     11.8 
GN0025 46,XY 17y        8.7  127 54 <10   




GN0027 46,XY 15y     665    <20 58.8 16.3 >20   
GN0028 46,XY 
10y       1.7/1.9*  86.3/187.4* 11.9 0.9  0.2/0.1*  
11y     1.3  2.5  290.5 30.4 7.1  0.5  
14y      1900   412.5 35.9 11.4   <0.1 
15y      2010 4.1  518 38.9 14.6  0.5 0.4 
GN0029 46,XY ND               
GN0031 46,XX 16d    3.49     19 0.8 <0.1 <10   
GN0033 46,XY 12y  11.2       16.1 0.4 <0.1   10.2 
GN0034 46,XY 
8m         << 1 2    
9y         17 2.8 <<    
11y         60 15 22  0.4*  
13y      2166   23.4 125 30.6 <<   
15y          110 31.4    
GN0035 46,XY 42y  9.2  <0.2 0.3 1866 0.7 1.8 16.8 69.1 19.3 11   
GN0037 46,XY 4y N/N*
 N   N    0.1/3.6      
11y         5.7/6.8*    0.4/0.5*  
GN0038 46,XY 11y      1400 3.9  200 18.1 11.8 53   
GN0039 46,XY ND               
GN0041 46,XY 
10y      368   <10 31 2.5 <10   
12y         <10 76 9 <10   
13y         <10 112 108 <10   
17y      627   15 23 10 <10   
GN0042 46,XY 
10y    4400 1.9  1.0  250 24 95 16   
27y     0.6  2.5   21.4 8.44 26.4   
GN0043 46,XY 5d  16 9  2.4  2.1  160    2.1  
GN0046 46,XY ND               
GN0050 46,XY 3y         29/22 111 6    
GN0051 46,XX 6y     <0.1 <180   <10/44.1*    0.3/0.1*  
GN0054 46,XX 
41y  23.8      7.5 63.5 31.7 5.3    
52y (After 
treatment)     0.8    616.3      
GN0055 46,XY ND               
GN0056 46,XY 
14d          1.8 1.8    
24d      0.2/0.2* 0.5/0.5*  110/325*    0.5/0.4*  




7d       0.7  56 9.1 3.9 15 0.5  
13d       0.8  40 9.8 1 20   
1m       0.5  14 18.5 2.4 15 0.3  
2y 37.4 18.5/30.7* 2.1/4.2*  1.1/4.1*  0.5/0.6*  28 217.0 58.2    
GN0064 47,XY At birth         << 41 <<    
GN0066 46,XY 
4d      689   65.9 <1.5 <1.5    
7d         21.5 <1.5 3.7    
8y     0.1 1690   16.7      
GN0068 46,XY ND               
GN0070 46,XY 9y         80*    N*  
GN0075 46,XY 2d  6.9    202   2360 <0.5 <0.5  1.5  
1m  10.4    400   6750 3.7 2.5    
GN0076 46,XY 
8d         105 0.4 0.2 17   
15d         121/900*      
GN0078 46,XY ND  17.8       170      
GN0080 46,XY ND               
GN0084 46,XX 
16y N/N*    1.5          
21y    1.3 1 3480   25 7 7.2 78   
22y    0.8 1.5 3490   25.3 6.5 5 37   
GN0088 46,XY 
3y         92.2 3.9* 2.7*    
4y         170.1 0.3 0.1/0.7*    
GN0090 46,XX 6y     0.2 <180 <0.3  <10/125* <1.5 <1.5  <0.1/0.1*  
GN0091 46,XY 8m 1550 1.63   1.8 8.32   <0.2 4.5 4.2    
GN0096 46,XX 
3y      24.9   <0.12/143.7* 2,3 <0.1  0.1  
4y       0.5/<0.3*  14/59 1,3 <0.1  0.1/0.1* 8.8 
GN0100 46,XY 16y 19.8 8.5   0.90 3032  6.7 34 145 41    
GN0101 46,XY 17y 1747 4   0.2    170 4.6 2.5    
GN0103 46,XY 
At birth      <17 0.1  <8 99.5 26.9    









16m     0.8  0.1 30.6 20 0.7 0.2  <0.1  
21m     0.1  <0.1        
GN0108 46,XY 
12y         95 11.4 6.3    
14y      2180 7.8  833 16.2 22 42 0.7 16.7 
GN0109 46,XY 14y 52 16.3   0.9 1690 1.7 12.8 193 112.5 37.8 16.7 0.5 0.4 
GN0111 46,XY 14y  18/27*    1960 2.1  36.6/46* 44.3 12.2 31.0  <0.1 
GN0112 46,XY 
4d  2.3   5 492   122 0.2 <0.1 22.2   
17d        94.4 43 0.2 <0.1 <11.8 0.2 105.2 
GN0114 46,XY ND          >> >>    
GN0118 46,XY 2y  17.7  0.2  <150 <0.3/<0.3*  <10/110.4*    
<0.1/<0.
1*  
GN0119 46,XY 6y  11   0.4 270 <0.3/<0.3*  <10/263.4 0.8 <0.1  0.1/0.3* 22.8 




10y         2/13      
14y N N   N    18/35 55 15    
15y         140/500* 39/72* 11/137*    
18y        9 200 33 21    
38y 36 14.3   0.4 1293 1.5 7 500 25 15.6 20  <0.1 
GN0124 46,XY 
4m      374 0.5  205 0.6 4.8 <12 0.2 99.4 
6m       0.3/0.8*  77.3/680*    0.1/0.3* 112.9 
GN0125 46,XY 17y 69 12.3        10 70    
GN0132 46,XY ND               
GN0133 46,XX 
42y        7.8 335  2.09 41.7   
44y        12.6 238  3.96 30.8   
GN0138 46,XY 
At birth     5.3    365 2.2 3.1   19.2 
4d         97    0.6*  
8d         69 6.2 14.5    
GN0139 46,XY 
16y    0.8 1.1 3060 2.1 17.4 463.3 14 52.5 22   
17y          89.3 53.7 19   
GN0141 46,XY 25y          71 33 49   
GN0142 46,XY 
4d  N     1.3  39 3.5 0.3  0.3 << 
12d       1.8  33    0.2 << 





5y      150   5 0.6 <0.1    
6y       0.4  <5/650* 0.5 <0.1  1.5*  
GN0145 46,XY 20y         607 N N    
GN0146 46,XY 
14y 79.3 11.6   0.3 575 0.5 3.8 6 1.87 0.3 30.6   
19y (During 
treatment)         8 2.2 0.6 30.5   
19y 80.8 10.3   <0.01 806 0.5 4.4  3.5 1.3 5   
GN0147 46,XY 35y 27.9 21.3   0.2 1390 1.3 7.6 19 67.0 48.5 5   
GN0148 46,XY 
20y  N    N N N 31 51 28 15.8   
25y (During 
treatment) 113
 17.8 3.4 0.9  344  23.9 20 24.8 16.7 26 0.3  
GN0150 46,XY 9y  6.5   0.4 683 <0.3  18 33.1 1.6 <12 0.1 <0.1 
GN0151 46,XX ND               
GN0152 46,XY 
5m  7.2   0.9 <150   9 3 1 <12 0.2  
19m 22.7 22.8   0.3/0.3* 1260 <0.3/<0.3*  3/17* 3.5 1.1 5 0.2/0.2*  
GN0153 46,XY 8m 2297 2.9   0.3          
GN0154 46,XX 15y  N     N   70 18 22   
GN0155 46,XY 37y         19      
GN0156 46,XY 
6y     1.4 0.6  14.1 434.7 4.6 4.6 22   
7y N N   0.9 N N  406 3.5/7.1* 2.5/25.0* N   
GN0157 46,XY 
6y    0.3 0.1 1100 <0.3  <20      
7y   1.4  0.3 1100   <20 0.5 <10    
GN0158 46,XX 3y  13.9   0.1 <150 <0.3/<0.3*  <10/72.8* 3 <0.1  <0.1 7 
GN0159 46,XX 
9y  13.1  0.1  480 <0.3 17 <10 1 0.1  <12/0.1*  
11y         <10 1 0.3    
12y         <10 0.7 1.2    
13y         35 0.8 2 <12   
GN0160 46,XX ND               
GN0162 46,XY 16m    0.2 0.4 168 <0.3  <10 0.7 <0.1  <0.1  
GN0163 46,XY 
10y       <0.3  <10 1.3 <0,1  0,1 193 
14y    0.4 0.9 1370 1.3  510 1.7 2.3 22 0.3 9 





5d     1.7 740 1.6  72 0.5 1.6 <5 0.3 66.3 
2m         108 1 5 <5 0.1 115.1 
GN0169 46,XY 
At birth       1.3  178      
8y       0.3  20 1.5 1.5  0.1 52.3 
GN0171 46,XY 
11 y         130 63.3 14    
14 y         130 36.7 18.5    
15 y         590 1.5 <0.5    
21 y         1180 9.5 4    
GN0173 46,XY 
At birth         211     0.5 
3m  34.9* 15.2* 2.1* 0.6* 37* 202.7*   3* 21.2* 0.8*  <0.1* 0.5* 
6m  13* 6.3* 1.6* 0.1* 8* 77.6*   3* 40.4* 6.0*   <0.1* 
GN0174 46,XY 5m    0.8 1.7 197 <0.3 43 134 0.8 1.8 <12.0 0.1 240 
GN0175 46,XX 14y          9/22* 9/99* 34   
GN0176 46,XY 3m     N  0.4/0.6*  146.8/624.3*    0.1/0.2* N 
GN0177 46,XY 10d 30.5
 12.8  4.4 1.2 13.1 6.4  122 4.6 2.3 8.7 0.5 75.6 
16d    2.5* 1.4* 2852* 4.5*  141/65* 20.6* 5*  0.4/0.2*  
GN0178 46,XY 
3m         387* <</<<* <</<<*  0.1*  
10y  17.8      29       
GN0179 46,XX ND               
GN0182 46,XY ND               
GN0183 46,XY 
20y        14.1 72.9 8.2 6.5 14   
21y     1.2 2270 1.2 8.8 71.3 9.9 6.3 14.3 0.5  
GN0185 46,XY 5d  14 4.3  1.9 92 0.9  0.1 11 1.5 <5 0.4  
GN0186 46,XY 
14y         450      
15y  10.4       5 3.1 6.7 51  471 
GN0187 46,XX 34y         416 46.4 20.8 36   
GN0189 46,XY 
4d              >21 
20d     3.0 710   1.6 0.5 3.4 <10 <0.1  
GN0190 46,XX 14y  35 4.5 0.4      169.4 61.3 5   
GN0191 46,XY/X0 19y  11.6       46 46 15 5   
GN0192 46,XY/X0 ND               
GN0194 46,XY ND               
GN0195 46,XY ND               
GN0196 46,XY 
4d   9.2  3.1    45 4.6 1.2    




GN0198 46, XX 17y          103 33.4 <5   
GN0199 46,XY 15d  21.4  0.6 8.2 247 3.2  1.5 17.3 17.1 16.2   
GN0200 46,XY 10y     0.6/1.6*  <</0.3*  2/40* 0.3 0.29    
GN0201 46,XY 
2mo  12   12 863 1.1  9/50* 4.3 7.8   942 
5y  6.5   0.4 168 <0.3  3 0.7 <0.1 <10 <0.1 >23 
GN0202 46,XY 
15y        10 38 77.3 35.3 <12   
17y  9.9   0.6 1580 1.5 8 0.3 63.7 30.5 25  <0.1 
GN0203 46,XY ND               
GN0204 46,XX 17d    <0.1     <10 103 31.5 <10  <0.2 
GN0205 46,XX 16y    0.4    16.4 27 6.0 6.8 35.1   
GN0207 46, XX 14y  12.2   0.4 240 <0.3  0.1 50.6 22.1 <5.4  <0.2 
OT0567 46,XY ND               
POL0274 46,XY 9mo <10 20.2   334 50 0.3  235.3 1.1/2.2* 1.1/5.6*    
POL0285 46,XY ND               
POL0301 46,XY 2y 777 2.3             
RE0045 46,XY ND               
ACTH, adrenocorticotropic hormone; AMH, anti-Müllerian hormone; D, days; DHEA-S, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; E2, estradiol; FSH, follicle-
stimulating hormone; hCG, human chorionic gonadotropin; LH, luteinizing hormone; Mo, month; N, normal; ND, not determined; PRL, prolactin; P4, progesterone; Y, years; 





Supplementary data 4. Hospitals in which the patients involved in the study were clinically diagnosed. 
 
• Hospital Universitario Cruces (Barakaldo, Spain) 
• Hospital Universitario Basurto (Bilbao, Spain) 
• Hospital Universitario Araba (Vitoria-Gasteiz, Spain) 
• Hospital Universitario Donostia (San Sebastián, Spain) 
• Hospital Bidasoa (Hondarribia, Spain) 
• Complejo Hospitalario de Navarra (Pamplona, Spain) 
• Complejo Hospitalario La Mancha Centro (Ciudad Real, Spain) 
• Hospital Universitario de Getafe (Getafe, Spain) 
• Hospital Manises (Manises, Spain) 
• Hospital Clínico Universitario Valladolid (Valladolid, Spain) 
• Hospital Comarcal de la Axarquia (Vélez-Málaga), Spain) 
• Hospital de Mérida (Mérida, Spain) 
• Hospital General Universitario de Alicante (Alicante, Spain) 
• Hospital General Universitario Gregorio Marañón (Madrid, Spain) 
• Hospital Público General de Tomelloso (Tomelloso, Spain) 
• Hospital Regional Universitario de Málaga (Málaga, Spain) 
• Hospital Sierrallana (Torrelavega, Spain) 
• Hospital Universitario Central de Asturias (Oviedo, Spain) 
• Hospital Universitario de La Princesa (Madrid, Spain) 
• Hospital Universitario Germans Trias i Pujol (Badalona, Spain) 
• Hospital Universitario Infanta Cristina (Parla, Spain) 
• Hospital Universitario Marqués de Valdecilla (Santander, Spain) 
• Hospital Universitario Nuestra Señora de la Candelaria (Santa Cruz de Tenerife, Spain) 
• Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Spain) 
• Hospital Universitario Puerta del Mar (Cádiz, Spain) 
• Hospital Universitario Ramón y Cajal (Madrid, Spain) 
• Hospital Universitario Vall d'Hebron (Barcelona, Spain) 
• Hospital Universitario Virgen de las nieves (Granada, Spain) 
• Hospital Universitario Virgen del Rocío (Sevilla, Spain) 
• Hospital Virgen del Puerto (Plasencia, Spain) 






Supplementary data 5. Clinical data sheet for the inclusion of a patient in the study. 
 
CLINICAL QUESTIONAIRE FOR THE GENETIC ANALYSIS OF DISORDERS OF SEX DEVELOPMENT 
FAMILY CODE:      Referring doctor:    
DATA AT BIRTH  
Date of birth:  
Gestational age (Weeks):  
Weight (gr):            Length (cm):             
Twins/Multiple birth:          Yes:                          No: 
ADDITIONAL DATA  
Karyotype:                                             SRY (FISH): 
Age at diagnosis (years/months/days):             
Assigned sex: Male  Female 
Gender reassignment:   Yes              No                 Unknown 
 If Yes, age at gender reassignment: (Years/months) 
REASONS FOR THE FIRST REFERRING 
Ambiguous genitalia: Yes                    No                       Unknown 
Inguinal hernia:   Yes                    No                       Unknown 
Gynecomastia:   Yes                    No                       Unknown 
Prenatal diagnosis:  Yes                    No                       Unknown  
Adrenal insufficiency/Salt loss:  Yes                    No                       Unknown 
Insufficient virilization:   Yes                    No                       Unknown 
Primary amenorrhea:   Yes                    No                       Unknown 
Others:  Yes                    No                       Unknown 
COMMENTS: 
 
FAMILY BACKGROUND  
PARENTS: Consanguinity:  Yes  No  Unknown 
Adopted:  Yes  No  Unknown 
MOTHER: Normal:  Yes  No  Unknown 
Virilization during pregnancy:   Yes  No  Unknown 
Drugs during pregnancy:    Yes  No  Unknown 
 If yes, which drug: 
FERTILISATION: 
-Coital:      -IVF (in vitro fertilization):    -
ICSI (intracytoplasmatic sperm injection):    -Others:  
BROTHERS/SISTERS:  




 Brief description:  
OTHER AFFECTED FAMILY MEMBERS: 
 Sex:  M F Unknown 
 Brief description:  
FAMILY BACKGROUND OF INFERTILITY: Yes No  Unknown 
 If yes, which family member? 




Penis/Clitoris  Hypospadias         Labioscrotal fusion        Gonads                 Right/Left 
Normal for M     Normal for M                  Yes                           Labioscrotal                   / 
Small for M        Distal Hyposp          No                             Inguinal                             
Big for M            Midpenile Hyposp Unknown                Abdominal                        
Normal for F      Proximal Hyposp                                                                                
Big for F              N for F                                                               
VIRILIZATION IN 46, XX: 
Prader scale:    I        II        III         IV        V 
FEMALE INTERNAL GENITALIA  
Are present:  Yes No Unknown  
Vagina:  Yes No Unknown Type:  
Uterus:  Yes No Unknown Type:    
Fallopian tubes:  Yes No Unknown  
Ultrasound: Age:  Report: 
   
Laparoscopy: Age:  Report: 
 
PUBERTAL SIGNS Spontaneous  Induced   Age (Years/months): 
FEMALE  
Thelarche (Tanner):     M1            M2          M3           M4             M5 Unknown 
Pubarche (Tanner):    P1            P2           P3             P4              P5  Unknown 
Menarche:        Yes              No          Unknown 
MALE  
Volume right testis (ml):   Volume left testis (ml):  
Penis length (cm):    Gynecomastia (diameter cm): 








Date:   
Karyotype: 
 -Blood:                                                                 -Gonad: 
AMH (ng/ml): 





LH (UI/l):                             FSH (UI/l): 
Testosterone (ng/dl):          Androstendione (ng/ml):          Dihidrotestosterone (ng/ml): 
Estradiol (pg/ml):                                       Estrone (pg/ml): 
17-OH Progesterone (ng/ml):                                         Progesterone (ng/ml): 
17-OH Pregnenolone (ng/ml):                                         11-Desoxicortisol (ng/ml):                
DHEA-S (ng/ml):                                       DHEA (mcg/dl):                          Cortisol (mcg/dl):     
Extraction date:  
After-stimulating 
Age   
-GnRH/LHRH test:   
 FSH peak (min      ) (UI/l):                            LH peak (min      ) (UI/l) 
Basal testosterone (ng/dl):                         Basal estradiol (pg/ml): 
-HCG test: dose (UI) y number of doses:  
Testosterone (ng/dl):                                                  Androstendione (ng/ml):             
Dihidrotestosterone (ng/ml):          
-ACTH test: peak at 60 mins 
17-OH Progesterone (ng/ml):                                        Cortisol (mcg/ml): 





LAPAROSCOPY:  Yes  No 
REPORT: 







MOLECULAR STUDY  
Previously studied genes:  
Affected gene and variant:  
 
PROGRESS 
-Treatment for micropenis: Yes/No 
 Testosterone for topical use: Dosage:                 Number of days: 
 IM testosterone: Type:                  Dosage (mg):       Number of doses/frecuency:  








-Other surgeries: Yes/No 
 Report: 
-Hormone replacement therapy during puberty: Yes/No 
Testosterone IM/topical use: Type:              Dosage (mg):          Number of doses/frecuency:  
GNRH: Dosage 
FSH: Drug name:   Dosage:  Frecuency:  
LH: Drugname:    Dosage:  Frecuency: 
Estrogens: Drugname:   Dosage:  Frecuency: 










Supplementary data 6. Primers, probes and conditions used for the amplification by PCR, QMPSF, genetic markers and site-directed mutagenesis. 
 
Primers and conditions used for the PCR-based amplification. 






Amplicon 1 F1-SRY gcttgagaatgaatacattgt 94ºC3'35X(94ºC1'15''58,7ºC1'15''72ºC2')72ºC7'4º 574   
R1-Int-SRY ggtatttctctctgtgcatg   





















R4-HSD17B3 gatgtatgacaacaagctttgcatc   
Exon 5 F5-HSD17B3 ctgatcttctgacacatttttgttt 95ºC5'35X(95ºC30''55,7ºC30''72ºC30'')72ºC7'4º 168   
R5-HSD17B3 ccaggttctgggtcccctggct   
Exon 6 F6-HSD17B3 gagaatttctctaatcatccggctg 95ºC5'35X(95ºC30''55,7ºC30''72ºC30'')72ºC7'4º 126   
R6-HSD17B3 acatgttaatgcatttcgcaca   
Exon 7 F7-HSD17B3 agttccttgtcgggcttacctttgg 95ºC5'35X(95ºC30''55,7ºC30''72ºC30'')72ºC7'4º 121   
R7-HSD17B3 agggcagggaggccatgttgctcca   
Exon 8 F8-HSD17B3 caacaaagccatgggaac 95ºC5'35X(95ºC30''55,7ºC30''72ºC30'')72ºC7'4º 154   
R8-HSD17B3 aaggaagagacttggaagtcatgac   










R11-HSD17B3 gaggaaaaggttgtgctggactcct   





Exon 1, Amplicon 1B 
F1B-AR cacaggctacctggtcctgga 
94ºC5'40X(94ºC45''58ºC45''72ºC45'')72ºC10'4º 416 DMSO (10%) R1B-AR ctgccttacacaactccttggc 
Exon 1, Amplicon 1C 
F1C-AR gctcccacttcctccaaggac 
94ºC5'40X(94ºC45''58ºC45''72ºC45'')72ºC10'4º 528 DMSO (10%) R1C-AR cgggttctccagcttgatgcg 
Exon 1, Amplicon 1D 
F1D-AR ccagagtcgcgactactacaactt 
94ºC5'40X(94ºC45''58ºC45''72ºC45'')72ºC10'4º 474 DMSO (10%) R1D-AR ggactgggatagggcactctgct 
Exon 1, Amplicon 1E F1E-AR gacttcaccgcacctgatgtg 94ºC5'35X(94ºC30''55,7ºC30''72ºC30'')72ºC7'4º 193 DMSO (10%) 
R1E-AR ccagaacacagagtgactctgcc 
Exon 2 F2-AR gcctatttctgccattca 94ºC5'35X(94ºC30''52,9ºC30''72ºC30'')72ºC7'4º 288   
R2-AR cctgggccctgaaaggt   
Exon 3 F3-AR ttatcaggtctatcaactcttgt 94ºC5'35X(94ºC30''50ºC30''72ºC30'')72ºC7'4º 313   
M13R3-AR ctgatggccacgttgcctatgaa   
Exon 4 F4-AR gataaattcaagtctctcttcct 94ºC5'35X(94ºC30''54ºC30''72ºC30'')72ºC7'4º 360 DMSO (10%) 
R4-AR gatcccccttatctcatgctccc 
Exon 5 M13F5-AR caacccgtcagtacccaga 94ºC5'40X(94ºC45''58ºC45''72ºC45'')72ºC10'4º 290 DMSO (10%) M13R5-AR agcttcactgtcaccccatcacca 
Exon 6 
M13F6-AR ctctgggcttattgtaaacttcc 





M13R7-AR ctctatcaggctgttctccctgat   
Exon 8 
M13F8-AR gaggccacctccttgtcaaccctg 




94ºC5'35X(94ºC60''62,3ºC60''72ºC60'')72ºC7'4º 526 DMSO (10%) R1-WT1 gcggagagtccctggcgc 
Exon 2 F2-WT1 cgagagcaccgctgacact 94ºC5'35X(94ºC60''56ºC60''72ºC60'')72ºC7'4º 199   
R2-WT1 gagaaggactccacttggttccg   
Exon 3 F3-WT1 ccaggctcaggatctcgtgt 94ºC5'35X(94ºC60''59,5ºC60''72ºC60'')72ºC7'4º 238   
R3-WT1 caaggacccagacgcagag   
Exon 4 F4-WT1 tgcttttgaagaaacagttgtg 94ºC5'35X(94ºC60''56ºC60''72ºC60'')72ºC7'4º 178   
R4-WT1 ggaaaggcaatggaatagaga   
Exon 5 F5-WT1 gggcttttcactggattctg 94ºC5'35X(94ºC60''56ºC60''72ºC60'')72ºC7'4º 174   













R7-WT1 cttagcagtgtgagagcctg   
Exon 8 F8-WT1 gagatccccttttccagtat 94ºC5'35X(94ºC60''55,7ºC60''72ºC60'')72ºC7'4º 220   
R8-WT1 caacaacaaagagaatca   
Exon 9 F9-WT1 aagtcagccttgtgggcctc 94ºC5'35X(94ºC60''55,7ºC60''72ºC60'')72ºC7'4º 246   
R9-WT1 tttccaatccctctcatcac   
Exon 10 F10-WT1 tgtgcctgtctctttgttgc 94ºC5'35X(94ºC60''56ºC60''72ºC60'')72ºC7'4º 224   
R10-WT1 gttcacacactgtgctgcct   
NR5A1 
Exon 1 M13F-UTR-NR5A1 gcgagaggcctgcagagt 95ºC5'35X(95ºC45''64ºC45''72ºC45'')72ºC7'4º 304   
M13R-UTR-NR5A1 gcactgcagaaggaggct   




94ºC5'35X(94ºC30''58,7ºC30''72ºC30'')72ºC7'4º 832 DMSO (10%) M13R3-NR5A1 ggacagtcgggctaaggct 
Exon 5 
M13F4-NR5A1 ggtgagaggaaggtccctgga 
95ºC5'35X(95ºC45''64ºC45''72ºC45'')72ºC7'4º 250 DMSO (10%) M13R4-NR5A1 cctgaatcctggaagtgca 
Exon 6 
M13F5-NR5A1 cctccaatccatgccctca 
95ºC5'35X(95ºC45''64ºC45''72ºC45'')72ºC7'4º 291 DMSO (10%) M13R5-NR5A1 cctctggctgtctccacct 
Exon 7 
M13F6-NR5A1 ggaaggtggtattggtgatgct 






M13R1-FSHR cgcaatgcacaaatgcca   
Exon 2 M13F2-FSHR ggtaactgtttgctga 94ºC5'35X(94ºC60''51,1ºC60''72ºC60'')72ºC7'4º 223   
M13R2-FSHR ggtctgaggttgctccct   
Exon 3 M13F3-FSHR ccagacacaaggctct 94ºC5'35X(94ºC60''51,1ºC60''72ºC60'')72ºC7'4º 234   
M13R3-FSHR ccaggaatgtagaaga   
Exon 4 M13F4-FSHR gcattccttaccatcaaga 94ºC5'35X(94ºC60''51,1ºC60''72ºC60'')72ºC7'4º 174   
M13R4-FSHR ggcttgcactatttaatca   
Exon 5 M13F5-FSHR gccagtttcattttcactca 94ºC5'35X(94ºC60''51,1ºC60''72ºC60'')72ºC7'4º 166   
M13R5-FSHR gcaagacagatactga   




M13R6-FSHR ggagcatccaattatgaga   









M13R9-FSHR ggacaaagttctacattgggga   
Exon 10 M13F10-FSHR cctgcacaaagacagtga 94ºC5'35X(94ºC60''51,1ºC60''72ºC60'')72ºC7'4º 1367   
M13R10-FSHR ccttcaaaggcaagactga   
WNT4 
Exon 1 M13F1-WNT4 cagcagcgggcaggctgccggcagg 94ºC5'35X(94ºC45''65ºC45''72ºC45'')72ºC7'4º 365 DMSO (10%) 
M13R1-WNT4 agcgagcgagcctccggtcc 
Exon 2 M13F2-WNT4 tggatccagagagaagtcgg 94ºC5'35X(94ºC45''65ºC45''72ºC45'')72ºC7'4º 460   
M13R2-WNT4 ttgctcacgagcgtctcatt   
Exon 3+4 M13F3-WNT4 ccagctctgccctccctctgc 94ºC5'35X(94ºC45''65ºC45''72ºC45'')72ºC7'4º 482   
M13R4-WNT4 tctgagtggccgtgtgggt   





















M13R4-SRD5A2 tggagaagaagaaagctacgt   
Exon 5 M13F5-SRD5A2 tcagccactgctccattatat 94ºC5'35X(94ºC45''58ºC45''72ºC45'')72ºC7'4º 166   
M13R5-SRD5A2 cagttttcatcagcattgtgg   
LHCGR 
Exon 1 F1-LHCGR ccgcactcagaggccgtccaaga 94ºC5'35X(94ºC30''55,5ºC30''72ºC30'')72ºC7'4º 279 DMSO (10%) 
R1-LHCGR ggcatagagcgatggagggtcctgca 
Exon 2 F2-LHCGR cctcagcctgaatccagttct 94ºC5'35X(94ºC30''55,5ºC30''72ºC30'')72ºC7'4º 290   
R2-LHCGR cccctttcaaatgtgttttctct   
Exon 3 F3-LHCGR ccagttgttgggtcacacacatagct 94ºC5'35X(94ºC30''55,5ºC30''72ºC30'')72ºC7'4º 236   
R3-LHCGR ccaagtgggctccagccagtga   
Exon 4 F4-LHCGR gccagcaacttctggtgacca 94ºC5'35X(94ºC30''55,5ºC30''72ºC30'')72ºC7'4º 301   













R7-LHCGR cctgagttagttgctgaaga   
Exon 8 F8-LHCGR ggagctacgaatgcttacacatgaggt 94ºC5'35X(94ºC30''55,5ºC30''72ºC30'')72ºC7'4º 203   
R8-LHCGR ggacaccctaagcagtcctgt   
Exon 9 F9-LHCGR ggcgacggagcaagactccgt 94ºC5'35X(94ºC30''65ºC30''72ºC30'')72ºC7'4º 366   
R9-LHCGR ggagtgaaggggagtggagct   
Exon 10 F10-LHCGR cgcacagtcaggtttagcctgaagt 94ºC5'35X(94ºC30''55,5ºC30''72ºC30'')72ºC7'4º 200   
110-LHCGR ggtgcacacagaacaagatacga   
Exon 11 F11-LHCGR gctattatggctttgtttcct 94ºC5'35X(94ºC30''55,5ºC30''72ºC30'')72ºC7'4º 1196   
R11-LHCGR ggtctcttgcctaatgtacct   
CYP17A1 Exon 8 M13F8-CYP17A1 ggtgctattttcataggt 94ºC10'35X(94ºC30''56,4ºC30''72ºC30'')72ºC7'4º 758   











M13R9-ESR1 gctataataaacccttga   
HSD17B4 Exon 8 M13F8-HSD17B4 gcttttgataggtgcagt 94ºC10'35X(94ºC30''58,9ºC30''72ºC30'')72ºC7'4º 432   M13R8-HSD17B4 ccacaatgaacacaatttaca   
WWOX 
Exon 3 
M13F3-WWOX gttgatgtgacaactgct          
94ºC5'35X(94ºC30''61ºC30''72ºC30'')72ºC7'4º 425 
  





M13R9-WWOX cctcaggctattctataacag   
STAR 
Exon 1 M13F1-STAR gcagaacaccaggtccaggct 94ºC5'35X(94ºC30''65ºC30''72ºC30'')72ºC7'4º 316   
M13R1-STAR ccagtaagaggcacaact   
Exon 4 M13F4-STAR ggcgtgaaccaccatg 94ºC5'35X(94ºC30''65ºC30''72ºC30'')72ºC7'4º 285   
M13R4-STAR gcattcacactgggctct   
AMH Exon 2+3+4 M13F2-AMH ggtgtggccttcaatggct 94ºC10'35X(94ºC30''64,7ºC30''72ºC30'')72ºC7'4º 794 DMSO (10%) 
M13R4-AMH ggaggagttgagagcggcca 
AMHR2 Exon 3+4 M13F3-AMHR2 ggaagggacgcctctga 94ºC5'35X(94ºC30''63,8ºC30''72ºC30'')72ºC7'4º 757   
M13R4-AMHR2 ggaatcaggctatagagat   












M13R13-MAP3K1 cctattcatgctctgagt   
DMRT2 




M13R4A-DMRT2 cctgatgaccctgaaggtca   
Exon 4, Amplicon B M13F4B-DMRT2 cctctaccagcaatgcct 94ºC10'35X(94ºC30''56,4ºC30''72ºC30'')72ºC7'4º 742   
M13R4B-DMRT2 tcatcatctttacattaga   
RXFP2 Exon 16 M13F16-RXFP2 ggaaactgatgacataca 94ºC5'35X(94ºC30''60ºC30''72ºC30'')72ºC7'4º 567   
M13R16-RXFP2 ggacacagtcttgactatgt   
GATA4 Exon 3 M13F3-GATA4 gctcaggggaactctcagt 94ºC10'35X(94ºC30''58,7ºC30''72ºC30'')72ºC7'4º 551   
M13R3-GATA4 cctggatcattctggtggct   
NR0B1 
Exon 1, Amplicon 1A M13F1A-NR0B1 ggtataaataggtcccagga 94ºC5'35X(94ºC30''55,7ºC30''72ºC30'')72ºC7'4º 375 DMSO (10%) 
R1A-NR0B1 agcatgctgtagaggatgc 
Exon 1, Amplicon 1B F1B-NR0B1 gcatcctctacagcatgct 94ºC5'35X(94ºC30''55,7ºC30''72ºC30'')72ºC7'4º 441 DMSO (10%) R1B-NR0B1 cctgcgcttgatttgt 
Exon 1, Amplicon 1C 
F1C-NR0B1 ctacttcgcgcagaggcc 
94ºC5'35X(94ºC30''55,7ºC30''72ºC30'')72ºC7'4º 445 DMSO (10%) R1C-NR0B1 ggtggtgaggatcttct 
Exon 1, Amplicon 1D 
F1D-NR0B1 gcagctggtgctggtgcgca 
94ºC5'35X(94ºC60''56ºC60''72ºC60'')72ºC7'4º 376 DMSO (10%) M13R1D-NR0B1 cccgatgcttttgtgagct 
MAMLD1 




M13R1A-MAMLD1 ggctgcccagcaggctga   




M13R1B-MAMLD1 ccactcaaattgtaacggga   
ATRX 
Exon 9, Amplicon 9A M13F9A-ATRX gagttttgttgggaata 94ºC10'35X(94ºC30''56,9ºC30''72ºC30'')72ºC7'4º 735   
M13R9A-ATRX ctttatgctctttggt   
Exon 9, Amplicon 9B M13F9B-ATRX caaattgtaatggaga 94ºC10'35X(94ºC30''56,9ºC30''72ºC30'')72ºC7'4º 813   
M13R9B-ATRX caggagtgagtttaaca   
Exon 9, Amplicon 9C M13F9C-ATRX gaagatttagacatgga 94ºC10'35X(94ºC30''56,9ºC30''72ºC30'')72ºC7'4º 914   
M13R9C-ATRX gaagactcagactgggt   
Exon 9, Amplicon 9D M13F9D-ATRX tcaaaattcagattctga 94ºC10'35X(94ºC30''56,9ºC30''72ºC30'')72ºC7'4º 960   













M13R27 ccatgttgtaaacctc   
Exon 35 M13F35 gatcttactaactggt 94ºC10'35X(94ºC30''55ºC30''72ºC30'')72ºC7'4º 543   
M13R35 gttctgttaagtcattga   
CBX2 Exon 1+2 M13F1 cgcacgggatttgggca 94ºC10'35X(94ºC30''61,1ºC30''72ºC30'')72ºC7'4º 493   
M13R2 ccgctctgcccgcgggc   
DHH Exon 3  M13F3 ggaaaattgtgttgtccatga 94ºC10'35X(94ºC30''51ºC30''72ºC30'')72ºC7'4º 873 DMSO (10%) 
M13R3 cctaagccaggcatagccccat 
ZFPM2 
Exon 8, Amplicon 8A  M13F8A ctctaggagtgaaaatgga 94ºC5'35X(94ºC30''65ºC30''72ºC30'')72ºC7'4º 963   
M13R8A ccttcccatttggccca   
Exon 8, Amplicon 8B M13F8B gctgctcattctgctgatcct 94ºC5'35X(94ºC30''65ºC30''72ºC30'')72ºC7'4º 995   
M13R8B ccttgcagggttgctaggt   




M13R8C gataccaaaggtgactga   
KISS1 Exon 3 M13F3 ggatgggatgacaggaggt 95ºC5'35X(95ºC30''58,9ºC30''72ºC30'')72ºC7'4º 549   M13R3 gcagaccacacgtcagtga   
KISS1R Exon 2 M13F2 cactcggaccaaggtg 94ºC5'35X(94ºC30''55,9ºC30''72ºC30'')72ºC7'4º 443   M13R2 ccagcttctgagtgcatct   




94ºC10'35X(94ºC30''58ºC30''72ºC30'')72ºC7'4º 770 DMSO (10%) M13R2 ctatgtaattaatacaat 
Exon 5 M13F5-ESR2 gctagtacggtcacgacca         94ºC5'35X(94ºC30''63.8ºC30''72ºC30'')72ºC7'4º 604   
M13R5-ESR2 ggtatgccaagacagaagga   
SOX3 
Exon 1, Amplicon 1A M13F1A-SOX3 cctccgggttgcgaggggc 94ºC10'35X(94ºC30''53,2ºC30''72ºC30'')72ºC7'4º 895   
M13R1A-SOX3 ggcccagccgttcacgt   
Exon 1, Amplicon 1B M13F1B-SOX3 cgccgactggaaactgct 94ºC10'35X(94ºC30''53,2ºC30''72ºC30'')72ºC7'4º 916   
M13R1B-SOX3 ggcaagcaaagctaaaca   
SOX9 Exon 3 M13F3-SOX9 gggagggtccccggagggt 94ºC5'35X(94ºC30''60ºC30''72ºC30'')72ºC7'4º 802 DMSO (10%) 
M13R3-SOX9 ggtgaaggtggagtaga 



















M13R14-RET ggtgagccatagcatggca     
Exon 15 F15-RET gtctcaccaggccgctac 94ºC10'35X(94ºC45''64ºC45''72ºC45'')72ºC7'4º 289   
R15-RET gtgcacctgggatccc   
Exon 16 M13F16-RET ccagcactgatgagggatgt 94ºC10'35X(94ºC45''64ºC45''72ºC45'')72ºC7'4º 673   
M13R16-RET ccactacatgtataagggtgt   
M13F tail: tgtaaaacgacggccagt; M13R tail: caggaaacagctatgacc 
 
PCR conditions and used primers in the CNV detection by QMPSF 
Gene  Amplicon 
























94°5'25X(94°45''57°45''72°45'')72°7'4° 184  
M13R5FAM-SRD5A2 /56-FAM/agcagggcagtgcgctgcact 





Genetic markers and primer pairs used to amplify by PCR the surroundings of the NR0B1 gene. 

















/5’ 6-FAM/AAGAATGGGACTCCATTTCA 201 94ºC5'35X(94ºC30''55,7ºC30''72ºC30'')72ºC7'4º 
GCTTATCCACTGGGACAGAA 
PCR, Polymerase Chain Reaction 
 
Primers used in the site-directed mutagenesis. 
Gene  Primers Name Primers sequence (5' to 3') 
GATA4 c.677T Forward tcgcctccagagcagggtggacatagc 
c.677T Reverse gctatgtccaccctgctctggaggcga 
LHCGR 
c.757C Forward cattcagaggctaattgccacgtcaccctattctctaaaaaaattg 
c.757C Reverse caatttttttagagaatagggtgacgtggcaattagcctctgaatg 
c.1660T Forward gctacattaaaatttattttgcagtttgaaacccagaattaatggctacc 
c.1660T Reverse tggtagccattaattctgggtttcaaactgcaaaataaattttaatgtag 
NR5A1 
c.88T>A Forward cttgcagctctcactcgtgagcagtccgt 
c.88T>A Reverse acggactgctcacgagtgagagctgcaag 
c.902G>A Forward gcagctcgctccagtagttctgcagcagc 
c.902G>A Reverse gctgctgcagaactactggagcgagctgc 
c.71A>T Forward gtgtccggctacctctacggactgctc 




Supplementary data 7. Preparation of the solutions used in the different methods.  
 
1 Agarose gel electrophoresis procedure 
1.1 TAE 1X buffer: Dilute 80mL of TAE 50X buffer in 4L of bidistilled water. 
1.2 5% agarose gel in TAE1X: In a 500mL bottle, mix 6g of agarose in 400mL of TAE1X. Melt in the 
microwave. 
 
2 Targeted gene sequencing panel procedure 
2.1 Fresh Melt-Off Solution: Mix 280μL Tween Solution and 40μL NaOH 1M. 
 
3 aCGH procedure 
3.1 10X Blocking Agent: Add 1350µL Milli-Q water to the vial containing the 10x aCGH.  
3.2 Blocking Agent. Leave at RT for 60 minutes.  
 
4 Capillary Sanger sequencing 
4.1 3M Sodium Acetate: Weigh 24.6g CH3COONa and mix with 80ml Milli-Q water.Adjust the volume 
to 100ml Milli-Q water and mix.  
4.2 125mM EDTA solution: Weight 4.65g EDTA and mix with 80ml Milli-Q water. Add NaOH solution to 
adjust the solution pH to 8.0. Adjust the volume to 100ml Milli-Q water and mix.  
 
5 FISH procedure  
5.1 1X PBS: Add 5 tablets of PBS to 1L of MilliQ water and mix. 
5.2 57mM KCL: Add 559g KCL to 100mL MilliQ water and mix. Preheat at 37° before use. 
5.3 Carnoy solution: Mix 10mL acetic acid and 30mL methanol. 
5.4 Supplemented RPMI medium: Mix 4.5mL RPMI culture medium, 500μL FBS and 50 μL 
phytohemagglutinin. 
5.5 20X SSC solution: Mix 132g 20X SCC in 400ml Milli-Q water. Adjust pH to 5.3. Add Milli-Q water to 
a final volume of 500mL and filter through a 0.45µm filtration unit. 
5.6 2X SSC/0.1% NP-40 wash solution: Mix 10mL 20X SCC solution 85mL Milli-Q water. Add 100µL NP-
40 and mix. Adjust pH to 7.0. Add Milli-Q water to a final volume of 100mL. 
5.7 Denaturation solution: Mix 49mL formamide, 7mL 20X SCC and 14mL Milli-Q water. Adjust pH to 7-
8.0. 
5.8 Preparation of 0.4X SCC/0.3% NP-40 Wash solution: Mix 2mL 20X SCC, 90mL Milli-Q water and 
300µL NP-40. Adjust pH to 7-8.0. Add milli-Q water to a final volume of 100mL. 
 
6 Cleaning of the slides for FISH procedure 
• Pour 50mL acetone 100%, hydrochloric acid 1%, ethanol 70% and Milli-Q water in four different 
Coplin jars. 
• Insert a slide in 50mL acetone 100%. 
• Transfer the slide to hydrochloric acid 1% for 10 minutes. 
• Transfer the slide to ethanol 70% for 10 minutes. 
• Transfer the slide to Milli-Q water for 5 minutes.  
• Dry the slide at RT and then refresh at 4°C for 15 minutes. Slides could be stored at 4°C. 
 
7 Transformation of E. coli competent cells 
7.1 LB liquid medium: In a 1L autoclave bottle, add 25g LB broth powder to 1L ultrapure water. 
Autoclave on liquid cycle (121°C) for 15 minutes. Cool to 60°C for 10 minutes before use. Store at 
RT until use. 
7.2 LB agar plates: In a 1L autoclave bottle, add 40g LB agar powder to 1L ultrapure water. Autoclave 
on liquid cycle (121°C) for 15 minutes. Cool to 60°C for 10 minutes before use. Add 300µL 
ampicillin (100mg/ml) and mix. Pour out the media into petri dishes. Cool to RT and store them 
upside room at 4ºC. 
7.3 Transformation Storage Solution (TSS) Buffer: In a 200mL bottle mix 5mL PEG 50%, 25mL DMSO, 
0,5mL MgCl2 1M, 0,5mL MgSO4 and 41,5mL bidistilled water for a total volume of 50mL.. 
7.4 KCM 5x Buffer: In a 200mL bottle mix 25mL KCl 1M, 7,5mL CaCl2 1M, 12,5mL MgCl2 1M and 5mL 





8 Cell lines and culture  
8.1 Supplemented MEM media (10% FBS, 1% L-glutamin, 1% Pen/strep): Remove 50mL of the MEM 
media bottle. Add 50mL FBS, 5mL L-glutamin and 5mL Penicillin-Streptomycin to the MEM bottle. 
Mix by inverting several times. 
8.2 Supplemented DMEM media (10% FBS, 1% Pen/strep, 1% Sodium pyruvate): Remove 50mL of the 
DMEM media bottle. Add 50mL FBS, 5mL Penicillin-Streptomycin and 5mL sodium pyruvate. Mix by 
inverting several times. 
 
9 Western-blot  
9.1 Protease Inhibitor cocktail: In a 1.5mL Eppendorf dissolve 1 tablet in 1mL bidistilled water. 
9.2 Protein Lysis Buffer 1X: In a 1L bottle mix 146mg EDTA, 1230mg Tris, 4350mg NaCl and 5g Triton X-
100. Add bidistilled water for a total volume of 50mL. 
9.3 MOPS 1X Buffer: Reconstitute the bag of powder in 1000 ml bidistilled water to make 1X running 
buffer. 
9.4 Transfer Buffer: Reconstitute the bag of powder in 900 ml bidistilled water and 100mL ethanol.  
9.5 PBS buffer: In a 1L bottle, prepare 800mL bidistilled water and add 8 g of NaCl, 200mg KCl, 1.44g 
Na2HPO4, 240 mg KH2PO4 and bidistilled water up to 1L 
9.6 Blocking buffer: In a 100mL bottle mix 2,5g milk with 50mL PBS buffer. 
9.7 Washing buffer: In a 200mL bottle mix 0.05mL Tween20 with 100mL PBS buffer. 
9.8 Primary antibody dilution: In a 15mL falcon mix 5mL washing buffer with 0.05g BSA. 
9.9 Monoclonal Anti-HA antibody produced in mouse: Add 1mL bidistilled water to a final 
concentration of 100μg/mL. 
9.10 IRDye® 800CW Goat anti-Mouse IgG (H + L): Add 1mL bidistilled water to a final concentration of 
100μg/mL. 
9.11 IRDye® 680RD Donkey anti-Mouse IgG (H + L): Add 1mL bidistilled water to a final concentration of 
100μg/mL. 
9.12 0.5X Odyssey Blocking Buffer: In a 50mL falcon mix 10mL Odyssey Blocking Buffer 1X with 10mL 
bidistilled water. 





Supplementary data 8. Coverage and localization of the regions amplified in the targeted gene panel. 
 
 Chromosome Bases  
Gene Number Start End Total Covered Missed Coverage (%) 
Number of 
amplicons 
AMH.1 chr19 2249310 2249746 436 418 18 95.9 2 
AMH.2 chr19 2250336 2250478 142 142 0 100 1 
AMH.3 chr19 2250649 2250760 111 111 0 100 1 
AMH.4 chr19 2250840 2251007 167 151 16 90.4 2 
AMH.5 chr19 2251098 2252072 974 542 432 55.6 3 
AMHR2 chr12 53817613 53825343 2413 2413 0 100 14 
AR chrX 66763848 66950486 11288 11288 0 100 43 
ATRX chrX 76760330 77041780 12970 12925 45 99.7 66 
BMP15 chrX 50653709 50659666 1362 1362 0 100 6 
CBX2 chr17 77751951 77761474 5246 5235 11 99.8 24 
CYP11A1 chr15 74630077 74660106 2928 2928 0 100 17 
CYP11B1.1 chr8 143960991 143961262 271 271 0 100 2 
CYP11B1.2 chr8 143960441 143960603 162 162 0 100 2 
CYP11B1.3 chr8 143958423 143958639 216 168 48 77.8 2 
CYP11B1.4 chr8 143958093 143958301 208 208 0 100 2 
CYP11B1.5 chr8 143957655 143957818 163 163 0 100 2 
CYP11B1.6 chr8 143957122 143957294 172 172 0 100 2 
CYP11B1.7 chr8 143956646 143956728 82 82 0 100 2 
CYP11B1.8 chr8 143956365 143956570 205 205 0 100 3 
CYP11B1.9 chr8 143954670 143955907 1237 1114 123 90.1 6 
CYP17A1 chr10 104590262 104597315 2270 2270 0 100 12 
CYP19A1 chr15 51500228 51630820 5064 5064 0 100 24 
CYP21A2.1 chr6 32006042 32006401 359 359 0 100 3 
CYP21A2.2 chr6 32006497 32006593 96 96 0 100 2 
CYP21A2.3 chr6 32006858 32007025 167 167 0 100 2 
CYP21A2.4 chr6 32007133 32007234 101 101 0 100 1 
CYP21A2.5 chr6 32007315 32007424 109 109 0 100 2 
CYP21A2.6 chr6 32007522 32007616 94 94 0 100 1 
CYP21A2.7 chr6 32007782 32007988 206 206 0 100 1 
CYP21A2.8 chr6 32008183 32008362 179 179 0 100 1 
CYP21A2.9 chr6 32008445 32008549 104 104 0 100 2 
CYP21A2.10 chr6 32008637 32009447 810 662 148 81.7 5 
DHH chr12 49483180 49488627 2084 2084 0 100 11 
DMRT1 chr9 841664 969115 2472 2469 3 99.9 12 
DMRT2 chr9 1050328 1057579 3135 3116 19 99.4 15 
ESR1 chr6 152011605 152424433 7568 7568 0 100 32 
ESR2 chr14 64693725 64805293 4519 4501 18 99.6 22 
FGF9 chr13 22245189 22278665 4680 4525 155 96.7 19 
FOXL2 chr3 138663040 138666007 2967 2863 104 96.5 13 
FOXO3.1 chr6 108882069 108883032 963 528 435 54.8 3 
FOXO3.2 chr6 108984658 108986092 1434 1434 0 100 6 
FOXO3.3 chr6 109001030 109005971 4941 4941 0 100 18 
FSHR chr2 49189270 49381691 3274 3274 0 100 17 
GATA4.1 chr8 11561713 11561813 100 100 0 100 1 
GATA4.2 chr8 11565365 11566437 1072 673 399 62.8 3 
GATA4.3 chr8 11606428 11606602 174 174 0 100 1 
GATA4.4 chr8 11607620 11607750 130 130 0 100 1 




GATA4.6 chr8 11614440 11614596 156 156 0 100 1 
GATA4.7 chr8 11615802 11617511 1709 1686 23 98.7 7 
HARS2 chr5 140070985 140078928 3260 3260 0 100 17 
HSD17B3 chr9 98997563 99064459 1684 1684 0 100 12 
HSD17B4 chr5 118788112 118878055 4188 4188 0 100 30 
HSD3B2 chr1 119957528 119965687 2099 2099 0 100 9 
INHA chr2 220436928 220440460 1531 1531 0 100 6 
INSL3 chr19 17927296 17932408 1050 1050 0 100 8 
KISS1 chr1 204159443 204165644 864 864 0 100 4 
KISS1R chr19 917316 921040 1875 1842 33 98.2 12 
LHCGR chr2 48913887 48982905 3643 3616 27 99.3 20 
MAMLD1 chrX 149531519 149682473 5260 5238 22 99.6 24 
MAP3K1.1 chr5 56111401 56111882 481 453 28 94.2 3 
MAP3K1.2 chr5 56152427 56152577 150 150 0 100 1 
MAP3K1.3 chr5 56155534 56155742 208 208 0 100 2 
MAP3K1.4 chr5 56160561 56160761 200 197 3 98.5 1 
MAP3K1.5 chr5 56161167 56161283 116 116 0 100 1 
MAP3K1.6 chr5 56161656 56161804 148 148 0 100 2 
MAP3K1.7 chr5 56167737 56167858 121 121 0 100 1 
MAP3K1.8 chr5 56168468 56168549 81 81 0 100 2 
MAP3K1.9 chr5 56168652 56168832 180 180 0 100 3 
MAP3K1.10 chr5 56170859 56171137 278 278 0 100 2 
MAP3K1.11 chr5 56174807 56174928 121 121 0 100 1 
MAP3K1.12 chr5 56176538 56176629 91 91 0 100 1 
MAP3K1.13 chr5 56176908 56177099 191 191 0 100 1 
MAP3K1.14 chr5 56177397 56178693 1296 1296 0 100 5 
MAP3K1.15 chr5 56179354 56179506 152 152 0 100 1 
MAP3K1.16 chr5 56180491 56180653 162 162 0 100 1 
MAP3K1.17 chr5 56181759 56181890 131 116 15 88.5 1 
MAP3K1.18 chr5 56183205 56183347 142 142 0 100 1 
MAP3K1.19 chr5 56184053 56184184 131 131 0 100 1 
MAP3K1.20 chr5 56189358 56191979 2621 2621 0 100 10 
NR0B1 chrX 30322513 30327520 1685 1685 0 100 7 
NR5A1 chr9 127243489 127269724 3445 3417 28 99.2 20 
POR.1 chr7 75544397 75544497 100 100 0 100 1 
POR.2 chr7 75583307 75583498 191 191 0 100 1 
POR.3 chr7 75601731 75601779 48 48 0 100 1 
POR.4 chr7 75608767 75608899 132 132 0 100 2 
POR.5 chr7 75609645 75609806 161 161 0 100 1 
POR.6 chr7 75609807 75610365 558 558 0 100 3 
POR.7 chr7 75610366 75610490 124 105 19 84.7 1 
POR.8 chr7 75610829 75610926 97 97 0 100 1 
POR.9 chr7 75611540 75611642 102 102 0 100 2 
POR.10 chr7 75612838 75612961 123 123 0 100 2 
POR.11 chr7 75613056 75613174 118 96 22 81.4 1 
POR.12 chr7 75614095 75614375 280 280 0 100 3 
POR.13 chr7 75614376 75614527 151 121 30 80.1 1 
POR.14 chr7 75614897 75615168 271 271 0 100 2 
POR.15 chr7 75615237 75615394 157 157 0 100 2 
POR.16 chr7 75615473 75615559 86 86 0 100 2 
POR.17 chr7 75615560 75615654 94 94 0 100 1 
POR.18 chr7 75615655 75616173 518 489 29 94.4 3 




RSPO1 chr1 38076925 38100620 3539 3535 4 99.9 17 
RXFP2 chr13 32313653 32377034 3703 3703 0 100 21 
SOX3 chrX 139585126 139587250 2124 2124 0 100 10 
SOX9 chr17 70117135 70122585 4084 4084 0 100 18 
SRD5A2 chr2 31749630 31806065 2695 2695 0 100 12 
SRY chrY 2654870 2655807 937 937 0 100 4 
STAR chr8 38000192 38008625 3045 3013 32 98.9 15 
TSPYL1 chr6 116595996 116601305 5309 5223 86 98.4 20 
WNT4 chr1 22443772 22469544 4155 3973 182 95.6 20 
WT1 chr11 32409296 32457106 3864 3864 0 100 22 
WWOX chr16 78133301 79246589 3373 3373 0 100 19 
ZFPM2 chr8 106331121 106816792 4880 4880 0 100 21 






Supplementary data 9. Targeted regions not covered according to the Ion Ampliseq Designer tool. 
 
Gene Locus Missed bases (bp) 
Targeted region in 
the gene 
AMH Chr19:2249310-2249746 18 Exon 1-Intron 1 
AMH Chr19:2250840-2251007 16 Exon 4  
AMH Chr19:2251098-2252072 432 Exon 5 
ATRX ChrX:76761410-76761454 45 Exon 35 NC 
CBX2 Chr17:77751952-77751962 11 Exon 1 NC 
CYP11B1 Chr8:143958423-143958639 48 Exon 3  
CYP11B1 Chr8:143954670-143955907 123 Exon 9 NC 
CYP21A2 Chr8:32008637-32009447 148 Exon 10  
DMRT1 Chr9:842215-842217 3 Intron 1 
DMRT2 Chr9:1052002-1052020 19 Exon 2 
ESR2 Chr14:64805031-64805048 18 5'UTR  
FGF9 Chr13:22245393-22245547 155 5'UTR 
FOXL2 Chr3:138664143-138664246 104 Exon 1 NC 
FOXO3 Chr6:108882069-108883032 435 Exon 1 
GATA4 Chr8:11565365-11566437 399 Exon 2 
GATA4 Chr8:11615802-11617511 23 Exon 7 NC 
KISS1R Chr19:917503-917518 16 Exon 1 
KISS1R Chr19:919984-919990 7 Exon 4 
KISS1R Chr19:920265-920274 10 Exon 5 
LHCGR Chr2:48925927-48925953 27 Intron 8-Exon 9 
MAMLD1 ChrX:149680802-149680823 22 Exon 5 
MAP3K1 Chr5:56111401-56111882 28 Exon 1 
MAP3K1 Chr5:56160561-56160761 3 Exon 4-intron 4 
MAP3K1 Chr5:56181759-56181890 15 Exon 17-intron 17 
NR5A1 Chr9:127243914-127243941 28 Exon 9 NC 
POR Chr7:75610366-75610490 19 Exon 6 
POR Chr7:75613056-75613174 22 Exon 10-intron 10 
POR Chr7:75614376-75614527 30 Exon 12 
POR Chr7:75615655-75616173 29 Exon 16 
RSPO1 Chr1:38100365-38100368 4 Exon 1 NC 
STAR Chr8:38000779-38000789+ Chr8:38001112-38001132 32 3'UTR 
TSPYL1 Chr6:116596977-116597001+ Chr6:116599093-116599153 86 Exon 1 NC, 3'UTR 
WNT4 Chr1:22469363-22469544 182 5'UTR-exon 1 





Supplementary data 10. Example of the quality values achieved after the NGS. 
 
Key quality metrics achieved in the patients harbouring a genetic variant. 







at 20x (%) 
 






Base coverage at 
20x (%) 
GN0011 423106 93.1 374.4 84.4 94.2  GN0158 226113 95.3 204.1 90.0 93.5 
GN0020 348581 95.0 306.0 89.4 94.6  GN0163 260668 95.1 243.1 89.2 93.7 
GN0028 201246 93.6 195.0 89.6 93.1  GN0164 282266 94.9 260.5 89.8 94.1 
GN0034 176079 94.1 172.3 87.6 89.8  GN0171 243138 92.6 232.5 89.7 93.3 
GN0046 258515 94.5 253.7 88.8 93.6  GN0182 255763 95.0 238.4 89.6 93.7 
GN0051 183729 95.8 169.7 90.5 93.8  GN0185 321454 95.9 302.1 89.8 94.4 
GN0070 227562 94.8 198.7 89.6 93.4  GN0186 292495 95.0 274.0 89.9 94.1 
GN0075 345109 95.4 304.4 90.4 94.9  GN0187 243457 95.1 227.6 89.9 93.5 
GN0090 235797 95.1 216.5 90.7 94.6  GN0189 239962 95.2 222.1 89.7 93.4 
GN0096 197700 94.4 178.5 90.2 93.6  GN0194 265677 95.2 249.2 89.8 93.8 
GN0118 160389 95.1 149.0 90.6 92.9  GN0198 220407 95.8 202.7 87.2 91.3 
GN0142 385663 94.7 338.6 90.1 94.9  GN0199 453904 95.3 476.4 88.5 94.7 
GN0147 297298 94.9 264.2 89.1 93.8  GN0203 548956 95.2 575.7 89.6 94.7 
GN0150 223689 94.7 205.4 87.9 94.1  GN0207 416516 95.6 434.7 88.4 94.2 
GN0154 316588 92.7 304.8 59.6 94.5  OT0567 359366 96.0 370.3 89.8 95.3 
GN0155 133276 93.7 118.5 87.9 89.8  RE0045 113944 95.0 104.5 89.1 89.6 
GN0156 214614 94.9 197.9 89.3 92.9  Mean 273756.7 94.7 258.3 88.4 93.5 








Quality metrics of the positive controls included in the panel. 
Case Run Mapped reads On target (%) 




Base coverage at 20x 
(%) 
GN0012 Run 8 339833 94.9 316.7 89.2 94.3 
GN0038 Run 2 160825 94.3 145.6 90.5 92.6 
GN0038 Run 5 411785 95.2 404.4 89.6 94.9 
GN0041 Run 3 231384 95.0 201.9 87.4 92.6 
GN0041 Run 6 284439 91.7 270.2 89.9 94.1 
GN0042 Run 4 291990 92.7 280.3 90.0 94.6 
GN0109 Run 3 166327 95.9 148.8 89.6 91.9 
GN0111 Run 9 315034 95.6 328.6 88.4 93.9 
GN0119 Run 10 376231 95.7 406.6 90.0 94.8 
GN0123 Run 10 452078 95.1 485.7 89.7 95.3 
GN0141 Run 1 417085 94.9 384.9 88.6 95.2 
OT0327 Run 4 256903 94.1 250.2 89.8 93.5 
OT0327 Run 5 364178 95.0 363.1 89.0 94.3 
POL0285 Run 6 345955 84.8 302.1 89.1 93.5 
Sane controls Run 1 218436 94.8 201.9 91.2 94.9 





Supplementary data 11. Amplicons not covered in most of the samples. 
 
Amplicon  Gene Locus Targeted region in the gene 
 Amplicon  Gene Locus Targeted region inn the gene 
AMPL7155526017 AR chrX: 66764106-66764373 5'UTR   AMPL7155127628 LHCGR chr2:48914044-48914364 Exon 1 NC 
AMPL7154768614 AR chrX: 66766558-66766723 Exon 1, intron 1  AMPL7153405652 MAMLD1 chrX:149671675-149671905 Intron 3  
AMPL7155525439 AR chrX: 66948258-66948258 Exon 8 NC  AMPL7158500630 MAMLD1 chrX:149681097-149681375 Exon 5  
AMPL7155525424 AR chrX:66944026-66944026 Exon 8 NC  AMPL7154592236 MAP3K1 chr5:56111784-56112084 Exon 1, intron 1 
AMPL7154768613 AR chrX:66766308-66766568 Exon 1  AMPL7154592239 MAP3K1 chr5:56111315-56111589 5'UTR, exon 1 
AMPL7155435957 ATRX chrX:76763526-76763843 Exon 35, exon 35 NC  AMPL7153033277 MAP3K1 chr5:56168711-56168877 Exon 9, intron 9 
AMPL7156609654 ATRX chrX: 76937989-76938290 Exon 9  AMPL7154591595 NR5A1 chr9:127265626-127265961 Intron 1, exon 2 
AMPL7154463818 ATRX chrX:76845183-76845498 Intron 26 to intron 27  AMPL7157234687 RSPO1 chr1:38077119-38077412 Exon 7 NC, 3'UTR 
AMPL7154592293 CBX2 chr17:77752094-77752403 Exon 1 to intron 2  AMPL7157234693 RSPO1 chr1:38097814-38098128 Intron 1 to intron 2 
AMPL7158539628 CYP11A1 chr15:74657976-74658296 Intron 1   AMPL7154809599 SOX3 chrX:139585781-139586094 Exon 1, exon 1 NC 
AMPL7154501291 CYP11B1 chr8:143958112-143958434 Intron 3, exon 4  AMPL7154809601 SOX3 chrX:139586276-139586598 Exon 1 
AMPL7156017306 CYP21A2 chr6:32005824-32006152 5'UTR, exon 1 NC  AMPL7158500104 SOX9 chr17: 70116917-70117240 5'UTR, exon 1 NC 
AMPL7158500645 DHH chr12:49483672-49483813 Exon 3  AMPL7154592302 SOX9 chr17:70120012-70120345 Exon 3 
AMPL7155128017 ESR2 chr14:64749208-64749531 Exon 2, intron 2  AMPL7157408783 SOX9 chr17:70119859-70120179 Exon 3 
AMPL7156599351 ESR2 chr14:64805252-64805452 5'UTR  AMPL7158539633 TSPYL1 chr6:116596344-116596668 3'UTR 
AMPL7154373786 FOXO3 chr6:108881843-108882156 5'UTR, exon 1 NC  AMPL7158539637 TSPYL1 chr6:116597283-116597577 3'UTR 
AMPL7158612785 FOXO3 chr6:109005657-109005971 Exon 3 NC  AMPL7153146546 WNT4 chr1:22469178-22469362 Exon 1, intron 1 
AMPL7154859626 FSHR chr2:49190282-49190576 Exon 10  AMPL7153218849 WT1 chr11:32456878-32457093 Exon 1 NC, exon 1 
AMPL7157052817 KISS1 chr1:204159383-204159693 Exon 3, 3'UTR  AMPL7154427779 WT1 chr11:32456429-32456759 Exon 1 
AMPL7157261487 KISS1R chr19:918338-918653 Intron 1, exon 2  AMPL7156733712 ZFPM2 chr8:106813199-106813518 Intron 7, exon 8 
AMPL7157052823 KISS1R chr19:920817-920968 Exon 5 NC       







Supplementary data 12. Regions amplified by PCR after NGS. 
 
Gene Locus Targeted region in the gene  Gene Locus Targeted region in the gene 
AMH Chr19:2249310-2249746 Exon 1  LHCGR Chr2:48925927-48925953 Exon 9 
AMH Chr19:2250840-2251007 Exon 4  MAMLD1 ChrX:149680802-149680823 Exon 5 
AMH Chr19:2251098-2252072 Exon 5  MAMLD1 chrX:149681097-149681375 Exon 5 
AR chrX: 66766558-66766723 Exon 1  MAP3K1 Chr5:56111401-56111882 Exon 1 
AR chrX:66766308-66766568 Exon 1  MAP3K1 Chr5:56160561-56160761 Exon 4 
ATRX chrX:76763526-76763843 Exon 35  MAP3K1 Chr5:56181759-56181890 Exon 17 
ATRX chrX: 76937989-76938290 Exon 9  MAP3K1 chr5:56111784-56112084 Exon 1 
ATRX chrX:76845183-76845498 Exon 27  MAP3K1 chr5:56111315-56111589 Exon 1 
CBX2 chr17:77752094-77752403 Exon 1, exon 2  MAP3K1 chr5:56168711-56168877 Exon 9 
CYP11B1 Chr8:143958423-143958639 Exon 3  NR5A1 chr9:127265626-127265961 Exon 2 
CYP11B1 chr8:143958112-143958434 Exon 4  POR Chr7:75610366-75610490 Exon 6 
CYP21A2 Chr8:32008637-32009447 Exon 10  POR Chr7:75613056-75613174 Exon 10 
DHH chr12:49483672-49483813 Exon 3  POR Chr7:75614376-75614527 Exon 12 
DMRT2 Chr9:1052002-1052020 Exon 2  POR Chr7:75615655-75616173 Exon 16 
ESR2 chr14:64749208-64749531 Exon 2  SOX3 chrX:139585781-139586094 Exon 1 
FOXO3 Chr6:108882069-108883032 Exon 1  SOX3 chrX:139586276-139586598 Exon 1 
FSHR chr2:49190282-49190576 Exon 10  SOX9 chr17:70120012-70120345 Exon 3 
GATA4 Chr8:11565365-11566437 Exon 2  SOX9 chr17:70119859-70120179 Exon 3 
KISS1 chr1:204159383-204159693 Exon 3  WNT4 Chr1:22469363-22469544 Exon 1 
KISS1R Chr19:917503-917518 Exon 1  WNT4 chr1:22469178-22469362 Exon 1 
KISS1R Chr19:919984-919990 Exon 4  WT1 chr11:32456878-32457093 Exon 1 
KISS1R Chr19:920265-920274 Exon 5  WT1 chr11:32456429-32456759 Exon 1 
KISS1R chr19:918338-918653 Exon 2  ZFPM2 chr8:106813199-106813518 Exon 8 





Supplementary data 13. Detected number of variants detected by the Ion Reporter software. 
 
  SNVs and indels CNVs and others 







Total Clinical feature  
Variant 






GN0001 287 54 15 39 0 301 0.131 1 0 
GN0003 270 40 15 25 0 276 0.114 0 0 
GN0011 298 52 10 42 1 341 0.251 5 0 
GN0012 255 46 8 38 0 284 0.256 6 0 
GN0013 264 47 13 34 0 272 0.226 0 0 
GN0014 290 40 15 25 0 312 0.421 0 0 
GN0017 270 50 18 32 0 429 0.355 36 0 
GN0020 245 34 10 24 1 261 0.085 0 0 
GN0025 265 54 15 39 1 446 0.427 55 0 
GN0026 266 42 10 32 0 285 0.236 1 0 
GN0027 240 37 9 28 0 256 0.148 1 0 
GN0028 232 40 13 27 2 250 0.132 0 0 
GN0029 235 38 11 27 0 240 0.107 0 0 
GN0031 289 40 11 29 0 299 0.149 0 0 
GN0033 284 41 10 31 0 313 0.257 4 0 
GN0034 217 35 10 25 0 237 0.216 1 1 
GN0038 
259 44 14 30 1 261 0.244 1 0 
252 44 11 33 1 261 0.119 0 0 
GN0039 246 48 13 35 0 260 0.13 0 0 
GN0041 
248 39 9 30 0 258 0.132 1 0 
249 40 12 28 0 263 0.194 0 0 
GN0042 282 54 13 41 2 291 0.134 0 0 
GN0043 253 37 13 24 0 484 0.647 14 0 
GN0046 255 42 13 29 1 276 0.157 1 0 
GN0050 287 49 17 32 0 301 0.207 1 0 
GN0051 271 69 12 57 0 283 0.228 0 0 
GN0056 237 42 12 30 0 338 0.402 32 0 
GN0059 263 49 10 39 0 278 0.149 1 0 
GN0064 246 52 15 37 0 304 0.307 10 0 
GN0066 546 35 10 25 0 262 0.088 0 0 
GN0070 315 63 10 53 0 326 0.113 0 0 
GN0075 266 33 13 20 1 280 0.114 0 0 
GN0084 266 45 10 35 0 277 0.147 0 0 
GN0090 335 100 11 89 0 346 0.236 1 0 
GN0096 325 86 11 75 0 333 0.202 0 0 
GN0100 262 38 12 26 0 266 0.27 1 0 
GN0103 257 44 10 34 0 264 0.207 0 0 
GN0104 253 45 11 34 0 265 0.135 0 0 
GN0108 266 53 15 38 0 269 0.242 0 0 
GN0109 274 39 8 31 1 258 0.104 0 0 
GN0111 268 44 13 31 1 295 0.232 3 0 




GN0118 294 74 18 56 0 295 0.157 0 0 
GN0119 269 68 8 60 0 319 0.199 7 0 
GN0122 238 41 13 28 0 257 0.207 0 0 
GN0123 250 45 13 32 1 284 0.189 3 0 
GN0124 245 39 8 31 0 255 0.179 0 0 
GN0138 280 47 17 30 0 291 0.19 0 0 
GN0141 269 43 17 26 1 310 0.323 8 0 
GN0142 262 52 11 41 1 277 0.087 0 0 
GN0144 272 52 11 41 0 300 0.255 7 0 
GN0145 271 45 9 36 0 290 0.123 2 0 
GN0147 262 46 10 36 1 282 0.15 1 0 
GN0148 284 54 15 39 0 494 0.433 80 0 
GN0150 258 49 16 33 1 310 0.409 9 0 
GN0151 239 43 11 32 0 251 0.143 1 0 
GN0152 283 41 11 30 0 294 0.141 2 0 
GN0154 253 40 13 27 1 264 0.124 0 0 
GN0155 268 52 12 40 1 266 0.224 0 0 
GN0156 284 50 10 40 1 309 0.241 4 0 
GN0157 296 74 10 64 1 320 0.248 3 0 
GN0158 338 86 14 72 0 334 0.266 2 0 
GN0160 257 46 12 34 0 267 0.131 0 0 
GN0162 281 37 11 26 0 304 0.223 4 0 
GN0163 234 33 7 26 0 264 0.259 6 0 
GN0164 234 42 8 34 1 268 0.265 3 0 
GN0167 248 39 7 32 0 270 0.251 5 0 
GN0169 272 45 11 34 0 283 0.21 1 0 
GN0171 260 47 13 34 2 270 0.213 0 0 
GN0173 268 35 7 28 0 286 0.244 5 0 
GN0174 255 44 13 31 0 269 0.206 0 0 
GN0175 275 47 9 38 0 323 0.212 4 0 
GN0176 255 43 12 31 0 266 0.223 0 0 
GN0178 256 42 17 25 0 261 0.222 0 0 
GN0179 280 51 10 41 0 297 0.205 1 0 
GN0182 298 42 10 32 0 328 0.249 5 0 
GN0183 252 39 9 30 0 286 0.173 6 0 
GN0185 242 40 10 30 1 265 0.24 3 0 
GN0186 247 50 11 39 1 270 0.258 4 0 
GN0187 249 43 10 33 0 261 0.243 2 1 
GN0189 265 48 10 38 1 285 0.257 3 0 
GN0190 288 38 10 28 0 313 0.25 4 0 
GN0191 240 32 10 22 0 273 0.244 4 0 
GN0192 268 43 11 32 0 308 0.196 7 0 
GN0194 258 46 13 33 1 281 0.259 5 0 
GN0195 279 34 10 24 0 316 0.257 6 0 
GN0196 290 45 10 35 0 214 0.172 9 0 
GN0198 265 61 13 48 2 286 0.336 0 0 
GN0199 284 44 10 34 0 323 0.205 7 0 




GN0201 261 38 9 29 0 296 0.185 4 0 
GN0202 226 31 9 22 0 253 0.203 3 0 
GN0203 326 61 12 49 1 355 0.18 4 0 
GN0204 243 37 11 26 0 283 0.234 9 0 
GN0205 273 43 11 32 0 322 0.198 7 0 
GN0207 283 51 13 38 1 339 0.23 7 0 
OT0327 
264 38 11 27 0 270 0.106 1 0 
272 47 10 37 0 290 0.149 1 0 
OT0567 275 54 8 46 0 356 0.278 12 1 
POL0285 242 34 12 22 0 264 0.189 1 1 
RE0045 274 50 15 35 1 276 0.16 0 0 
NC 308     0   310 0.158   0 
Mean 269.0 46.4 11.5 34.5 0.3 292.9 0.21 4.5 0.04 
Total 27444 4688 1165 3523 34 29885   457 4 




Supplementary data 14. Alignment of multiple protein sequences (A, SRY; B, SF1; C, WT1; D, GATA4; E, 
WWOX; F, ESR1 and ESR2; G, DMRT2; H, ZFPM2; I, MAMLD1; .J, AR; K, LHCGR; L, STAR; M, AMH) across 







aa position at SRY 131 aa position at SF1 24 30 301
Hsapiens P N Y K Y R P R R K A K M Hsapiens D K V S G Y H Y G L L T C S C K G F … M T L L Q N C W S E L L V
Ptroglodytes P N Y K Y R P R R K A N M Ptroglodytes No homologue … No homologue
Mmulatta No homologue Mmulatta D K V S G Y H Y G L L T C S C K G F … C W S E L L V
Fcatus No homologue Fcatus No homologue … M T L L Q N C W S E L L V
Mmusculus No homologue Mmusculus D K V S G Y H Y G L L T C S C K G F … N C W S E L L V
Ggallus P D Y K Y R P R R K T K T Ggallus No homologue … M K L L Q N C W S E L L V
Trubripes No homologue Trubripes No homologue … No homologue
Drerio P D Y K Y R P R R K T KT L Drerio D K V S G Y H Y G L L T C S C K G F … M R L L H N C W S E L L L
Dmelanogaster P D Y K Y R P R R K T K T Dmelanogaster D K V S G Y H Y G L L T C S C K G F … M K L L Q H S W S D M L V
Xtropicalis P D Y K Y R P R R K T KT L Xtropicalis D K V S G Y H Y G L L T C S C K G F … No homologue
aa position at WT1 75 182 aa position at GATA4 226
Hsapiens Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Hsapiens C G A M S T P L W R R D G
Ptroglodytes Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Ptroglodytes C G A M S T P L W R R D G
Mmulatta Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmulatta C G A M S T P L W R R D G
Fcatus No homologue … No homologue Fcatus C G A M S T P L W R R D G
Mmusculus Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmusculus C G A M S T P L W R R D G
Ggallus Q Q P S L G D Q Q Y S V P … F K H E D P M S Q Q P S L Ggallus C G A M S T P L W R R D G
Trubripes P P N N I V E Q Q F P A P … F K H E D T L S P P N N I Trubripes C G A M S T P L W R R D G
Drerio Q Q S N M G D Q Q Y P V P … F K H E D S I T Q Q S N M Drerio C G A M S T P L W R R D G
Dmelanogaster No homologue … No homologue Dmelanogaster C G A I S T P L W R R D G
Xtropicalis Q Q T S L G E Q Q Y S V P … F K H E D P M G Q Q T S L Xtropicalis C G A M S T P L W R R D G
aa position at SRY 131 a positi SF1 24 30 301
Hsapiens P N Y K Y R P R R K A K M i D K V S G Y H Y G L L T C S C K G F … M T L L Q N C W S E L L V
Ptroglodytes P N Y K Y R P R R K A N M Ptr gl ytes No homologue … No homologue
Mmulatta No homologue ulatta D K V S G Y H Y G L L T C S C K G F … C W S E L L V
Fcatus No homologue Fcatus No homologue … M T L L Q N C W S E L L V
Mmusculus No homologue Mmusculus D K V S G Y H Y G L L T C S C K G F … N C W S E L L V
Ggallus P D Y K Y R P R R K T K T Ggallus No homologue … M K L L Q N C W S E L L V
Trubripes No homologue Trubripes No homologue … No homologue
Drerio P D Y K Y R P R R K T KT L Drerio D K V S G Y H Y G L L T C S C K G F … M R L L H N C W S E L L L
Dmelanogaster P D Y K Y R P R R K T K T Dmelanogaster D K V S G Y H Y G L L T C S C K G F … M K L L Q H S W S D M L V
Xtropicalis P D Y K Y R P R R K T KT L Xtropicalis D K V S G Y H Y G L L T C S C K G F … No homologue
aa position at WT1 75 182 aa position at GATA4 226
Hsapiens Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Hsapiens C G A M S T P L W R R D G
Ptroglodytes Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Ptroglodytes C G A M S T P L W R R D G
Mmulatta Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmulatta C G A M S T P L W R R D G
Fcatus No homologue … No homologue Fcatus C G A M S T P L W R R D G
Mmusculus Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmusculus C G A M S T P L W R R D G
Ggallus Q Q P S L G D Q Q Y S V P … F K H E D P M S Q Q P S L Ggallus C G A M S T P L W R R D G
Trubripes P P N N I V E Q Q F P A P … F K H E D T L S P P N N I Trubripes C G A M S T P L W R R D G
Drerio Q Q S N M G D Q Q Y P V P … F K H E D S I T Q Q S N M Drerio C G A M S T P L W R R D G
Dmelanogaster No homologue … No homologue Dmelanogaster C G A I S T P L W R R D G
Xtropicalis Q Q T S L G E Q Q Y S V P … F K H E D P M G Q Q T S L Xtropicalis C G A M S T P L W R R D G
 iti  t RY 131 aa position at SF1 24 30 301
P N Y K Y R P R R K A K M Hsapiens D K V S G Y H Y G L L T C S C K G F … M T L L Q N C W S E L L V
t s P N Y K Y R P R R K A N M Ptroglodytes No homologue … No homologue
No homologue Mmulatta D K V S G Y H Y G L L T C S C K G F … C W S E L L V
No homologue Fcatus No homologue … M T L L Q N C W S E L L V
sc l s No homologue Mmusculus D K V S G Y H Y G L L T C S C K G F … N C W S E L L V
Ggallus P D Y K Y R P R R K T K T Ggallus No homologue … M K L L Q N C W S E L L V
Trubripes No homologue Trubripes No homologue … No homologue
Drerio P D Y K Y R P R R K T KT L Drerio D K V S G Y H Y G L L T C S C K G F … M R L L H N C W S E L L L
Dmelanogaster P D Y K Y R P R R K T K T Dmelanogaster D K V S G Y H Y G L L T C S C K G F … M K L L Q H S W S D M L V
Xtropicalis P D Y K Y R P R R K T KT L Xtropicalis D K V S G Y H Y G L L T C S C K G F … No homologue
aa position at WT1 75 182 aa position at GATA4 226
Hsapiens Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Hsapiens C G A M S T P L W R R D G
Ptroglodytes Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Ptroglodytes C G A M S T P L W R R D G
Mmulatta Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmulatta C G A M S T P L W R R D G
Fcatus No homologue … No homologue Fcatus C G A M S T P L W R R D G
Mmusculus Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmusculus C G A M S T P L W R R D G
Ggallus Q Q P S L G D Q Q Y S V P … F K H E D P M S Q Q P S L Ggallus C G A M S T P L W R R D G
Trubripes P P N N I V E Q Q F P A P … F K H E D T L S P P N N I Trubripes C G A M S T P L W R R D G
Drerio Q Q S N M G D Q Q Y P V P … F K H E D S I T Q Q S N M Drerio C G A M S T P L W R R D G
Dmelanogaster No homologue … No homologue Dmelanogaster C G A I S T P L W R R D G

















aa position at SRY 131 aa position at SF1 24 30 301
Hsapiens P N Y K Y R P R R K A K M Hsapiens D K V S G Y H Y G L L T C S C K G F … M T L L Q N C W S E L L V
Ptroglodytes P N Y K Y R P R R K A N M Ptroglodytes No homologue … No homologue
Mmulatta No homologue Mmulatta D K V S G Y H Y G L L T C S C K G F … C W S E L L V
Fcatus No homologue Fcatus No homologue … M T L L Q N C W S E L L V
Mmusculus No homologue Mmusculus D K V S G Y H Y G L L T C S C K G F … N C W S E L L V
Ggallus P D Y K Y R P R R K T K T Ggallus No homologue … M K L L Q N C W S E L L V
Trubripes No homologue Trubripes No homologue … No homologue
Drerio P D Y K Y R P R R K T KT L Drerio D K V S G Y H Y G L L T C S C K G F … M R L L H N C W S E L L L
Dmelanogaster P D Y K Y R P R R K T K T Dmelanogaster D K V S G Y H Y G L L T C S C K G F … M K L L Q H S W S D M L V
Xtropicalis P D Y K Y R P R R K T KT L Xtropicalis D K V S G Y H Y G L L T C S C K G F … No homologue
aa position at WT1 75 182 aa position at GATA4 226
Hsapiens Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Hsapiens C G A M S T P L W R R D G
Ptroglodytes Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Ptroglodytes C G A M S T P L W R R D G
Mmulatta Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmulatta C G A M S T P L W R R D G
Fcatus No homologue … No homologue Fcatus C G A M S T P L W R R D G
Mmusculus Q Q G S L G E Q Q Y S V P … F K H E D P M G Q Q G S L Mmusculus C G A M S T P L W R R D G
Ggallus Q Q P S L G D Q Q Y S V P … F K H E D P M S Q Q P S L Ggallus C G A M S T P L W R R D G
Trubripes P P N N I V E Q Q F P A P … F K H E D T L S P P N N I Trubripes C G A M S T P L W R R D G
Drerio Q Q S N M G D Q Q Y P V P … F K H E D S I T Q Q S N M Drerio C G A M S T P L W R R D G
Dmelanogaster No homologue … No homologue Dmelanogaster C G A I S T P L W R R D G
Xtropicalis Q Q T S L G E Q Q Y S V P … F K H E D P M G Q Q T S L Xtropicalis C G A M S T P L W R R D G
aa position at WWOX 62 366 aa position at ESR1 594 aa position at ESR2 221
Hsapiens A G D L P Y G W E Q E T D … V Y C A A V P E L E G L G Hsapiens A E G F P A T V * Hsapiens V K C G S R R E R C G Y R
Ptroglodytes Y G W E Q E T D … Y C A A A P E L E G L G Ptroglodytes A E G F P A T V Ptroglodytes V K C G S R R E R C G Y R
Mmulatta Y G W E Q E T D … No homologue Mmulatta A E G F P A T V Mmulatta V K C G S R R E R C G Y R
Fcatus No homologue … V Y C A A A P E L E G L G Fcatus No homologue Fcatus V K C G S R R E R C G Y R
Mmusculus Y G W E Q E T D … Y C A V A P E L E G L G Mmusculus A E G F P N T I Mmusculus V K C G S R R E R C G Y R
Ggallus Y G W E Q E T D … Y C A T A A E L E G L G Ggallus No homologue Ggallus M K C G S R R E R C
Trubripes No homologue … No homologue Trubripes No homologue Trubripes M K C G V R R E R C G Y R
Drerio Y G W E Q E T D … No homologue Drerio No homologue Drerio M K C G L R R D R S S Y Q
Dmelanogaster T G E L P L G W E K Y Y D … T A N E L T G L S Dmelanogaster No homologue Dmelanogaster L K E G V RLD R V R G G R Q
Xtropicalis No homologue … No homologue Xtropicalis E V S L Q S T V Xtropicalis M K C G T R R E R C G Y R
aa position at DMRT2 536 aa position at ZFPM2 1026 aa position at MAMLD1 670
Hsapiens Q V G T K L S V N E P L S Hsapiens S S N G C A A L K K D S L Hsapiens H L M P P R T G L L Q N N
Ptroglodytes Q V G T K L S V N E P Ptroglodytes S N G C A A L K K D S L Ptroglodytes L L S Q Q Q Q Q Q Q Q Q Q
Mmulatta Q V G T K L S V N E P Mmulatta S S N G C A A L K K D S L Mmulatta No homologue
Fcatus No homologue Fcatus S S N G C A P P K K D P L Fcatus P L S Q Q Q Q P P S Q Q P
Mmusculus Q V G T K L S A N E P Mmusculus S N G C A V P K K D S L Mmusculus S I F K P
Ggallus No homologue Ggallus P S N G C A V Q K K E S L Ggallus H M L P S N P A M L Q S T
Trubripes P V G S K M V P Trubripes QQPP A N G C P H P G K E S L Trubripes No homologue
Drerio P R C S K V T A G E S L S Drerio A A N G C P H P N K D P L Drerio No homologue
Dmelanogaster No homologue Dmelanogaster No homologue Dmelanogaster No homologue
Xtropicalis E S G T K L T V S E P L P Xtropicalis P S N R C S L M K K E S L Xtropicalis R M I A S P Q G
aa position at WWOX 62 366 a p ition at ESR1 594 aa position at ESR2 221
Hsapiens A G D L P Y G W E Q E T D … V Y C A A V P E L E G L G Hs iens A E G F P A T V * Hsapiens V K C G S R R E R C G Y R
Ptroglodytes Y G W E Q E T D … Y C A A A P E L E G L G Ptroglodytes A E G F P A T V Ptroglodytes V K C G S R R E R C G Y R
Mmulatta Y G W E Q E T D … No homologue Mmulatta A E G F P A T V Mmulatta V K C G S R R E R C G Y R
Fcatus No homologue … V Y C A A A P E L E G L G Fcatus No homologue Fcatus V K C G S R R E R C G Y R
Mmusculus Y G W E Q E T D … Y C A V A P E L E G L G Mmusculus A E G F P N T I Mmusculus V K C G S R R E R C G Y R
Ggallus Y G W E Q E T D … Y C A T A A E L E G L G Ggallus No homologue Ggallus M K C G S R R E R C
Trubripes No homologue … No homologue Trubripes No homologue Trubripes M K C G V R R E R C G Y R
Drerio Y G W E Q E T D … No homologue Drerio No homologue Drerio M K C G L R R D R S S Y Q
Dmelanogaster T G E L P L G W E K Y Y D … T A N E L T G L S Dmelanogaster No homologue Dmelanogaster L K E G V RLD R V R G G R Q
Xtropicalis No homologue … No homologue Xtropicalis E V S L Q S T V Xtropicalis M K C G T R R E R C G Y R
aa position at DMRT2 536 aa position at ZFPM2 1026 aa position at MAMLD1 670
Hsapiens Q V G T K L S V N E P L S Hsapiens S S N G C A A L K K D S L Hsapiens H L M P P R T G L L Q N N
Ptroglodytes Q V G T K L S V N E P Ptroglodytes S N G C A A L K K D S L Ptroglodytes L L S Q Q Q Q Q Q Q Q Q Q
Mmulatta Q V G T K L S V N E P Mmulatta S S N G C A A L K K D S L Mmulatta No homologue
Fcatus No homologue Fcatus S S N G C A P P K K D P L Fcatus P L S Q Q Q Q P P S Q Q P
Mmusculus Q V G T K L S A N E P Mmusculus S N G C A V P K K D S L Mmusculus S I F K P
Ggallus No homologue Ggallus P S N G C A V Q K K E S L Ggallus H M L P S N P A M L Q S T
Trubripes P V G S K M V P Trubripes QQPP A N G C P H P G K E S L Trubripes No homologue
Drerio P R C S K V T A G E S L S Drerio A A N G C P H P N K D P L Drerio No homologue
Dmelanogaster No homologue Dmelanogaster No homologue Dmelanogaster No homologue
















aa position at WWOX 62 366 aa position at ESR1 594 aa position at ESR2 221
Hsapiens A G D L P Y G W E Q E T D … V Y C A A V P E L E G L G Hsapiens A E G F P A T V * Hsapiens V K C G S R R E R C G Y R
Ptroglodytes Y G W E Q E T D … Y C A A A P E L E G L G Ptroglodytes A E G F P A T V Ptroglodytes V K C G S R R E R C G Y R
Mmulatta Y G W E Q E T D … No homologue Mmulatta A E G F P A T V Mmulatta V K C G S R R E R C G Y R
Fcatus No homologue … V Y C A A A P E L E G L G Fcatus No homologue Fcatus V K C G S R R E R C G Y R
Mmusculus Y G W E Q E T D … Y C A V A P E L E G L G Mmusculus A E G F P N T I Mmusculus V K C G S R R E R C G Y R
Ggallus Y G W E Q E T D … Y C A T A A E L E G L G Ggallus No homologue Ggallus M K C G S R R E R C
Trubripes No homologue … No homologue Trubripes No homologue Trubripes M K C G V R R E R C G Y R
Drerio Y G W E Q E T D … No homologue Drerio No homologue Drerio M K C G L R R D R S S Y Q
Dmelanogaster T G E L P L G W E K Y Y D … T A N E L T G L S Dmelanogaster No homologue Dmelanogaster L K E G V RLD R V R G G R Q
Xtropicalis No homologue … No homologue Xtropicalis E V S L Q S T V Xtropicalis M K C G T R R E R C G Y R
aa position at DMRT2 536 aa position at ZFPM2 1026 aa position at MAMLD1 670
Hsapiens Q V G T K L S V N E P L S Hsapiens S S N G C A A L K K D S L Hsapiens H L M P P R T G L L Q N N
Ptroglodytes Q V G T K L S V N E P Ptroglodytes S N G C A A L K K D S L Ptroglodytes L L S Q Q Q Q Q Q Q Q Q Q
Mmulatta Q V G T K L S V N E P Mmulatta S S N G C A A L K K D S L Mmulatta No homologue
Fcatus No homologue Fcatus S S N G C A P P K K D P L Fcatus P L S Q Q Q Q P P S Q Q P
Mmusculus Q V G T K L S A N E P Mmusculus S N G C A V P K K D S L Mmusculus S I F K P
Ggallus No homologue Ggallus P S N G C A V Q K K E S L Ggallus H M L P S N P A M L Q S T
Trubripes P V G S K M V P Trubripes QQPP A N G C P H P G K E S L Trubripes No homologue
Drerio P R C S K V T A G E S L S Drerio A A N G C P H P N K D P L Drerio No homologue
Dmelanogaster No homologue Dmelanogaster No homologue Dmelanogaster No homologue
Xtropicalis E S G T K L T V S E P L P Xtropicalis P S N R C S L M K K E S L Xtropicalis R M I A S P Q G
aa position at WWOX 62 366 aa position at ESR1 594 aa position at ESR2 221
Hsapiens A G D L P Y G W E Q E T D … V Y C A A V P E L E G L G Hsapiens A E G F P A T V * Hsapiens V K C G S R R E R C G Y R
Ptroglodytes Y G W E Q E T D … Y C A A A P E L E G L G Ptroglodytes A E G F P A T V Ptroglodytes V K C G S R R E R C G Y R
Mmulatta Y G W E Q E T D … No homologue Mmulatta A E G F P A T V Mmulatta V K C G S R R E R C G Y R
Fcatus No homologue … V Y C A A A P E L E G L G Fcatus No homologue Fcatus V K C G S R R E R C G Y R
Mmusculus Y G W E Q E T D … Y C A V A P E L E G L G Mmusculus A E G F P N T I Mmusculus V K C G S R R E R C G Y R
Ggallus Y G W E Q E T D … Y C A T A A E L E G L G Ggallus No homologue Ggallus M K C G S R R E R C
Trubripes No homologue … No homologue Trubripes No homologue Trubripes M K C G V R R E R C G Y R
Drerio Y G W E Q E T D … No homologue Drerio No homologue Drerio M K C G L R R D R S S Y Q
Dmelanogaster T G E L P L G W E K Y Y D … T A N E L T G L S Dmelanogaster No homologue Dmelanogaster L K E G V RLD R V R G G R Q
Xtropicalis No homologue … No homologue Xtropicalis E V S L Q S T V Xtropicalis M K C G T R R E R C G Y R
aa position at DMRT2 536 aa position at ZFPM2 1026 aa position at MAMLD1 670
Hsapiens Q V G T K L S V N E P L S Hsapiens S S N G C A A L K K D S L Hsapiens H L M P P R T G L L Q N N
Ptroglodytes Q V G T K L S V N E P Ptroglodytes S N G C A A L K K D S L Ptroglodytes L L S Q Q Q Q Q Q Q Q Q Q
Mmulatta Q V G T K L S V N E P Mmulatta S S N G C A A L K K D S L Mmulatta No homologue
Fcatus No homologue Fcatus S S N G C A P P K K D P L Fcatus P L S Q Q Q Q P P S Q Q P
Mmusculus Q V G T K L S A N E P Mmusculus S N G C A V P K K D S L Mmusculus S I F K P
Ggallus No homologue Ggallus P S N G C A V Q K K E S L Ggallus H M L P S N P A M L Q S T
Trubripes P V G S K M V P Trubripes QQPP A N G C P H P G K E S L Trubripes No homologue
Drerio P R C S K V T A G E S L S Drerio A A N G C P H P N K D P L Drerio No homologue
Dmelanogaster No homologue Dmelanogaster No homologue Dmelanogaster No homologue
Xtropicalis E S G T K L T V S E P L P Xtropicalis P S N R C S L M K K E S L Xtropicalis R M I A S P Q G
aa position at WWOX 62 366 aa position at E R1 594 aa position at ESR2 221
Hsapiens A G D L P Y G W E Q E T D … V Y C A A V P E L E G L G Hsapiens A E G F P A T V * Hsapiens V K C S R R E R C G Y R
Ptroglodytes Y G W E Q E T D … Y C A A A P E L E G L G Ptroglodytes A E G F P A T V Ptroglodytes V K C G S R R E R C G Y R
Mmulatta Y G W E Q E T D … No homologue Mmulatta A E G F P A T V Mmulatta V K C G S R R E R C G Y R
Fcatus No homologue … V Y C A A A P E L E G L G Fcatus No homologue Fcatus V K C G S R R E R C G Y R
Mmusculus Y G W E Q E T D … Y C A V A P E L E G L G Mmusculus A E G F P N T I Mmusculus V K C G S R R E R C G Y R
Ggallus Y G W E Q E T D … Y C A T A A E L E G L G Ggallus No homologue Ggallus M K C G S R R E R C
Trubripes No homologue … No homologue Trubripes No homologue Trubripes M K C G V R R E R C G Y R
Drerio Y G W E Q E T D … No homologue Drerio No homologue Drerio M K C G L R R D R S S Y Q
Dmelanogaster T G E L P L G W E K Y Y D … T A N E L T G L S Dmelanogaster No homologue Dmelanogaster L K E G V RLD R V R G G R Q
Xtropicalis No homologue … No homologue Xtropicalis E V S L Q S T V Xtropicalis M K C G T R R E R C G Y R
aa position at DMRT2 536 aa position at ZFPM2 1026 aa position at MAMLD1 670
Hsapiens Q V G T K L S V N E P L S Hsapiens S S N G C A A L K K D S L Hsapiens H L M P P R T G L L Q N N
Ptroglodytes Q V G T K L S V N E P Ptroglodytes S N G C A A L K K D S L Ptroglodytes L L S Q Q Q Q Q Q Q Q Q Q
Mmulatta Q V G T K L S V N E P Mmulatta S S N G C A A L K K D S L Mmulatta No homologue
Fcatus No homologue Fcatus S S N G C A P P K K D P L Fcatus P L S Q Q Q Q P P S Q Q P
Mmusculus Q V G T K L S A N E P Mmusculus S N G C A V P K K D S L Mmusculus S I F K P
Ggallus No homologue Ggallus P S N G C A V Q K K E S L Ggallus H M L P S N P A M L Q S T
Trubripes P V G S K M V P Trubripes QQPP A N G C P H P G K E S L Trubripes No homologue
Drerio P R C S K V T A G E S L S Drerio A A N G C P H P N K D P L Drerio No homologue
Dmelanogaster No homologue Dmelanogaster No homologue Dmelanogaster No homologue


















aa position at AR 881 aa position at LHCGR 190 253
Hsapiens H Q F T F D L L I K S H M Hsapiens N G F E E V Q S H A F N G … R L I A T S S Y S L K K L
Ptroglodytes  No homologue Ptroglodytes N G F E E V Q S H A F N G … R L I A T S S Y S L K K L
Mmulatta  H Q F T F D L L I K S H M Mmulatta N G F E E V Q S H A F N G … T L I A T S S Y S L K K L
Fcatus  H Q F T F D L L I K S H M Fcatus N G F E E I Q S H A F N G … T L I A T S S Y S L K K L
Mmusculus  H Q F T F D L L I K Mmusculus E E V Q S H A F N G … T L I A T S S Y S L K T L
Ggallus  H Q F T F D L L I K A H M Ggallus No homologue … No homologue
Trubripes  H Q F T F D L F V Q A Q S Trubripes N G F R T I R S H A F N G … T L K A T L T F A L K T L
Drerio  H Q F T F D L F V Q A R S Drerio N G F Q E I E S H A F N G … M L T A R S A F A L K K L
Dmelanogaster  No homologue Dmelanogaster N E I S Y V D D S A F F G … A L Y I Q N T H T L K T I
Xtropicalis  H Q F T F D L F V K A Q M Xtropicalis N G F E D I Q S Y A F N G … V L V A E Y S Y Y L K Q L
aa position at STAR 17 121 aa position at AMH 143
Hsapiens G S S Y R H M R N M K G L … D V G K V F R L E V V V D Hsapiens E V T W E P T P S L R F Q
Ptroglodytes G S S Y R H M R N M K G L … R L E V V V D mutated E V T W E P I P S L R F Q
Mmulatta G S S Y R H M R N M K G L … Q L E V V V D Ptroglodytes No homologue
Fcatus G S S Y R H V R N M K G L … R L E V V V D Mmulatta No homologue
Mmusculus G S S Y R H M R N M K G L … R L E V V V D Fcatus E V T W E P T P S L K F Q
Ggallus A I S Y Q H L R N V T G L … R L E V V V D Mmusculus E V I W E P E L L L K F Q
Trubripes G I S Y R H M R N M T G L … K L E V V L E Ggallus E GR S W R V V P T L SMGLS W R
Drerio G I S Y R H M R N M T G L … K L E V T L E Drerio No homologue
Dmelanogaster No homologue Dmelanogaster No homologue
Xtropicalis G I S Y R H L R N M T G L … K L E A V V E Xtropicalis No homologue
aa position at AR 881 aa position at LHCGR 190 253
Hsapiens H Q F T F D L L I K S H M Hsapiens N G F E E V Q S H A F N G … R L I A T S S Y S L K K L
Ptroglodytes  No homologue Ptroglodytes N G F E E V Q S H A F N G … R L I A T S S Y S L K K L
Mmulatta  H Q F T F D L L I K S H M Mmulatta N G F E E V Q S H A F N G … T L I A T S S Y S L K K L
Fcatus  H Q F T F D L L I K S H M Fcatus N G F E E I Q S H A F N G … T L I A T S S Y S L K K L
Mmusculus  H Q F T F D L L I K Mmusculus E E V Q S H A F N G … T L I A T S S Y S L K T L
Ggallus  H Q F T F D L L I K A H M Ggallus No homologue … No homologue
Trubripes  H Q F T F D L F V Q A Q S Trubripes N G F R T I R S H A F N G … T L K A T L T F A L K T L
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Supplementary data 15. Genetic tests in the relatives of the index case. 
 
Case Gene and variants Zygosity Family studies 
GN0004 SRY; 46,XX (SRY+) - N/A 
GN0007 SRY; c.289C>T; p.Gln97Ter Hemi Affected sister: hemi, father: mosaicism. Other relatives: wt. 
GN0009 WT1; c.1447+5G>A Het Mother: wt. 
GN0011 MAP3K1; c.2291T>G; p.Leu764Arg Het Parents and brother: wt. 
GN0012 NR5A1; c.437G>C; p.Gly146Ala Het Mother: wt. 
GN0018 AR; c.2323C>T; p.Arg775Cys Hemi N/A 
GN0020 WWOX; c.1096C>G; p.Pro366Ala Het N/A 
GN0023 SRY; 46,XX (SRY+) - N/A 
GN0024 AR; c.2086G>A; p.Asp69Asn Hemi N/A 
GN0028 NR5A1; c.88T>A; p.Cys30Ser Het Parents and brother: wt. STAR; c.361C>T; p.Arg121Trp Het Father: het. Mother and brother: wt. 
GN0034 LHCGR; arr [hg19] 2p16.3(48,905,663-48,983,208)x0 Hom N/A 
GN0035 AR; c.2522G>A; Arg841His Hemi N/A 
GN0037 AR; c.2178C>G; p.Phe726Leu Hemi Mother: het. Father and sister: wt. 
GN0038 HSD17B3; c.845C>T; p.Pro282Leu Hom Mother: het.  
GN0041 AR; c.(1616+1_1617-1)_(1768+1_1767-1)del; p.(Arg539_Asp305del) Hemi Mother: het, affected sister: hemi. Father: wt. 
GN0042 
NR5A1; c.614_615insC; p.Gln206ThrfsTer20 Het Mother: wt. 
AMH; c.428C>T; p.Thr143Ile Het Mother: wt. 
GN0046 SRD5A2; c.377A>G; p.Gln126Arg Het Father: het. Mother: wt. SRD5A2; c.(-1+1_1-1)_(281+1_280-1)del; p.(Met1_Arg94del). Het Parents: wt. 
GN0051 NR5A1; c.437G>C; p.Gly146Ala Het N/A 
GN0054 SRY; 46,XX (SRY+) - N/A 
GN0055 AR; c.2710G>A; p.Val904Met Hemi Mother: mosaicism. 
GN0068 LHCGR; c.1713G>T; p.Met571Ile Het Affected father: het. Mother and paternal aunts: wt. 
GN0070 NR5A1; c.437G>C; p.Gly146Ala Het N/A 
GN0075 NR5A1; c.250C>T; p.Arg84Cys Het Mother, brother, grandfather, maternal aunt and uncle: het. Father, 
grandmother and sister: wt. 
GN0076 AR; c.2566C>T; p.Arg856Cys Hemi Mother: het. 




GN0080 AR; c.298insC; p.His100ProfsTer3 Hemi Mother: het. Father and sister: wt. 
GN0088 LHCGR; c.1193T>C; p.Met398Thr Het Parents: wt. 
GN0090 NR5A1; c.437G>C; p.Gly146Ala Hom N/A 
GN0091 NR0B1; c.291delC; p.Glu98ArgfsTer166 Hemi Mother: het. Father, maternal aunt and grandmother: wt. 
GN0096 NR5A1; c.437G>C; p.Gly146Ala Hom N/A 
GN0101 NR0B1; g.(?_30327014)_(30361290_?)del Hemi N/A 
GN0109 NR5A1; c.910_913delGAGC; p.Glu304CysfsTer26 Het Mother: het. Sister: wt. 
GN0111 NR5A1; c.902G>A; p.Cys301Tyr Het Mother: mosaicism. Father and Brother: wt. 
GN0112 AR; c.827delC;p.Pro276HisfsTer20 Hemi Mother: het. Father: wt. 
GN0118 NR5A1; c.437G>C; p.Gly146Ala Het N/A 
GN0119 NR5A1; c.437G>C; p.Gly146Ala Hom N/A 
GN0123 NR5A1; c.71A>T; p.His24Leu Het N/A 
GN0125 AR; c.865G>T; p.Glu289Ter Hemi N/A 
GN0132 WT1; c.1447+4C>T Het N/A 
GN0133 SRY; 46,XX (SRY+) - N/A 
GN0139 AR; c.2642T>G; p.Leu881Arg Hemi Mother: het. 
GN0141 SRY; c.391C>T; p.Pro131Ser Hemi N/A 
GN0142 DMRT2; c.1607C>T; p.Ser536Leu Het Mother: het. Other relatives: wt 
GN0146 AR; c.2473C>A; p.Gln825Lys Hemi N/A 
GN0147 LHCGR; c.757T>C; p.Ser253Pro Hom N/A 
NR5A1; c.437G>C; p.Gly146Ala Het 
GN0150 WT1; c.223G>A;p.Glu75Lys Het Mother: het. 
GN0153 NR0B1; c.528C>G; p.Tyr176Ter Hemi Mother and grandmother: het. Father and aunt: wt. 
GN0154 MAMLD1; c.2009C>T; p.Thr670Ile Het N/A 
GN0155 ZFPM2; c.3077C>T, p.Ala1026Val Het N/A 
GN0156 WT1; c.545T>A; p.Met182Lys Het N/A NR5A1; c.437G>C; p.Gly146Ala Hom 
GN0157 LHCGR; c.568C>A; p.Gln190Lys Het Father: het. Mother: wt NR5A1; c.437G>C; p.Gly146Ala Het Father: homo. Mother: wt. 
GN0158 NR5A1; c.437G>C; p.Gly146Ala Hom N/A 
GN0159 SRY; 46,XX.ish der(X)t(X;Y)(p22.3;p11.3)(SRY) - Parents: wt. 




GN0164 AR; c.2270A>G; p.Asn757Ser Hemi N/A 
GN0171 GATA4; c.677C>T; p.Pro226Leu Het Mother: het. LHCGR; c.1660C>T; p.Arg554Ter Het Mother: wt. 
GN0177 AR; c.1301C>T; p.Ser434Phe Hemi N/A 
GN0182 NR5A1; c.437G>C; p.Gly146Ala Het N/A 
GN0185 STAR; c.50T>G; p.Met17Arg Het Father: het. Mother: wt. 
GN0186 SRD5A2; c.271T>G; Tyr91Asp Hom Parents: het. 
GN0187 SRY; 46,XX.ish der(X)t(X;Y)(p22.3;p11.3)(SRY) - N/A 
GN0189 AR; c.2567G>A; p.Arg856His Hemi Mother: het. Father: wt. 
GN0194 AR; c.2323C>T; p.Arg775Cys Hemi N/A 
NR5A1; c.437G>C; p.Gly146Ala Het 
GN0198 HSD17B4; c.524delC; p.Ala175GlufsTer26 Het Mother: het. Father: wt. 
ESR1; c.1781C>T;p.Thr594Met Het Mother: het. Father: wt. 
GN0199 NR5A1; c.437G>C; p.Gly146Ala Het Mother: het. Father: wt. 
GN0203 WWOX; c.184G>A; p.Gly62Arg Het N/A 
GN0207 ESR2; c.661A>G; p.Arg221Gly Het N/A 
OT0567 WT1; c.(1099-?_1551+?)del; p.(Asp367?_Leu517?)del Het Parents: wt. 
POL0274 NR0B1; c.871T>A; p.Trp291Arg Hemi Mother: het. Father: wt. 
POL0285 NR0B1; g.(?_29978097)_(30361290_?)del Hemi N/A 
POL0301 NR0B1; c.712_713delAC; p.Thr238LeufsTer60 Hemi Mother: het. Father: wt. 
RE0045 CYP17A1; c.1246C>T; p.Arg416Cys Hom Affected sister: homo. Mother, sister and niece: het. 





Supplementary data 16. Article originated from this work 
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